[
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b001",
    "text": "Review and Evaluation of Clinical Data",
    "bbox": [
      196.0,
      72.3,
      419.4,
      85.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "TITLE"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b002",
    "text": "NDA (Serial Number)",
    "bbox": [
      90.0,
      102.4,
      212.0,
      115.8
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b003",
    "text": "20823 (SE1-016)",
    "bbox": [
      306.0,
      102.4,
      400.7,
      115.8
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b004",
    "text": "Sponsor:",
    "bbox": [
      90.0,
      116.2,
      146.0,
      129.6
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b005",
    "text": "Novartis",
    "bbox": [
      306.0,
      116.2,
      357.3,
      129.6
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b006",
    "text": "Drug:",
    "bbox": [
      90.0,
      130.0,
      125.3,
      143.4
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b007",
    "text": "Exelon® (rivastigmine tartrate)",
    "bbox": [
      306.0,
      130.0,
      487.6,
      143.4
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b008",
    "text": "Proposed Indication:",
    "bbox": [
      90.0,
      143.8,
      212.7,
      157.2
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b009",
    "text": "Dementia Associated With Parkinson's Disease",
    "bbox": [
      306.0,
      143.8,
      512.0,
      157.2
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b010",
    "text": "Material Submitted:",
    "bbox": [
      90.0,
      157.6,
      204.7,
      171.0
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b011",
    "text": "Supplemental New Drug Application",
    "bbox": [
      306.0,
      157.6,
      516.1,
      171.0
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b012",
    "text": "Correspondence Date:",
    "bbox": [
      90.0,
      171.4,
      222.1,
      184.8
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b013",
    "text": "8/31/05",
    "bbox": [
      306.0,
      171.4,
      349.4,
      184.8
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b014",
    "text": "Date Received / Agency:",
    "bbox": [
      90.0,
      185.2,
      232.8,
      198.6
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b015",
    "text": "9/1/05",
    "bbox": [
      306.1,
      185.2,
      342.8,
      198.6
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b016",
    "text": "Date Review Completed",
    "bbox": [
      90.0,
      199.0,
      229.4,
      212.4
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b017",
    "text": "4/18/06",
    "bbox": [
      306.1,
      199.0,
      349.4,
      212.4
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b018",
    "text": "Reviewer:",
    "bbox": [
      90.0,
      212.8,
      150.1,
      226.2
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b019",
    "text": "Ranjit B. Mani, M.D.",
    "bbox": [
      306.0,
      212.8,
      420.7,
      226.2
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b020",
    "text": "TABLE OF CONTENTS",
    "bbox": [
      90.0,
      241.2,
      375.9,
      256.8
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b021",
    "text": "Executive Summary..............................................................................................3",
    "bbox": [
      90.0,
      260.1,
      524.5,
      273.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b022",
    "text": "Recommendation ..............................................................................................3",
    "bbox": [
      102.0,
      273.9,
      524.5,
      287.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b023",
    "text": "Proposed Indication...........................................................................................3",
    "bbox": [
      102.0,
      287.7,
      524.5,
      301.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b024",
    "text": "Summary Of Clinical Findings ...........................................................................3",
    "bbox": [
      102.0,
      301.5,
      524.5,
      315.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b025",
    "text": "Conclusions.......................................................................................................6",
    "bbox": [
      102.0,
      315.3,
      524.5,
      328.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b026",
    "text": "Background....................................................................................................7",
    "bbox": [
      114.0,
      329.1,
      524.5,
      342.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b027",
    "text": "Contents Of Submission ................................................................................7",
    "bbox": [
      114.0,
      342.9,
      524.5,
      356.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b028",
    "text": "Contents Of Review.......................................................................................8",
    "bbox": [
      114.0,
      356.7,
      524.5,
      370.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b029",
    "text": "Key Diagnostic Instruments Used in Efficacy Study (Study 2311).................9",
    "bbox": [
      114.0,
      370.5,
      524.5,
      384.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b030",
    "text": "4.1",
    "bbox": [
      102.0,
      384.3,
      121.7,
      397.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b031",
    "text": "UK Parkinson’s Disease Society Brain Bank Clinical Diagnostic Criteria",
    "bbox": [
      138.0,
      384.3,
      518.1,
      397.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b032",
    "text": "For Parkinson’s Disease ...................................................................................9",
    "bbox": [
      102.0,
      398.1,
      524.5,
      411.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b033",
    "text": "4.2",
    "bbox": [
      102.0,
      411.9,
      121.7,
      425.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b034",
    "text": "DSM-IV Criteria For Dementia Due To Parkinson’s Disease................10",
    "bbox": [
      138.0,
      411.9,
      524.5,
      425.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b035",
    "text": "Efficacy Outcome Measures And Selected Additional Instruments Used In",
    "bbox": [
      114.0,
      425.7,
      508.8,
      439.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b036",
    "text": "Efficacy Study .....................................................................................................10",
    "bbox": [
      90.0,
      439.5,
      524.5,
      453.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b037",
    "text": "5.1",
    "bbox": [
      102.0,
      453.3,
      121.7,
      466.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b038",
    "text": "Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-",
    "bbox": [
      138.0,
      453.3,
      508.7,
      466.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b039",
    "text": "Cog) 10",
    "bbox": [
      102.0,
      467.1,
      154.3,
      480.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b040",
    "text": "5.2",
    "bbox": [
      102.0,
      480.9,
      121.7,
      494.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b041",
    "text": "Alzheimer’s Disease Cooperative Study – Clinician’s Global Impression",
    "bbox": [
      138.0,
      480.9,
      519.5,
      494.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b042",
    "text": "Of Change (ADCS-CGIC) ...............................................................................10",
    "bbox": [
      102.0,
      494.7,
      524.5,
      508.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b043",
    "text": "5.3",
    "bbox": [
      102.0,
      508.5,
      121.7,
      522.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b044",
    "text": "Alzheimer’s Disease Cooperative Study – Activities Of Daily Living",
    "bbox": [
      138.0,
      508.5,
      493.6,
      521.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b045",
    "text": "Scale (ADCS-ADL)..........................................................................................11",
    "bbox": [
      102.0,
      522.3,
      524.5,
      535.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b046",
    "text": "5.4",
    "bbox": [
      102.0,
      536.1,
      121.7,
      549.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b047",
    "text": "Cognitive Drug Research Computerized Assessment System.............11",
    "bbox": [
      138.0,
      536.1,
      524.5,
      549.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b048",
    "text": "5.5",
    "bbox": [
      102.0,
      549.9,
      121.7,
      563.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b049",
    "text": "Delis-Kaplan Executive Functioning System (D-KEFS) Test Battery....12",
    "bbox": [
      138.0,
      549.9,
      524.5,
      563.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b050",
    "text": "5.6",
    "bbox": [
      102.0,
      563.7,
      121.7,
      577.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b051",
    "text": "Mini-Mental Status Examination ...........................................................13",
    "bbox": [
      138.0,
      563.7,
      524.5,
      577.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b052",
    "text": "5.7",
    "bbox": [
      102.0,
      577.5,
      121.7,
      591.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b053",
    "text": "Neuropsychiatry Inventory....................................................................13",
    "bbox": [
      138.0,
      577.5,
      524.5,
      591.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b054",
    "text": "5.8",
    "bbox": [
      102.0,
      591.3,
      121.7,
      604.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b055",
    "text": "Ten-Point Clock Test ............................................................................13",
    "bbox": [
      138.0,
      591.3,
      524.5,
      604.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b056",
    "text": "5.9",
    "bbox": [
      102.0,
      605.1,
      121.7,
      618.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b057",
    "text": "Symbol-Digit Modalities Test ................................................................14",
    "bbox": [
      138.0,
      605.1,
      524.5,
      618.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b058",
    "text": "5.10",
    "bbox": [
      102.0,
      618.9,
      128.3,
      632.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b059",
    "text": "Health Economic Parameters...............................................................14",
    "bbox": [
      138.0,
      618.9,
      524.5,
      632.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b060",
    "text": "5.11",
    "bbox": [
      102.0,
      632.7,
      128.3,
      646.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b061",
    "text": "Unified Parkinson’s Disease Rating Scale (UPDRS)............................14",
    "bbox": [
      138.0,
      632.7,
      524.5,
      646.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b062",
    "text": "Summary Of Key Efficacy Study (EXPRESS Study; Study 2311) ...............15",
    "bbox": [
      114.0,
      646.5,
      524.5,
      660.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b063",
    "text": "6.1",
    "bbox": [
      102.0,
      660.3,
      121.7,
      673.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b064",
    "text": "Outline ..................................................................................................15",
    "bbox": [
      138.0,
      660.3,
      524.5,
      673.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b065",
    "text": "6.2",
    "bbox": [
      102.0,
      674.1,
      121.7,
      687.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b066",
    "text": "Results Of Primary Efficacy Analysis....................................................15",
    "bbox": [
      138.0,
      674.1,
      524.5,
      687.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b067",
    "text": "Description Of Efficacy Study 2311 (EXPRESS Study) ...............................16",
    "bbox": [
      114.0,
      687.9,
      524.5,
      701.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b068",
    "text": "7.1",
    "bbox": [
      102.0,
      701.7,
      121.7,
      715.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 1,
    "block_id": "1055_p1_b069",
    "text": "Protocol ................................................................................................16",
    "bbox": [
      138.0,
      701.7,
      524.5,
      715.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b002",
    "text": "Page 2 of 93",
    "bbox": [
      464.2,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b005",
    "text": "7.2",
    "bbox": [
      102.0,
      72.2,
      121.7,
      85.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b006",
    "text": "Study Results .......................................................................................27",
    "bbox": [
      138.0,
      72.2,
      524.5,
      85.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b007",
    "text": "7.3",
    "bbox": [
      102.0,
      86.0,
      121.7,
      99.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b008",
    "text": "Sponsor’s Conclusions .........................................................................45",
    "bbox": [
      138.0,
      86.0,
      524.5,
      99.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b009",
    "text": "7.4",
    "bbox": [
      102.0,
      99.8,
      121.7,
      113.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b010",
    "text": "Study Abstract ......................................................................................46",
    "bbox": [
      138.0,
      99.8,
      524.5,
      113.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b011",
    "text": "7.5",
    "bbox": [
      102.0,
      113.6,
      121.7,
      127.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b012",
    "text": "Additional Observations And Comments By Agency Statistical Reviewer",
    "bbox": [
      138.0,
      113.6,
      522.8,
      127.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b013",
    "text": "About Study 2311............................................................................................47",
    "bbox": [
      102.0,
      127.4,
      524.5,
      140.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b014",
    "text": "7.6",
    "bbox": [
      102.0,
      141.2,
      121.7,
      154.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b015",
    "text": "Reviewer’s Comments..........................................................................49",
    "bbox": [
      138.0,
      141.2,
      524.5,
      154.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b016",
    "text": "Study 2311E1 (Open-Label Uncontrolled Extension To Study 2311) ..........50",
    "bbox": [
      114.0,
      155.0,
      524.5,
      168.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b017",
    "text": "8.1",
    "bbox": [
      102.0,
      168.8,
      121.7,
      182.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b018",
    "text": "Protocol 2311E1...................................................................................50",
    "bbox": [
      138.0,
      168.8,
      524.5,
      182.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b019",
    "text": "8.2",
    "bbox": [
      102.0,
      182.6,
      121.7,
      196.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b020",
    "text": "Safety Results Of Study 2311E1 ..........................................................52",
    "bbox": [
      138.0,
      182.6,
      524.5,
      196.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b021",
    "text": "8.3",
    "bbox": [
      102.0,
      196.4,
      121.7,
      209.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b022",
    "text": "Sponsor’s Conclusions Regarding Safety.............................................56",
    "bbox": [
      138.0,
      196.4,
      524.5,
      209.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b023",
    "text": "8.4",
    "bbox": [
      102.0,
      210.2,
      121.7,
      223.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b024",
    "text": "Reviewer’s Comments..........................................................................56",
    "bbox": [
      138.0,
      210.2,
      524.5,
      223.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b025",
    "text": "Study 2314 (Non-Interventional Validation Study) .......................................57",
    "bbox": [
      114.0,
      224.0,
      524.5,
      237.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b026",
    "text": "9.1",
    "bbox": [
      102.0,
      237.8,
      121.7,
      251.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b027",
    "text": "Protocol ................................................................................................57",
    "bbox": [
      138.0,
      237.8,
      524.5,
      251.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b028",
    "text": "9.2",
    "bbox": [
      102.0,
      251.6,
      121.7,
      265.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b029",
    "text": "Main Results.........................................................................................60",
    "bbox": [
      138.0,
      251.6,
      524.5,
      265.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b030",
    "text": "9.3",
    "bbox": [
      102.0,
      265.4,
      121.7,
      278.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b031",
    "text": "Sponsor’s Conclusions .........................................................................66",
    "bbox": [
      138.0,
      265.4,
      524.5,
      278.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b032",
    "text": "10.",
    "bbox": [
      90.0,
      279.2,
      109.7,
      292.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b033",
    "text": "Summary Of Earlier Meeting Between Division And Sponsor Regarding",
    "bbox": [
      126.0,
      279.2,
      507.4,
      292.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b034",
    "text": "This Application...................................................................................................67",
    "bbox": [
      90.0,
      293.0,
      524.5,
      306.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b035",
    "text": "11.",
    "bbox": [
      90.0,
      306.8,
      109.7,
      320.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b036",
    "text": "Sponsor’s Current View Of Dementia Associated With Parkinson’s",
    "bbox": [
      126.0,
      306.8,
      480.7,
      320.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b037",
    "text": "Disease, And Appropriateness Of ADAS-Cog And ADCS-ADL In Evaluating",
    "bbox": [
      90.0,
      320.6,
      494.8,
      334.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b038",
    "text": "Treatment Effects In Dementia Associated With Parkinson’s Disease ...............69",
    "bbox": [
      90.0,
      334.4,
      524.5,
      347.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b039",
    "text": "11.1",
    "bbox": [
      102.0,
      348.2,
      128.3,
      361.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b040",
    "text": "Dementia Associated With Parkinson’s Disease (Expert Report:",
    "bbox": [
      138.0,
      348.2,
      478.8,
      361.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b041",
    "text": "Diagnosing Dementia Associated With Parkinson’s Disease And Distinguishing",
    "bbox": [
      102.0,
      362.0,
      524.2,
      375.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b042",
    "text": "It From Alzheimer’s Disease) ..........................................................................69",
    "bbox": [
      102.0,
      375.8,
      524.5,
      389.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b043",
    "text": "11.2",
    "bbox": [
      102.0,
      389.6,
      128.3,
      403.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b044",
    "text": "Appropriateness Of Using The ADAS-Cog And ADCS-ADL As Outcome",
    "bbox": [
      138.0,
      389.6,
      522.8,
      403.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b045",
    "text": "Measures In Dementia Associated With Parkinson’s Disease ........................74",
    "bbox": [
      102.0,
      403.4,
      524.5,
      416.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b046",
    "text": "12.",
    "bbox": [
      90.0,
      417.2,
      109.7,
      430.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b047",
    "text": "Financial Disclosure Certification .............................................................77",
    "bbox": [
      126.0,
      417.2,
      524.5,
      430.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b048",
    "text": "12.1",
    "bbox": [
      102.0,
      431.0,
      128.3,
      444.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b049",
    "text": "Components Of Certification.................................................................77",
    "bbox": [
      138.0,
      431.0,
      524.5,
      444.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b050",
    "text": "This certification has been provided on FDA Form 3454. ...................................77",
    "bbox": [
      90.0,
      444.8,
      524.5,
      458.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b051",
    "text": "This certification has been provided on FDA Form 3455. ...................................77",
    "bbox": [
      90.0,
      458.6,
      524.5,
      472.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b052",
    "text": "12.2",
    "bbox": [
      102.0,
      472.4,
      128.3,
      485.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b053",
    "text": "Reviewer’s Comments..........................................................................77",
    "bbox": [
      138.0,
      472.4,
      524.5,
      485.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b054",
    "text": "13.",
    "bbox": [
      90.0,
      486.2,
      109.7,
      499.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b055",
    "text": "Site Inspection Report..............................................................................77",
    "bbox": [
      126.0,
      486.2,
      524.5,
      499.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b056",
    "text": "14.",
    "bbox": [
      90.0,
      500.0,
      109.7,
      513.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b057",
    "text": "Review Of Proposed Labeling..................................................................78",
    "bbox": [
      126.0,
      500.0,
      524.5,
      513.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b058",
    "text": "15.",
    "bbox": [
      90.0,
      513.8,
      109.7,
      527.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b059",
    "text": "Comments................................................................................................78",
    "bbox": [
      126.0,
      513.8,
      524.5,
      527.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b060",
    "text": "15.1",
    "bbox": [
      102.0,
      527.6,
      128.3,
      541.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b061",
    "text": "General.................................................................................................78",
    "bbox": [
      138.0,
      527.6,
      524.5,
      541.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b062",
    "text": "15.2",
    "bbox": [
      102.0,
      541.4,
      128.3,
      554.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b063",
    "text": "Efficacy.................................................................................................78",
    "bbox": [
      138.0,
      541.4,
      524.5,
      554.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b064",
    "text": "15.3",
    "bbox": [
      102.0,
      555.2,
      128.3,
      568.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b065",
    "text": "Safety ...................................................................................................92",
    "bbox": [
      138.0,
      555.2,
      524.5,
      568.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b066",
    "text": "16.",
    "bbox": [
      90.0,
      569.0,
      109.7,
      582.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b067",
    "text": "Conclusions..............................................................................................93",
    "bbox": [
      126.0,
      569.0,
      524.5,
      582.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b068",
    "text": "17.",
    "bbox": [
      90.0,
      582.8,
      109.7,
      596.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 2,
    "block_id": "1055_p2_b069",
    "text": "Recommendation.....................................................................................93",
    "bbox": [
      126.0,
      582.8,
      524.5,
      596.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b002",
    "text": "Page 3 of 93",
    "bbox": [
      464.2,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b005",
    "text": "Executive Summary",
    "bbox": [
      90.0,
      98.2,
      226.9,
      113.8
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b006",
    "text": "Recommendation",
    "bbox": [
      90.0,
      123.2,
      194.0,
      136.6
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b007",
    "text": "Deferred, pending discussion of this application at a scheduled meeting of the",
    "bbox": [
      90.0,
      139.9,
      505.6,
      153.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b008",
    "text": "Peripheral and Central Nervous Systems Drugs Advisory Committee",
    "bbox": [
      90.0,
      153.7,
      456.9,
      167.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b009",
    "text": "Proposed Indication",
    "bbox": [
      90.0,
      187.4,
      208.6,
      200.8
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b010",
    "text": "“Treatment of mild to moderate dementia associated with Parkinson’s Disease”",
    "bbox": [
      90.0,
      204.1,
      512.2,
      217.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b011",
    "text": "Summary Of Clinical Findings",
    "bbox": [
      90.0,
      237.8,
      264.1,
      251.2
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b012",
    "text": "Exelon® is currently approved for marketing in this country, as both capsule and",
    "bbox": [
      90.0,
      254.5,
      518.4,
      267.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b013",
    "text": "oral solution formulations, for the treatment of mild to moderate dementia of the",
    "bbox": [
      90.0,
      268.3,
      513.6,
      281.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b014",
    "text": "Alzheimer’s type.",
    "bbox": [
      90.0,
      282.1,
      184.8,
      295.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b015",
    "text": "The sponsor has provided evidence from two completed clinical studies in",
    "bbox": [
      90.0,
      309.7,
      484.8,
      323.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b016",
    "text": "support of the efficacy and safety of Exelon® for the proposed new indication.",
    "bbox": [
      90.0,
      323.5,
      505.1,
      336.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b017",
    "text": "These are:",
    "bbox": [
      90.0,
      337.3,
      154.1,
      350.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b018",
    "text": "Study 2311, which was randomized, double-blind, placebo-controlled, and",
    "bbox": [
      126.0,
      364.9,
      488.6,
      377.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b019",
    "text": "parallel-arm in design",
    "bbox": [
      126.0,
      377.6,
      234.3,
      389.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b020",
    "text": "Study 2311E1, the open-label uncontrolled extension to Study 2311",
    "bbox": [
      126.0,
      390.3,
      458.0,
      402.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b021",
    "text": "In addition, the sponsor has performed a non-interventional study (Study 2314) of",
    "bbox": [
      90.0,
      416.6,
      525.0,
      430.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b022",
    "text": "the validity of a number of assessment scales in the Parkinson’s Disease",
    "bbox": [
      90.0,
      430.4,
      480.2,
      443.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b023",
    "text": "Dementia (and vascular dementia); partial results for this study have been",
    "bbox": [
      90.0,
      444.2,
      485.6,
      457.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b024",
    "text": "submitted in this application.",
    "bbox": [
      90.0,
      458.0,
      244.1,
      471.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b025",
    "text": "The data for these studies as they pertain to the efficacy and safety of Exelon® in",
    "bbox": [
      90.0,
      485.6,
      525.1,
      499.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b026",
    "text": "this population are summarized below, as are the results of the non-",
    "bbox": [
      90.0,
      499.4,
      450.8,
      512.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b027",
    "text": "interventional validation study listed above.",
    "bbox": [
      90.0,
      513.2,
      321.5,
      526.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b028",
    "text": "Efficacy",
    "bbox": [
      90.0,
      546.9,
      135.3,
      560.3
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b029",
    "text": "The results of a single randomized, double-blind, placebo-controlled study (also",
    "bbox": [
      90.0,
      563.6,
      514.9,
      577.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b030",
    "text": "referred to as the EXPRESS Study) of the efficacy of rivastigmine in the",
    "bbox": [
      90.0,
      577.4,
      473.6,
      590.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b031",
    "text": "proposed entity of dementia associated with Parkinson’s Disease (also referred",
    "bbox": [
      90.0,
      591.2,
      513.5,
      604.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b032",
    "text": "to interchangeably as Parkinson’s Disease Dementia) have been submitted in",
    "bbox": [
      90.0,
      605.0,
      505.6,
      618.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b033",
    "text": "this application.  The main features of this study were as follows",
    "bbox": [
      90.0,
      618.8,
      432.2,
      632.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b034",
    "text": "This was a randomized (2:1 [Exelon®:Placebo]), double-blind, placebo-",
    "bbox": [
      126.0,
      646.5,
      472.9,
      658.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b035",
    "text": "controlled, parallel-arm study",
    "bbox": [
      126.0,
      659.1,
      273.2,
      671.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 3,
    "block_id": "1055_p3_b036",
    "text": "The key inclusion criteria for the study were as follows",
    "bbox": [
      126.0,
      684.4,
      391.8,
      696.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b002",
    "text": "Page 4 of 93",
    "bbox": [
      464.2,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b005",
    "text": "Clinical diagnosis of idiopathic Parkinson’s Disease according to the UK",
    "bbox": [
      198.0,
      72.2,
      518.1,
      83.4
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b006",
    "text": "Parkinson’s Disease Society Brain Bank clinical diagnostic criteria",
    "bbox": [
      198.0,
      83.7,
      492.0,
      94.9
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b007",
    "text": "Clinical diagnosis of Parkinson’s Disease Dementia according to DSM-IV",
    "bbox": [
      198.0,
      95.2,
      523.0,
      106.3
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b008",
    "text": "criteria (Code 294.1) with onset of symptoms of dementia within at least",
    "bbox": [
      198.0,
      106.7,
      517.5,
      117.9
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b009",
    "text": "2 years of the first diagnosis of idiopathic Parkinson’s Disease",
    "bbox": [
      198.0,
      118.2,
      480.3,
      129.4
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b010",
    "text": "Mini-Mental Status Examination score of 10 – 24 at entry",
    "bbox": [
      198.0,
      129.7,
      452.0,
      140.8
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b011",
    "text": "The study was of 24 weeks’ duration",
    "bbox": [
      126.0,
      154.7,
      306.9,
      167.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b012",
    "text": "The 2 parallel treatment arms were",
    "bbox": [
      126.0,
      180.7,
      299.6,
      193.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b013",
    "text": "Rivastigmine 3 to 12 mg/day (flexible dose) as BID dosing",
    "bbox": [
      198.0,
      205.9,
      457.0,
      217.1
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b014",
    "text": "Placebo",
    "bbox": [
      198.0,
      217.4,
      237.0,
      228.6
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b015",
    "text": "The primary efficacy measures were the Alzheimer’s Disease Assessment Scale-",
    "bbox": [
      126.0,
      241.3,
      521.6,
      253.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b016",
    "text": "Cognitive subscale (ADAS-Cog) and Alzheimer’s Disease Cooperative Study –",
    "bbox": [
      126.0,
      253.9,
      512.3,
      266.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b017",
    "text": "Clinician’s Global Impression Of Change (ADCS-CGIC).",
    "bbox": [
      126.0,
      266.5,
      404.7,
      278.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b018",
    "text": "The secondary efficacy measures were the following: Alzheimer’s Disease",
    "bbox": [
      126.0,
      292.6,
      490.3,
      304.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b019",
    "text": "Cooperative Study – Activities of Daily Living Scale (ADCS-ADL);",
    "bbox": [
      126.0,
      305.2,
      446.2,
      317.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b020",
    "text": "Neuropsychiatry Inventory-10; Mini-Mental Status Examination; Cognitive Drug",
    "bbox": [
      126.0,
      317.8,
      512.3,
      330.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b021",
    "text": "Research Computerized Assessment System; Delis-Kaplan Executive",
    "bbox": [
      126.0,
      330.5,
      469.5,
      342.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b022",
    "text": "Functioning System (D-KEFS) Verbal Fluency Test; and Ten Point Clock-",
    "bbox": [
      126.0,
      343.2,
      482.9,
      355.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b023",
    "text": "Drawing Test",
    "bbox": [
      126.0,
      355.8,
      193.8,
      368.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b024",
    "text": "Safety was assessed through adverse events, vital signs, safety laboratory tests,",
    "bbox": [
      126.0,
      381.9,
      521.6,
      394.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b025",
    "text": "electrocardiograms, and Unified Parkinson’s Disease Rating Scale motor score",
    "bbox": [
      126.0,
      394.5,
      513.6,
      406.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b026",
    "text": "The sponsor’s primary efficacy analysis was performed on the intent-to-treat plus",
    "bbox": [
      126.0,
      420.6,
      522.1,
      432.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b027",
    "text": "retrieved dropouts dataset using the following statistical models",
    "bbox": [
      126.0,
      433.2,
      440.4,
      445.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b028",
    "text": "The change from baseline to endpoint in the ADAS-Cog score was to be",
    "bbox": [
      162.0,
      458.4,
      484.3,
      469.6
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b029",
    "text": "compared between the treatment groups using an analysis of covariance with",
    "bbox": [
      162.0,
      469.9,
      507.0,
      481.1
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b030",
    "text": "treatment, country, and baseline ADAS-Cog score as explanatory variables",
    "bbox": [
      162.0,
      481.4,
      497.2,
      492.6
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b031",
    "text": "The ADCS-CGIC score at endpoint was to be analyzed using a Cochran-Mantel-",
    "bbox": [
      162.0,
      492.9,
      518.3,
      504.1
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b032",
    "text": "Haenszel test with modified ridits scores and with country as a stratification",
    "bbox": [
      162.0,
      504.4,
      496.1,
      515.6
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b033",
    "text": "variable",
    "bbox": [
      162.0,
      515.9,
      202.6,
      527.1
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b034",
    "text": "Key results for this study were as follows.",
    "bbox": [
      90.0,
      540.1,
      312.8,
      553.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b035",
    "text": "541 patients were randomized, of whom 442 patients completed the study. Their",
    "bbox": [
      90.0,
      567.7,
      519.6,
      581.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b036",
    "text": "distribution by treatment group was as follows:",
    "bbox": [
      90.0,
      581.5,
      339.4,
      594.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b037",
    "text": "Treatment Group",
    "bbox": [
      95.4,
      607.9,
      179.1,
      620.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b038",
    "text": "Exelon®",
    "bbox": [
      239.4,
      607.9,
      284.1,
      620.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b039",
    "text": "Placebo",
    "bbox": [
      353.4,
      607.9,
      393.2,
      620.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b040",
    "text": "Number randomized",
    "bbox": [
      95.4,
      620.6,
      198.1,
      632.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b041",
    "text": "362",
    "bbox": [
      239.4,
      620.6,
      260.8,
      632.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b042",
    "text": "179",
    "bbox": [
      353.4,
      620.6,
      374.8,
      632.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b043",
    "text": "Number completed",
    "bbox": [
      95.4,
      633.3,
      191.4,
      645.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b044",
    "text": "263",
    "bbox": [
      239.4,
      633.3,
      260.8,
      645.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b045",
    "text": "147",
    "bbox": [
      353.4,
      633.3,
      374.8,
      645.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b046",
    "text": "The main efficacy results of this study were as follows",
    "bbox": [
      90.0,
      659.7,
      378.7,
      673.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b047",
    "text": "The primary efficacy analysis, using Study Week 24 as the endpoint, revealed",
    "bbox": [
      126.0,
      686.2,
      507.5,
      698.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 4,
    "block_id": "1055_p4_b048",
    "text": "statistically significant differences between the treatment groups on the ADAS-",
    "bbox": [
      126.0,
      698.8,
      507.4,
      711.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b002",
    "text": "Page 5 of 93",
    "bbox": [
      464.2,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b005",
    "text": "Cog (difference in mean change from baseline score at endpoint: 2.90; p <",
    "bbox": [
      126.0,
      72.3,
      491.3,
      84.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b006",
    "text": "0.001) and ADCS-CGIC (difference in mean score between treatment groups at",
    "bbox": [
      126.0,
      84.9,
      516.7,
      97.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b007",
    "text": "endpoint: 0.5; p = 0.007). Note that an Agency statistical reviewer has judged the",
    "bbox": [
      126.0,
      97.6,
      522.5,
      109.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b008",
    "text": "distribution of ADAS-Cog data not to be normal and therefore in violation of the",
    "bbox": [
      126.0,
      110.2,
      512.3,
      122.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b009",
    "text": "assumptions of the analysis of covariance model proposed; however, even with",
    "bbox": [
      126.0,
      122.8,
      514.8,
      135.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b010",
    "text": "the use of a non-parametric model, the Wilcoxon rank sum test, the Exelon®",
    "bbox": [
      126.0,
      135.5,
      501.0,
      147.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b011",
    "text": "group showed a statistically significant superiority over placebo on this measure",
    "bbox": [
      126.0,
      148.2,
      516.6,
      160.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b012",
    "text": "Nominally statistically significant differences were seen between the treatment",
    "bbox": [
      126.0,
      173.5,
      508.6,
      185.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b013",
    "text": "groups on all secondary efficacy variables at Week 24 in the same dataset as",
    "bbox": [
      126.0,
      186.1,
      505.6,
      198.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b014",
    "text": "that used for the primary efficacy analysis",
    "bbox": [
      126.0,
      198.7,
      331.4,
      211.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b015",
    "text": "Analyses of the primary efficacy parameters using other datasets (intent-to-treat",
    "bbox": [
      126.0,
      225.2,
      517.3,
      237.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b016",
    "text": "last-observation-carried-forward, and observed cases) yielded similar results.",
    "bbox": [
      126.0,
      237.9,
      506.9,
      250.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b017",
    "text": "Safety",
    "bbox": [
      90.0,
      270.4,
      127.4,
      283.8
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b018",
    "text": "Study 2311",
    "bbox": [
      90.0,
      293.2,
      154.1,
      306.6
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b019",
    "text": "This study has already been summarized above. Salient safety findings for this",
    "bbox": [
      90.0,
      309.9,
      510.9,
      323.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b020",
    "text": "study were as follows.",
    "bbox": [
      90.0,
      323.7,
      210.8,
      337.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b021",
    "text": "The incidence of nausea, vomiting, and tremor was appreciably higher in the",
    "bbox": [
      126.0,
      351.3,
      500.7,
      363.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b022",
    "text": "rivastigmine group than in the placebo group; a similar adverse event profile was",
    "bbox": [
      126.0,
      363.9,
      521.0,
      376.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b023",
    "text": "seen in the key controlled clinical trials of Exelon® in Alzheimer’s Disease",
    "bbox": [
      126.0,
      376.6,
      487.5,
      388.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b024",
    "text": "Several treatment-emergent adverse events that may have represented a",
    "bbox": [
      126.0,
      389.2,
      486.7,
      401.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b025",
    "text": "worsening in the motor manifestations of Parkinson’s Disease, and tremor in",
    "bbox": [
      126.0,
      401.9,
      500.1,
      414.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b026",
    "text": "particular, were more frequent in those treated with Exelon® than in those",
    "bbox": [
      126.0,
      414.6,
      488.1,
      426.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b027",
    "text": "treated with placebo. However, changes in UPDRS total and individual motor",
    "bbox": [
      126.0,
      427.2,
      503.1,
      439.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b028",
    "text": "scores, probably a more objective measure of change in the motor",
    "bbox": [
      126.0,
      439.8,
      451.8,
      452.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b029",
    "text": "manifestations of Parkinson’s Disease than the incidence of treatment-emergent",
    "bbox": [
      126.0,
      452.5,
      519.1,
      464.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b030",
    "text": "adverse events, showed no meaningful difference between treatment groups.",
    "bbox": [
      126.0,
      465.1,
      505.1,
      477.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b031",
    "text": "Study 2311E1",
    "bbox": [
      90.0,
      496.4,
      168.7,
      509.8
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b032",
    "text": "This was a 24-week open-label uncontrolled extension to Study 2311 intended",
    "bbox": [
      90.0,
      513.2,
      508.9,
      526.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b033",
    "text": "primarily to evaluate the safety and tolerability of Exelon® in the study",
    "bbox": [
      90.0,
      527.0,
      463.7,
      540.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b034",
    "text": "population. Patients given the option of enrolling in this study had either",
    "bbox": [
      90.0,
      540.8,
      472.4,
      554.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b035",
    "text": "completed the double-blind treatment phase of Study 2311 or discontinued early",
    "bbox": [
      90.0,
      554.6,
      518.9,
      568.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b036",
    "text": "during that study, but returned for all the remaining scheduled efficacy",
    "bbox": [
      90.0,
      568.4,
      464.2,
      581.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b037",
    "text": "assessments without significant protocol violations. Regardless of their previous",
    "bbox": [
      90.0,
      582.2,
      516.9,
      595.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b038",
    "text": "treatment assignment, patients enrolled in the extension study were all re-titrated",
    "bbox": [
      90.0,
      596.0,
      522.3,
      609.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b039",
    "text": "to a flexible dose of Exelon® that ranged from 1.5 mg BID to 6.0 mg BID, based",
    "bbox": [
      90.0,
      609.8,
      516.5,
      623.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b040",
    "text": "on tolerability.",
    "bbox": [
      90.0,
      623.6,
      170.8,
      637.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b041",
    "text": "433 patients enrolled in Study 2311 were eligible to enroll in Study 2311E1, of",
    "bbox": [
      90.0,
      651.2,
      505.7,
      664.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b042",
    "text": "whom 334 patients actually consented to participate in, and 273 patients,",
    "bbox": [
      90.0,
      665.0,
      480.3,
      678.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 5,
    "block_id": "1055_p5_b043",
    "text": "completed the latter study.",
    "bbox": [
      90.0,
      678.8,
      237.4,
      692.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b002",
    "text": "Page 6 of 93",
    "bbox": [
      464.2,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b005",
    "text": "The adverse event profile of Exelon® in Study 2311 was broadly similar to that",
    "bbox": [
      90.0,
      72.2,
      509.8,
      85.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b006",
    "text": "seen in Study 2311E1.",
    "bbox": [
      90.0,
      86.0,
      214.1,
      99.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b007",
    "text": "Non-Interventional Validation Study (Study 2314)",
    "bbox": [
      90.0,
      119.7,
      353.6,
      133.1
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b008",
    "text": "This 4-week cross-sectional study was intended to evaluate the validity and",
    "bbox": [
      90.0,
      136.4,
      492.8,
      149.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b009",
    "text": "reliability of several measures of cognition, activities of daily living, executive",
    "bbox": [
      90.0,
      150.2,
      498.1,
      163.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b010",
    "text": "function and behavior in patients with Parkinson’s Disease Dementia and",
    "bbox": [
      90.0,
      164.0,
      480.9,
      177.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b011",
    "text": "vascular dementia, and to compare the performance of the same measures in",
    "bbox": [
      90.0,
      177.8,
      506.1,
      191.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b012",
    "text": "those conditions with their performance in Alzheimer’s Disease. This submission",
    "bbox": [
      90.0,
      191.6,
      519.5,
      205.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b013",
    "text": "contains an interim report that only pertains to Parkinson’s Disease Dementia.",
    "bbox": [
      90.0,
      205.4,
      506.9,
      218.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b014",
    "text": "The interim report indicates that 55 patients with Parkinson’s Disease Dementia",
    "bbox": [
      90.0,
      233.0,
      515.4,
      246.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b015",
    "text": "(diagnosed using the DSM-IV criteria) and 58 patients with Alzheimer’s Disease",
    "bbox": [
      90.0,
      246.8,
      515.4,
      260.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b016",
    "text": "(diagnosed using the NINCDS-ADRDA criteria) were enrolled in the study;",
    "bbox": [
      90.0,
      260.6,
      486.9,
      274.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b017",
    "text": "patients with each diagnosis were further grouped into mild and moderate",
    "bbox": [
      90.0,
      274.4,
      483.5,
      287.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b018",
    "text": "categories based on Mini-Mental Status Examination scores of 18 to 24 and 10",
    "bbox": [
      90.0,
      288.2,
      512.2,
      301.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b019",
    "text": "to 17, respectively, at study entry. The efficacy instruments evaluated were the",
    "bbox": [
      90.0,
      302.0,
      510.1,
      315.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b020",
    "text": "ADAS-Cog, Global Deterioration Scale, ADCS-ADL, D-KEFS Verbal Fluency",
    "bbox": [
      90.0,
      315.8,
      500.2,
      329.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b021",
    "text": "Test, Ten-Point Clock Test, Trailmaking Tests A and B, Neuropsychiatry",
    "bbox": [
      90.0,
      329.6,
      476.1,
      343.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b022",
    "text": "Inventory, including Neuropsychiatry Inventory-Distress, and Cognitive Drug",
    "bbox": [
      90.0,
      343.4,
      496.1,
      356.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b023",
    "text": "Research Computerized Assessment System tests for the assessment of",
    "bbox": [
      90.0,
      357.2,
      481.5,
      370.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b024",
    "text": "attention. Each enrolled patient was to be evaluated using these measures at",
    "bbox": [
      90.0,
      371.0,
      502.8,
      384.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b025",
    "text": "baseline and Week 4; all but 2 patients, both in the Parkinson’s Disease",
    "bbox": [
      90.0,
      384.8,
      474.1,
      398.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b026",
    "text": "Dementia group, completed  their evaluations.",
    "bbox": [
      90.0,
      398.6,
      341.5,
      412.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b027",
    "text": "The results of this study have been interpreted as demonstrating the following:",
    "bbox": [
      90.0,
      426.2,
      508.9,
      439.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b028",
    "text": "That the ADAS-Cog score can differentiate between dementia associated with",
    "bbox": [
      126.0,
      453.8,
      508.7,
      466.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b029",
    "text": "Parkinson’s Disease of mild and moderate severities, as can the scores for",
    "bbox": [
      126.0,
      466.5,
      492.7,
      478.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b030",
    "text": "several of the other instruments evaluated in this study",
    "bbox": [
      126.0,
      479.1,
      395.1,
      491.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b031",
    "text": "That the ADAS-Cog and several other efficacy measures had test-retest",
    "bbox": [
      126.0,
      491.8,
      479.4,
      504.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b032",
    "text": "reliability in dementia associated with Parkinson’s Disease",
    "bbox": [
      126.0,
      504.4,
      412.7,
      516.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b033",
    "text": "That the ADAS-Cog scores correlated with those of several other efficacy",
    "bbox": [
      126.0,
      517.1,
      485.5,
      529.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b034",
    "text": "instruments in dementia associated with Parkinson’s Disease, whether the latter",
    "bbox": [
      126.0,
      529.7,
      517.9,
      542.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b035",
    "text": "measures assessed cognition or other domains",
    "bbox": [
      126.0,
      542.4,
      359.5,
      554.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b036",
    "text": "A factor analysis that compared populations with Parkinson’s Disease Dementia",
    "bbox": [
      126.0,
      555.0,
      517.9,
      567.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b037",
    "text": "and Alzheimer’s Disease on ADAS-Cog sub-item scores had indicated that the",
    "bbox": [
      126.0,
      567.7,
      511.2,
      579.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b038",
    "text": "sub-items grouped differently in each  population, suggesting that the cognitive",
    "bbox": [
      126.0,
      580.3,
      511.8,
      592.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b039",
    "text": "and behavioral profiles in these populations might differ",
    "bbox": [
      126.0,
      592.9,
      398.1,
      605.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b040",
    "text": "Conclusions",
    "bbox": [
      90.0,
      625.4,
      165.3,
      638.8
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b041",
    "text": "Deferred, pending discussion of this application at a scheduled meeting of the",
    "bbox": [
      90.0,
      642.2,
      505.6,
      655.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 6,
    "block_id": "1055_p6_b042",
    "text": "Peripheral and Central Nervous Systems Drugs Advisory Committee",
    "bbox": [
      90.0,
      656.0,
      456.9,
      669.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b002",
    "text": "Page 7 of 93",
    "bbox": [
      464.2,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b005",
    "text": "1. Background",
    "bbox": [
      90.0,
      98.2,
      194.4,
      113.8
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b006",
    "text": "This submission, a Supplemental New Drug Application, seeks the approval of",
    "bbox": [
      90.0,
      117.1,
      508.8,
      130.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b007",
    "text": "Exelon® (rivastigmine tartrate) for the treatment of “mild to moderate dementia",
    "bbox": [
      90.0,
      130.9,
      509.7,
      144.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b008",
    "text": "associated with Parkinson’s Disease.”",
    "bbox": [
      90.0,
      144.7,
      298.1,
      158.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b009",
    "text": "The data supporting this application are stated to be derived entirely from the",
    "bbox": [
      90.0,
      172.3,
      501.5,
      185.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b010",
    "text": "results of the EXPRESS (“Rivastigmine for Dementia Associated with",
    "bbox": [
      90.0,
      186.1,
      460.8,
      199.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b011",
    "text": "Parkinson’s Disease”) Study, also referred to as Study 2311. An open-label",
    "bbox": [
      90.0,
      199.9,
      492.2,
      213.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b012",
    "text": "uncontrolled extension to that Study 2311, designated as Study 2311E1 has also",
    "bbox": [
      90.0,
      213.7,
      522.3,
      227.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b013",
    "text": "bee completed.",
    "bbox": [
      90.0,
      227.5,
      175.4,
      240.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b014",
    "text": "A meeting to discuss this submission and the results of the EXPRESS Study was",
    "bbox": [
      90.0,
      255.1,
      523.5,
      268.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b015",
    "text": "held between the Division and sponsor on May 18, 2005, and is summarized",
    "bbox": [
      90.0,
      268.9,
      499.6,
      282.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b016",
    "text": "later in this review.",
    "bbox": [
      90.0,
      282.7,
      199.5,
      296.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b017",
    "text": "Exelon® (rivastigmine tartrate) is an acetylcholinesterase inhibitor drug approved",
    "bbox": [
      90.0,
      310.0,
      523.0,
      324.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b018",
    "text": "by this Agency on April 21, 2000, for the treatment of mild to moderate dementia",
    "bbox": [
      90.0,
      325.0,
      518.9,
      338.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b019",
    "text": "of the Alzheimer’s type, as immediate-release capsule and oral solution",
    "bbox": [
      90.0,
      338.8,
      472.1,
      352.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b020",
    "text": "formulations. Please refer to the primary reviews of NDAs #s 20823 (for the",
    "bbox": [
      90.0,
      352.6,
      492.9,
      366.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b021",
    "text": "immediate-release capsule formulation) and 21025 (for the oral solution",
    "bbox": [
      90.0,
      366.4,
      472.8,
      379.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b022",
    "text": "formulation) for full details.",
    "bbox": [
      90.0,
      380.2,
      234.0,
      393.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b023",
    "text": "In this review, the terms “Exelon®” and “rivastigmine” are used interchangeably.",
    "bbox": [
      90.0,
      407.8,
      517.0,
      421.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b024",
    "text": "Also note that “dementia associated with Parkinson’s Disease” is also referred to,",
    "bbox": [
      90.0,
      421.6,
      524.3,
      435.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b025",
    "text": "apparently interchangeably, as Parkinson’s Disease Dementia (PDD) in the",
    "bbox": [
      90.0,
      435.4,
      493.0,
      448.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b026",
    "text": "sponsor’s submission.",
    "bbox": [
      90.0,
      449.2,
      211.4,
      462.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b027",
    "text": "The Biometrics Reviewer of this submission is Dr Juan (Joanne) Zhang.",
    "bbox": [
      90.0,
      476.8,
      474.1,
      490.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b028",
    "text": "2. Contents Of Submission",
    "bbox": [
      90.0,
      516.6,
      275.7,
      532.2
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b029",
    "text": "This submission has been provided in accordance, as per the sponsor, with the",
    "bbox": [
      90.0,
      535.5,
      513.6,
      548.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b030",
    "text": "guidance for industry entitled Providing Regulatory Submissions In Electronic",
    "bbox": [
      90.0,
      549.3,
      502.2,
      562.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b031",
    "text": "Format-NDAs (January 1999)",
    "bbox": [
      90.0,
      563.1,
      250.7,
      576.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b032",
    "text": "The key items in this application are:",
    "bbox": [
      90.0,
      590.7,
      290.8,
      604.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b033",
    "text": "• Cover letter",
    "bbox": [
      108.0,
      617.9,
      191.4,
      632.6
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b034",
    "text": "• Proposed product labeling",
    "bbox": [
      108.0,
      646.3,
      268.7,
      661.0
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b035",
    "text": "• Application summary",
    "bbox": [
      108.0,
      674.8,
      240.8,
      689.4
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 7,
    "block_id": "1055_p7_b036",
    "text": "• Clinical and statistical section, containing the following:",
    "bbox": [
      108.0,
      703.1,
      423.6,
      717.8
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b002",
    "text": "Page 8 of 93",
    "bbox": [
      464.2,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b005",
    "text": "Tabular listing of all clinical study reports",
    "bbox": [
      162.0,
      86.1,
      362.5,
      98.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b006",
    "text": "Reports of efficacy and safety studies: Study 2311 and Study 2311E1",
    "bbox": [
      162.0,
      98.7,
      503.2,
      111.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b007",
    "text": "Report of Study 2314 (non-interventional validation study)",
    "bbox": [
      162.0,
      111.4,
      445.6,
      123.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b008",
    "text": "Publication references",
    "bbox": [
      162.0,
      124.0,
      273.9,
      136.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b009",
    "text": "Tables for Summary of Clinical Safety",
    "bbox": [
      162.0,
      136.6,
      349.0,
      148.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b010",
    "text": "Tables and appendices for Summary of Clinical Efficacy",
    "bbox": [
      162.0,
      149.3,
      437.1,
      161.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b011",
    "text": "• Case Report Tabulations",
    "bbox": [
      108.0,
      175.4,
      262.1,
      190.1
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b012",
    "text": "• Case Report Forms",
    "bbox": [
      108.0,
      203.8,
      234.1,
      218.4
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b013",
    "text": "• Patent Information",
    "bbox": [
      108.0,
      232.2,
      227.4,
      246.9
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b014",
    "text": "• Debarment Certification",
    "bbox": [
      108.0,
      260.6,
      255.3,
      275.3
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b015",
    "text": "• Use Fee Cover Sheet",
    "bbox": [
      108.0,
      289.0,
      244.7,
      303.7
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b016",
    "text": "• Financial Disclosure Information",
    "bbox": [
      108.0,
      317.4,
      300.0,
      332.1
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b017",
    "text": "• Confidentiality Statement",
    "bbox": [
      108.0,
      345.8,
      262.8,
      360.5
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b018",
    "text": "3. Contents Of Review",
    "bbox": [
      90.0,
      386.8,
      244.6,
      402.4
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b019",
    "text": "The contents of this submission will be addressed under the following principal",
    "bbox": [
      90.0,
      405.7,
      509.5,
      419.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b020",
    "text": "headings and in the same order as below",
    "bbox": [
      90.0,
      419.5,
      312.8,
      432.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b021",
    "text": "Key diagnostic instruments used in efficacy study (Study 2311)",
    "bbox": [
      126.0,
      447.1,
      437.8,
      459.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b022",
    "text": "Efficacy outcome measures and selected additional instruments used in efficacy",
    "bbox": [
      126.0,
      459.7,
      518.7,
      472.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b023",
    "text": "study",
    "bbox": [
      126.0,
      472.4,
      155.3,
      484.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b024",
    "text": "Summary of efficacy study",
    "bbox": [
      126.0,
      485.1,
      261.1,
      497.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b025",
    "text": "Description of efficacy study",
    "bbox": [
      126.0,
      497.7,
      266.0,
      509.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b026",
    "text": "Study 2311E1 (open-label uncontrolled extension to Study 2311)",
    "bbox": [
      126.0,
      510.3,
      444.0,
      522.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b027",
    "text": "Study 2314 (non-interventional validation study)",
    "bbox": [
      126.0,
      523.0,
      361.3,
      535.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b028",
    "text": "Summary of earlier meeting between Division and sponsor regarding this",
    "bbox": [
      126.0,
      535.6,
      483.7,
      547.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b029",
    "text": "application",
    "bbox": [
      126.0,
      548.3,
      181.7,
      560.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b030",
    "text": "Sponsor’s current view of dementia associated with Parkinson’s Disease, and",
    "bbox": [
      126.0,
      561.0,
      506.3,
      573.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b031",
    "text": "appropriateness of ADAS-Cog and ADCS-ADL for evaluating treatment effects in",
    "bbox": [
      126.0,
      573.6,
      522.8,
      585.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b032",
    "text": "dementia associated with Parkinson’s Disease",
    "bbox": [
      126.0,
      586.2,
      355.3,
      598.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b033",
    "text": "Financial disclosure certification",
    "bbox": [
      126.0,
      598.9,
      284.4,
      611.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b034",
    "text": "Site inspection report",
    "bbox": [
      126.0,
      611.5,
      232.4,
      623.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b035",
    "text": "Review of proposed labeling",
    "bbox": [
      126.0,
      624.2,
      267.3,
      636.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b036",
    "text": "Comments",
    "bbox": [
      126.0,
      636.8,
      182.2,
      649.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b037",
    "text": "Conclusion",
    "bbox": [
      126.0,
      649.5,
      183.5,
      661.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 8,
    "block_id": "1055_p8_b038",
    "text": "Recommendation",
    "bbox": [
      126.0,
      662.1,
      215.3,
      674.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b002",
    "text": "Page 9 of 93",
    "bbox": [
      464.2,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b005",
    "text": "4. Key Diagnostic Instruments Used in Efficacy Study (Study",
    "bbox": [
      90.0,
      72.4,
      499.2,
      88.0
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b006",
    "text": "2311)",
    "bbox": [
      90.0,
      88.5,
      129.0,
      104.1
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b007",
    "text": "The criteria for 2 diagnostic instruments used in the efficacy study are listed",
    "bbox": [
      90.0,
      107.5,
      493.4,
      120.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b008",
    "text": "below:",
    "bbox": [
      90.0,
      121.3,
      128.0,
      134.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b009",
    "text": "4.1 UK Parkinson’s Disease Society Brain Bank Clinical Diagnostic Criteria",
    "bbox": [
      90.0,
      154.9,
      523.4,
      168.3
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b010",
    "text": "For Parkinson’s Disease",
    "bbox": [
      90.0,
      168.7,
      232.7,
      182.1
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b011",
    "text": "Step 1 Diagnosis of Parkinsonian syndrome",
    "bbox": [
      90.0,
      199.0,
      298.4,
      212.8
    ],
    "font_size": 12.0,
    "font_name": "ArialNarrow-Bold",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b012",
    "text": " Bradykinesia (slowness of initiation of voluntary movement with progressive reduction in",
    "bbox": [
      108.0,
      212.8,
      511.1,
      226.5
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b013",
    "text": "speed and amplitude of repetitive actions)",
    "bbox": [
      126.0,
      226.5,
      310.9,
      240.3
    ],
    "font_size": 12.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b014",
    "text": " And at least one of the following:",
    "bbox": [
      108.0,
      254.0,
      271.0,
      267.8
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b015",
    "text": "o Muscular rigidity",
    "bbox": [
      144.0,
      281.6,
      229.7,
      295.1
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b016",
    "text": "o 4-6 Hz rest tremor",
    "bbox": [
      144.0,
      294.2,
      237.1,
      307.8
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b017",
    "text": "o Postural instability not caused by primary visual, vestibular, cerebellar, or proprioceptive",
    "bbox": [
      144.0,
      306.8,
      514.4,
      320.4
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b018",
    "text": "dysfunction.",
    "bbox": [
      162.0,
      319.5,
      212.6,
      332.1
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b019",
    "text": "Step 2 Exclusion criteria for Parkinson’s disease",
    "bbox": [
      90.0,
      345.8,
      320.2,
      359.6
    ],
    "font_size": 12.0,
    "font_name": "ArialNarrow-Bold",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b020",
    "text": " History of repeated strokes with stepwise progression of parkinsonian features",
    "bbox": [
      108.0,
      359.6,
      469.6,
      373.4
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b021",
    "text": " History of repeated head injury",
    "bbox": [
      108.0,
      373.4,
      262.7,
      387.1
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b022",
    "text": " History of definite encephalitis",
    "bbox": [
      108.0,
      387.2,
      259.5,
      400.9
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b023",
    "text": " Oculogyric crises",
    "bbox": [
      108.0,
      400.9,
      203.6,
      414.7
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b024",
    "text": " Neuroleptic treatment at onset of symptoms",
    "bbox": [
      108.0,
      414.7,
      319.2,
      428.5
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b025",
    "text": " Sustained remission",
    "bbox": [
      108.0,
      428.5,
      217.3,
      442.2
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b026",
    "text": " Strictly unilateral features after 3 years",
    "bbox": [
      108.0,
      442.3,
      296.8,
      456.0
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b027",
    "text": " Supranuclear gaze palsy",
    "bbox": [
      108.0,
      456.0,
      237.0,
      469.8
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b028",
    "text": " Cerebellar signs",
    "bbox": [
      108.0,
      469.8,
      199.8,
      483.6
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b029",
    "text": " Early severe autonomic involvement",
    "bbox": [
      108.0,
      483.5,
      286.8,
      497.3
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b030",
    "text": " Early severe dementia with disturbances of memory, language, and praxis",
    "bbox": [
      108.0,
      497.3,
      451.5,
      511.1
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b031",
    "text": " Babinski sign",
    "bbox": [
      108.0,
      511.1,
      186.7,
      524.8
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b032",
    "text": " Presence of cerebral tumor or communicating hydrocephalus on CT scan",
    "bbox": [
      108.0,
      524.9,
      447.6,
      538.6
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b033",
    "text": " Negative response to large doses of levodopa (if malabsorption excluded)",
    "bbox": [
      108.0,
      538.6,
      449.8,
      552.4
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b034",
    "text": " MPTP exposure",
    "bbox": [
      108.0,
      552.4,
      199.3,
      566.2
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b035",
    "text": "Step 3 Supportive prospective positive criteria for Parkinson’s disease",
    "bbox": [
      90.0,
      580.0,
      423.1,
      593.7
    ],
    "font_size": 12.0,
    "font_name": "ArialNarrow-Bold",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b036",
    "text": "(Three or more required for diagnosis of definite Parkinson’s disease)",
    "bbox": [
      90.0,
      593.7,
      419.2,
      607.5
    ],
    "font_size": 12.0,
    "font_name": "ArialNarrow-Bold",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b037",
    "text": " Unilateral onset",
    "bbox": [
      108.0,
      607.5,
      197.1,
      621.3
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b038",
    "text": " Rest tremor present",
    "bbox": [
      108.0,
      621.2,
      215.7,
      635.0
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b039",
    "text": " Progressive disorder",
    "bbox": [
      108.0,
      635.0,
      219.0,
      648.8
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b040",
    "text": " Persistent asymmetry affecting side of onset most",
    "bbox": [
      108.0,
      648.8,
      345.9,
      662.5
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b041",
    "text": " Excellent response (70-100%) to levodopa",
    "bbox": [
      108.0,
      662.6,
      314.2,
      676.3
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b042",
    "text": " Severe levodopa-induced chorea",
    "bbox": [
      108.0,
      676.3,
      273.1,
      690.1
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b043",
    "text": " Levodopa response for 5 years or more",
    "bbox": [
      108.0,
      690.1,
      301.1,
      703.9
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 9,
    "block_id": "1055_p9_b044",
    "text": " Clinical course of 10 years or more",
    "bbox": [
      108.0,
      703.9,
      280.9,
      717.6
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b002",
    "text": "Page 10 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b005",
    "text": "4.2 DSM-IV Criteria For Dementia Due To Parkinson’s Disease",
    "bbox": [
      90.0,
      92.1,
      448.6,
      105.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b006",
    "text": "294.1    Dementia Due To Parkinson’s Disease",
    "bbox": [
      90.0,
      108.6,
      262.7,
      120.1
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b007",
    "text": "The essential feature of Dementia Due To Parkinson’s Disease is the presence of dementia that is judged to be of",
    "bbox": [
      90.0,
      131.5,
      504.8,
      143.0
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b008",
    "text": "direct pathophysiological consequence of Parkinson’s disease. Parkinson’s disease is a slowly progressive",
    "bbox": [
      90.0,
      143.0,
      479.1,
      154.5
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b009",
    "text": "neurological condition, characterized by tremor, rigidity, bradykinesia, and postural instability. Dementia has been",
    "bbox": [
      90.0,
      154.5,
      502.5,
      166.0
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b010",
    "text": "reported to occur in approximately 20%-60% of individuals with Parkinson’s disease and is more likely to be present in",
    "bbox": [
      90.0,
      166.0,
      520.2,
      177.4
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b011",
    "text": "older individuals or in those with more severe or advanced disease. The dementia associated with Parkinson’s disease",
    "bbox": [
      90.0,
      177.4,
      522.5,
      188.9
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b012",
    "text": "is characterized by cognitive and motor slowing, executive dysfunction and impairment in memory retrieval. Declining",
    "bbox": [
      90.0,
      188.9,
      516.1,
      200.4
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b013",
    "text": "cognitive performance in individuals with Parkinson’s disease is frequently exacerbated by depression. Findings on",
    "bbox": [
      90.0,
      200.4,
      508.3,
      211.9
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b014",
    "text": "physical examination include the characteristic abnormal motor signs of resting tremor, evidence of slowness and",
    "bbox": [
      90.0,
      211.9,
      502.3,
      223.4
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b015",
    "text": "poverty of movement (such as micrographia), or muscular rigidity and loss of associated movements. At autopsy,",
    "bbox": [
      90.0,
      223.3,
      501.5,
      234.8
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b016",
    "text": "neuronal loss and Lewy bodies are evident in the substantia nigra. There are a number of syndromes that manifest",
    "bbox": [
      90.0,
      234.9,
      508.1,
      246.3
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b017",
    "text": "with dementia, Parkinsonian movement disorders, and additional neurological features (e.g., progressive supranuclear",
    "bbox": [
      90.0,
      246.3,
      520.7,
      257.8
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b018",
    "text": "palsy, olivopontocerebellar degeneration, and Vascular Dementia). Some individuals with Parkinson’s disease and",
    "bbox": [
      90.0,
      257.8,
      506.5,
      269.3
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b019",
    "text": "dementia are found at autopsy to have coexisting neuropathology indicative of Alzheimer’s disease or of diffuse Lewy",
    "bbox": [
      90.0,
      269.2,
      517.1,
      280.7
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b020",
    "text": "body disease.",
    "bbox": [
      90.0,
      280.8,
      142.8,
      292.3
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b021",
    "text": "5. Efficacy Outcome Measures And Selected Additional",
    "bbox": [
      90.0,
      318.4,
      463.5,
      334.0
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b022",
    "text": "Instruments Used In Efficacy Study",
    "bbox": [
      90.0,
      334.5,
      328.3,
      350.1
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b023",
    "text": "These instruments are outlined below:",
    "bbox": [
      90.0,
      353.4,
      295.9,
      366.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b024",
    "text": "5.1 Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-",
    "bbox": [
      90.0,
      387.1,
      507.9,
      400.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b025",
    "text": "Cog)",
    "bbox": [
      90.0,
      400.9,
      120.6,
      414.3
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b026",
    "text": "This is a validated instrument  consisting of the following 11 items: Word Recall",
    "bbox": [
      90.0,
      417.6,
      512.8,
      431.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b027",
    "text": "Task, Naming Fingers and Objects, Orientation Questions, Constructional Praxis",
    "bbox": [
      90.0,
      431.4,
      520.7,
      444.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b028",
    "text": "Task, Following Commands, Ideational Praxis Task, Word Recognition Task,",
    "bbox": [
      90.0,
      445.2,
      500.8,
      458.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b029",
    "text": "Rating of Spoken Language, Rating of Language Comprehension, Rating of",
    "bbox": [
      90.0,
      459.0,
      496.3,
      472.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b030",
    "text": "Word Finding Difficulty and Rating of Ability to Recall Test Instructions. The total",
    "bbox": [
      90.0,
      472.8,
      518.3,
      486.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b031",
    "text": "scores range from 0-70 with higher scores indicating greater cognitive",
    "bbox": [
      90.0,
      486.6,
      463.5,
      500.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b032",
    "text": "impairment.",
    "bbox": [
      90.0,
      500.4,
      156.1,
      513.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b033",
    "text": "5.2 Alzheimer’s Disease Cooperative Study – Clinician’s Global Impression",
    "bbox": [
      90.0,
      534.1,
      523.9,
      547.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b034",
    "text": "Of Change (ADCS-CGIC)",
    "bbox": [
      90.0,
      547.9,
      233.4,
      561.3
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b035",
    "text": "This instrument provides for a rating of overall (global) change from baseline by",
    "bbox": [
      90.0,
      564.6,
      514.2,
      578.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b036",
    "text": "an independent clinician experienced in the assessment of patients with",
    "bbox": [
      90.0,
      578.4,
      474.3,
      591.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b037",
    "text": "dementia. The term “independent” implies that the rater is not to be involved in",
    "bbox": [
      90.0,
      592.2,
      509.0,
      605.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b038",
    "text": "any additional manner in the evaluation and/or treatment of patients enrolled in",
    "bbox": [
      90.0,
      606.0,
      511.0,
      619.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b039",
    "text": "this study",
    "bbox": [
      90.0,
      619.8,
      144.1,
      633.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b040",
    "text": "Assessments will be performed at baseline and at subsequent visits. It is",
    "bbox": [
      90.0,
      647.4,
      478.3,
      660.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b041",
    "text": "recommended that the baseline interview be conducted by 2 independent raters,",
    "bbox": [
      90.0,
      661.2,
      520.3,
      674.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b042",
    "text": "one designated as the primary rater and the other as a backup. Post-baseline",
    "bbox": [
      90.0,
      675.0,
      504.3,
      688.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b043",
    "text": "ratings are to be conducted solely by the primary rater or, in his/her absence, by",
    "bbox": [
      90.0,
      688.8,
      517.7,
      702.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 10,
    "block_id": "1055_p10_b044",
    "text": "the back-up rater.",
    "bbox": [
      90.0,
      702.6,
      194.2,
      716.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b002",
    "text": "Page 11 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b005",
    "text": "At baseline both raters will have access to all of the patients’ available records",
    "bbox": [
      90.0,
      86.0,
      507.5,
      99.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b006",
    "text": "and evaluations. At all subsequent visits, the rater is to rely (for baseline data)",
    "bbox": [
      90.0,
      99.8,
      505.6,
      113.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b007",
    "text": "solely upon information obtained during the baseline assessment of the patient",
    "bbox": [
      90.0,
      113.6,
      511.0,
      127.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b008",
    "text": "and caregiver by that rater (including written notes and, if available, the baseline",
    "bbox": [
      90.0,
      127.4,
      517.6,
      140.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b009",
    "text": "interview audiotape or videotape). At post-baseline visits, data obtained directly",
    "bbox": [
      90.0,
      141.2,
      513.6,
      154.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b010",
    "text": "from the patient may be supplemented by that obtained from the caregiver. The",
    "bbox": [
      90.0,
      155.0,
      514.3,
      168.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b011",
    "text": "rater will not have access to other safety or efficacy data, including all previous",
    "bbox": [
      90.0,
      168.8,
      510.2,
      182.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b012",
    "text": "post-baseline ADCS-CGIC ratings by either rater.",
    "bbox": [
      90.0,
      182.6,
      362.2,
      196.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b013",
    "text": "A standard 7-point categorical rating scale and its dichotomized version will both",
    "bbox": [
      90.0,
      210.2,
      518.8,
      223.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b014",
    "text": "be used for rating and are further described below:",
    "bbox": [
      90.0,
      224.0,
      362.1,
      237.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b015",
    "text": "The 7-point categorical scale is as follows:",
    "bbox": [
      126.0,
      252.4,
      335.1,
      264.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b016",
    "text": "Change",
    "bbox": [
      131.4,
      278.1,
      166.9,
      288.1
    ],
    "font_size": 9.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b017",
    "text": "Rating",
    "bbox": [
      251.4,
      278.1,
      281.9,
      288.1
    ],
    "font_size": 9.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b018",
    "text": "Marked improvement",
    "bbox": [
      131.4,
      288.9,
      208.7,
      297.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b019",
    "text": "Moderate improvement",
    "bbox": [
      131.4,
      298.6,
      215.8,
      307.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b020",
    "text": "Minimal improvement",
    "bbox": [
      131.4,
      308.3,
      209.6,
      317.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b021",
    "text": "No change",
    "bbox": [
      131.4,
      318.0,
      172.2,
      326.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b022",
    "text": "Minimal worsening",
    "bbox": [
      131.4,
      327.7,
      199.8,
      336.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b023",
    "text": "Moderate worsening",
    "bbox": [
      131.4,
      337.4,
      206.1,
      346.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b024",
    "text": "Marked worsening",
    "bbox": [
      131.4,
      347.1,
      198.9,
      356.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b025",
    "text": "The dichotomized version of the 7-point categorical scale is derived as follows",
    "bbox": [
      126.0,
      366.9,
      508.1,
      379.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b026",
    "text": "Rating On 7-Point Scale",
    "bbox": [
      131.4,
      392.5,
      236.0,
      402.6
    ],
    "font_size": 9.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b027",
    "text": "Rating On Dichotomized Scale",
    "bbox": [
      257.4,
      392.5,
      390.5,
      402.6
    ],
    "font_size": 9.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b028",
    "text": "1, 2, or 3",
    "bbox": [
      131.4,
      403.4,
      165.1,
      412.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b029",
    "text": "4, 5, 6, or 7",
    "bbox": [
      131.4,
      413.1,
      174.0,
      422.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b030",
    "text": "The format for assessment is semi-structured with a guideline provided for",
    "bbox": [
      90.0,
      435.5,
      486.7,
      448.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b031",
    "text": "assessing the global impression of change based on ratings of change for the",
    "bbox": [
      90.0,
      449.3,
      504.8,
      462.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b032",
    "text": "following individual domains: cognition, behavior, and function.",
    "bbox": [
      90.0,
      463.1,
      424.8,
      476.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b033",
    "text": "A semi-structured format for assessing the severity of disease at baseline has",
    "bbox": [
      90.0,
      490.7,
      505.5,
      504.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b034",
    "text": "also been used, again with a guideline provided for assessing the global",
    "bbox": [
      90.0,
      504.5,
      475.5,
      517.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b035",
    "text": "impression of severity based on ratings of change for the following individual",
    "bbox": [
      90.0,
      518.3,
      498.2,
      531.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b036",
    "text": "domains: cognition, behavior, and function.",
    "bbox": [
      90.0,
      532.1,
      321.6,
      545.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b037",
    "text": "5.3 Alzheimer’s Disease Cooperative Study – Activities Of Daily Living",
    "bbox": [
      90.0,
      565.8,
      496.6,
      579.2
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b038",
    "text": "Scale (ADCS-ADL)",
    "bbox": [
      90.0,
      579.6,
      198.6,
      593.0
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b039",
    "text": "This is a rating scale used to assess basic and instrumental activities of daily",
    "bbox": [
      90.0,
      596.3,
      500.4,
      609.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b040",
    "text": "living.  23 items are rated by the investigator using information supplied by the",
    "bbox": [
      90.0,
      610.1,
      506.8,
      623.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b041",
    "text": "caregiver. The maximum total score is 78. Higher scores indicate better function.",
    "bbox": [
      90.0,
      623.9,
      520.9,
      637.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b042",
    "text": "5.4 Cognitive Drug Research Computerized Assessment System",
    "bbox": [
      90.0,
      657.6,
      463.9,
      671.0
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b043",
    "text": "This is a computer-based system for assessing cognitive function. A series of",
    "bbox": [
      90.0,
      674.3,
      502.9,
      687.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 11,
    "block_id": "1055_p11_b044",
    "text": "tasks is used to assess each of several specific functions as indicated in the",
    "bbox": [
      90.0,
      688.1,
      496.2,
      701.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b002",
    "text": "Page 12 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b005",
    "text": "table below. Only Level I (Attention) is assessed in the study contained in this",
    "bbox": [
      90.0,
      72.2,
      503.6,
      85.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b006",
    "text": "submission.",
    "bbox": [
      90.0,
      86.0,
      156.7,
      99.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b007",
    "text": "Level",
    "bbox": [
      90.0,
      128.0,
      118.8,
      139.3
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b008",
    "text": "Function Assessed",
    "bbox": [
      132.8,
      128.0,
      218.0,
      139.3
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b009",
    "text": "Tests",
    "bbox": [
      288.3,
      128.0,
      315.4,
      139.3
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b010",
    "text": "Level I",
    "bbox": [
      90.0,
      140.1,
      115.8,
      149.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b011",
    "text": "Attention",
    "bbox": [
      132.8,
      140.1,
      166.6,
      149.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b012",
    "text": "Simple Reaction Time",
    "bbox": [
      288.4,
      140.1,
      368.8,
      149.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b013",
    "text": "Choice Reaction Time",
    "bbox": [
      288.4,
      149.4,
      369.3,
      158.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b014",
    "text": "Digit Vigilance",
    "bbox": [
      288.4,
      158.6,
      341.4,
      167.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b015",
    "text": "Level II",
    "bbox": [
      90.0,
      168.5,
      118.0,
      177.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b016",
    "text": "Short-Term or Working Memory",
    "bbox": [
      132.8,
      168.5,
      247.5,
      177.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b017",
    "text": "Numeric Working Memory",
    "bbox": [
      288.4,
      168.5,
      383.1,
      177.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b018",
    "text": "Spatial Working Memory",
    "bbox": [
      288.4,
      177.7,
      377.7,
      186.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b019",
    "text": "Level III",
    "bbox": [
      90.0,
      187.7,
      120.2,
      196.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b020",
    "text": "Long-Term or Episodic Secondary",
    "bbox": [
      132.8,
      187.7,
      256.4,
      196.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b021",
    "text": "Memory",
    "bbox": [
      132.8,
      196.8,
      163.9,
      205.7
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b022",
    "text": "Word Recall",
    "bbox": [
      288.4,
      187.7,
      334.2,
      196.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b023",
    "text": "Word Recognition",
    "bbox": [
      288.4,
      196.8,
      354.2,
      205.7
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b024",
    "text": "Picture Recognition",
    "bbox": [
      288.4,
      206.1,
      360.0,
      215.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b025",
    "text": "Face Recognition",
    "bbox": [
      288.4,
      215.3,
      352.8,
      224.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b026",
    "text": "Level IV",
    "bbox": [
      90.0,
      225.2,
      121.1,
      234.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b027",
    "text": "Motor Control",
    "bbox": [
      132.8,
      225.2,
      183.5,
      234.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b028",
    "text": "Tracking",
    "bbox": [
      288.4,
      225.2,
      321.3,
      234.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b029",
    "text": "Postural Stability",
    "bbox": [
      288.4,
      234.4,
      350.2,
      243.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b030",
    "text": "Other",
    "bbox": [
      90.0,
      245.7,
      112.2,
      254.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b031",
    "text": "Miscellaneous Functions",
    "bbox": [
      132.9,
      245.7,
      222.6,
      254.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b032",
    "text": "Rapid Visual Information",
    "bbox": [
      288.4,
      245.7,
      377.7,
      254.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b033",
    "text": "Processing",
    "bbox": [
      288.4,
      254.9,
      330.2,
      263.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b034",
    "text": "Logical Reasoning",
    "bbox": [
      288.4,
      264.1,
      356.5,
      273.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b035",
    "text": "Tapping Rates",
    "bbox": [
      288.4,
      273.3,
      342.6,
      282.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b036",
    "text": "Critical Flicker Fusion Frequency",
    "bbox": [
      288.4,
      282.5,
      407.1,
      291.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b037",
    "text": "Digit Symbol Substitution Task",
    "bbox": [
      288.4,
      291.7,
      399.2,
      300.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b038",
    "text": "Pencil and Paper Procedures",
    "bbox": [
      288.4,
      300.9,
      394.6,
      309.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b039",
    "text": "Visual Analogue Scales",
    "bbox": [
      288.4,
      310.1,
      374.7,
      319.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b040",
    "text": "A description of each of the tests at Level I is presented below",
    "bbox": [
      90.0,
      333.9,
      422.8,
      347.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b041",
    "text": "Test",
    "bbox": [
      90.0,
      361.8,
      112.2,
      373.0
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b042",
    "text": "Description",
    "bbox": [
      203.4,
      361.8,
      256.2,
      373.0
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b043",
    "text": "Simple Reaction Time",
    "bbox": [
      90.0,
      384.9,
      170.4,
      393.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b044",
    "text": "The patient is asked to press the “YES” response button as quickly as possible every time",
    "bbox": [
      203.4,
      384.9,
      522.9,
      393.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b045",
    "text": "the word “YES” is presented on the monitor",
    "bbox": [
      203.4,
      394.2,
      358.9,
      403.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b046",
    "text": "Digit Vigilance Task",
    "bbox": [
      90.0,
      413.1,
      162.4,
      422.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b047",
    "text": "A target digit is randomly selected and constantly displayed to the right of the monitor",
    "bbox": [
      203.3,
      413.1,
      506.5,
      422.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b048",
    "text": "screen. A series of digits is presented in the center of the screen at the rate of 80 per",
    "bbox": [
      203.4,
      422.3,
      505.2,
      431.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b049",
    "text": "minute and the patient is required to press the “YES” button every time the digit in the",
    "bbox": [
      203.4,
      431.4,
      507.5,
      440.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b050",
    "text": "series matches the target digit",
    "bbox": [
      203.4,
      440.7,
      312.3,
      449.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b051",
    "text": "Choice Reaction Time",
    "bbox": [
      90.0,
      459.6,
      170.8,
      468.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b052",
    "text": "Either the word “NO” or the word “YES” is presented on the monitor and the patient is",
    "bbox": [
      203.3,
      459.6,
      507.0,
      468.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b053",
    "text": "instructed to press the corresponding button as quickly as possible",
    "bbox": [
      203.4,
      468.8,
      443.5,
      477.7
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b054",
    "text": "5.5 Delis-Kaplan Executive Functioning System (D-KEFS) Test Battery",
    "bbox": [
      90.0,
      507.6,
      496.0,
      521.0
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b055",
    "text": "This test battery assesses verbal and non-verbal executive functions. 9 tests are",
    "bbox": [
      90.0,
      524.3,
      519.6,
      537.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b056",
    "text": "included in this battery; each test is intended to be used as either a stand-alone",
    "bbox": [
      90.0,
      538.1,
      514.2,
      551.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b057",
    "text": "instrument or in conjunction with other tests in the same battery. The tests are as",
    "bbox": [
      90.0,
      551.9,
      522.1,
      565.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b058",
    "text": "follows: Trail Making Test, Verbal Fluency Test, Design Fluency Test, Color-",
    "bbox": [
      90.0,
      565.7,
      494.3,
      579.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b059",
    "text": "Word Interference Test, Sorting Test (formerly called the California Card Sorting",
    "bbox": [
      90.0,
      579.5,
      517.4,
      592.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b060",
    "text": "Test), Twenty Questions Test, Word Context Test, Tower Test, and Proverb Test",
    "bbox": [
      90.0,
      593.3,
      522.2,
      606.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b061",
    "text": "(formerly called the California Proverb Test).",
    "bbox": [
      90.0,
      607.1,
      328.7,
      620.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b062",
    "text": "Only the Verbal Fluency Test from this battery was eventually used as a uniform",
    "bbox": [
      90.0,
      634.7,
      518.3,
      648.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b063",
    "text": "outcome measure for this study; only one condition of this test, letter fluency, was",
    "bbox": [
      90.0,
      648.5,
      525.0,
      661.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b064",
    "text": "used; here the patient was asked to generate as many words as possible for 3",
    "bbox": [
      90.0,
      662.3,
      508.3,
      675.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b065",
    "text": "different letters of the alphabet (“F,” “A,” and “S,”) with 60 seconds being allowed",
    "bbox": [
      90.0,
      676.1,
      520.2,
      689.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 12,
    "block_id": "1055_p12_b066",
    "text": "for each alphabet tested. 2 other tests, the Sorting Test and the Color-Word",
    "bbox": [
      90.0,
      689.9,
      494.2,
      703.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b002",
    "text": "Page 13 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b005",
    "text": "Interference Test were used at selected centers.  The main outcome variable for",
    "bbox": [
      90.0,
      72.2,
      518.9,
      85.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b006",
    "text": "each of these measures is listed below:",
    "bbox": [
      90.0,
      86.0,
      302.8,
      99.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b007",
    "text": "Test",
    "bbox": [
      95.4,
      114.0,
      116.4,
      124.1
    ],
    "font_size": 9.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b008",
    "text": "Main Outcome Variable",
    "bbox": [
      251.4,
      114.0,
      353.4,
      124.1
    ],
    "font_size": 9.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b009",
    "text": "D-KEFS Verbal Fluency Test",
    "bbox": [
      95.4,
      124.9,
      200.2,
      133.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b010",
    "text": "Number of correct responses",
    "bbox": [
      251.4,
      124.9,
      356.8,
      133.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b011",
    "text": "D-KEFS Sorting Test",
    "bbox": [
      95.4,
      134.6,
      172.3,
      143.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b012",
    "text": "Sort recognition description score",
    "bbox": [
      251.4,
      134.6,
      372.3,
      143.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b013",
    "text": "D-KEFS Color-Word Interference Test",
    "bbox": [
      95.4,
      144.3,
      232.8,
      153.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b014",
    "text": "Completion time adjusted for errors",
    "bbox": [
      251.5,
      144.3,
      378.5,
      153.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b015",
    "text": "5.6 Mini-Mental Status Examination",
    "bbox": [
      90.0,
      183.1,
      301.4,
      196.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b016",
    "text": "This is a validated multi-item instrument that examines orientation, registration,",
    "bbox": [
      90.0,
      199.9,
      510.8,
      213.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b017",
    "text": "attention, calculation, recall, visuospatial abilities and language. The maximum",
    "bbox": [
      90.0,
      213.7,
      509.5,
      227.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b018",
    "text": "score is 30, with higher scores indicating better cognitive function.",
    "bbox": [
      90.0,
      227.5,
      442.3,
      240.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b019",
    "text": "5.7 Neuropsychiatry Inventory",
    "bbox": [
      90.0,
      261.1,
      272.6,
      274.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b020",
    "text": "This is a validated instrument that assesses the following 12 domains",
    "bbox": [
      90.0,
      277.9,
      460.9,
      291.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b021",
    "text": "(subscales): delusions, hallucinations, agitation/aggression,",
    "bbox": [
      90.0,
      291.7,
      408.9,
      305.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b022",
    "text": "depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition,",
    "bbox": [
      90.0,
      305.5,
      524.9,
      318.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b023",
    "text": "irritability/lability, aberrant motor behavior, sleep/night-time behavior, and",
    "bbox": [
      90.0,
      319.3,
      479.5,
      332.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b024",
    "text": "appetite/eating changes . Each domain is rated according to its frequency (score",
    "bbox": [
      90.0,
      333.1,
      520.2,
      346.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b025",
    "text": "ranging from 1 to 4) and severity (score ranging from 1 to 3); rating is based on",
    "bbox": [
      90.0,
      346.9,
      512.3,
      360.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b026",
    "text": "interviewing a caregiver; if a symptom subsumed by a particular domain is",
    "bbox": [
      90.0,
      360.7,
      486.1,
      374.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b027",
    "text": "absent, it will receive a rating of 0. For each domain, the score is the product of",
    "bbox": [
      90.0,
      374.5,
      512.4,
      387.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b028",
    "text": "frequency and severity, with a maximum score of 12. The maximum total score",
    "bbox": [
      90.0,
      388.3,
      511.6,
      401.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b029",
    "text": "for the 12 domains (the sum of the subscale scores) is 144 with a higher score",
    "bbox": [
      90.0,
      402.1,
      508.9,
      415.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b030",
    "text": "indicating greater behavioral abnormality.",
    "bbox": [
      90.0,
      415.9,
      312.7,
      429.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b031",
    "text": "An earlier version of the Neuropsychiatry Inventory (Neuropsychiatry Inventory-",
    "bbox": [
      90.0,
      443.5,
      510.2,
      456.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b032",
    "text": "10), consisting of the first 10 items above, and with a maximum total score of 100",
    "bbox": [
      90.0,
      457.3,
      523.5,
      470.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b033",
    "text": "has also been used.",
    "bbox": [
      90.0,
      471.1,
      200.8,
      484.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b034",
    "text": "5.7.1 Neuropsychiatry Inventory – Distress",
    "bbox": [
      90.0,
      504.7,
      323.3,
      518.1
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b035",
    "text": "For each of the 12 items on the Neuropsychiatry Inventory, caregiver distress is",
    "bbox": [
      90.0,
      521.5,
      515.0,
      534.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b036",
    "text": "rated on a 5-point scale from 1 to 5, with higher scores indicating greater",
    "bbox": [
      90.0,
      535.3,
      478.2,
      548.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b037",
    "text": "distress.",
    "bbox": [
      90.0,
      549.1,
      138.0,
      562.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b038",
    "text": "5.8 Ten-Point Clock Test",
    "bbox": [
      90.0,
      582.7,
      236.6,
      596.1
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b039",
    "text": "This test is intended to measure executive functioning and visuospatial skills. The",
    "bbox": [
      90.0,
      599.5,
      524.8,
      612.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b040",
    "text": "subject is asked to insert the numbers on the face of the clock and when that",
    "bbox": [
      90.0,
      613.3,
      500.3,
      626.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b041",
    "text": "task is completed to insert the hands of the clock so as to indicate a time of ten",
    "bbox": [
      90.0,
      627.1,
      511.5,
      640.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b042",
    "text": "minutes past eleven o’clock. The maximum score on this task is 10, with lower",
    "bbox": [
      90.0,
      640.9,
      508.2,
      654.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 13,
    "block_id": "1055_p13_b043",
    "text": "scores indicating greater degrees of impairment",
    "bbox": [
      90.0,
      654.7,
      346.8,
      668.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b002",
    "text": "Page 14 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b005",
    "text": "5.9 Symbol-Digit Modalities Test",
    "bbox": [
      90.0,
      72.3,
      281.3,
      85.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b006",
    "text": "This test is intended to measure information processing speed and attention.",
    "bbox": [
      90.0,
      89.0,
      499.5,
      102.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b007",
    "text": "Subjects match numbers to symbols using a key; the symbols are printed and the",
    "bbox": [
      90.0,
      102.8,
      524.8,
      116.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b008",
    "text": "numbers written in by the subject. 110 items are to be filled in a period of 90",
    "bbox": [
      90.0,
      116.6,
      495.6,
      130.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b009",
    "text": "seconds.",
    "bbox": [
      90.0,
      130.4,
      141.4,
      143.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b010",
    "text": "5.10 Health Economic Parameters",
    "bbox": [
      90.0,
      164.1,
      289.9,
      177.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b011",
    "text": "These are to include the following",
    "bbox": [
      90.0,
      180.8,
      275.5,
      194.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b012",
    "text": "• Caregiver burden",
    "bbox": [
      108.0,
      208.1,
      222.0,
      222.8
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b013",
    "text": "• Caregiver productivity costs",
    "bbox": [
      108.0,
      222.7,
      276.8,
      237.3
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b014",
    "text": "• Caregiver and patient outpatient visits and hospitalizations",
    "bbox": [
      108.0,
      237.3,
      438.9,
      252.0
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b015",
    "text": "• Time to institutionalization",
    "bbox": [
      108.0,
      251.9,
      267.4,
      266.6
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b016",
    "text": "5.11 Unified Parkinson’s Disease Rating Scale (UPDRS)",
    "bbox": [
      90.0,
      286.7,
      413.2,
      300.1
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b017",
    "text": "This is a composite scale intended for rating patients with Parkinson’s Disease.",
    "bbox": [
      90.0,
      303.5,
      512.9,
      316.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b018",
    "text": "The scale is composed of 6 sections, each of which is rated categorically",
    "bbox": [
      90.0,
      317.3,
      479.5,
      330.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b019",
    "text": "Part",
    "bbox": [
      90.0,
      345.2,
      110.9,
      356.4
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b020",
    "text": "Functions assessed",
    "bbox": [
      144.9,
      345.2,
      234.1,
      356.4
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b021",
    "text": "Number Of Items Rated",
    "bbox": [
      338.4,
      345.2,
      443.6,
      356.4
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b022",
    "text": "Part I",
    "bbox": [
      90.0,
      357.3,
      113.5,
      366.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b023",
    "text": "Cognition, behavior and mood",
    "bbox": [
      144.9,
      357.3,
      253.8,
      366.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b024",
    "text": "Part II",
    "bbox": [
      90.0,
      367.3,
      113.6,
      376.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b025",
    "text": "Activities of daily living",
    "bbox": [
      145.0,
      367.3,
      228.9,
      376.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b026",
    "text": "Part III",
    "bbox": [
      90.0,
      377.3,
      115.8,
      386.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b027",
    "text": "Motor examination",
    "bbox": [
      144.9,
      377.3,
      212.9,
      386.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b028",
    "text": "Part IV",
    "bbox": [
      90.0,
      387.2,
      116.6,
      396.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b029",
    "text": "Complications of therapy",
    "bbox": [
      144.9,
      387.2,
      235.1,
      396.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b030",
    "text": "Part V",
    "bbox": [
      90.0,
      397.1,
      114.4,
      406.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b031",
    "text": "Modified Hoehn and Yahr staging",
    "bbox": [
      144.9,
      397.1,
      265.9,
      406.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b032",
    "text": "Overall single rating",
    "bbox": [
      338.5,
      397.1,
      411.3,
      406.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b033",
    "text": "Part VI",
    "bbox": [
      90.0,
      407.1,
      116.7,
      416.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b034",
    "text": "Disability scale",
    "bbox": [
      144.9,
      407.1,
      200.0,
      416.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b035",
    "text": "Overall single rating",
    "bbox": [
      338.4,
      407.1,
      411.3,
      416.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b036",
    "text": "Individual items are rated as follows",
    "bbox": [
      90.0,
      430.9,
      283.4,
      444.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b037",
    "text": "Part I, II and III",
    "bbox": [
      90.0,
      445.4,
      146.9,
      454.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b038",
    "text": "0-4 (0 = normal; 4 = maximal deficit, symptoms or impairment)",
    "bbox": [
      162.6,
      445.4,
      384.8,
      454.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b039",
    "text": "Part IV",
    "bbox": [
      90.0,
      455.3,
      116.7,
      464.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b040",
    "text": "0-4 or 0-1 (0 = normal; 1,4 = maximal deficit, symptoms or impairment)",
    "bbox": [
      162.6,
      455.3,
      414.6,
      464.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b041",
    "text": "Part V",
    "bbox": [
      90.0,
      465.3,
      114.4,
      474.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b042",
    "text": "8 stages from 0 to 5 (0 = no signs of disease; 5 = wheelchair bound or bedridden unless aided)",
    "bbox": [
      162.6,
      465.3,
      500.0,
      474.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b043",
    "text": "Part VI",
    "bbox": [
      90.0,
      475.2,
      116.7,
      484.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b044",
    "text": "11 percentile points from 0% (loss of vegetative functions; bedridden) to 100% (completely",
    "bbox": [
      162.6,
      475.2,
      484.4,
      484.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b045",
    "text": "independent)",
    "bbox": [
      162.6,
      484.4,
      211.4,
      493.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b046",
    "text": "Part III of this scale (Motor Examination) will be used as an outcome measure in",
    "bbox": [
      90.0,
      508.2,
      517.6,
      521.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b047",
    "text": "this study. The individual items in Part III are",
    "bbox": [
      90.0,
      522.0,
      332.1,
      535.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b048",
    "text": "• Speech",
    "bbox": [
      108.0,
      549.2,
      170.0,
      563.9
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b049",
    "text": "• Facial expression",
    "bbox": [
      108.0,
      563.9,
      222.6,
      578.6
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b050",
    "text": "• Tremor at rest",
    "bbox": [
      108.0,
      578.5,
      204.8,
      593.1
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b051",
    "text": "• Action or postural tremor of hands",
    "bbox": [
      108.0,
      593.1,
      310.1,
      607.8
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b052",
    "text": "• Rigidity",
    "bbox": [
      108.0,
      607.7,
      168.6,
      622.4
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b053",
    "text": "• Finger taps",
    "bbox": [
      108.0,
      622.3,
      189.4,
      637.0
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b054",
    "text": "• Hand movements",
    "bbox": [
      108.0,
      636.9,
      223.4,
      651.6
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b055",
    "text": "• Rapid alternating movements",
    "bbox": [
      108.0,
      651.5,
      285.4,
      666.2
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b056",
    "text": "• Leg agility",
    "bbox": [
      108.0,
      666.1,
      183.3,
      680.8
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b057",
    "text": "• Arising from chair",
    "bbox": [
      108.0,
      680.7,
      222.7,
      695.4
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 14,
    "block_id": "1055_p14_b058",
    "text": "• Posture",
    "bbox": [
      108.0,
      695.3,
      170.7,
      710.0
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b002",
    "text": "Page 15 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b005",
    "text": "• Gait",
    "bbox": [
      108.0,
      71.9,
      151.4,
      86.6
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b006",
    "text": "• Postural stability",
    "bbox": [
      108.0,
      86.5,
      216.7,
      101.1
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b007",
    "text": "• Body bradykinesia and hypokinesia",
    "bbox": [
      108.0,
      101.1,
      317.5,
      115.8
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b008",
    "text": "6. Summary Of Key Efficacy Study (EXPRESS Study; Study",
    "bbox": [
      90.0,
      142.0,
      490.1,
      157.6
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b009",
    "text": "2311)",
    "bbox": [
      90.0,
      158.2,
      129.0,
      173.8
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b010",
    "text": "The study protocol and main efficacy results for this study are summarized",
    "bbox": [
      90.0,
      177.1,
      488.2,
      190.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b011",
    "text": "below.",
    "bbox": [
      90.0,
      190.9,
      128.0,
      204.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b012",
    "text": "6.1 Outline",
    "bbox": [
      90.0,
      224.5,
      158.5,
      237.9
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b013",
    "text": "The study outline is below",
    "bbox": [
      90.0,
      241.3,
      231.3,
      254.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b014",
    "text": "Design",
    "bbox": [
      90.0,
      268.8,
      114.9,
      277.7
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b015",
    "text": "Randomized, double-blind, placebo-controlled, parallel-arm study",
    "bbox": [
      287.4,
      268.8,
      520.3,
      277.7
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b016",
    "text": "Duration",
    "bbox": [
      90.0,
      287.1,
      120.2,
      296.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b017",
    "text": "24 weeks",
    "bbox": [
      287.4,
      287.1,
      323.4,
      296.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b018",
    "text": "Key Inclusion Criteria",
    "bbox": [
      90.0,
      305.6,
      165.5,
      314.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b019",
    "text": "Clinical diagnosis of idiopathic Parkinson’s Disease according to the UK",
    "bbox": [
      287.4,
      305.6,
      543.5,
      314.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b020",
    "text": "Parkinson’s Disease Society Brain Bank clinical diagnostic criteria",
    "bbox": [
      287.4,
      314.7,
      522.6,
      323.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b021",
    "text": "Clinical diagnosis of Parkinson’s Disease Dementia according to DSM-IV criteria",
    "bbox": [
      288.0,
      333.2,
      574.2,
      342.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b022",
    "text": "(Code 294.1) with onset of symptoms of dementia within at least 2 years of the",
    "bbox": [
      288.0,
      342.3,
      568.0,
      351.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b023",
    "text": "first diagnosis of idiopathic Parkinson’s Disease",
    "bbox": [
      288.0,
      351.6,
      463.2,
      360.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b024",
    "text": "Mini-Mental Status Examination of 10 – 24",
    "bbox": [
      288.0,
      369.9,
      440.4,
      378.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b025",
    "text": "Primary Efficacy Measures",
    "bbox": [
      90.0,
      388.4,
      185.0,
      397.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b026",
    "text": "ADAS-Cog",
    "bbox": [
      287.4,
      388.4,
      328.7,
      397.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b027",
    "text": "ADCS-CGIC",
    "bbox": [
      287.4,
      406.8,
      336.6,
      415.7
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b028",
    "text": "Population For Primary Efficacy Analysis",
    "bbox": [
      90.0,
      425.1,
      234.0,
      434.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b029",
    "text": "Intent-to-treat plus retrieved dropouts",
    "bbox": [
      287.4,
      425.1,
      421.2,
      434.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b030",
    "text": "Secondary Efficacy Measures",
    "bbox": [
      90.0,
      443.6,
      198.0,
      452.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b031",
    "text": "Cognitive Drug Research Computerized Assessment System-Power Of Attention",
    "bbox": [
      287.4,
      443.6,
      575.4,
      452.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b032",
    "text": "D-KEFS* Verbal Fluency Test",
    "bbox": [
      287.4,
      452.7,
      397.5,
      461.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b033",
    "text": "Neuropsychiatry Inventory-10",
    "bbox": [
      287.4,
      462.0,
      396.2,
      470.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b034",
    "text": "Mini-Mental Status Examination",
    "bbox": [
      287.4,
      471.2,
      404.2,
      480.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b035",
    "text": "Ten-Point Clock Drawing Test",
    "bbox": [
      287.4,
      480.3,
      395.9,
      489.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b036",
    "text": "(*D-KEFS: Delis-Kaplan Executive Function System)",
    "bbox": [
      287.4,
      503.1,
      442.0,
      512.2
    ],
    "font_size": 8.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b037",
    "text": "Safety Measures",
    "bbox": [
      90.0,
      521.7,
      152.2,
      530.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b038",
    "text": "Adverse events, vital signs, safety laboratory tests, electrocardiograms, Unified",
    "bbox": [
      287.4,
      521.7,
      568.8,
      530.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b039",
    "text": "Parkinson’s Disease Rating Scale score",
    "bbox": [
      287.4,
      530.9,
      431.4,
      539.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b040",
    "text": "Dose Arms",
    "bbox": [
      90.0,
      549.3,
      129.5,
      558.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b041",
    "text": "Rivastigmine",
    "bbox": [
      287.4,
      549.3,
      335.4,
      558.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b042",
    "text": "(3 - 12 mg/day)",
    "bbox": [
      287.4,
      558.5,
      346.0,
      567.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b043",
    "text": "Placebo",
    "bbox": [
      386.1,
      549.3,
      417.2,
      558.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b044",
    "text": "Number randomized",
    "bbox": [
      90.0,
      576.9,
      162.5,
      585.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b045",
    "text": "362",
    "bbox": [
      287.4,
      576.9,
      302.9,
      585.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b046",
    "text": "179",
    "bbox": [
      386.1,
      576.9,
      401.6,
      585.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b047",
    "text": "Number completing",
    "bbox": [
      90.0,
      595.3,
      159.3,
      604.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b048",
    "text": "263",
    "bbox": [
      287.4,
      595.3,
      302.9,
      604.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b049",
    "text": "147",
    "bbox": [
      386.1,
      595.3,
      401.6,
      604.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b050",
    "text": "6.2 Results Of Primary Efficacy Analysis",
    "bbox": [
      90.0,
      638.3,
      327.2,
      651.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b051",
    "text": "The results of the primary efficacy analysis as performed on the intent-to-treat",
    "bbox": [
      90.0,
      655.0,
      505.5,
      668.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 15,
    "block_id": "1055_p15_b052",
    "text": "plus retrieved dropout population is summarized below",
    "bbox": [
      90.0,
      668.8,
      383.4,
      682.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b002",
    "text": "Page 16 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b005",
    "text": "Rivastigmine",
    "bbox": [
      269.4,
      72.5,
      342.2,
      83.8
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b006",
    "text": "Placebo",
    "bbox": [
      359.4,
      72.5,
      413.0,
      83.8
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b007",
    "text": "Parameter",
    "bbox": [
      90.0,
      72.5,
      138.4,
      83.8
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b008",
    "text": "Mean ± SD",
    "bbox": [
      299.4,
      84.3,
      348.2,
      95.5
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b009",
    "text": "Mean ± SD",
    "bbox": [
      389.4,
      84.3,
      438.2,
      95.5
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b010",
    "text": "Mean",
    "bbox": [
      449.4,
      72.5,
      475.6,
      83.8
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b011",
    "text": "difference",
    "bbox": [
      449.4,
      83.8,
      499.2,
      95.0
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b012",
    "text": "p-value",
    "bbox": [
      515.4,
      72.5,
      549.6,
      83.8
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b013",
    "text": "ADAS-Cog change from baseline to Week 24",
    "bbox": [
      90.0,
      96.2,
      252.7,
      105.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b014",
    "text": "329",
    "bbox": [
      269.4,
      96.2,
      284.9,
      105.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b015",
    "text": "2.1 ± 8.2",
    "bbox": [
      299.4,
      96.2,
      332.6,
      105.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b016",
    "text": "161",
    "bbox": [
      359.4,
      96.2,
      374.9,
      105.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b017",
    "text": "- 0.7 ± 7.5",
    "bbox": [
      389.4,
      96.2,
      427.5,
      105.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b018",
    "text": "2.88*",
    "bbox": [
      449.4,
      96.2,
      472.5,
      105.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b019",
    "text": "(LS means)",
    "bbox": [
      449.4,
      105.4,
      492.9,
      114.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b020",
    "text": "< 0.001**",
    "bbox": [
      515.4,
      96.2,
      550.8,
      105.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b021",
    "text": "ADCS-CGIC at Week 24",
    "bbox": [
      90.0,
      133.5,
      179.7,
      142.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b022",
    "text": "329",
    "bbox": [
      269.4,
      133.5,
      284.9,
      142.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b023",
    "text": "3.8 ± 1.4",
    "bbox": [
      299.4,
      133.5,
      332.6,
      142.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b024",
    "text": "165",
    "bbox": [
      359.4,
      133.5,
      374.9,
      142.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b025",
    "text": "4.3 ± 1.5",
    "bbox": [
      389.4,
      133.5,
      422.6,
      142.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b026",
    "text": "0.5",
    "bbox": [
      449.4,
      133.5,
      462.7,
      142.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b027",
    "text": "0.007***",
    "bbox": [
      515.4,
      133.5,
      546.9,
      142.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b028",
    "text": "*95% confidence interval: 1.44 to 4.31",
    "bbox": [
      90.0,
      152.4,
      229.2,
      161.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b029",
    "text": "**Based on two-way analysis of covariance model using treatment and country as factors and baseline ADAS-Cog as a",
    "bbox": [
      90.0,
      161.6,
      513.3,
      170.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b030",
    "text": "covariate",
    "bbox": [
      90.0,
      170.8,
      124.7,
      179.7
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b031",
    "text": "***Based on van Elteren test blocking for country",
    "bbox": [
      90.0,
      180.0,
      264.6,
      188.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b032",
    "text": "Note that in the above table, negative ADAS-Cog change scores indicate a worsening and positive ADAS-Cog change",
    "bbox": [
      90.0,
      189.2,
      510.0,
      198.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b033",
    "text": "scores an improvement",
    "bbox": [
      90.0,
      198.4,
      175.3,
      207.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b034",
    "text": "7. Description Of Efficacy Study 2311 (EXPRESS Study)",
    "bbox": [
      90.0,
      229.1,
      465.5,
      244.7
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b035",
    "text": "This study was conducted outside the purview of an IND application, and the",
    "bbox": [
      90.0,
      248.0,
      499.6,
      261.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b036",
    "text": "protocol was not submitted to this Division for review prior to the study being",
    "bbox": [
      90.0,
      261.8,
      497.5,
      275.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b037",
    "text": "conducted or at any time while the study was ongoing.",
    "bbox": [
      90.0,
      275.6,
      381.6,
      289.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b038",
    "text": "Note that the results of this study have also been published. The abstract of that",
    "bbox": [
      90.0,
      303.2,
      517.6,
      316.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b039",
    "text": "publication has been provided later in this section",
    "bbox": [
      90.0,
      317.0,
      355.6,
      330.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b040",
    "text": "7.1 Protocol",
    "bbox": [
      90.0,
      350.6,
      165.9,
      364.0
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b041",
    "text": "The protocol described below is the final version",
    "bbox": [
      90.0,
      380.5,
      325.0,
      391.6
    ],
    "font_size": 10.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b042",
    "text": "7.1.1 Title",
    "bbox": [
      90.0,
      410.9,
      149.8,
      424.3
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b043",
    "text": "A 24-Week, Prospective, Randomized, Multicenter, Double-Blind, Placebo-",
    "bbox": [
      90.0,
      427.7,
      487.4,
      441.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b044",
    "text": "Controlled, Parallel-Group Study Of the Efficacy, Tolerability, And Safety Of 3 –",
    "bbox": [
      90.0,
      441.5,
      513.5,
      454.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b045",
    "text": "12 Mg/Day Of Exelon® (Rivastigmine) Capsules In Patients With Parkinson’s",
    "bbox": [
      90.0,
      455.3,
      502.3,
      468.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b046",
    "text": "Disease Dementia",
    "bbox": [
      90.0,
      469.1,
      194.7,
      482.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b047",
    "text": "7.1.2 Objectives",
    "bbox": [
      90.0,
      502.7,
      183.2,
      516.1
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b048",
    "text": "7.1.2.1 Primary",
    "bbox": [
      90.0,
      525.6,
      171.8,
      537.8
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b049",
    "text": "To evaluate the efficacy of Exelon® (3 to 12 mg/day) compared with placebo for",
    "bbox": [
      90.0,
      541.1,
      517.1,
      554.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b050",
    "text": "a treatment period of 24 weeks in patients with Parkinson’s Disease Dementia.",
    "bbox": [
      90.0,
      554.9,
      510.9,
      568.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b051",
    "text": "Efficacy will be evaluated on the following:",
    "bbox": [
      90.0,
      568.7,
      320.7,
      582.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b052",
    "text": "ADAS-Cog, a measure of cognition",
    "bbox": [
      126.0,
      597.1,
      300.3,
      609.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b053",
    "text": "ADCS-ADL, a measure of global function",
    "bbox": [
      126.0,
      610.5,
      329.0,
      622.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b054",
    "text": "7.1.2.2 Secondary",
    "bbox": [
      90.0,
      641.8,
      186.5,
      654.1
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b055",
    "text": "• To evaluate the effects of Exelon® on attention, executive functioning,",
    "bbox": [
      108.0,
      657.1,
      501.1,
      671.7
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b056",
    "text": "activities of daily living, behavior, caregiver distress, and health economic",
    "bbox": [
      126.0,
      672.0,
      518.1,
      685.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 16,
    "block_id": "1055_p16_b057",
    "text": "parameters",
    "bbox": [
      126.0,
      685.8,
      189.9,
      699.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b002",
    "text": "Page 17 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b005",
    "text": "• To explore differences of efficacy of Exelon® depending on pre-existing",
    "bbox": [
      108.0,
      71.9,
      509.0,
      86.6
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b006",
    "text": "attentional deficits",
    "bbox": [
      126.0,
      86.8,
      225.4,
      100.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b007",
    "text": "• To explore potential genetic factors related to Parkinson’s Disease",
    "bbox": [
      108.0,
      100.3,
      481.6,
      114.9
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b008",
    "text": "Dementia",
    "bbox": [
      126.0,
      115.3,
      180.6,
      128.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b009",
    "text": "• To explore potential biomarkers related to Parkinson’s Disease Dementia",
    "bbox": [
      108.0,
      128.7,
      520.9,
      143.4
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b010",
    "text": "• To evaluate the safety and tolerability of Exelon®",
    "bbox": [
      108.0,
      143.3,
      393.8,
      158.0
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b011",
    "text": "7.1.3 Design, Duration, Sample Size, Dosage",
    "bbox": [
      90.0,
      178.1,
      338.7,
      191.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b012",
    "text": "This was to be a 24-week randomized, double-blind, placebo-controlled, parallel-",
    "bbox": [
      90.0,
      194.9,
      518.2,
      208.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b013",
    "text": "arm study.",
    "bbox": [
      90.0,
      208.7,
      149.4,
      222.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b014",
    "text": "About 540 patients were to be randomized 2:1 to Exelon® or placebo (i.e., about",
    "bbox": [
      90.0,
      236.3,
      520.5,
      249.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b015",
    "text": "360 patients to Exelon® and about 180 patients to placebo).",
    "bbox": [
      90.0,
      250.1,
      412.5,
      263.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b016",
    "text": "The overall study design is summarized in the following table:",
    "bbox": [
      90.0,
      277.7,
      419.4,
      291.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b017",
    "text": "4 dose levels were to be used for Exelon® (and for matching placebo). The dose",
    "bbox": [
      90.0,
      404.6,
      521.1,
      418.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b018",
    "text": "levels for Exelon® are shown in the following table",
    "bbox": [
      90.0,
      418.4,
      360.9,
      431.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b019",
    "text": "Dose Level",
    "bbox": [
      95.4,
      446.6,
      146.0,
      457.8
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b020",
    "text": "Exelon® Dose",
    "bbox": [
      155.4,
      446.6,
      218.6,
      457.8
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b021",
    "text": "1.5 mg BID",
    "bbox": [
      155.4,
      458.7,
      202.0,
      467.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b022",
    "text": "3.0 mg BID",
    "bbox": [
      155.4,
      468.6,
      199.8,
      477.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b023",
    "text": "4.5 mg BID",
    "bbox": [
      155.4,
      478.6,
      199.8,
      487.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b024",
    "text": "6.0 mg BID",
    "bbox": [
      155.4,
      488.5,
      199.8,
      497.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b025",
    "text": "The actual dosing regime was to be as follows:",
    "bbox": [
      90.0,
      512.3,
      342.1,
      525.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b026",
    "text": "• For the titration period",
    "bbox": [
      108.0,
      539.6,
      246.8,
      554.3
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b027",
    "text": "All patients were to begin at Dose Level 1",
    "bbox": [
      162.0,
      568.3,
      367.5,
      580.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b028",
    "text": "After 4 weeks, the dose was to be increased to Dose Level 2 unless",
    "bbox": [
      162.0,
      581.0,
      495.3,
      593.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b029",
    "text": "tolerability was impaired",
    "bbox": [
      162.0,
      593.7,
      282.4,
      605.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b030",
    "text": "Subsequent increases to Dose Levels 3 and 4 were to be based on the",
    "bbox": [
      162.0,
      606.3,
      510.6,
      618.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b031",
    "text": "tolerability of the preceding dose, and were to be considered only after 4",
    "bbox": [
      162.0,
      618.9,
      516.6,
      631.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b032",
    "text": "weeks of treatment at the previous dose",
    "bbox": [
      162.0,
      631.6,
      360.1,
      643.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b033",
    "text": "In the event of poor tolerability, an investigator could decide to reduce a",
    "bbox": [
      162.0,
      644.2,
      513.0,
      656.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b034",
    "text": "dose to the preceding level, with increases to the next dose level being",
    "bbox": [
      162.0,
      656.9,
      509.4,
      669.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b035",
    "text": "made as clinically indicated",
    "bbox": [
      162.0,
      669.6,
      298.3,
      681.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b036",
    "text": "All patients were expected to have found their highest tolerated dose by",
    "bbox": [
      162.0,
      682.2,
      513.6,
      694.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 17,
    "block_id": "1055_p17_b037",
    "text": "Week 16.",
    "bbox": [
      162.0,
      694.8,
      214.6,
      707.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b002",
    "text": "Page 18 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b005",
    "text": "• For the maintenance period",
    "bbox": [
      108.0,
      85.7,
      276.0,
      100.4
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b006",
    "text": "The highest well-tolerated dose for each patient was to be maintained for",
    "bbox": [
      162.0,
      114.4,
      519.6,
      126.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b007",
    "text": "the entire maintenance period",
    "bbox": [
      162.0,
      127.1,
      310.6,
      139.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b008",
    "text": "However, dose adjustments were permitted at any time",
    "bbox": [
      162.0,
      139.8,
      433.4,
      152.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b009",
    "text": "After completing the double-blind phase, patients were to have the option of",
    "bbox": [
      90.0,
      165.1,
      495.0,
      178.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b010",
    "text": "receiving open-label treatment for up to 6 months.",
    "bbox": [
      90.0,
      178.9,
      358.3,
      192.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b011",
    "text": "Note that the Exelon® dose range proposed for use in this trial was identical to",
    "bbox": [
      90.0,
      206.5,
      510.6,
      219.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b012",
    "text": "that used in clinical trials in Alzheimer’s Disease.",
    "bbox": [
      90.0,
      220.3,
      351.5,
      233.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b013",
    "text": "7.1.4 Selection",
    "bbox": [
      90.0,
      253.9,
      176.5,
      267.3
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b014",
    "text": "7.1.4.1 Key Inclusion Criteria",
    "bbox": [
      90.0,
      276.7,
      237.9,
      289.0
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b015",
    "text": "• Male or female",
    "bbox": [
      108.0,
      291.9,
      208.7,
      306.6
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b016",
    "text": "• Age ≥ 50 years",
    "bbox": [
      108.0,
      320.3,
      210.0,
      335.0
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b017",
    "text": "• Clinical diagnosis of idiopathic Parkinson’s Disease according to the UK",
    "bbox": [
      108.0,
      348.7,
      510.2,
      363.4
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b018",
    "text": "Parkinson’s Disease Society Brain Bank",
    "bbox": [
      126.0,
      363.7,
      346.1,
      377.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b019",
    "text": "• Diagnosis of Dementia Due To Parkinson’s Disease according to DSM-IV",
    "bbox": [
      108.0,
      391.0,
      518.8,
      405.6
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b020",
    "text": "criteria",
    "bbox": [
      126.0,
      405.9,
      168.7,
      419.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b021",
    "text": "• Mini-Mental Status Examination score of 12 to 24",
    "bbox": [
      108.0,
      433.1,
      390.9,
      447.8
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b022",
    "text": "• Sufficient education to read, write, and communicate effectively during the",
    "bbox": [
      108.0,
      461.6,
      521.4,
      476.3
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b023",
    "text": "pre-morbid stage",
    "bbox": [
      126.0,
      476.5,
      220.1,
      489.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b024",
    "text": "• Cooperative",
    "bbox": [
      108.0,
      503.8,
      194.0,
      518.4
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b025",
    "text": "• Able to ingest oral medication",
    "bbox": [
      108.0,
      532.1,
      286.8,
      546.8
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b026",
    "text": "• Capable of completing the study either alone or with the assistance of a",
    "bbox": [
      108.0,
      560.6,
      508.9,
      575.3
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b027",
    "text": "responsible caregiver",
    "bbox": [
      126.0,
      575.5,
      243.4,
      588.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b028",
    "text": "• Reliable caregiver",
    "bbox": [
      108.0,
      602.8,
      225.3,
      617.4
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b029",
    "text": "• Informed consent",
    "bbox": [
      108.0,
      631.2,
      222.0,
      645.9
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b030",
    "text": "7.1.4.2 Key Exclusion Criteria",
    "bbox": [
      90.0,
      666.0,
      241.6,
      678.3
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b031",
    "text": "• Any advanced, severe or unstable disease that could interfere with study",
    "bbox": [
      108.0,
      681.2,
      514.9,
      695.9
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 18,
    "block_id": "1055_p18_b032",
    "text": "evaluations",
    "bbox": [
      126.0,
      696.2,
      193.4,
      709.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b002",
    "text": "Page 19 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b005",
    "text": "• Any disability that interferes with completion of study requirements",
    "bbox": [
      108.0,
      85.7,
      480.8,
      100.4
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b006",
    "text": "• Active uncontrolled peptic ulceration within the previous 3 months",
    "bbox": [
      108.0,
      114.1,
      476.8,
      128.7
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b007",
    "text": "• Women of child-bearing potential",
    "bbox": [
      108.0,
      142.5,
      304.7,
      157.2
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b008",
    "text": "• Bradycardia (< 50 beats per minute), sick sinus syndrome, conduction",
    "bbox": [
      108.0,
      170.9,
      500.5,
      185.6
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b009",
    "text": "deficits (S-A block, second or third degree A-V block)",
    "bbox": [
      126.0,
      185.9,
      410.8,
      199.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b010",
    "text": "• Current diagnosis of any primary neurodegenerative disease other than",
    "bbox": [
      108.0,
      213.1,
      508.2,
      227.8
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b011",
    "text": "Parkinson’s Disease or any other causes of dementia",
    "bbox": [
      126.0,
      228.1,
      412.9,
      241.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b012",
    "text": "• A current diagnosis of probable or possible vascular dementia according",
    "bbox": [
      108.0,
      255.3,
      512.9,
      270.0
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b013",
    "text": "to the NINDS-AIREN criteria",
    "bbox": [
      126.0,
      270.3,
      280.0,
      283.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b014",
    "text": "• Deep brain stimulation implants",
    "bbox": [
      108.0,
      297.5,
      300.0,
      312.2
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b015",
    "text": "• Current diagnosis of active, uncontrolled seizure disorder",
    "bbox": [
      108.0,
      325.9,
      435.5,
      340.6
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b016",
    "text": "• Current diagnosis of major depressive episode according to DSM-IV",
    "bbox": [
      108.0,
      354.3,
      490.9,
      369.0
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b017",
    "text": "criteria or any other DSM-IV Axis I diagnosis that may interfere with the",
    "bbox": [
      126.0,
      369.3,
      506.1,
      382.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b018",
    "text": "response of the patient to study medication, including bipolar disorder or",
    "bbox": [
      126.0,
      383.1,
      512.4,
      396.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b019",
    "text": "schizophrenia as assessed by psychiatric examination",
    "bbox": [
      126.0,
      396.9,
      417.5,
      410.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b020",
    "text": "• A known exaggerated pharmacological sensitivity or hypersensitivity to",
    "bbox": [
      108.0,
      424.1,
      504.2,
      438.8
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b021",
    "text": "drugs similar to Exelon® or other cholinergic compounds",
    "bbox": [
      126.0,
      438.8,
      431.1,
      453.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b022",
    "text": "• Participation in a previous study of cholinesterase inhibitor therapy during",
    "bbox": [
      108.0,
      467.2,
      518.1,
      481.9
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b023",
    "text": "the 6 months prior to randomization",
    "bbox": [
      126.0,
      482.2,
      318.0,
      495.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b024",
    "text": "• Use of any of the following substances during the 4 weeks prior to",
    "bbox": [
      108.0,
      509.5,
      479.0,
      524.1
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b025",
    "text": "randomization",
    "bbox": [
      126.0,
      524.4,
      204.6,
      537.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b026",
    "text": "o Any investigational drug",
    "bbox": [
      144.0,
      552.0,
      284.8,
      565.3
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b027",
    "text": "o A drug or treatment known to cause major organ toxicity",
    "bbox": [
      144.0,
      564.7,
      440.7,
      577.9
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b028",
    "text": "o Other cholinesterase inhibitors or cholinergic drugs (except topical",
    "bbox": [
      144.0,
      577.3,
      486.7,
      590.6
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b029",
    "text": "pilocarpine)",
    "bbox": [
      162.0,
      590.0,
      225.0,
      602.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b030",
    "text": "o Centrally acting anticholinergic drugs, including tricyclic antidepressants",
    "bbox": [
      144.0,
      602.6,
      514.1,
      615.8
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b031",
    "text": "o Neuroleptics other than clozapine, quetiapine, or olanzapine",
    "bbox": [
      144.0,
      615.3,
      457.3,
      628.5
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b032",
    "text": "o Lithium",
    "bbox": [
      144.0,
      627.9,
      203.5,
      641.2
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b033",
    "text": "• Commencement of any of the following medications or change in",
    "bbox": [
      108.0,
      652.9,
      473.5,
      667.5
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 19,
    "block_id": "1055_p19_b034",
    "text": "medication dose during the 4 weeks prior to randomization",
    "bbox": [
      126.0,
      667.8,
      440.2,
      681.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b002",
    "text": "Page 20 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b005",
    "text": "o Psychotropic medications (clozapine, quetiapine, olanzapine,",
    "bbox": [
      144.0,
      72.3,
      462.2,
      85.5
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b006",
    "text": "antidepressants, anxiolytics or hynotics, including benzodiazepines and",
    "bbox": [
      162.0,
      84.9,
      512.4,
      97.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b007",
    "text": "anticonvulsants)",
    "bbox": [
      162.0,
      97.6,
      244.6,
      109.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b008",
    "text": "o Anti-Parkinsonian medications",
    "bbox": [
      144.0,
      110.2,
      313.0,
      123.4
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b009",
    "text": "7.1.4.3 Concomitant Medications",
    "bbox": [
      90.0,
      142.7,
      257.4,
      155.0
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b010",
    "text": "7.1.4.3.1 Prohibited",
    "bbox": [
      90.0,
      170.3,
      192.6,
      182.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b011",
    "text": " Any investigational drug",
    "bbox": [
      108.0,
      185.9,
      260.0,
      199.3
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b012",
    "text": " A drug or treatment known to cause major organ toxicity",
    "bbox": [
      108.0,
      199.7,
      430.1,
      213.1
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b013",
    "text": " Other cholinesterase inhibitors or cholinergic drugs (except topical",
    "bbox": [
      108.0,
      213.5,
      480.1,
      226.9
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b014",
    "text": "pilocarpine)",
    "bbox": [
      126.0,
      227.3,
      194.8,
      240.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b015",
    "text": " Centrally acting anticholinergic drugs, including tricyclic antidepressants",
    "bbox": [
      108.0,
      241.1,
      510.2,
      254.5
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b016",
    "text": " Neuroleptics other than clozapine, quetiapine, or olanzapine",
    "bbox": [
      108.0,
      254.9,
      448.3,
      268.3
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b017",
    "text": " Lithium",
    "bbox": [
      108.0,
      268.7,
      171.4,
      282.1
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b018",
    "text": " New psychotropic medications (clozapine, quetiapine, olanzapine,",
    "bbox": [
      108.0,
      282.5,
      479.5,
      295.9
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b019",
    "text": "antidepressants, anxiolytics or hynotics, including benzodiazepines and",
    "bbox": [
      126.0,
      296.3,
      508.2,
      309.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b020",
    "text": "anticonvulsants)",
    "bbox": [
      126.0,
      310.1,
      216.1,
      323.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b021",
    "text": " New anti-Parkinsonian medications",
    "bbox": [
      108.0,
      323.9,
      316.7,
      337.3
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b022",
    "text": " Dose increases for dopaminomimetic medications",
    "bbox": [
      108.0,
      337.7,
      394.1,
      351.1
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b023",
    "text": " Dose increases for anxiolytics or hypnotics, including benzodiazepines",
    "bbox": [
      108.0,
      351.5,
      506.8,
      364.9
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b024",
    "text": "7.1.4.3.2 Permitted (With Limitations)",
    "bbox": [
      90.0,
      391.2,
      278.1,
      403.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b025",
    "text": " Psychosis should be treated according to the clinical standard. If",
    "bbox": [
      108.0,
      406.7,
      471.0,
      420.1
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b026",
    "text": "persistent and if clinically indicated:",
    "bbox": [
      126.0,
      420.5,
      316.8,
      433.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b027",
    "text": "o In patients already treated with atypical neuroleptics, a dose increase is",
    "bbox": [
      144.0,
      448.2,
      512.4,
      461.4
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b028",
    "text": "permitted",
    "bbox": [
      162.0,
      460.8,
      210.9,
      473.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b029",
    "text": "o In neuroleptic-naïve, atypical neuroleptics, such as clozapine, quetiapine,",
    "bbox": [
      144.0,
      473.5,
      520.9,
      486.7
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b030",
    "text": "or olanzapine should be started at very low doses that are increased",
    "bbox": [
      162.0,
      486.1,
      497.7,
      498.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b031",
    "text": "gradually",
    "bbox": [
      162.0,
      498.8,
      209.7,
      511.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b032",
    "text": "While a decrease in dose or discontinuation of anti-Parkinsonian medication as a",
    "bbox": [
      126.0,
      524.1,
      522.2,
      536.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b033",
    "text": "treatment for psychosis is permitted, elimination of all dopaminomimetic",
    "bbox": [
      126.0,
      536.7,
      476.9,
      549.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b034",
    "text": "treatment is not recommended. However, changes in dose of amantadine and",
    "bbox": [
      126.0,
      549.4,
      508.2,
      561.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b035",
    "text": "selegiline are not permitted during the trial, even during a psychotic episode.",
    "bbox": [
      126.0,
      562.0,
      500.1,
      574.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b036",
    "text": " For isolated insomnia, the use of non-benzodiazepine hypnotics such as",
    "bbox": [
      108.0,
      587.3,
      512.9,
      600.7
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b037",
    "text": "zopiclone, is permitted",
    "bbox": [
      126.0,
      601.1,
      248.7,
      614.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b038",
    "text": " Patients on Vitamin E, estrogens, Ginkgo biloba, and nootropics, and in",
    "bbox": [
      108.0,
      628.7,
      508.2,
      642.1
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b039",
    "text": "whom discontinuation of these drugs is not feasible, may continue with",
    "bbox": [
      126.0,
      642.5,
      503.7,
      655.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b040",
    "text": "these agents, but the dose should remain unchanged throughout the trial",
    "bbox": [
      126.0,
      656.3,
      515.6,
      669.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b041",
    "text": " Peripherally-acting anticholinergic drugs are permitted if patients have",
    "bbox": [
      108.0,
      683.9,
      500.1,
      697.3
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 20,
    "block_id": "1055_p20_b042",
    "text": "been on a stable dose for 4 weeks prior to randomization, and if doses are",
    "bbox": [
      126.0,
      697.7,
      523.6,
      711.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 21,
    "block_id": "1055_p21_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 21,
    "block_id": "1055_p21_b002",
    "text": "Page 21 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 21,
    "block_id": "1055_p21_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 21,
    "block_id": "1055_p21_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 21,
    "block_id": "1055_p21_b005",
    "text": "kept stable during the study. In addition, if urinary urgency and",
    "bbox": [
      126.0,
      72.2,
      460.2,
      85.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 21,
    "block_id": "1055_p21_b006",
    "text": "incontinence develop newly during the trial, and cannot be overcome by",
    "bbox": [
      126.0,
      86.0,
      510.4,
      99.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 21,
    "block_id": "1055_p21_b007",
    "text": "non-pharmacological means, initiation of treatment with peripheral",
    "bbox": [
      126.0,
      99.8,
      479.5,
      113.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 21,
    "block_id": "1055_p21_b008",
    "text": "anticholinergics such as tolterodine and oxybutinin will be permitted",
    "bbox": [
      126.0,
      113.6,
      486.7,
      127.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 21,
    "block_id": "1055_p21_b009",
    "text": "7.1.5 Schedule",
    "bbox": [
      90.0,
      147.3,
      177.2,
      160.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 21,
    "block_id": "1055_p21_b010",
    "text": "The study schedule is summarized in the following table, which I have copied",
    "bbox": [
      90.0,
      164.0,
      502.1,
      177.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 21,
    "block_id": "1055_p21_b011",
    "text": "from the submission.",
    "bbox": [
      90.0,
      177.8,
      203.9,
      191.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 21,
    "block_id": "1055_p21_b012",
    "text": "Note that brain imaging (i.e., computerized tomography or magnetic",
    "bbox": [
      90.0,
      579.8,
      480.1,
      593.2
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 21,
    "block_id": "1055_p21_b013",
    "text": "resonance scanning) was not required prior to entry into the study.",
    "bbox": [
      90.0,
      593.6,
      475.9,
      607.0
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 21,
    "block_id": "1055_p21_b014",
    "text": "Special diagnostic laboratory tests at screening included serum TSH, folic acid,",
    "bbox": [
      90.0,
      621.2,
      512.9,
      634.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 21,
    "block_id": "1055_p21_b015",
    "text": "Vitamin B12 and RPR.",
    "bbox": [
      90.0,
      635.0,
      216.7,
      648.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 21,
    "block_id": "1055_p21_b016",
    "text": "Also note the following",
    "bbox": [
      90.0,
      662.6,
      213.4,
      676.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 21,
    "block_id": "1055_p21_b017",
    "text": " All primary and other cognitive outcome variables were to be assessed",
    "bbox": [
      108.0,
      690.2,
      504.9,
      703.6
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 21,
    "block_id": "1055_p21_b018",
    "text": "before lunch, beginning 1 hour after the intake of dopaminergic",
    "bbox": [
      126.0,
      704.0,
      463.0,
      717.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b002",
    "text": "Page 22 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b005",
    "text": "medications, at the same time of day throughout the study for each",
    "bbox": [
      126.0,
      72.2,
      484.2,
      85.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b006",
    "text": "patient, and using the same sequence of tests",
    "bbox": [
      126.0,
      86.0,
      374.2,
      99.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b007",
    "text": " For patients with motor fluctuations and/or dyskinesias, efficacy",
    "bbox": [
      108.0,
      99.8,
      465.7,
      113.2
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b008",
    "text": "assessments were to be performed during their “on” time (defined as",
    "bbox": [
      126.0,
      113.6,
      493.5,
      127.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b009",
    "text": "intervals when parkinsonian symptoms were replaced by increased",
    "bbox": [
      126.0,
      127.4,
      485.5,
      140.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b010",
    "text": "mobility)",
    "bbox": [
      126.0,
      141.2,
      174.0,
      154.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b011",
    "text": " For patients with an acute psychosis, efficacy assessments were to be",
    "bbox": [
      108.0,
      155.0,
      502.9,
      168.4
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b012",
    "text": "performed after remission of the psychosis",
    "bbox": [
      126.0,
      168.8,
      355.3,
      182.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b013",
    "text": " Raters were advised to identify and discount if possible potential",
    "bbox": [
      108.0,
      182.6,
      470.2,
      196.0
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b014",
    "text": "behavioral and functional changes due to the motor symptoms of",
    "bbox": [
      126.0,
      196.4,
      473.6,
      209.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b015",
    "text": "Parkinson’s Disease",
    "bbox": [
      126.0,
      210.2,
      241.4,
      223.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b016",
    "text": "7.1.6 Outcome Measures",
    "bbox": [
      90.0,
      243.9,
      231.9,
      257.3
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b017",
    "text": "7.1.6.1 Primary Efficacy Measures",
    "bbox": [
      90.0,
      266.7,
      264.7,
      279.0
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b018",
    "text": "• ADAS-Cog",
    "bbox": [
      108.0,
      281.9,
      188.0,
      296.6
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b019",
    "text": "• ADCS-CGIC",
    "bbox": [
      108.0,
      310.3,
      200.0,
      325.0
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b020",
    "text": "7.1.6.2 Secondary Efficacy Measures",
    "bbox": [
      90.0,
      345.1,
      279.4,
      357.4
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b021",
    "text": "• Cognitive Drug Research Computerized Assessment System tests for the",
    "bbox": [
      108.0,
      360.4,
      519.5,
      375.0
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b022",
    "text": "assessment of attention",
    "bbox": [
      126.0,
      375.4,
      256.1,
      388.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b023",
    "text": "• ADCS-ADL",
    "bbox": [
      108.0,
      402.6,
      193.4,
      417.3
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b024",
    "text": "• Neuropsychiatry Inventory",
    "bbox": [
      108.0,
      431.0,
      272.1,
      445.7
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b025",
    "text": "• Neuropsychiatry Inventory Caregiver Distress Scale",
    "bbox": [
      108.0,
      459.4,
      404.1,
      474.1
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b026",
    "text": "• Executive Function Battery",
    "bbox": [
      108.0,
      487.8,
      272.1,
      502.5
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b027",
    "text": "Ten-Point Clock Drawing Test",
    "bbox": [
      162.0,
      516.6,
      311.2,
      528.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b028",
    "text": "D-KEFS Verbal Fluency Test",
    "bbox": [
      162.0,
      529.2,
      306.2,
      541.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b029",
    "text": "D-KEFS Color Word Interference Test*",
    "bbox": [
      162.0,
      541.9,
      354.5,
      554.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b030",
    "text": "D-KEFS Card Sorting Test*",
    "bbox": [
      162.0,
      554.5,
      299.0,
      566.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b031",
    "text": "Symbol Digit Modalities Test*",
    "bbox": [
      162.0,
      567.2,
      308.1,
      579.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b032",
    "text": "*These were designated as exploratory assessments",
    "bbox": [
      162.0,
      592.4,
      375.6,
      602.4
    ],
    "font_size": 9.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b033",
    "text": "and were considered optional for English and French",
    "bbox": [
      162.0,
      602.8,
      375.1,
      612.8
    ],
    "font_size": 9.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b034",
    "text": "speaking patients",
    "bbox": [
      162.0,
      613.1,
      234.5,
      623.1
    ],
    "font_size": 9.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b035",
    "text": "• Health Economic Parameters, including caregiver burden, and patient and",
    "bbox": [
      108.0,
      635.8,
      522.2,
      650.5
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b036",
    "text": "caregiver resource utilization",
    "bbox": [
      126.0,
      650.8,
      282.0,
      664.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 22,
    "block_id": "1055_p22_b037",
    "text": "• Mini-Mental Status Examination",
    "bbox": [
      108.0,
      678.0,
      301.4,
      692.7
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b002",
    "text": "Page 23 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b005",
    "text": "7.1.6.3 Safety Measures",
    "bbox": [
      90.0,
      72.3,
      216.5,
      84.6
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b006",
    "text": "Adverse events, safety laboratory tests, vital signs, body weight,",
    "bbox": [
      90.0,
      87.9,
      433.5,
      101.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b007",
    "text": "electrocardiograms, and UPDRS Part III",
    "bbox": [
      90.0,
      101.7,
      306.2,
      115.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b008",
    "text": "7.1.7 Safety Monitoring",
    "bbox": [
      90.0,
      135.4,
      220.6,
      148.8
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b009",
    "text": "Adverse events, safety laboratory tests, vital signs, body weight,",
    "bbox": [
      90.0,
      152.1,
      433.6,
      165.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b010",
    "text": "electrocardiograms, and UPDRS Part III",
    "bbox": [
      90.0,
      165.9,
      306.2,
      179.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b011",
    "text": "7.1.8 Analysis Plan",
    "bbox": [
      90.0,
      199.6,
      199.2,
      213.0
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b012",
    "text": "7.1.8.1 General",
    "bbox": [
      90.0,
      222.4,
      173.0,
      234.6
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b013",
    "text": "The data from each center were intended to be pooled with data from other",
    "bbox": [
      90.0,
      237.9,
      491.6,
      251.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b014",
    "text": "centers so that an adequate number of patients would be available for analysis.",
    "bbox": [
      90.0,
      251.7,
      514.3,
      265.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b015",
    "text": "Unless otherwise specified, all statistical tests were to be conducted using a two-",
    "bbox": [
      90.0,
      279.3,
      518.1,
      292.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b016",
    "text": "sided Type I error of 0.05.",
    "bbox": [
      90.0,
      293.1,
      230.8,
      306.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b017",
    "text": "7.1.8.2 Study Populations",
    "bbox": [
      90.0,
      326.8,
      222.6,
      339.0
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b018",
    "text": "7.1.8.2.1 Intent-To-Treat With Retrieved Dropouts",
    "bbox": [
      90.0,
      354.4,
      339.5,
      366.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b019",
    "text": "This population was to include all randomized patients who received at least one",
    "bbox": [
      90.0,
      370.0,
      520.2,
      383.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b020",
    "text": "dose of study medication and had at least a pre- and post-baseline assessment",
    "bbox": [
      90.0,
      383.8,
      514.8,
      397.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b021",
    "text": "for one of the primary efficacy variables.",
    "bbox": [
      90.0,
      397.6,
      306.0,
      411.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b022",
    "text": "The imputation scheme that was to be used to create a score for every",
    "bbox": [
      90.0,
      425.2,
      468.2,
      438.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b023",
    "text": "randomized subject is described as follows in the study protocol: If available, the",
    "bbox": [
      90.0,
      439.0,
      518.8,
      452.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b024",
    "text": "endpoint assessment is used; if missing, the retrieved dropout assessment is",
    "bbox": [
      90.0,
      452.8,
      501.5,
      466.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b025",
    "text": "used; if the retrieved dropout assessment is unavailable, the last observation",
    "bbox": [
      90.0,
      466.6,
      500.2,
      480.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b026",
    "text": "available on the subject is used.",
    "bbox": [
      90.0,
      480.4,
      263.5,
      493.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b027",
    "text": "7.1.8.2.2 Intent-To-Treat-Last-Observation-Carried-Forward",
    "bbox": [
      90.0,
      520.0,
      387.5,
      532.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b028",
    "text": "This population was to include all randomized patients who received at least one",
    "bbox": [
      90.0,
      535.7,
      520.2,
      549.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b029",
    "text": "dose of study medication and had at least a pre- and post-baseline assessment",
    "bbox": [
      90.0,
      549.5,
      514.8,
      562.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b030",
    "text": "for one of the primary efficacy variables.",
    "bbox": [
      90.0,
      563.3,
      306.0,
      576.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b031",
    "text": "The imputation scheme that was to be used to create a score for every",
    "bbox": [
      90.0,
      590.9,
      468.2,
      604.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b032",
    "text": "randomized subject is described as follows in the study protocol: If available, the",
    "bbox": [
      90.0,
      604.7,
      518.8,
      618.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b033",
    "text": "endpoint assessment is used; if missing, the immediate preceding observation",
    "bbox": [
      90.0,
      618.4,
      508.1,
      631.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b034",
    "text": "available, scheduled or unscheduled, is utilized, provided that the assessment is",
    "bbox": [
      90.0,
      632.2,
      519.0,
      645.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b035",
    "text": "made while the subject is still considered to be a participant in the study, i.e., at",
    "bbox": [
      90.0,
      646.0,
      512.9,
      659.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b036",
    "text": "most 2 days after the last dose of study medication.",
    "bbox": [
      90.0,
      659.8,
      366.8,
      673.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 23,
    "block_id": "1055_p23_b037",
    "text": "7.1.8.2.3 Observed Cases",
    "bbox": [
      90.0,
      699.4,
      225.1,
      711.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b002",
    "text": "Page 24 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b005",
    "text": "This population was to consist of all randomized patients who had an evaluation",
    "bbox": [
      90.0,
      72.2,
      516.8,
      85.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b006",
    "text": "on treatment at the designated assessment time (either interim scheduled or",
    "bbox": [
      90.0,
      86.0,
      498.3,
      99.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b007",
    "text": "endpoint). Evaluations done more than 2 days after the last dose of study",
    "bbox": [
      90.0,
      99.8,
      482.2,
      113.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b008",
    "text": "medication were not to be included. No imputation is involved with this population",
    "bbox": [
      90.0,
      113.6,
      524.2,
      127.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b009",
    "text": "7.1.8.2.4 Safety Population",
    "bbox": [
      90.0,
      153.3,
      229.4,
      165.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b010",
    "text": "This population was to consist of all patients who have received at least one",
    "bbox": [
      90.0,
      168.9,
      496.3,
      182.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b011",
    "text": "dose of study medication and had at least one safety assessment after baseline.",
    "bbox": [
      90.0,
      182.7,
      519.5,
      196.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b012",
    "text": "7.1.8.3 Demographic And Other Baseline Characteristics",
    "bbox": [
      90.0,
      216.4,
      373.6,
      228.6
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b013",
    "text": "• These characteristics were to be presented by treatment group and",
    "bbox": [
      108.0,
      231.5,
      486.2,
      246.2
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b014",
    "text": "country",
    "bbox": [
      126.0,
      246.5,
      168.7,
      259.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b015",
    "text": "• Continuous variables were to be summarized using descriptive statistics",
    "bbox": [
      108.0,
      260.0,
      511.4,
      274.7
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b016",
    "text": "• Discrete variables were to be summarized by frequencies and",
    "bbox": [
      108.0,
      274.6,
      457.4,
      289.2
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b017",
    "text": "percentages",
    "bbox": [
      126.0,
      289.6,
      195.4,
      303.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b018",
    "text": "• Descriptive p-values were to be generated using appropriate test statistics",
    "bbox": [
      108.0,
      303.0,
      522.1,
      317.7
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b019",
    "text": "7.1.8.4 Study Medications",
    "bbox": [
      90.0,
      337.8,
      223.9,
      350.1
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b020",
    "text": "Descriptive statistics for study drug exposure by treatment and data listings for",
    "bbox": [
      90.0,
      353.4,
      508.9,
      366.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b021",
    "text": "study drug doses administered were also to be provided",
    "bbox": [
      90.0,
      367.2,
      390.9,
      380.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b022",
    "text": "7.1.8.5 Concomitant Therapy",
    "bbox": [
      90.0,
      400.9,
      252.0,
      414.3
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b023",
    "text": "Descriptive statistics (frequency counts and percentages) for concomitant",
    "bbox": [
      90.0,
      417.6,
      482.8,
      431.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b024",
    "text": "medication were to be presented by treatment group for patients in the safety",
    "bbox": [
      90.0,
      431.4,
      502.3,
      444.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b025",
    "text": "population",
    "bbox": [
      90.0,
      445.2,
      148.7,
      458.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b026",
    "text": "7.1.8.6 Primary Efficacy Parameters",
    "bbox": [
      90.0,
      478.9,
      273.3,
      491.1
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b027",
    "text": " The primary efficacy parameters were the following",
    "bbox": [
      108.0,
      494.5,
      400.6,
      507.9
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b028",
    "text": "o Change from baseline to endpoint in ADAS-Cog score",
    "bbox": [
      144.0,
      522.1,
      428.6,
      535.3
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b029",
    "text": "o ADCS-CGIC rating at endpoint (on the 7-point scale)",
    "bbox": [
      144.0,
      534.7,
      421.2,
      547.9
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b030",
    "text": "[Note that the statistical analysis plan does not explicitly state that the endpoint",
    "bbox": [
      126.0,
      560.0,
      511.8,
      572.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b031",
    "text": "used for the primary efficacy analysis was to be Week 24, rather than Week 16.]",
    "bbox": [
      126.0,
      572.7,
      518.5,
      584.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b032",
    "text": " The population for the primary efficacy analysis was to be the intent-to-",
    "bbox": [
      108.0,
      598.0,
      502.3,
      611.4
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b033",
    "text": "treat plus retrieved dropouts population as defined above. Analyses on",
    "bbox": [
      126.0,
      611.8,
      504.3,
      625.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b034",
    "text": "other populations were to be considered supportive to the main efficacy",
    "bbox": [
      126.0,
      625.6,
      508.3,
      639.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b035",
    "text": "analysis",
    "bbox": [
      126.0,
      639.4,
      172.7,
      652.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b036",
    "text": " The main analysis for the change from baseline to endpoint in ADAS-Cog",
    "bbox": [
      108.0,
      666.9,
      518.8,
      680.3
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 24,
    "block_id": "1055_p24_b037",
    "text": "score was to be as follows",
    "bbox": [
      126.0,
      680.7,
      269.4,
      694.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b002",
    "text": "Page 25 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b005",
    "text": "o The treatment groups were to be compared using least square means",
    "bbox": [
      144.0,
      72.3,
      505.0,
      85.5
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b006",
    "text": "derived from an analysis of covariance model with the following",
    "bbox": [
      162.0,
      84.9,
      472.6,
      97.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b007",
    "text": "explanatory variables: treatment, country, and baseline ADAS-Cog score",
    "bbox": [
      162.0,
      97.6,
      519.1,
      109.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b008",
    "text": "o 95% confidence intervals for the difference in treatment groups based on",
    "bbox": [
      144.0,
      110.2,
      519.0,
      123.4
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b009",
    "text": "the analysis of covariance were to be reported",
    "bbox": [
      162.0,
      122.8,
      390.0,
      135.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b010",
    "text": "o In addition, summary statistics were to be presented by treatment group",
    "bbox": [
      144.0,
      135.5,
      514.1,
      148.7
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b011",
    "text": "for baseline and post-baseline evaluations for the populations being",
    "bbox": [
      162.0,
      148.2,
      494.0,
      160.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b012",
    "text": "analyzed",
    "bbox": [
      162.0,
      160.8,
      209.1,
      173.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b013",
    "text": " The main analysis of the ADCS-CGIC was to be by comparing the",
    "bbox": [
      108.0,
      187.3,
      480.2,
      200.7
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b014",
    "text": "treatment groups using a Cochran-Mantel-Haenszel test with modified ridit",
    "bbox": [
      126.0,
      201.0,
      523.5,
      214.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b015",
    "text": "scores with country as stratification variable. In addition, a proportional",
    "bbox": [
      126.0,
      214.8,
      502.8,
      228.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b016",
    "text": "odds regression analysis with the following explanatory variables was to",
    "bbox": [
      126.0,
      228.6,
      510.9,
      242.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b017",
    "text": "be performed: treatment and country. A secondary analysis was also to be",
    "bbox": [
      126.0,
      242.4,
      524.3,
      255.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b018",
    "text": "performed on the dichotomized ADCS-CGIC using  logistic regression with",
    "bbox": [
      126.0,
      256.2,
      524.7,
      269.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b019",
    "text": "the same explanatory variables as the proportional odds regression model",
    "bbox": [
      126.0,
      270.0,
      522.8,
      283.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b020",
    "text": "7.1.8.7 Secondary Efficacy Parameters And Additional Analyses",
    "bbox": [
      90.0,
      303.7,
      409.6,
      315.9
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b021",
    "text": "Secondary efficacy variables were to be analyzed using an analysis of",
    "bbox": [
      90.0,
      319.3,
      465.7,
      332.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b022",
    "text": "covariance model with treatment, country, and the corresponding baseline",
    "bbox": [
      90.0,
      333.1,
      486.1,
      346.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b023",
    "text": "measurement as the covariates.",
    "bbox": [
      90.0,
      346.9,
      267.5,
      360.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b024",
    "text": "Secondary efficacy analyses of the primary efficacy variables were to be",
    "bbox": [
      90.0,
      374.5,
      477.0,
      387.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b025",
    "text": "performed on population subgroups defined by the presence of impaired",
    "bbox": [
      90.0,
      388.3,
      476.9,
      401.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b026",
    "text": "attention and concentration on the baseline attentional task scores of the",
    "bbox": [
      90.0,
      402.1,
      478.7,
      415.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b027",
    "text": "Cognitive Drug Research computerized battery.",
    "bbox": [
      90.0,
      415.9,
      346.2,
      429.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b028",
    "text": "7.1.8.8 Safety Parameters",
    "bbox": [
      90.0,
      449.5,
      225.0,
      461.8
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b029",
    "text": " The safety parameters were to be adverse events, vital signs,",
    "bbox": [
      108.0,
      465.1,
      456.1,
      478.5
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b030",
    "text": "electrocardiograms and safety laboratory tests.",
    "bbox": [
      126.0,
      478.9,
      382.1,
      492.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b031",
    "text": " Adverse events will be coded using the MedDRA dictionary and presented",
    "bbox": [
      108.0,
      506.5,
      523.5,
      519.9
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b032",
    "text": "(number and proportion) by treatment group, body system, and individual",
    "bbox": [
      126.0,
      520.3,
      516.9,
      533.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b033",
    "text": "event, and also grouped according to severity, relationship to study",
    "bbox": [
      126.0,
      534.1,
      485.0,
      547.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b034",
    "text": "medication, and outcome. The proportion of patients in each treatment",
    "bbox": [
      126.0,
      547.9,
      502.9,
      561.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b035",
    "text": "group discontinuing prematurely for any reason and for adverse events",
    "bbox": [
      126.0,
      561.7,
      505.7,
      575.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b036",
    "text": "was to be compared descriptively",
    "bbox": [
      126.0,
      575.5,
      310.2,
      588.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b037",
    "text": " Laboratory data were to be summarized by presenting shift tables for",
    "bbox": [
      108.0,
      603.1,
      494.9,
      616.5
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b038",
    "text": "change from baseline to most extreme post-baseline value, and",
    "bbox": [
      126.0,
      616.9,
      466.8,
      630.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b039",
    "text": "descriptive statistics of raw data and change from baseline values, and by",
    "bbox": [
      126.0,
      630.7,
      520.8,
      644.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b040",
    "text": "flagging notable values in data listings.",
    "bbox": [
      126.0,
      644.5,
      338.2,
      657.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b041",
    "text": "• Data from vital signs and electrocardiograms were to be listed, notable",
    "bbox": [
      108.0,
      671.8,
      503.6,
      686.4
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 25,
    "block_id": "1055_p25_b042",
    "text": "values were to be flagged, and any other information collected was to be",
    "bbox": [
      126.0,
      686.7,
      514.4,
      700.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b002",
    "text": "Page 26 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b005",
    "text": "listed as appropriate. Any statistical tests performed were to be",
    "bbox": [
      126.0,
      72.2,
      463.5,
      85.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b006",
    "text": "exploratory",
    "bbox": [
      126.0,
      86.0,
      188.7,
      99.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b007",
    "text": "• The change from baseline on the UPDRS score was to be analyzed using",
    "bbox": [
      108.0,
      113.3,
      520.8,
      128.0
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b008",
    "text": "an analysis of covariance model",
    "bbox": [
      126.0,
      128.2,
      300.1,
      141.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b009",
    "text": "7.1.8.9 Sample Size Rationale",
    "bbox": [
      90.0,
      161.9,
      245.1,
      174.2
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b010",
    "text": "Sample size estimates were performed using the two primary efficacy",
    "bbox": [
      90.0,
      177.5,
      462.0,
      190.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b011",
    "text": "parameters the ADAS-Cog and the ADCS-CGIC, and is further summarized",
    "bbox": [
      90.0,
      191.3,
      495.3,
      204.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b012",
    "text": "below",
    "bbox": [
      90.0,
      205.1,
      124.6,
      218.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b013",
    "text": "7.1.8.9.1 Sample Size Estimate Based On ADAS-Cog",
    "bbox": [
      90.0,
      244.7,
      362.5,
      257.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b014",
    "text": "Estimates of standard deviation from the intent-to-treat analysis of 6-month",
    "bbox": [
      90.0,
      260.3,
      490.3,
      273.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b015",
    "text": "change from baseline ADAS-Cog data in clinical trials of Exelon® in Alzheimer’s",
    "bbox": [
      90.0,
      274.1,
      517.7,
      287.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b016",
    "text": "Disease range from 6 to 7 points",
    "bbox": [
      90.0,
      287.9,
      266.8,
      301.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b017",
    "text": "To ensure adequate power in case of a higher variability in 6-month change from",
    "bbox": [
      90.0,
      315.5,
      521.6,
      328.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b018",
    "text": "baseline ADAS-Cog scores in those with Parkinson’s Disease as compared with",
    "bbox": [
      90.0,
      329.3,
      518.1,
      342.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b019",
    "text": "those with Alzheimer’s Disease, a standard deviation of 7.5 points was assumed",
    "bbox": [
      90.0,
      343.1,
      522.9,
      356.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b020",
    "text": "for this sample size estimate",
    "bbox": [
      90.0,
      356.9,
      244.8,
      370.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b021",
    "text": "Using a two-sided test with a significance level of 0.05, and a pooled standard",
    "bbox": [
      90.0,
      384.5,
      506.2,
      397.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b022",
    "text": "deviation of 7.5 points, a total sample size of 531 patients (354 on Exelon® and",
    "bbox": [
      90.0,
      398.3,
      514.4,
      411.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b023",
    "text": "177 on placebo) is required to detect a difference of at least 2.25 points in the",
    "bbox": [
      90.0,
      412.1,
      504.4,
      425.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b024",
    "text": "ADAS-Cog change from baseline score between Exelon® and placebo with a",
    "bbox": [
      90.0,
      425.9,
      503.7,
      439.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b025",
    "text": "power of 90%.",
    "bbox": [
      90.0,
      439.7,
      170.1,
      453.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b026",
    "text": "7.1.8.9.2 Sample Size Estimate Based On ADCS-CGIC",
    "bbox": [
      90.0,
      479.4,
      367.4,
      491.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b027",
    "text": "Assumptions regarding the variability and treatment differences for the ADCS-",
    "bbox": [
      90.0,
      494.9,
      503.6,
      508.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b028",
    "text": "CGIC are based on data available for the CIBIC-Plus from completed Exelon®",
    "bbox": [
      90.0,
      508.7,
      509.0,
      522.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b029",
    "text": "studies in Alzheimer’s Disease; the ADCS-CGIC and CIBIC-Plus are very similar",
    "bbox": [
      90.0,
      522.5,
      520.8,
      535.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b030",
    "text": "instruments.",
    "bbox": [
      90.0,
      536.3,
      158.7,
      549.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b031",
    "text": "To ensure adequate power in case of a higher variability in ADCS-CGIC scores",
    "bbox": [
      90.0,
      563.9,
      513.6,
      577.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b032",
    "text": "in those with Parkinson’s Disease as compared with those with Alzheimer’s",
    "bbox": [
      90.0,
      577.7,
      492.1,
      591.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b033",
    "text": "Disease, a standard deviation of 1.3 points was assumed  for this sample size",
    "bbox": [
      90.0,
      591.5,
      506.2,
      604.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b034",
    "text": "estimate",
    "bbox": [
      90.0,
      605.3,
      138.7,
      618.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b035",
    "text": "Using a two-sided test with a significance level of 0.05, and a pooled standard",
    "bbox": [
      90.0,
      632.9,
      506.2,
      646.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b036",
    "text": "deviation of 1.3 points, a total sample size of 525 patients (350 on Exelon® and",
    "bbox": [
      90.0,
      646.7,
      514.4,
      660.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b037",
    "text": "175 on placebo) is required to detect a difference of at least 0.40 points on the",
    "bbox": [
      90.0,
      660.5,
      508.3,
      673.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b038",
    "text": "intent-to-treat analysis in the ADCS-CGIC score at Month 6 between Exelon®",
    "bbox": [
      90.0,
      674.3,
      505.0,
      687.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 26,
    "block_id": "1055_p26_b039",
    "text": "and placebo with a power of 90%.",
    "bbox": [
      90.0,
      688.1,
      273.5,
      701.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 27,
    "block_id": "1055_p27_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 27,
    "block_id": "1055_p27_b002",
    "text": "Page 27 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 27,
    "block_id": "1055_p27_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 27,
    "block_id": "1055_p27_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 27,
    "block_id": "1055_p27_b005",
    "text": "7.1.8.9.3 Overall Sample Size Estimate",
    "bbox": [
      90.0,
      72.3,
      288.6,
      84.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 27,
    "block_id": "1055_p27_b006",
    "text": "To ensure that the study has adequate power to detect statistically significant",
    "bbox": [
      90.0,
      87.9,
      502.2,
      101.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 27,
    "block_id": "1055_p27_b007",
    "text": "results for both primary efficacy variables, 540 patients were to be enrolled.",
    "bbox": [
      90.0,
      101.7,
      492.2,
      115.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 27,
    "block_id": "1055_p27_b008",
    "text": "7.2 Study Results",
    "bbox": [
      90.0,
      135.4,
      197.3,
      148.8
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 27,
    "block_id": "1055_p27_b009",
    "text": "The study was conducted in Austria, Belgium, Canada, France, Germany, Italy,",
    "bbox": [
      90.0,
      152.1,
      513.5,
      165.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 27,
    "block_id": "1055_p27_b010",
    "text": "the Netherlands, Norway, Portugal, Spain, Turkey, and the United Kingdom,",
    "bbox": [
      90.0,
      165.9,
      496.3,
      179.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 27,
    "block_id": "1055_p27_b011",
    "text": "between October 10, 2002, and January 20, 2004.",
    "bbox": [
      90.0,
      179.7,
      360.9,
      193.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 27,
    "block_id": "1055_p27_b012",
    "text": "A total of 68 centers participated in the study.",
    "bbox": [
      90.0,
      207.3,
      336.8,
      220.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 27,
    "block_id": "1055_p27_b013",
    "text": "7.2.1 Patient Disposition",
    "bbox": [
      90.0,
      241.0,
      226.5,
      254.4
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 27,
    "block_id": "1055_p27_b014",
    "text": "A total of 650 patients were screened, of whom 541 were randomized, 362 to the",
    "bbox": [
      90.0,
      257.7,
      522.3,
      271.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 27,
    "block_id": "1055_p27_b015",
    "text": "Exelon® group and 179 to the placebo.",
    "bbox": [
      90.0,
      271.5,
      305.0,
      284.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 27,
    "block_id": "1055_p27_b016",
    "text": "As the above sponsor table indicates, a total of 410 patients (263 [72.7%] who",
    "bbox": [
      90.0,
      538.6,
      507.6,
      552.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 27,
    "block_id": "1055_p27_b017",
    "text": "received Exelon®, and 147 [82.1%] who received placebo, completed the study).",
    "bbox": [
      90.0,
      552.4,
      522.5,
      565.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 27,
    "block_id": "1055_p27_b018",
    "text": "As the table above also indicates, the majority of discontinuations were due to",
    "bbox": [
      90.0,
      580.0,
      506.4,
      593.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 27,
    "block_id": "1055_p27_b019",
    "text": "adverse events: 17.1% of patients in the Exelon® group and 7.8% of patients in",
    "bbox": [
      90.0,
      593.8,
      515.1,
      607.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 27,
    "block_id": "1055_p27_b020",
    "text": "the placebo group discontinued on account of adverse events.",
    "bbox": [
      90.0,
      607.6,
      423.6,
      621.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 27,
    "block_id": "1055_p27_b021",
    "text": "7.2.2 Protocol Deviations",
    "bbox": [
      90.0,
      641.3,
      230.6,
      654.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 27,
    "block_id": "1055_p27_b022",
    "text": "Protocol violations are summarized in the following table, which I have copied",
    "bbox": [
      90.0,
      658.0,
      504.1,
      671.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 27,
    "block_id": "1055_p27_b023",
    "text": "from the submission.",
    "bbox": [
      90.0,
      671.8,
      203.9,
      685.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 28,
    "block_id": "1055_p28_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 28,
    "block_id": "1055_p28_b002",
    "text": "Page 28 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 28,
    "block_id": "1055_p28_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 28,
    "block_id": "1055_p28_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 28,
    "block_id": "1055_p28_b005",
    "text": "The table indicates that protocol violations were slightly more frequent in the",
    "bbox": [
      90.0,
      229.4,
      496.8,
      242.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 28,
    "block_id": "1055_p28_b006",
    "text": "Exelon® group than in the placebo group. The most common protocol violation",
    "bbox": [
      90.0,
      243.2,
      511.1,
      256.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 28,
    "block_id": "1055_p28_b007",
    "text": "was an increase in dose or the new introduction of a psychotropic or",
    "bbox": [
      90.0,
      257.0,
      454.8,
      270.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 28,
    "block_id": "1055_p28_b008",
    "text": "dopaminergic medication; this category of violation was about equal in incidence",
    "bbox": [
      90.0,
      270.8,
      519.6,
      284.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 28,
    "block_id": "1055_p28_b009",
    "text": "between the treatment groups.",
    "bbox": [
      90.0,
      284.6,
      256.1,
      298.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 28,
    "block_id": "1055_p28_b010",
    "text": "7.2.3 Groupings For Analysis",
    "bbox": [
      90.0,
      318.2,
      252.0,
      331.6
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 28,
    "block_id": "1055_p28_b011",
    "text": "The groupings for analysis are summarized in the following sponsor table.",
    "bbox": [
      90.0,
      334.9,
      484.9,
      348.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 28,
    "block_id": "1055_p28_b012",
    "text": "ITT: Intent-to-treat",
    "bbox": [
      90.0,
      476.7,
      158.9,
      485.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 28,
    "block_id": "1055_p28_b013",
    "text": "LOCF: Last-observation-carried-forward",
    "bbox": [
      90.0,
      486.0,
      233.5,
      494.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 28,
    "block_id": "1055_p28_b014",
    "text": "Note that similar proportions of those in the Exelon® and placebo groups are in",
    "bbox": [
      90.0,
      504.4,
      513.1,
      517.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 28,
    "block_id": "1055_p28_b015",
    "text": "the intent-to-treat plus retrieved dropout groups used for the primary efficacy",
    "bbox": [
      90.0,
      518.2,
      498.1,
      531.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 28,
    "block_id": "1055_p28_b016",
    "text": "analysis.",
    "bbox": [
      90.0,
      532.0,
      140.0,
      545.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 28,
    "block_id": "1055_p28_b017",
    "text": "7.2.4 Demographic And Other Baseline Characteristics",
    "bbox": [
      90.0,
      565.7,
      388.7,
      579.1
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 28,
    "block_id": "1055_p28_b018",
    "text": "As the sponsor table below indicates, baseline characteristics for age, gender,",
    "bbox": [
      90.0,
      582.4,
      507.6,
      595.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 28,
    "block_id": "1055_p28_b019",
    "text": "and race were comparable between treatment groups. The table pertains to the",
    "bbox": [
      90.0,
      596.2,
      514.2,
      609.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 28,
    "block_id": "1055_p28_b020",
    "text": "randomized/safety population",
    "bbox": [
      90.0,
      610.0,
      253.4,
      623.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 29,
    "block_id": "1055_p29_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 29,
    "block_id": "1055_p29_b002",
    "text": "Page 29 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 29,
    "block_id": "1055_p29_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 29,
    "block_id": "1055_p29_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 29,
    "block_id": "1055_p29_b005",
    "text": "Baseline Parkinson’s Disease and dementia characteristics were also broadly",
    "bbox": [
      90.0,
      245.8,
      505.0,
      259.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 29,
    "block_id": "1055_p29_b006",
    "text": "comparable between treatment groups, including entry Mini-Mental Status",
    "bbox": [
      90.0,
      259.6,
      485.6,
      273.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 29,
    "block_id": "1055_p29_b007",
    "text": "Examination scores; the table depicts the randomized/safety population.",
    "bbox": [
      90.0,
      273.4,
      478.9,
      286.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 30,
    "block_id": "1055_p30_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 30,
    "block_id": "1055_p30_b002",
    "text": "Page 30 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 30,
    "block_id": "1055_p30_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 30,
    "block_id": "1055_p30_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 30,
    "block_id": "1055_p30_b005",
    "text": "7.2.5 Study Medication",
    "bbox": [
      90.0,
      72.3,
      219.2,
      85.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 30,
    "block_id": "1055_p30_b006",
    "text": "The cumulative duration of patient exposure is summarized by treatment group in",
    "bbox": [
      90.0,
      89.0,
      524.2,
      102.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 30,
    "block_id": "1055_p30_b007",
    "text": "the next table, which I have copied from the submission. As might be expected",
    "bbox": [
      90.0,
      102.8,
      510.1,
      116.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 30,
    "block_id": "1055_p30_b008",
    "text": "from the discontinuation rates in each treatment group alluded to before, the",
    "bbox": [
      90.0,
      116.6,
      496.8,
      130.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 30,
    "block_id": "1055_p30_b009",
    "text": "mean duration of exposure was slightly lower in the Exelon® group than in the",
    "bbox": [
      90.0,
      130.4,
      507.7,
      143.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 30,
    "block_id": "1055_p30_b010",
    "text": "placebo group.",
    "bbox": [
      90.0,
      144.2,
      172.7,
      157.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 30,
    "block_id": "1055_p30_b011",
    "text": "The average daily Exelon® dose per treatment interval is in the next table, which",
    "bbox": [
      90.0,
      380.6,
      521.2,
      394.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 30,
    "block_id": "1055_p30_b012",
    "text": "I have copied from the submission. The average daily Exelon® dose for the",
    "bbox": [
      90.0,
      394.4,
      493.1,
      407.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 30,
    "block_id": "1055_p30_b013",
    "text": "entire study (± standard deviation) is 6.3 mg (± 2.3 mg).",
    "bbox": [
      90.0,
      408.2,
      388.1,
      421.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 30,
    "block_id": "1055_p30_b014",
    "text": "7.2.6 Concomitant  (And Prior) Medication",
    "bbox": [
      90.0,
      573.4,
      320.6,
      586.8
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 30,
    "block_id": "1055_p30_b015",
    "text": "Non-central nervous system related concomitant medications, taken both prior to",
    "bbox": [
      90.0,
      590.2,
      521.7,
      603.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 30,
    "block_id": "1055_p30_b016",
    "text": "and after the start of the study, were used by 80.7% of patients in the Exelon®",
    "bbox": [
      90.0,
      604.0,
      508.4,
      617.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 30,
    "block_id": "1055_p30_b017",
    "text": "group and 79.3% of patients in the placebo group. The most frequently reported",
    "bbox": [
      90.0,
      617.8,
      516.2,
      631.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 30,
    "block_id": "1055_p30_b018",
    "text": "medication was aspirin (16.3% of Exelon®-treated patients and 19.6% of",
    "bbox": [
      90.0,
      631.6,
      479.1,
      645.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 30,
    "block_id": "1055_p30_b019",
    "text": "placebo-treated patients).",
    "bbox": [
      90.0,
      645.4,
      229.5,
      658.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 30,
    "block_id": "1055_p30_b020",
    "text": "Central nervous system-related concomitant medication taken within 4 weeks",
    "bbox": [
      90.0,
      673.0,
      503.5,
      686.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 30,
    "block_id": "1055_p30_b021",
    "text": "prior to start of the study were used by 100% of those in the Exelon® group and",
    "bbox": [
      90.0,
      686.8,
      516.4,
      700.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 30,
    "block_id": "1055_p30_b022",
    "text": "99.4% of those in the placebo group as might have been expected for a",
    "bbox": [
      90.0,
      700.6,
      473.0,
      714.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 31,
    "block_id": "1055_p31_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 31,
    "block_id": "1055_p31_b002",
    "text": "Page 31 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 31,
    "block_id": "1055_p31_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 31,
    "block_id": "1055_p31_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 31,
    "block_id": "1055_p31_b005",
    "text": "population with Parkinson’s Disease. Concomitant medications that were central",
    "bbox": [
      90.0,
      72.2,
      519.0,
      85.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 31,
    "block_id": "1055_p31_b006",
    "text": "nervous system-related were used by 100% of patients in both treatment groups.",
    "bbox": [
      90.0,
      86.0,
      522.3,
      99.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 31,
    "block_id": "1055_p31_b007",
    "text": "The most widely used central-nervous system related concomitant medications",
    "bbox": [
      90.0,
      99.8,
      512.2,
      113.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 31,
    "block_id": "1055_p31_b008",
    "text": "were those in the dopaminergic class. The pattern of dopaminergic agent use in",
    "bbox": [
      90.0,
      113.6,
      516.3,
      127.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 31,
    "block_id": "1055_p31_b009",
    "text": "various classes is summarized in the following table, taken from the submission.",
    "bbox": [
      90.0,
      127.4,
      518.1,
      140.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 31,
    "block_id": "1055_p31_b010",
    "text": "7.2.7 Efficacy Results",
    "bbox": [
      90.0,
      409.6,
      212.5,
      423.0
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 31,
    "block_id": "1055_p31_b011",
    "text": "7.2.7.1 Primary Efficacy Results",
    "bbox": [
      90.0,
      432.4,
      253.2,
      444.7
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 31,
    "block_id": "1055_p31_b012",
    "text": "7.2.7.1.1 ADAS-Cog",
    "bbox": [
      90.0,
      460.0,
      200.0,
      472.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 31,
    "block_id": "1055_p31_b013",
    "text": "In the protocol-specified primary efficacy analysis of the ADAS-Cog (intent-to-",
    "bbox": [
      90.0,
      475.7,
      501.4,
      489.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 31,
    "block_id": "1055_p31_b014",
    "text": "treat plus retrieved dropouts), the Exelon® treatment group improved by a mean",
    "bbox": [
      90.0,
      489.5,
      519.0,
      502.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 31,
    "block_id": "1055_p31_b015",
    "text": "of 2.1 points, whereas the placebo group deteriorated by a mean of 0.7 points,",
    "bbox": [
      90.0,
      503.3,
      509.0,
      516.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 31,
    "block_id": "1055_p31_b016",
    "text": "both at Week 24, with the difference being statistically significant as displayed in",
    "bbox": [
      90.0,
      517.1,
      518.3,
      530.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 31,
    "block_id": "1055_p31_b017",
    "text": "the following table",
    "bbox": [
      90.0,
      530.9,
      189.4,
      544.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 32,
    "block_id": "1055_p32_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 32,
    "block_id": "1055_p32_b002",
    "text": "Page 32 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 32,
    "block_id": "1055_p32_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 32,
    "block_id": "1055_p32_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 32,
    "block_id": "1055_p32_b005",
    "text": "Somewhat greater treatment differences, which were again nominally statistically",
    "bbox": [
      90.0,
      276.5,
      522.1,
      289.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 32,
    "block_id": "1055_p32_b006",
    "text": "significant, were seen for both the intent-to-treat last-observation-carried-forward",
    "bbox": [
      90.0,
      290.3,
      520.2,
      303.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 32,
    "block_id": "1055_p32_b007",
    "text": "and observed cases populations.",
    "bbox": [
      90.0,
      304.1,
      268.8,
      317.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 32,
    "block_id": "1055_p32_b008",
    "text": "The time-course of the change in ADAS-Cog score in the intent-to-treat plus",
    "bbox": [
      90.0,
      331.7,
      496.2,
      345.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 32,
    "block_id": "1055_p32_b009",
    "text": "retrieved dropouts  population in this study is displayed in the next figure, which I",
    "bbox": [
      90.0,
      345.5,
      521.0,
      358.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 32,
    "block_id": "1055_p32_b010",
    "text": "have copied from the published report of this study.",
    "bbox": [
      90.0,
      359.3,
      365.5,
      372.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 32,
    "block_id": "1055_p32_b011",
    "text": "A categorical analysis of the ADAS-Cog based on the proportion of patients",
    "bbox": [
      90.0,
      573.2,
      493.5,
      586.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 32,
    "block_id": "1055_p32_b012",
    "text": "improving (i.e., improving by at least 4 points) in each treatment group at Weeks",
    "bbox": [
      90.0,
      587.0,
      518.3,
      600.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 32,
    "block_id": "1055_p32_b013",
    "text": "16 and 24 is summarized in the following sponsor table.",
    "bbox": [
      90.0,
      600.8,
      388.8,
      614.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 33,
    "block_id": "1055_p33_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 33,
    "block_id": "1055_p33_b002",
    "text": "Page 33 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 33,
    "block_id": "1055_p33_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 33,
    "block_id": "1055_p33_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 33,
    "block_id": "1055_p33_b005",
    "text": "For the categorical analysis above, nominally statistically significant treatment",
    "bbox": [
      90.0,
      197.0,
      504.8,
      210.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 33,
    "block_id": "1055_p33_b006",
    "text": "differences were seen, as indicated by the table for the both the intent-to-treat",
    "bbox": [
      90.0,
      210.8,
      505.6,
      224.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 33,
    "block_id": "1055_p33_b007",
    "text": "last-observation-carried-forward and observed cases populations.",
    "bbox": [
      90.0,
      224.6,
      441.4,
      238.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 33,
    "block_id": "1055_p33_b008",
    "text": "7.2.7.1.2 ADCS-CGIC",
    "bbox": [
      90.0,
      264.3,
      207.8,
      276.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 33,
    "block_id": "1055_p33_b009",
    "text": "In the protocol-specified primary efficacy analysis of the ADCS-CGIC (intent-to-",
    "bbox": [
      90.0,
      279.9,
      510.1,
      293.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 33,
    "block_id": "1055_p33_b010",
    "text": "treat plus retrieved dropouts), the Exelon® treatment group showed a mean",
    "bbox": [
      90.0,
      293.7,
      495.1,
      307.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 33,
    "block_id": "1055_p33_b011",
    "text": "score of 3.8 at Week 24, whereas the placebo group showed a mean score of",
    "bbox": [
      90.0,
      307.5,
      505.6,
      320.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 33,
    "block_id": "1055_p33_b012",
    "text": "4.3 at the same time timepoint, with the difference being statistically significant as",
    "bbox": [
      90.0,
      321.3,
      524.9,
      334.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 33,
    "block_id": "1055_p33_b013",
    "text": "displayed in the following sponsor table.",
    "bbox": [
      90.0,
      335.1,
      305.5,
      348.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 33,
    "block_id": "1055_p33_b014",
    "text": "The categorical data for the intent-to-treat plus retrieved dropouts population in",
    "bbox": [
      90.0,
      533.2,
      511.0,
      546.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 33,
    "block_id": "1055_p33_b015",
    "text": "the above table are also displayed in the following figure which I have copied",
    "bbox": [
      90.0,
      547.0,
      500.2,
      560.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 33,
    "block_id": "1055_p33_b016",
    "text": "from the published report of this study.",
    "bbox": [
      90.0,
      560.8,
      297.6,
      574.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 34,
    "block_id": "1055_p34_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 34,
    "block_id": "1055_p34_b002",
    "text": "Page 34 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 34,
    "block_id": "1055_p34_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 34,
    "block_id": "1055_p34_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 34,
    "block_id": "1055_p34_b005",
    "text": "Similar treatment differences, which were nominally statistically significant, were",
    "bbox": [
      90.0,
      317.8,
      517.5,
      331.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 34,
    "block_id": "1055_p34_b006",
    "text": "seen for both the intent-to-treat last-observation-carried-forward and observed",
    "bbox": [
      90.0,
      331.6,
      506.9,
      345.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 34,
    "block_id": "1055_p34_b007",
    "text": "cases populations.",
    "bbox": [
      90.0,
      345.4,
      192.7,
      358.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 34,
    "block_id": "1055_p34_b008",
    "text": "The categorical analysis of the ADCS-CGIC in the next sponsor table indicates",
    "bbox": [
      90.0,
      373.0,
      510.9,
      386.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 34,
    "block_id": "1055_p34_b009",
    "text": "that there were nominally statistically significantly higher proportions of patients",
    "bbox": [
      90.0,
      386.8,
      512.9,
      400.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 34,
    "block_id": "1055_p34_b010",
    "text": "improving in the Exelon® group relative to the placebo group in all populations",
    "bbox": [
      90.0,
      400.6,
      508.4,
      414.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 34,
    "block_id": "1055_p34_b011",
    "text": "analyzed.",
    "bbox": [
      90.0,
      414.4,
      144.7,
      427.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 34,
    "block_id": "1055_p34_b012",
    "text": "7.2.7.2 Secondary Efficacy Results",
    "bbox": [
      90.0,
      644.8,
      267.9,
      657.1
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 34,
    "block_id": "1055_p34_b013",
    "text": "7.2.7.2.1 ADCS-ADL",
    "bbox": [
      90.0,
      672.4,
      201.8,
      684.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 34,
    "block_id": "1055_p34_b014",
    "text": "Nominal statistically significant treatment differences favoring Exelon® over",
    "bbox": [
      90.0,
      688.1,
      493.0,
      701.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 34,
    "block_id": "1055_p34_b015",
    "text": "placebo were seen at Week 24 for the mean change from baseline to endpoint in",
    "bbox": [
      90.0,
      701.9,
      522.4,
      715.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 35,
    "block_id": "1055_p35_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 35,
    "block_id": "1055_p35_b002",
    "text": "Page 35 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 35,
    "block_id": "1055_p35_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 35,
    "block_id": "1055_p35_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 35,
    "block_id": "1055_p35_b005",
    "text": "the ADCS-ADL in all 3 populations analyzed, including the intent-to-treat",
    "bbox": [
      90.0,
      72.2,
      477.0,
      85.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 35,
    "block_id": "1055_p35_b006",
    "text": "retrieved dropout population. These results are in the sponsor table below.",
    "bbox": [
      90.0,
      86.0,
      488.3,
      99.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 35,
    "block_id": "1055_p35_b007",
    "text": "7.2.7.2.2 Neuropsychiatry Inventory",
    "bbox": [
      90.0,
      323.2,
      273.8,
      335.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 35,
    "block_id": "1055_p35_b008",
    "text": "Nominal statistically significant treatment differences favoring Exelon® over",
    "bbox": [
      90.0,
      338.8,
      493.0,
      352.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 35,
    "block_id": "1055_p35_b009",
    "text": "placebo were seen at Week 24 for the mean change from baseline to endpoint in",
    "bbox": [
      90.0,
      352.6,
      522.4,
      366.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 35,
    "block_id": "1055_p35_b010",
    "text": "the 10-point Neuropsychiatry Inventory total score in the intent-to-treat retrieved",
    "bbox": [
      90.0,
      366.4,
      515.6,
      379.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 35,
    "block_id": "1055_p35_b011",
    "text": "dropout and intent-to-treat last-observation-carried-forward populations (these",
    "bbox": [
      90.0,
      380.2,
      506.1,
      393.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 35,
    "block_id": "1055_p35_b012",
    "text": "results are displayed in the table below).",
    "bbox": [
      90.0,
      394.0,
      307.4,
      407.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 35,
    "block_id": "1055_p35_b013",
    "text": "The proportion of patients with an improved 10-point Neuropsychiatry Inventory",
    "bbox": [
      90.0,
      616.9,
      513.5,
      630.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 35,
    "block_id": "1055_p35_b014",
    "text": "total score was also reported to show a nominally statistically significant",
    "bbox": [
      90.0,
      630.7,
      473.4,
      644.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 35,
    "block_id": "1055_p35_b015",
    "text": "superiority to placebo in all 3 analysis populations. Treatment group differences",
    "bbox": [
      90.0,
      644.5,
      514.3,
      657.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 35,
    "block_id": "1055_p35_b016",
    "text": "on the 12- point Neuropsychiatry Inventory were not even nominally statistically",
    "bbox": [
      90.0,
      658.3,
      513.4,
      671.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 35,
    "block_id": "1055_p35_b017",
    "text": "significant.",
    "bbox": [
      90.0,
      672.1,
      150.1,
      685.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 36,
    "block_id": "1055_p36_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 36,
    "block_id": "1055_p36_b002",
    "text": "Page 36 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 36,
    "block_id": "1055_p36_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 36,
    "block_id": "1055_p36_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 36,
    "block_id": "1055_p36_b005",
    "text": "A nominally statistically significant treatment difference favoring Exelon® was",
    "bbox": [
      90.0,
      72.2,
      502.8,
      85.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 36,
    "block_id": "1055_p36_b006",
    "text": "seen for the Neuropsychiatry Inventory Caregiver Distress score for a single",
    "bbox": [
      90.0,
      86.0,
      496.2,
      99.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 36,
    "block_id": "1055_p36_b007",
    "text": "item: aberrant motor behavior.",
    "bbox": [
      90.0,
      99.8,
      254.1,
      113.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 36,
    "block_id": "1055_p36_b008",
    "text": "7.2.7.2.3 Health Economic Parameters",
    "bbox": [
      90.0,
      139.5,
      286.2,
      151.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 36,
    "block_id": "1055_p36_b009",
    "text": "The analysis of these measures is to be reported separately.",
    "bbox": [
      90.0,
      155.1,
      414.9,
      168.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 36,
    "block_id": "1055_p36_b010",
    "text": "7.2.7.2.4 Cognitive Drug Research – Attention Battery",
    "bbox": [
      90.0,
      194.7,
      359.5,
      207.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 36,
    "block_id": "1055_p36_b011",
    "text": "The combined Power of Attention mean change from baseline score at Week 24",
    "bbox": [
      90.0,
      210.4,
      519.0,
      223.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 36,
    "block_id": "1055_p36_b012",
    "text": "showed a nominally statistically significant difference from placebo.",
    "bbox": [
      90.0,
      224.1,
      452.3,
      237.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 36,
    "block_id": "1055_p36_b013",
    "text": "7.2.7.2.5 Executive Functioning Tests",
    "bbox": [
      90.0,
      451.5,
      280.7,
      463.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 36,
    "block_id": "1055_p36_b014",
    "text": "Since D-KEFS executive function tests were not performed at all centers, the",
    "bbox": [
      90.0,
      467.2,
      501.0,
      480.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 36,
    "block_id": "1055_p36_b015",
    "text": "analyses were performed only in the Observed Cases population.",
    "bbox": [
      90.0,
      481.0,
      440.9,
      494.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 36,
    "block_id": "1055_p36_b016",
    "text": "On the D-KEFS Letter Fluency test change score, a nominally statistically",
    "bbox": [
      90.0,
      508.6,
      482.7,
      522.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 36,
    "block_id": "1055_p36_b017",
    "text": "significant treatment difference was seen at Week 24, with the Exelon® group",
    "bbox": [
      90.0,
      522.4,
      505.6,
      535.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 36,
    "block_id": "1055_p36_b018",
    "text": "improving and placebo group deteriorating on mean scores (see sponsor table",
    "bbox": [
      90.0,
      536.2,
      509.0,
      549.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 36,
    "block_id": "1055_p36_b019",
    "text": "below).",
    "bbox": [
      90.0,
      550.0,
      132.0,
      563.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 36,
    "block_id": "1055_p36_b020",
    "text": "In the D-KEFS Color Word Interference and Card Sorting Tests, a few sub-",
    "bbox": [
      90.0,
      682.1,
      487.5,
      695.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 36,
    "block_id": "1055_p36_b021",
    "text": "scores showed nominally statistically significant differences favoring Exelon®.",
    "bbox": [
      90.0,
      695.9,
      505.7,
      709.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b002",
    "text": "Page 37 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b005",
    "text": "On the Symbol Digits Modality Test, the number of correct substitutions showed",
    "bbox": [
      90.0,
      86.0,
      516.1,
      99.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b006",
    "text": "a nominally statistically significant improvement in favor of Exelon® at Week 24.",
    "bbox": [
      90.0,
      99.8,
      517.2,
      113.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b007",
    "text": "7.2.7.2.6 Ten Point Clock Test",
    "bbox": [
      90.0,
      139.5,
      245.3,
      151.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b008",
    "text": "This test too was performed only on a subset of the study population and",
    "bbox": [
      90.0,
      155.1,
      479.5,
      168.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b009",
    "text": "analyses were confined to the Observed Cases dataset. As the sponsor-supplied",
    "bbox": [
      90.0,
      168.9,
      522.7,
      182.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b010",
    "text": "table below indicates, the mean change from baseline score for this small subset",
    "bbox": [
      90.0,
      182.7,
      521.7,
      196.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b011",
    "text": "improved slightly in the Exelon® group and deteriorated slightly in the placebo",
    "bbox": [
      90.0,
      196.5,
      507.2,
      209.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b012",
    "text": "group, with the difference being nominally statistically significant.",
    "bbox": [
      90.0,
      210.3,
      436.2,
      223.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b013",
    "text": "7.2.7.2.7 Mini-Mental Status Examination",
    "bbox": [
      90.0,
      324.4,
      300.8,
      336.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b014",
    "text": "In the intent-to-treat plus retrieved dropouts population, mean Mini-Mental Status",
    "bbox": [
      90.0,
      340.1,
      521.7,
      353.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b015",
    "text": "Examination scores increased by 0.8 points in the Exelon® group and decreased",
    "bbox": [
      90.0,
      353.9,
      523.0,
      367.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b016",
    "text": "by 0.2 points in the placebo, at Week 24, with the difference being nominally",
    "bbox": [
      90.0,
      367.7,
      497.5,
      381.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b017",
    "text": "statistically significant. Similar results were seen with the other two analysis",
    "bbox": [
      90.0,
      381.5,
      492.6,
      394.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b018",
    "text": "populations.",
    "bbox": [
      90.0,
      395.3,
      158.1,
      408.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b019",
    "text": "7.2.7.3 Overall Efficacy Response",
    "bbox": [
      90.0,
      429.0,
      262.9,
      441.2
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b020",
    "text": "An overall responder was defined as a patient with a combination of the following",
    "bbox": [
      90.0,
      444.5,
      522.8,
      457.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b021",
    "text": "o An improvement in ADAS-Cog of at least 4 points",
    "bbox": [
      108.0,
      472.2,
      370.1,
      485.4
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b022",
    "text": "o ADCS-CGIC category of 1 to 4",
    "bbox": [
      108.0,
      484.8,
      278.8,
      498.0
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b023",
    "text": "o ADCS-ADL change ≥ 0 points",
    "bbox": [
      108.0,
      497.4,
      274.5,
      510.7
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b024",
    "text": "The categorical analysis of the percentage of overall responders showed a",
    "bbox": [
      90.0,
      523.9,
      488.8,
      537.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b025",
    "text": "nominally statistically significant treatment difference favoring Exelon® over",
    "bbox": [
      90.0,
      537.7,
      493.6,
      551.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b026",
    "text": "placebo at Week 24 for the intent-to-treat-last-observation-carried-forward",
    "bbox": [
      90.0,
      551.5,
      484.8,
      564.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b027",
    "text": "population only (20% of patients in the Exelon® group and 13% of patients in the",
    "bbox": [
      90.0,
      565.3,
      521.8,
      578.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b028",
    "text": "placebo group were considered responders in this dataset).",
    "bbox": [
      90.0,
      579.1,
      408.9,
      592.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b029",
    "text": "7.2.7.4 Pharmacogenetic Analyses",
    "bbox": [
      90.0,
      612.7,
      267.2,
      625.0
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b030",
    "text": "302 out of 541 randomized patients consented to pharmacogenetic sampling.",
    "bbox": [
      90.0,
      628.3,
      503.7,
      641.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b031",
    "text": "The results of these analyses are to be reported separately.",
    "bbox": [
      90.0,
      642.1,
      410.2,
      655.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b032",
    "text": "7.2.7.5 Biomarker Analyses",
    "bbox": [
      90.0,
      675.8,
      231.8,
      688.1
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b033",
    "text": "356 and 324 patients consent to biomarker serum and urine sampling,",
    "bbox": [
      90.0,
      691.3,
      465.6,
      704.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 37,
    "block_id": "1055_p37_b034",
    "text": "respectively. The results of these analyses are to be reported separately.",
    "bbox": [
      90.0,
      705.1,
      480.2,
      718.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 38,
    "block_id": "1055_p38_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 38,
    "block_id": "1055_p38_b002",
    "text": "Page 38 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 38,
    "block_id": "1055_p38_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 38,
    "block_id": "1055_p38_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 38,
    "block_id": "1055_p38_b005",
    "text": "7.2.8 Safety Results",
    "bbox": [
      90.0,
      92.1,
      204.6,
      105.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 38,
    "block_id": "1055_p38_b006",
    "text": "7.2.8.1 Overall Adverse Event Experience",
    "bbox": [
      90.0,
      114.9,
      301.5,
      127.2
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 38,
    "block_id": "1055_p38_b007",
    "text": "The overall incidence of all adverse events (i.e., proportion of patients",
    "bbox": [
      90.0,
      130.5,
      462.9,
      143.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 38,
    "block_id": "1055_p38_b008",
    "text": "randomized who had any adverse event) was higher in the Exelon® group",
    "bbox": [
      90.0,
      144.3,
      487.1,
      157.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 38,
    "block_id": "1055_p38_b009",
    "text": "(83.7%) than in the placebo group (70.9%).",
    "bbox": [
      90.0,
      158.1,
      322.8,
      171.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 38,
    "block_id": "1055_p38_b010",
    "text": "The following table, copied from the submission, summarizes the incidence of the",
    "bbox": [
      90.0,
      185.7,
      524.9,
      199.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 38,
    "block_id": "1055_p38_b011",
    "text": "most common adverse events (those with an incidence of at least 5% in either",
    "bbox": [
      90.0,
      199.5,
      507.6,
      212.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 38,
    "block_id": "1055_p38_b012",
    "text": "treatment group) in this study, in descending order of frequency.",
    "bbox": [
      90.0,
      213.3,
      440.3,
      226.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 38,
    "block_id": "1055_p38_b013",
    "text": "As the table above indicates, the most common of the adverse events, all of",
    "bbox": [
      90.0,
      502.2,
      495.6,
      515.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 38,
    "block_id": "1055_p38_b014",
    "text": "which were more frequent in the Exelon® group than in the placebo group, were",
    "bbox": [
      90.0,
      516.0,
      518.5,
      529.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 38,
    "block_id": "1055_p38_b015",
    "text": "nausea, vomiting, tremor, diarrhea, and anorexia. The incidence of dizziness was",
    "bbox": [
      90.0,
      529.8,
      524.2,
      543.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 38,
    "block_id": "1055_p38_b016",
    "text": "also substantially greater in the Exelon® group than in the placebo group.",
    "bbox": [
      90.0,
      543.6,
      483.8,
      557.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 38,
    "block_id": "1055_p38_b017",
    "text": "The next table, also copied from the submission, indicates the overall incidence",
    "bbox": [
      90.0,
      571.2,
      514.2,
      584.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 38,
    "block_id": "1055_p38_b018",
    "text": "of adverse events during each (4-week) treatment period.",
    "bbox": [
      90.0,
      584.9,
      398.2,
      598.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 39,
    "block_id": "1055_p39_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 39,
    "block_id": "1055_p39_b002",
    "text": "Page 39 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 39,
    "block_id": "1055_p39_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 39,
    "block_id": "1055_p39_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 39,
    "block_id": "1055_p39_b005",
    "text": "As the table above indicates, these events appear to have been more frequent,",
    "bbox": [
      90.0,
      262.3,
      513.1,
      275.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 39,
    "block_id": "1055_p39_b006",
    "text": "in the Exelon® group, during the titration phase of this study than during the",
    "bbox": [
      90.0,
      276.1,
      495.0,
      289.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 39,
    "block_id": "1055_p39_b007",
    "text": "maintenance phase.",
    "bbox": [
      90.0,
      289.9,
      204.8,
      303.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 39,
    "block_id": "1055_p39_b008",
    "text": "7.2.8.2 Deaths, Serious Adverse Events, And Discontinuations Due To Adverse Events",
    "bbox": [
      90.0,
      323.5,
      520.9,
      335.8
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 39,
    "block_id": "1055_p39_b009",
    "text": "The incidence of adverse events in each item in this grouping is summarized in",
    "bbox": [
      90.0,
      339.1,
      512.4,
      352.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 39,
    "block_id": "1055_p39_b010",
    "text": "the following table, which I have copied from the submission.",
    "bbox": [
      90.0,
      352.9,
      415.4,
      366.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 39,
    "block_id": "1055_p39_b011",
    "text": "7.2.8.2.1 Deaths",
    "bbox": [
      90.0,
      519.6,
      178.0,
      531.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 39,
    "block_id": "1055_p39_b012",
    "text": "4 patients (1.1% of those randomized) in the Exelon® group and 7 patients in the",
    "bbox": [
      90.0,
      535.2,
      523.0,
      548.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 39,
    "block_id": "1055_p39_b013",
    "text": "placebo group (3.9% of those randomized) died during the study. All deaths",
    "bbox": [
      90.0,
      549.0,
      494.1,
      562.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 39,
    "block_id": "1055_p39_b014",
    "text": "listed occurred while receiving study drug or within 15 days of study drug",
    "bbox": [
      90.0,
      562.8,
      478.9,
      576.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 39,
    "block_id": "1055_p39_b015",
    "text": "discontinuation (all deaths that occurred while on study drug or within 30 days of",
    "bbox": [
      90.0,
      576.6,
      519.0,
      590.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 39,
    "block_id": "1055_p39_b016",
    "text": "study drug discontinuation were to be captured).",
    "bbox": [
      90.0,
      590.4,
      349.6,
      603.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 39,
    "block_id": "1055_p39_b017",
    "text": "Individual deaths in both the Exelon® and placebo groups are listed in the",
    "bbox": [
      90.0,
      618.0,
      485.1,
      631.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 39,
    "block_id": "1055_p39_b018",
    "text": "following table, which I have copied from the submission.",
    "bbox": [
      90.0,
      631.8,
      395.5,
      645.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 40,
    "block_id": "1055_p40_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 40,
    "block_id": "1055_p40_b002",
    "text": "Page 40 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 40,
    "block_id": "1055_p40_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 40,
    "block_id": "1055_p40_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 40,
    "block_id": "1055_p40_b005",
    "text": "7.2.8.2.2 Non-Fatal Serious Adverse Events",
    "bbox": [
      90.0,
      306.4,
      311.8,
      318.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 40,
    "block_id": "1055_p40_b006",
    "text": "13.0% of those in the Exelon® group and 14.5% of those in the placebo group",
    "bbox": [
      90.0,
      322.1,
      507.8,
      335.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 40,
    "block_id": "1055_p40_b007",
    "text": "experienced a non-fatal serious adverse event during this study. The incidence of",
    "bbox": [
      90.0,
      335.9,
      525.0,
      349.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 40,
    "block_id": "1055_p40_b008",
    "text": "such events by system organ class is in the following table.",
    "bbox": [
      90.0,
      349.7,
      406.9,
      363.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 40,
    "block_id": "1055_p40_b009",
    "text": "I have read the listings for all individual serious adverse events. It is hard to link",
    "bbox": [
      90.0,
      642.4,
      513.6,
      655.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 40,
    "block_id": "1055_p40_b010",
    "text": "the individual events that occurred in patients treated with Exelon® to the drug.",
    "bbox": [
      90.0,
      656.2,
      511.8,
      669.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 40,
    "block_id": "1055_p40_b011",
    "text": "All events appeared to be consistent with intercurrent illnesses common in the",
    "bbox": [
      90.0,
      670.0,
      506.9,
      683.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 40,
    "block_id": "1055_p40_b012",
    "text": "elderly, and their complications.",
    "bbox": [
      90.0,
      683.8,
      261.4,
      697.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b002",
    "text": "Page 41 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b005",
    "text": "7.2.8.2.3 Discontinuations Due To Adverse Events",
    "bbox": [
      90.0,
      72.3,
      343.0,
      84.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b006",
    "text": "66 patients (18.2%) receiving Exelon® and 20 patients (11.2%) of those",
    "bbox": [
      90.0,
      87.9,
      474.3,
      101.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b007",
    "text": "receiving placebo discontinued study drug prematurely on account of an adverse",
    "bbox": [
      90.0,
      101.7,
      521.6,
      115.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b008",
    "text": "event.",
    "bbox": [
      90.0,
      115.5,
      126.1,
      128.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b009",
    "text": "Individual adverse events leading to discontinuation that occurred in at least 2",
    "bbox": [
      90.0,
      143.1,
      505.7,
      156.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b010",
    "text": "Exelon®-treated patients are in the following table which I have created from one",
    "bbox": [
      90.0,
      156.9,
      522.5,
      170.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b011",
    "text": "supplied by the sponsor.",
    "bbox": [
      90.0,
      170.7,
      223.4,
      184.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b012",
    "text": "Exelon® (n = 362)",
    "bbox": [
      178.6,
      194.0,
      258.2,
      205.2
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b013",
    "text": "Placebo (n = 179)",
    "bbox": [
      275.3,
      194.0,
      354.0,
      205.2
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b014",
    "text": "Adverse Events",
    "bbox": [
      90.0,
      194.0,
      160.7,
      205.2
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b015",
    "text": "Nausea",
    "bbox": [
      90.0,
      217.7,
      119.7,
      226.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b016",
    "text": "3.6",
    "bbox": [
      215.4,
      217.7,
      228.7,
      226.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b017",
    "text": "0.6",
    "bbox": [
      317.4,
      217.7,
      330.7,
      226.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b018",
    "text": "Vomiting",
    "bbox": [
      90.0,
      227.3,
      123.3,
      236.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b019",
    "text": "1.9",
    "bbox": [
      215.4,
      227.3,
      228.7,
      236.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b020",
    "text": "0.6",
    "bbox": [
      317.4,
      227.3,
      330.7,
      236.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b021",
    "text": "Diarrhea",
    "bbox": [
      90.0,
      237.0,
      122.8,
      245.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b022",
    "text": "1.1",
    "bbox": [
      215.4,
      237.0,
      228.7,
      245.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b023",
    "text": "1.1",
    "bbox": [
      317.4,
      237.0,
      330.7,
      245.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b024",
    "text": "Asthenia",
    "bbox": [
      90.0,
      246.8,
      123.3,
      255.7
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b025",
    "text": "0.6",
    "bbox": [
      215.4,
      246.8,
      228.7,
      255.7
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b026",
    "text": "0.0",
    "bbox": [
      317.4,
      246.8,
      330.7,
      255.7
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b027",
    "text": "Abasia",
    "bbox": [
      90.0,
      256.4,
      116.6,
      265.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b028",
    "text": "0.6",
    "bbox": [
      215.3,
      256.4,
      228.7,
      265.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b029",
    "text": "0.0",
    "bbox": [
      317.4,
      256.4,
      330.7,
      265.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b030",
    "text": "Dehydration",
    "bbox": [
      90.0,
      266.1,
      135.3,
      275.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b031",
    "text": "0.6",
    "bbox": [
      215.4,
      266.1,
      228.7,
      275.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b032",
    "text": "0.6",
    "bbox": [
      317.4,
      266.1,
      330.7,
      275.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b033",
    "text": "Tremor",
    "bbox": [
      90.0,
      275.9,
      118.0,
      284.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b034",
    "text": "1.7",
    "bbox": [
      215.4,
      275.9,
      228.7,
      284.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b035",
    "text": "0.0",
    "bbox": [
      317.4,
      275.9,
      330.7,
      284.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b036",
    "text": "Parkinson’s Disease",
    "bbox": [
      90.0,
      285.5,
      166.8,
      294.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b037",
    "text": "0.8",
    "bbox": [
      215.3,
      285.5,
      228.7,
      294.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b038",
    "text": "0.0",
    "bbox": [
      317.4,
      285.5,
      330.7,
      294.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b039",
    "text": "Dizziness",
    "bbox": [
      90.0,
      295.2,
      126.4,
      304.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b040",
    "text": "0.6",
    "bbox": [
      215.4,
      295.2,
      228.7,
      304.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b041",
    "text": "0.0",
    "bbox": [
      317.4,
      295.2,
      330.7,
      304.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b042",
    "text": "Headache",
    "bbox": [
      90.0,
      305.0,
      128.6,
      313.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b043",
    "text": "0.6",
    "bbox": [
      215.4,
      305.0,
      228.7,
      313.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b044",
    "text": "0.0",
    "bbox": [
      317.4,
      305.0,
      330.7,
      313.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b045",
    "text": "Parkinsonism",
    "bbox": [
      90.0,
      314.6,
      140.2,
      323.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b046",
    "text": "0.6",
    "bbox": [
      215.3,
      314.6,
      228.7,
      323.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b047",
    "text": "0.0",
    "bbox": [
      317.4,
      314.6,
      330.7,
      323.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b048",
    "text": "Balance disorder",
    "bbox": [
      90.0,
      324.3,
      152.2,
      333.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b049",
    "text": "0.6",
    "bbox": [
      215.3,
      324.3,
      228.7,
      333.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b050",
    "text": "0.0",
    "bbox": [
      317.4,
      324.3,
      330.7,
      333.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b051",
    "text": "Hallucination",
    "bbox": [
      90.0,
      334.1,
      138.0,
      343.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b052",
    "text": "1.1",
    "bbox": [
      215.3,
      334.1,
      228.7,
      343.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b053",
    "text": "1.1",
    "bbox": [
      317.3,
      334.1,
      330.7,
      343.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b054",
    "text": "Confusional state",
    "bbox": [
      90.0,
      343.7,
      154.0,
      352.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b055",
    "text": "0.8",
    "bbox": [
      215.4,
      343.7,
      228.7,
      352.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b056",
    "text": "0.6",
    "bbox": [
      317.4,
      343.7,
      330.7,
      352.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b057",
    "text": "Hypotension",
    "bbox": [
      90.0,
      353.4,
      136.6,
      362.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b058",
    "text": "0.6",
    "bbox": [
      215.4,
      353.4,
      228.7,
      362.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b059",
    "text": "0.0",
    "bbox": [
      317.4,
      353.4,
      330.7,
      362.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b060",
    "text": "I have read the listings for all individual adverse events that led to treatment",
    "bbox": [
      90.0,
      372.4,
      494.3,
      385.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b061",
    "text": "discontinuation. With the exception of events such as nausea, vomiting, and",
    "bbox": [
      90.0,
      386.2,
      496.3,
      399.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b062",
    "text": "diarrhea, which could be a consequence of the cholinomimetic effects of",
    "bbox": [
      90.0,
      400.0,
      476.3,
      413.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b063",
    "text": "Exelon®, it is hard to link the individual events that occurred in patients treated",
    "bbox": [
      90.0,
      413.8,
      509.7,
      427.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b064",
    "text": "with Exelon® to the drug. All other events appeared to be consistent with",
    "bbox": [
      90.0,
      427.6,
      479.8,
      441.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b065",
    "text": "intercurrent illnesses common in the elderly (and in the study population) and",
    "bbox": [
      90.0,
      441.4,
      502.2,
      454.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b066",
    "text": "their complications.",
    "bbox": [
      90.0,
      455.2,
      194.9,
      468.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b067",
    "text": "7.2.8.3 Other Significant Adverse Events",
    "bbox": [
      90.0,
      488.9,
      295.4,
      501.2
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b068",
    "text": "Adverse event terms that might be considered to possibly represent a worsening",
    "bbox": [
      90.0,
      504.5,
      520.1,
      517.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b069",
    "text": "of Parkinson’s Disease were pre-specified in the study protocol. The incidence of",
    "bbox": [
      90.0,
      518.3,
      522.3,
      531.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b070",
    "text": "all such events was higher in the Exelon® group (27.3%) than in the placebo",
    "bbox": [
      90.0,
      532.1,
      499.7,
      545.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b071",
    "text": "group (15.6%). The incidence of individual adverse events is summarized in the",
    "bbox": [
      90.0,
      545.9,
      515.5,
      559.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 41,
    "block_id": "1055_p41_b072",
    "text": "following table.  [A number of additional event terms did not occur at all].",
    "bbox": [
      90.0,
      559.7,
      476.4,
      573.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 42,
    "block_id": "1055_p42_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 42,
    "block_id": "1055_p42_b002",
    "text": "Page 42 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 42,
    "block_id": "1055_p42_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 42,
    "block_id": "1055_p42_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 42,
    "block_id": "1055_p42_b005",
    "text": "A higher incidence of tremor, worsening of Parkinson’s Disease, worsening of",
    "bbox": [
      90.0,
      489.7,
      504.9,
      503.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 42,
    "block_id": "1055_p42_b006",
    "text": "parkinsonism, bradykinesia, dyskinesia, abnormal gait, and salivary",
    "bbox": [
      90.0,
      503.5,
      450.7,
      516.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 42,
    "block_id": "1055_p42_b007",
    "text": "hypersecretion in the Exelon® group is noteworthy.",
    "bbox": [
      90.0,
      517.3,
      364.9,
      530.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 42,
    "block_id": "1055_p42_b008",
    "text": "7.2.8.4 Laboratory Tests",
    "bbox": [
      90.0,
      551.0,
      216.5,
      563.3
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 42,
    "block_id": "1055_p42_b009",
    "text": "The sponsor has highlighted changes from baseline in serum amylase, lipase,",
    "bbox": [
      90.0,
      566.6,
      506.9,
      580.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 42,
    "block_id": "1055_p42_b010",
    "text": "and prolactin, which were more apparent in the Exelon® group than in the",
    "bbox": [
      90.0,
      580.4,
      485.2,
      593.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 42,
    "block_id": "1055_p42_b011",
    "text": "placebo.",
    "bbox": [
      90.0,
      594.2,
      138.7,
      607.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 42,
    "block_id": "1055_p42_b012",
    "text": "As the sponsor table below indicates, the mean change from baseline in these",
    "bbox": [
      90.0,
      621.7,
      508.2,
      635.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 42,
    "block_id": "1055_p42_b013",
    "text": "parameters was greater in the Exelon® group than in the placebo group. The",
    "bbox": [
      90.0,
      635.5,
      501.8,
      648.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 42,
    "block_id": "1055_p42_b014",
    "text": "table also shows the mean levels for each parameter at Week 24.",
    "bbox": [
      90.0,
      649.3,
      441.6,
      662.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b002",
    "text": "Page 43 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b005",
    "text": "The proportions of patients in each treatment group who had normal serum",
    "bbox": [
      90.0,
      186.5,
      491.6,
      199.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b006",
    "text": "amylase, lipase, and prolactin levels at baseline, but higher than normal values at",
    "bbox": [
      90.0,
      200.3,
      525.0,
      213.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b007",
    "text": "Week 24 are in the following table. Again, the proportion of such elevations is",
    "bbox": [
      90.0,
      214.1,
      503.0,
      227.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b008",
    "text": "higher in the Exelon® group than in the placebo group.",
    "bbox": [
      90.0,
      227.9,
      384.4,
      241.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b009",
    "text": "Proportion with normal values at baseline and elevations at Week 24*",
    "bbox": [
      161.4,
      255.8,
      469.4,
      267.0
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b010",
    "text": "Parameter",
    "bbox": [
      90.0,
      255.8,
      138.4,
      267.0
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b011",
    "text": "Exelon®",
    "bbox": [
      161.4,
      267.6,
      200.2,
      278.8
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b012",
    "text": "Placebo",
    "bbox": [
      287.4,
      267.6,
      325.2,
      278.8
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b013",
    "text": "Serum amylase",
    "bbox": [
      90.0,
      279.5,
      147.7,
      288.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b014",
    "text": "17.1%",
    "bbox": [
      161.4,
      279.5,
      186.2,
      288.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b015",
    "text": "10.1%",
    "bbox": [
      287.4,
      279.5,
      312.2,
      288.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b016",
    "text": "Serum lipase",
    "bbox": [
      90.0,
      289.2,
      138.8,
      298.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b017",
    "text": "9.0%",
    "bbox": [
      161.3,
      289.2,
      181.8,
      298.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b018",
    "text": "3.6%",
    "bbox": [
      287.4,
      289.2,
      307.8,
      298.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b019",
    "text": "Serum prolactin",
    "bbox": [
      90.0,
      298.8,
      150.4,
      307.7
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b020",
    "text": "9.5%",
    "bbox": [
      161.4,
      298.8,
      181.8,
      307.7
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b021",
    "text": "7.9%",
    "bbox": [
      287.4,
      298.8,
      307.8,
      307.7
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b022",
    "text": "*The data for serum prolactin are for values outside the reference range, not merely",
    "bbox": [
      90.0,
      308.6,
      390.1,
      317.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b023",
    "text": "Narratives have been provided for all patients with elevated serum amylase",
    "bbox": [
      90.0,
      331.7,
      492.8,
      345.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b024",
    "text": "and/or lipase during the study.",
    "bbox": [
      90.0,
      345.5,
      254.1,
      358.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b025",
    "text": "The sponsor also points out the following:",
    "bbox": [
      90.0,
      373.1,
      314.1,
      386.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b026",
    "text": " The maximum serum amylase at Week 24 was 196 U/L (reference range",
    "bbox": [
      108.0,
      400.7,
      516.1,
      414.1
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b027",
    "text": "of 1 to 88 U/L); the maximum serum lipase at Week 24 was 342 U/L",
    "bbox": [
      126.0,
      414.5,
      489.6,
      427.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b028",
    "text": "(reference range of 0 to 63 U/L)",
    "bbox": [
      126.0,
      428.3,
      297.5,
      441.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b029",
    "text": " No patient was diagnosed to have pancreatitis (as an adverse event",
    "bbox": [
      108.0,
      442.1,
      490.2,
      455.5
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b030",
    "text": "during the study)",
    "bbox": [
      126.0,
      455.9,
      218.7,
      469.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b031",
    "text": " No patient discontinued treatment on account of elevated serum amylase",
    "bbox": [
      108.0,
      469.6,
      517.6,
      483.0
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b032",
    "text": "or lipase",
    "bbox": [
      126.0,
      483.4,
      178.0,
      496.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b033",
    "text": "The incidence of other newly occurring notable laboratory abnormalities is in the",
    "bbox": [
      90.0,
      511.0,
      517.6,
      524.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 43,
    "block_id": "1055_p43_b034",
    "text": "following table which I have copied from the submission:",
    "bbox": [
      90.0,
      524.8,
      392.2,
      538.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 44,
    "block_id": "1055_p44_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 44,
    "block_id": "1055_p44_b002",
    "text": "Page 44 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 44,
    "block_id": "1055_p44_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 44,
    "block_id": "1055_p44_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 44,
    "block_id": "1055_p44_b005",
    "text": "7.2.8.5 Vital Signs",
    "bbox": [
      90.0,
      380.1,
      185.9,
      392.4
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 44,
    "block_id": "1055_p44_b006",
    "text": "The number of patients with newly occurring or worsening vital sign and weight",
    "bbox": [
      90.0,
      395.7,
      511.5,
      409.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 44,
    "block_id": "1055_p44_b007",
    "text": "abnormalities was comparable between treatment groups, as indicated in the",
    "bbox": [
      90.0,
      409.5,
      501.7,
      422.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 44,
    "block_id": "1055_p44_b008",
    "text": "following sponsor table.",
    "bbox": [
      90.0,
      423.3,
      218.8,
      436.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 44,
    "block_id": "1055_p44_b009",
    "text": "The mean changes from baseline in these parameters were comparable in the 2",
    "bbox": [
      90.0,
      659.7,
      518.8,
      673.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 44,
    "block_id": "1055_p44_b010",
    "text": "treatment groups.",
    "bbox": [
      90.0,
      673.5,
      187.5,
      686.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b002",
    "text": "Page 45 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b005",
    "text": "7.2.8.6 Electrocardiograms",
    "bbox": [
      90.0,
      72.3,
      228.7,
      84.6
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b006",
    "text": "Summary statistics for electrocardiogram parameters have been reviewed fully.",
    "bbox": [
      90.0,
      87.9,
      513.5,
      101.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b007",
    "text": "The sponsor has drawn attention to the following:",
    "bbox": [
      90.0,
      101.7,
      354.7,
      115.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b008",
    "text": "The mean QTc interval remained unchanged in the placebo group over the",
    "bbox": [
      126.0,
      129.3,
      490.8,
      142.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b009",
    "text": "course of the study, but decreased slightly in the Exelon® group at Week 24",
    "bbox": [
      126.0,
      142.0,
      499.1,
      154.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b010",
    "text": "A slight increase in mean RR interval was seen in the Exelon® group, but the",
    "bbox": [
      126.0,
      154.6,
      504.7,
      166.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b011",
    "text": "change was not felt to be statistically significant",
    "bbox": [
      126.0,
      167.2,
      362.5,
      179.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b012",
    "text": "Newly occurring clinically significant electrocardiogram abnormalities were seen",
    "bbox": [
      126.0,
      179.9,
      516.6,
      192.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b013",
    "text": "in 1.4% of patients in the Exelon® group and 1.1% of patients in the placebo",
    "bbox": [
      126.0,
      192.6,
      500.4,
      204.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b014",
    "text": "group. The new abnormalities seen in the Exelon® group were artificial",
    "bbox": [
      126.0,
      205.2,
      474.1,
      217.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b015",
    "text": "pacemaker rhythm, right bundle branch block, inferior myocardial infarction, and",
    "bbox": [
      126.0,
      217.8,
      517.3,
      230.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b016",
    "text": "T wave inversion",
    "bbox": [
      126.0,
      230.5,
      211.6,
      242.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b017",
    "text": "7.2.8.7 UPDRS Part III Scores",
    "bbox": [
      90.0,
      263.0,
      248.6,
      276.4
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b018",
    "text": "The UPDRS motor scores were used as a means of assessing changes in the",
    "bbox": [
      90.0,
      279.5,
      507.6,
      292.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b019",
    "text": "motor manifestations of Parkinson’s Disease during the study. The mean change",
    "bbox": [
      90.0,
      293.3,
      522.1,
      306.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b020",
    "text": "from baseline scores at Weeks 16 and 24 are summarized in the following table,",
    "bbox": [
      90.0,
      307.1,
      518.8,
      320.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b021",
    "text": "which I have copied from the submission.",
    "bbox": [
      90.0,
      320.9,
      312.7,
      334.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b022",
    "text": "The changes in each treatment group at each timepoint were similar and were",
    "bbox": [
      90.0,
      470.3,
      507.6,
      483.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b023",
    "text": "not considered clinically significant. The differences in change score were not",
    "bbox": [
      90.0,
      484.1,
      503.6,
      497.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b024",
    "text": "even nominally statistically significant.",
    "bbox": [
      90.0,
      497.9,
      294.8,
      511.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b025",
    "text": "The sponsor also points out that statistically significant treatment differences",
    "bbox": [
      90.0,
      525.5,
      498.3,
      538.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b026",
    "text": "were not seen for any of the individual UPDRS Part III item scores. The mean",
    "bbox": [
      90.0,
      539.3,
      504.9,
      552.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b027",
    "text": "change from baseline for the tremor score at Week 24 was 0.1 ± 2.6 for the",
    "bbox": [
      90.0,
      553.1,
      492.2,
      566.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b028",
    "text": "Exelon® group and 0.0 ± 2.1 in the placebo group.",
    "bbox": [
      90.0,
      566.9,
      361.6,
      580.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b029",
    "text": "7.3 Sponsor’s Conclusions",
    "bbox": [
      90.0,
      600.5,
      251.2,
      613.9
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b030",
    "text": "In this trial, which was conducted in dementia associated with Parkinson’s",
    "bbox": [
      90.0,
      617.3,
      484.9,
      630.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b031",
    "text": "Disease, the efficacy of Exelon® in a dose of 3 to 12 mg/day for 24 weeks was",
    "bbox": [
      90.0,
      631.1,
      510.5,
      644.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b032",
    "text": "significantly superior to that of placebo on a measure of cognition (which was",
    "bbox": [
      90.0,
      644.9,
      501.6,
      658.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b033",
    "text": "assessed by the ADAS-Cog) and on a measure of the clinical global rating of",
    "bbox": [
      90.0,
      658.7,
      501.0,
      672.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b034",
    "text": "change (ADCS-CGIC). The primary objective of the study was therefore",
    "bbox": [
      90.0,
      672.5,
      474.3,
      685.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 45,
    "block_id": "1055_p45_b035",
    "text": "achieved",
    "bbox": [
      90.0,
      686.3,
      141.3,
      699.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b002",
    "text": "Page 46 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b005",
    "text": "Secondary efficacy measures that assessed activities of daily living, behavior,",
    "bbox": [
      90.0,
      72.2,
      505.5,
      85.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b006",
    "text": "attention and executive functioning also improved more significantly in those",
    "bbox": [
      90.0,
      86.0,
      497.5,
      99.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b007",
    "text": "treated with Exelon® than in those treated with placebo.",
    "bbox": [
      90.0,
      99.8,
      390.4,
      113.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b008",
    "text": "The safety profile of Exelon® in this study was consistent with published data for",
    "bbox": [
      90.0,
      127.4,
      519.7,
      140.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b009",
    "text": "Exelon® administered to patients with Alzheimer’s Disease. While the incidence",
    "bbox": [
      90.0,
      141.2,
      517.0,
      154.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b010",
    "text": "of adverse events associated with a worsening of Parkinson’s Disease was",
    "bbox": [
      90.0,
      155.0,
      491.5,
      168.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b011",
    "text": "higher in the Exelon® group than in the placebo group, the UPDRS Part III",
    "bbox": [
      90.0,
      168.8,
      488.4,
      182.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b012",
    "text": "(motor) ratings did not reveal any clinically or statistically relevant difference",
    "bbox": [
      90.0,
      182.6,
      494.9,
      196.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b013",
    "text": "between treatment groups for either the total score or any of the individual item",
    "bbox": [
      90.0,
      196.4,
      511.6,
      209.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b014",
    "text": "scores. Changes in laboratory tests and electrocardiograms were considered",
    "bbox": [
      90.0,
      210.2,
      501.4,
      223.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b015",
    "text": "clinically insignificant.",
    "bbox": [
      90.0,
      224.0,
      207.4,
      237.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b016",
    "text": "7.4 Study Abstract",
    "bbox": [
      90.0,
      257.7,
      202.6,
      271.1
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b017",
    "text": "Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van",
    "bbox": [
      90.0,
      274.2,
      509.7,
      288.0
    ],
    "font_size": 12.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b018",
    "text": "Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R.",
    "bbox": [
      90.0,
      287.9,
      475.0,
      301.7
    ],
    "font_size": 12.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b019",
    "text": "Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004;351:2509-18",
    "bbox": [
      90.0,
      301.7,
      516.4,
      315.5
    ],
    "font_size": 12.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b020",
    "text": "BACKGROUND: Cholinergic deficits are prominent in patients who have dementia associated with",
    "bbox": [
      90.0,
      329.3,
      484.5,
      341.9
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b021",
    "text": "Parkinson's disease. We investigated the effects of the dual cholinesterase inhibitor rivastigmine in such",
    "bbox": [
      90.0,
      341.9,
      507.0,
      354.5
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b022",
    "text": "patients.",
    "bbox": [
      90.0,
      354.5,
      129.1,
      367.0
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b023",
    "text": "METHODS: Patients in whom mild-to-moderate dementia developed at least 2 years after they received a",
    "bbox": [
      90.0,
      379.7,
      513.7,
      392.3
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b024",
    "text": "clinical diagnosis of Parkinson's disease were randomly assigned to receive placebo or 3 to 12 mg of",
    "bbox": [
      90.0,
      392.4,
      494.2,
      405.0
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b025",
    "text": "rivastigmine per day for 24 weeks. Primary efficacy variables were the scores for the cognitive subscale of",
    "bbox": [
      90.0,
      405.0,
      515.1,
      417.6
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b026",
    "text": "the Alzheimer's Disease Assessment Scale (ADAS-cog) and Alzheimer's Disease Cooperative Study-",
    "bbox": [
      90.0,
      417.6,
      494.9,
      430.2
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b027",
    "text": "Clinician's Global Impression of Change (ADCS-CGIC). Secondary clinical outcomes were the scores for",
    "bbox": [
      90.0,
      430.2,
      509.8,
      442.8
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b028",
    "text": "the Alzheimer's Disease Cooperative Study-Activities of Daily Living, the 10-item Neuropsychiatric",
    "bbox": [
      90.0,
      442.8,
      482.7,
      455.4
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b029",
    "text": "Inventory, the Mini-Mental State Examination, Cognitive Drug Research power of attention tests, the Verbal",
    "bbox": [
      90.0,
      455.4,
      519.7,
      468.0
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b030",
    "text": "Fluency test, and the Ten Point Clock-Drawing test.",
    "bbox": [
      90.0,
      468.1,
      300.5,
      480.7
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b031",
    "text": "RESULTS: A total of 541 patients were enrolled, and 410 completed the study. The outcomes were better",
    "bbox": [
      90.0,
      493.3,
      513.7,
      505.9
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b032",
    "text": "among patients treated with rivastigmine than among those who received placebo; however, the differences",
    "bbox": [
      90.0,
      506.0,
      521.8,
      518.6
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b033",
    "text": "between these two groups were moderate and similar to those reported in trials of rivastigmine for",
    "bbox": [
      90.0,
      518.6,
      482.2,
      531.1
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b034",
    "text": "Alzheimer's disease. Rivastigmine-treated patients had a mean improvement of 2.1 points in the score for",
    "bbox": [
      90.0,
      531.2,
      512.9,
      543.8
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b035",
    "text": "the 70-point ADAS-cog, from a baseline score of 23.8, as compared with a 0.7-point worsening in the",
    "bbox": [
      90.0,
      543.8,
      495.1,
      556.4
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b036",
    "text": "placebo group, from a baseline score of 24.3 (P<0.001). Clinically meaningful improvements in the scores",
    "bbox": [
      90.0,
      556.4,
      513.5,
      569.0
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b037",
    "text": "for the ADCS-CGIC were observed in 19.8 percent of patients in the rivastigmine group and 14.5 percent of",
    "bbox": [
      90.0,
      569.1,
      520.2,
      581.7
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b038",
    "text": "those in the placebo group, and clinically meaningful worsening was observed in 13.0 percent and 23.1",
    "bbox": [
      90.0,
      581.7,
      503.2,
      594.2
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b039",
    "text": "percent, respectively (mean score at 24 weeks, 3.8 and 4.3, respectively; P=0.007). Significantly better",
    "bbox": [
      90.0,
      594.3,
      501.9,
      606.8
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b040",
    "text": "outcomes were seen with rivastigmine with respect to all secondary efficacy variables. The most frequent",
    "bbox": [
      90.0,
      606.9,
      511.2,
      619.5
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b041",
    "text": "adverse events were nausea (affecting 29.0 percent of patients in the rivastigmine group and 11.2 percent",
    "bbox": [
      90.0,
      619.5,
      515.3,
      632.1
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b042",
    "text": "of those in the placebo group, P<0.001), vomiting (16.6 and 1.7 percent, P<0.001), and tremor (10.2 and 3.9",
    "bbox": [
      90.0,
      632.2,
      523.8,
      644.8
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b043",
    "text": "percent, P=0.01).",
    "bbox": [
      90.0,
      644.8,
      164.5,
      657.4
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b044",
    "text": "CONCLUSIONS: In this placebo-controlled study, rivastigmine was associated with moderate improvements",
    "bbox": [
      90.0,
      670.1,
      523.5,
      682.6
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 46,
    "block_id": "1055_p46_b045",
    "text": "in dementia associated with Parkinson's disease but also with higher rates of nausea, vomiting, and tremor.",
    "bbox": [
      90.0,
      682.7,
      520.6,
      695.2
    ],
    "font_size": 11.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b002",
    "text": "Page 47 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b005",
    "text": "7.5 Additional Observations And Comments By Agency Statistical",
    "bbox": [
      90.0,
      72.3,
      473.5,
      85.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b006",
    "text": "Reviewer About Study 2311",
    "bbox": [
      90.0,
      86.1,
      250.7,
      99.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b007",
    "text": "The Agency Biometrics Reviewer for this submission, Dr Joanne Zhang, has",
    "bbox": [
      90.0,
      102.8,
      498.2,
      116.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b008",
    "text": "made the following main observations, and drawn the overall conclusions",
    "bbox": [
      90.0,
      116.6,
      481.4,
      130.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b009",
    "text": "outlined below regarding the efficacy results of this study",
    "bbox": [
      90.0,
      130.4,
      394.2,
      143.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b010",
    "text": "7.5.1  Observations",
    "bbox": [
      90.0,
      164.1,
      201.3,
      177.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b011",
    "text": "• Dr Zhang has independently performed the protocol-specified primary",
    "bbox": [
      108.0,
      180.5,
      498.9,
      195.2
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b012",
    "text": "efficacy analyses and has obtained results that agree with those obtained",
    "bbox": [
      126.0,
      195.4,
      518.8,
      208.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b013",
    "text": "by the sponsor. However she has the following concerns about these",
    "bbox": [
      126.0,
      209.2,
      495.6,
      222.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b014",
    "text": "analyses",
    "bbox": [
      126.0,
      223.0,
      176.6,
      236.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b015",
    "text": "An assumption underlying the use of an analysis of covariance (used in",
    "bbox": [
      162.0,
      250.6,
      511.8,
      262.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b016",
    "text": "this instance for the primary efficacy analysis of the ADAS-Cog) is that",
    "bbox": [
      162.0,
      263.3,
      506.8,
      275.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b017",
    "text": "the data be normally distributed. Dr Zhang tested the residuals for the",
    "bbox": [
      162.0,
      276.0,
      503.2,
      288.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b018",
    "text": "analysis of covariance model used for the ADAS-Cog analysis with the",
    "bbox": [
      162.0,
      288.6,
      508.1,
      300.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b019",
    "text": "Wilk-Shapiro test; the hypothesis of normality of the residuals was",
    "bbox": [
      162.0,
      301.3,
      485.4,
      313.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b020",
    "text": "rejected (p-values of 0.0072 for Week 16, and < 0.0072 for Week 24). Dr",
    "bbox": [
      162.0,
      313.9,
      518.2,
      326.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b021",
    "text": "Zhang therefore used a non-parametric method, the Wilcoxon rank sum",
    "bbox": [
      162.0,
      326.5,
      513.7,
      338.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b022",
    "text": "test, for the analysis of the ADAS-Cog and demonstrated statistically",
    "bbox": [
      162.0,
      339.2,
      498.3,
      351.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b023",
    "text": "significant differences favoring Exelon® over placebo at both Weeks 16",
    "bbox": [
      162.0,
      351.9,
      512.6,
      364.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b024",
    "text": "and 24 (p < 0.005 at both timepoints)",
    "bbox": [
      162.0,
      364.5,
      345.1,
      376.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b025",
    "text": "Another assumption underlying the use of an analysis of covariance",
    "bbox": [
      162.0,
      389.8,
      494.6,
      402.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b026",
    "text": "model to test for differences between the drug and placebo groups is that",
    "bbox": [
      162.0,
      402.4,
      520.8,
      414.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b027",
    "text": "of a constant regression relationship between the 2 treatment groups; if",
    "bbox": [
      162.0,
      415.1,
      511.8,
      427.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b028",
    "text": "that assumption is violated it is indicative of an interaction between the",
    "bbox": [
      162.0,
      427.8,
      507.5,
      440.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b029",
    "text": "treatment groups and independent variable (i.e., the baseline value) and",
    "bbox": [
      162.0,
      440.4,
      516.0,
      452.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b030",
    "text": "this interaction renders difficult the interpretation of the final treatment",
    "bbox": [
      162.0,
      453.0,
      502.5,
      465.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b031",
    "text": "effect due to the drug. Dr Zhang tested the heterogeneity of the slopes for",
    "bbox": [
      162.0,
      465.7,
      523.4,
      477.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b032",
    "text": "the 2 treatment groups for the ADAS-Cog at Weeks 16 and 24 in the",
    "bbox": [
      162.0,
      478.3,
      497.6,
      490.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b033",
    "text": "intent-to-treat plus retrieved dropouts population; while the slopes at",
    "bbox": [
      162.0,
      491.0,
      495.8,
      503.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b034",
    "text": "Week 16 were similar, those at Week 24 were statistically significantly",
    "bbox": [
      162.0,
      503.7,
      504.9,
      515.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b035",
    "text": "different, as indicated by the table below. Therefore, if the analysis of",
    "bbox": [
      162.0,
      516.2,
      500.1,
      528.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b036",
    "text": "covariance model is relied on to predict the treatment effect due to the",
    "bbox": [
      162.0,
      528.9,
      505.6,
      541.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b037",
    "text": "drug, the drug will be underestimated at low baseline values and",
    "bbox": [
      162.0,
      541.6,
      478.1,
      553.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b038",
    "text": "overestimated at high baseline values. The results of the sponsor’s",
    "bbox": [
      162.0,
      554.2,
      490.3,
      566.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b039",
    "text": "analysis of covariance applied to the ADAS-Cog change from baseline",
    "bbox": [
      162.0,
      566.9,
      507.5,
      579.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b040",
    "text": "data at Week 24 therefore need to be interpreted with caution",
    "bbox": [
      162.0,
      579.5,
      463.9,
      591.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b041",
    "text": "Timepoint",
    "bbox": [
      251.4,
      627.1,
      290.9,
      636.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b042",
    "text": "Estimate",
    "bbox": [
      305.6,
      627.1,
      338.9,
      636.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b043",
    "text": "Standard Error",
    "bbox": [
      358.0,
      627.1,
      412.7,
      636.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b044",
    "text": "P-values for the",
    "bbox": [
      450.1,
      617.9,
      508.2,
      626.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b045",
    "text": "heterogeneity of slopes",
    "bbox": [
      436.7,
      627.0,
      521.6,
      635.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b046",
    "text": "Slope for Exelon®",
    "bbox": [
      167.4,
      640.4,
      236.4,
      649.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b047",
    "text": "Week 16",
    "bbox": [
      254.3,
      640.4,
      288.0,
      649.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b048",
    "text": "0.216",
    "bbox": [
      311.1,
      640.4,
      333.3,
      649.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b049",
    "text": "0.037",
    "bbox": [
      374.2,
      640.4,
      396.4,
      649.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b050",
    "text": "Slope for placebo",
    "bbox": [
      167.4,
      653.6,
      231.8,
      662.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b051",
    "text": "Week 16",
    "bbox": [
      253.1,
      653.6,
      289.1,
      662.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b052",
    "text": "0.215",
    "bbox": [
      311.1,
      653.6,
      333.3,
      662.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b053",
    "text": "0.051",
    "bbox": [
      374.2,
      653.6,
      396.4,
      662.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b054",
    "text": "0.982",
    "bbox": [
      468.0,
      653.6,
      490.2,
      662.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b055",
    "text": "Slope for Exelon®",
    "bbox": [
      167.4,
      666.9,
      236.4,
      675.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b056",
    "text": "Week 24",
    "bbox": [
      254.3,
      666.9,
      288.0,
      675.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b057",
    "text": "0.270",
    "bbox": [
      311.1,
      666.9,
      333.3,
      675.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b058",
    "text": "0.041",
    "bbox": [
      374.2,
      666.9,
      396.4,
      675.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b059",
    "text": "Slope for placebo",
    "bbox": [
      167.4,
      680.1,
      231.8,
      689.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b060",
    "text": "Week 24",
    "bbox": [
      253.1,
      680.1,
      289.1,
      689.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b061",
    "text": "0.120",
    "bbox": [
      311.1,
      680.1,
      333.3,
      689.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b062",
    "text": "0.057",
    "bbox": [
      374.2,
      680.1,
      396.4,
      689.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 47,
    "block_id": "1055_p47_b063",
    "text": "0.034",
    "bbox": [
      468.0,
      680.1,
      490.2,
      689.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b002",
    "text": "Page 48 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b005",
    "text": "When the percentage of those improving on the ADCS-CGIC at Weeks",
    "bbox": [
      162.0,
      72.3,
      510.5,
      84.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b006",
    "text": "16 and 24  in the Exelon® and placebo groups was compared by country",
    "bbox": [
      162.0,
      84.9,
      519.9,
      97.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b007",
    "text": "(Austria, Norway, and Portugal were combined as the sample size for",
    "bbox": [
      162.0,
      97.6,
      502.6,
      109.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b008",
    "text": "each was very small), the Exelon® group performed better than the",
    "bbox": [
      162.0,
      110.2,
      492.3,
      122.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b009",
    "text": "placebo group for most countries whereas the placebo group performed",
    "bbox": [
      162.0,
      122.8,
      514.1,
      135.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b010",
    "text": "better than the Exelon® group for the remaining countries",
    "bbox": [
      162.0,
      135.5,
      445.3,
      147.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b011",
    "text": "• Dr Zhang also repeated the primary efficacy analyses on subgroups",
    "bbox": [
      108.0,
      161.6,
      489.5,
      176.3
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b012",
    "text": "defined by gender. Some of her findings are reproduced below",
    "bbox": [
      126.0,
      176.5,
      461.5,
      189.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b013",
    "text": "The number of male and female patients in each treatment group was as",
    "bbox": [
      162.0,
      204.1,
      519.1,
      216.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b014",
    "text": "follows",
    "bbox": [
      162.0,
      216.8,
      198.7,
      229.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b015",
    "text": "Treatment Group",
    "bbox": [
      167.4,
      242.5,
      230.5,
      251.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b016",
    "text": "Exelon®",
    "bbox": [
      251.4,
      242.5,
      286.2,
      251.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b017",
    "text": "Placebo",
    "bbox": [
      311.4,
      242.5,
      342.5,
      251.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b018",
    "text": "Women",
    "bbox": [
      167.4,
      261.4,
      199.4,
      270.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b019",
    "text": "128",
    "bbox": [
      251.4,
      261.4,
      266.9,
      270.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b020",
    "text": "Men",
    "bbox": [
      167.4,
      271.1,
      185.1,
      280.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b021",
    "text": "234",
    "bbox": [
      251.4,
      271.1,
      266.9,
      280.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b022",
    "text": "117",
    "bbox": [
      311.4,
      271.1,
      326.9,
      280.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b023",
    "text": "Her subgroup analyses for the intent-to-treat plus retrieved dropouts",
    "bbox": [
      162.0,
      290.1,
      495.8,
      302.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b024",
    "text": "populations on the ADAS-Cog change from baseline score at Week 24",
    "bbox": [
      162.0,
      302.7,
      508.7,
      315.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b025",
    "text": "are below",
    "bbox": [
      162.0,
      315.4,
      212.7,
      327.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b026",
    "text": "Subgroup",
    "bbox": [
      167.4,
      341.1,
      204.2,
      350.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b027",
    "text": "Exelon®",
    "bbox": [
      239.4,
      341.1,
      274.1,
      350.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b028",
    "text": "Mean change (SD)",
    "bbox": [
      239.4,
      350.3,
      308.7,
      359.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b029",
    "text": "Placebo",
    "bbox": [
      323.4,
      341.1,
      354.5,
      350.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b030",
    "text": "Mean change (SD)",
    "bbox": [
      323.4,
      350.3,
      392.7,
      359.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b031",
    "text": "p-value",
    "bbox": [
      413.4,
      341.1,
      441.8,
      350.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b032",
    "text": "Women",
    "bbox": [
      167.4,
      360.0,
      197.1,
      368.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b033",
    "text": "1.9 (8.4)",
    "bbox": [
      239.3,
      360.0,
      271.3,
      368.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b034",
    "text": "-0.9 (8.0)",
    "bbox": [
      323.4,
      360.0,
      358.0,
      368.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b035",
    "text": "0.027",
    "bbox": [
      413.4,
      360.0,
      435.6,
      368.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b036",
    "text": "Men",
    "bbox": [
      167.4,
      369.7,
      187.4,
      378.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b037",
    "text": "2.2 (8.1)",
    "bbox": [
      239.4,
      369.7,
      271.4,
      378.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b038",
    "text": "-0.7 (7.2)",
    "bbox": [
      323.4,
      369.7,
      358.0,
      378.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b039",
    "text": "0.001",
    "bbox": [
      413.4,
      369.7,
      435.6,
      378.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b040",
    "text": "Her subgroup analyses for the intent-to-treat plus retrieved dropouts",
    "bbox": [
      162.0,
      388.7,
      495.8,
      401.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b041",
    "text": "populations on the ADCS-CGIC score at Week 24 are below",
    "bbox": [
      162.0,
      401.4,
      459.0,
      413.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b042",
    "text": "Women",
    "bbox": [
      325.2,
      430.6,
      354.9,
      439.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b043",
    "text": "Men",
    "bbox": [
      448.8,
      430.6,
      466.5,
      439.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b044",
    "text": "Exelon®",
    "bbox": [
      293.8,
      443.9,
      326.4,
      452.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b045",
    "text": "Placebo",
    "bbox": [
      357.6,
      443.9,
      388.7,
      452.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b046",
    "text": "Exelon®",
    "bbox": [
      413.8,
      443.9,
      446.4,
      452.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b047",
    "text": "Placebo",
    "bbox": [
      471.9,
      443.9,
      503.0,
      452.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b048",
    "text": "116",
    "bbox": [
      302.3,
      457.1,
      317.9,
      466.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b049",
    "text": "213",
    "bbox": [
      422.3,
      457.1,
      437.9,
      466.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b050",
    "text": "108",
    "bbox": [
      479.6,
      457.1,
      495.2,
      466.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b051",
    "text": "Mean ± SD",
    "bbox": [
      167.4,
      470.4,
      209.5,
      479.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b052",
    "text": "3.9 ± 1.5",
    "bbox": [
      293.4,
      470.4,
      326.7,
      479.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b053",
    "text": "4.3 ± 1.4",
    "bbox": [
      356.4,
      470.4,
      389.7,
      479.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b054",
    "text": "3.8 ± 1.4",
    "bbox": [
      413.4,
      470.4,
      446.7,
      479.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b055",
    "text": "4.3 ± 1.5",
    "bbox": [
      470.7,
      470.4,
      504.0,
      479.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b056",
    "text": "Markedly improved (%)",
    "bbox": [
      167.4,
      483.6,
      251.8,
      492.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b057",
    "text": "Moderately improved (%)",
    "bbox": [
      167.4,
      496.8,
      258.9,
      505.7
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b058",
    "text": "Minimally improved (%)",
    "bbox": [
      167.4,
      510.1,
      252.6,
      519.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b059",
    "text": "Unchanged (%)",
    "bbox": [
      167.4,
      523.4,
      225.1,
      532.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b060",
    "text": "Minimally worse (%)",
    "bbox": [
      167.4,
      536.6,
      241.0,
      545.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b061",
    "text": "Moderately worse (%)",
    "bbox": [
      167.4,
      549.9,
      247.4,
      558.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b062",
    "text": "Markedly worse (%)",
    "bbox": [
      167.4,
      563.1,
      240.2,
      572.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b063",
    "text": "p-value",
    "bbox": [
      167.4,
      576.3,
      195.8,
      585.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b064",
    "text": "0.350",
    "bbox": [
      329.0,
      576.3,
      351.2,
      585.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b065",
    "text": "0.045",
    "bbox": [
      449.3,
      576.3,
      471.5,
      585.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b066",
    "text": "• She has noted that the sponsor has used the intent-to-treat plus retrieved",
    "bbox": [
      108.0,
      599.6,
      518.3,
      614.3
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b067",
    "text": "dropouts population for the primary efficacy analysis, whereas the Agency",
    "bbox": [
      126.0,
      614.5,
      521.5,
      627.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b068",
    "text": "usually recommends that the intent-to-treat last-observation-carried-",
    "bbox": [
      126.0,
      628.3,
      486.8,
      641.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b069",
    "text": "forward population be used for that purpose. She does, however, also",
    "bbox": [
      126.0,
      642.1,
      499.7,
      655.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b070",
    "text": "note that when the same analysis was repeated for the intent-to-treat last-",
    "bbox": [
      126.0,
      655.9,
      517.6,
      669.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 48,
    "block_id": "1055_p48_b071",
    "text": "observation-carried-forward population, the results were similar.",
    "bbox": [
      126.0,
      669.7,
      467.5,
      683.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b002",
    "text": "Page 49 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b005",
    "text": "7.5.2 Conclusions",
    "bbox": [
      90.0,
      72.3,
      192.5,
      85.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b006",
    "text": "Dr Zhang has concluded that the data provided support the efficacy of Exelon®",
    "bbox": [
      90.0,
      89.0,
      513.1,
      102.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b007",
    "text": "in Parkinson’s Disease Dementia, based on the prospectively-specified statistical",
    "bbox": [
      90.0,
      102.8,
      522.8,
      116.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b008",
    "text": "analysis plan; several sensitivity analyses support this conclusion. She does,",
    "bbox": [
      90.0,
      116.6,
      500.2,
      130.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b009",
    "text": "however, note that a gender-based subgroup analysis suggests that this benefit",
    "bbox": [
      90.0,
      130.4,
      515.8,
      143.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b010",
    "text": "may not extend to women.",
    "bbox": [
      90.0,
      144.2,
      234.1,
      157.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b011",
    "text": "7.6 Reviewer’s Comments",
    "bbox": [
      90.0,
      177.9,
      245.2,
      191.3
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b012",
    "text": "7.6.1 Efficacy Of Exelon®",
    "bbox": [
      90.0,
      200.7,
      237.4,
      214.1
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b013",
    "text": "This study does indicate that Exelon® in a dose of 3 to 12 mg/day did have",
    "bbox": [
      90.0,
      217.4,
      491.0,
      230.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b014",
    "text": "efficacy in the entire study population, based on prospectively-specified criteria.",
    "bbox": [
      90.0,
      231.2,
      514.2,
      244.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b015",
    "text": "Although a statistically significant treatment effect was not seen in women alone",
    "bbox": [
      90.0,
      245.0,
      517.0,
      258.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b016",
    "text": "on the gender-based subgroup analysis for the ADCS-CGIC performed by the",
    "bbox": [
      90.0,
      258.8,
      506.2,
      272.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b017",
    "text": "Agency Biometrics Reviewer, the effect sizes (and variance) in that subgroup for",
    "bbox": [
      90.0,
      272.6,
      519.7,
      286.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b018",
    "text": "the mean change from baseline to Week 24 in ADAS-Cog score and mean",
    "bbox": [
      90.0,
      286.4,
      489.6,
      299.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b019",
    "text": "ADCS-CGIC score were similar to those seen in men, while fewer women than",
    "bbox": [
      90.0,
      300.2,
      510.7,
      313.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b020",
    "text": "men were enrolled in the study.",
    "bbox": [
      90.0,
      314.0,
      260.1,
      327.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b021",
    "text": "The implications of the results of this study in the context of the new claim (i.e.,",
    "bbox": [
      90.0,
      341.6,
      511.0,
      355.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b022",
    "text": "“treatment of mild to moderate dementia associated with Parkinson’s Disease”)",
    "bbox": [
      90.0,
      355.4,
      512.2,
      368.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b023",
    "text": "sought by the sponsor in this Supplemental Application are discussed later in the",
    "bbox": [
      90.0,
      369.2,
      521.6,
      382.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b024",
    "text": "review.",
    "bbox": [
      90.0,
      383.0,
      131.3,
      396.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b025",
    "text": "7.6.2 Safety Of Exelon®",
    "bbox": [
      90.0,
      416.7,
      226.1,
      430.1
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b026",
    "text": "The safety data for this study indicate that the adverse event profile of Exelon® in",
    "bbox": [
      90.0,
      433.4,
      525.1,
      446.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b027",
    "text": "the study population was largely similar to that seen in clinical trials with",
    "bbox": [
      90.0,
      447.2,
      473.5,
      460.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b028",
    "text": "Alzheimer’s Disease, in that there was a distinctly higher frequency of nausea,",
    "bbox": [
      90.0,
      461.0,
      508.3,
      474.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b029",
    "text": "vomiting, diarrhea, and anorexia in those exposed to Exelon® than in those",
    "bbox": [
      90.0,
      474.8,
      493.1,
      488.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b030",
    "text": "exposed to placebo.",
    "bbox": [
      90.0,
      488.6,
      204.1,
      502.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b031",
    "text": "Of special relevance to a population with Parkinson’s Disease, was the",
    "bbox": [
      90.0,
      516.2,
      468.8,
      529.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b032",
    "text": "observation that tremor (which was not further characterized) was recorded as a",
    "bbox": [
      90.0,
      530.0,
      518.3,
      543.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b033",
    "text": "treatment-emergent adverse event in about 10% of those received Exelon® and",
    "bbox": [
      90.0,
      543.8,
      517.8,
      557.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b034",
    "text": "4% of those who received placebo in this study (in the controlled clinical trials of",
    "bbox": [
      90.0,
      557.6,
      516.3,
      571.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b035",
    "text": "Exelon® that were conducted prior to its approval for Alzheimer’s Disease,",
    "bbox": [
      90.0,
      571.4,
      488.5,
      584.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b036",
    "text": "tremor was seen in about 4% of  those who received Exelon® and 1% of those",
    "bbox": [
      90.0,
      585.2,
      511.0,
      598.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b037",
    "text": "who received placebo). Several other adverse events that may conceivably have",
    "bbox": [
      90.0,
      599.0,
      521.0,
      612.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b038",
    "text": "been linked to a worsening in Parkinson’s Disease were also more frequent in",
    "bbox": [
      90.0,
      612.8,
      506.2,
      626.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b039",
    "text": "those treated with Exelon® than in those treated with placebo, but their incidence",
    "bbox": [
      90.0,
      626.6,
      523.8,
      640.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b040",
    "text": "in the Exelon®-treated group was lower than that of tremor. However, changes in",
    "bbox": [
      90.0,
      640.4,
      523.9,
      653.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b041",
    "text": "UPDRS total motor scores, probably a more objective measure of change in the",
    "bbox": [
      90.0,
      654.2,
      516.8,
      667.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b042",
    "text": "motor manifestations of Parkinson’s Disease than the incidence of treatment-",
    "bbox": [
      90.0,
      668.0,
      498.8,
      681.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b043",
    "text": "emergent adverse events, showed no meaningful difference between treatment",
    "bbox": [
      90.0,
      681.8,
      514.3,
      695.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 49,
    "block_id": "1055_p49_b044",
    "text": "groups.",
    "bbox": [
      90.0,
      695.6,
      133.4,
      709.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b002",
    "text": "Page 50 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b005",
    "text": "8. Study 2311E1 (Open-Label Uncontrolled Extension To Study",
    "bbox": [
      90.0,
      98.2,
      511.8,
      113.8
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b006",
    "text": "2311)",
    "bbox": [
      90.0,
      114.3,
      129.0,
      129.9
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b007",
    "text": "The protocol and main safety results for this study will be summarized briefly",
    "bbox": [
      90.0,
      133.3,
      498.8,
      146.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b008",
    "text": "below. Note that I have not summarized the efficacy data for this study at all,",
    "bbox": [
      90.0,
      147.1,
      498.9,
      160.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b009",
    "text": "despite presentation of those data by the sponsor in the study report, as",
    "bbox": [
      90.0,
      160.9,
      475.0,
      174.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b010",
    "text": "uncontrolled data are not used to determine efficacy for regulatory purposes.",
    "bbox": [
      90.0,
      174.7,
      499.6,
      188.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b011",
    "text": "8.1 Protocol 2311E1",
    "bbox": [
      90.0,
      208.3,
      210.5,
      221.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b012",
    "text": "Only a brief outline of the protocol has been provided below.",
    "bbox": [
      90.0,
      225.0,
      412.8,
      238.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b013",
    "text": "8.1.1 Title",
    "bbox": [
      90.0,
      258.7,
      149.8,
      272.1
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b014",
    "text": "An Open-Label 24-Week Extension To A 24-Week, Prospective, Randomized,",
    "bbox": [
      90.0,
      275.4,
      508.2,
      288.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b015",
    "text": "Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The",
    "bbox": [
      90.0,
      289.2,
      494.2,
      302.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b016",
    "text": "Efficacy, Tolerability, And Safety Of Exelon® (Rivastigmine) Capsules In Patients",
    "bbox": [
      90.0,
      303.0,
      523.7,
      316.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b017",
    "text": "With Parkinson’s Disease Dementia",
    "bbox": [
      90.0,
      316.8,
      284.1,
      330.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b018",
    "text": "8.1.2 Objectives",
    "bbox": [
      90.0,
      350.5,
      183.2,
      363.9
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b019",
    "text": "8.1.2.1 Primary",
    "bbox": [
      90.0,
      373.3,
      181.9,
      386.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b020",
    "text": "To evaluate the safety and tolerability of open-label Exelon® (3 to 12 mg/day) for",
    "bbox": [
      90.0,
      390.0,
      521.8,
      403.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b021",
    "text": "up to 24 weeks in patients who previously completed Study 2311, and to provide",
    "bbox": [
      90.0,
      403.8,
      520.3,
      417.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b022",
    "text": "continued access to Exelon®",
    "bbox": [
      90.0,
      417.6,
      251.5,
      431.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b023",
    "text": "8.1.2.2 Secondary",
    "bbox": [
      90.0,
      451.3,
      194.6,
      464.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b024",
    "text": "To evaluate the effects of Exelon® on cognition, including executive function,",
    "bbox": [
      90.0,
      468.0,
      501.8,
      481.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b025",
    "text": "activities of daily living, behavioral symptoms and health economic parameters",
    "bbox": [
      90.0,
      481.8,
      509.5,
      495.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b026",
    "text": "including caregiver distress and caregiver burden",
    "bbox": [
      90.0,
      495.6,
      354.7,
      509.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b027",
    "text": "8.1.3 Design, Duration, Sample Size, Dosage",
    "bbox": [
      90.0,
      529.3,
      338.7,
      542.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b028",
    "text": "This was to be an open-label uncontrolled extension study.",
    "bbox": [
      90.0,
      546.0,
      408.8,
      559.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b029",
    "text": "540 patients were planned to be enrolled in the preceding double-blind study.",
    "bbox": [
      90.0,
      573.6,
      503.0,
      587.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b030",
    "text": "The design of this study and its predecessor are summarized in the following",
    "bbox": [
      90.0,
      601.2,
      500.1,
      614.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 50,
    "block_id": "1055_p50_b031",
    "text": "table, which I have copied from the submission.",
    "bbox": [
      90.0,
      615.0,
      348.8,
      628.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b002",
    "text": "Page 51 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b005",
    "text": "4 dose levels were to be used for Exelon® (and for matching placebo). The dose",
    "bbox": [
      90.0,
      220.4,
      521.1,
      233.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b006",
    "text": "levels for Exelon® are shown in the following table.",
    "bbox": [
      90.0,
      234.2,
      364.3,
      247.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b007",
    "text": "Dose Level",
    "bbox": [
      95.4,
      262.4,
      146.0,
      273.6
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b008",
    "text": "Exelon® Dose",
    "bbox": [
      155.4,
      262.4,
      218.6,
      273.6
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b009",
    "text": "1.5 mg BID",
    "bbox": [
      155.4,
      274.5,
      202.0,
      283.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b010",
    "text": "3.0 mg BID",
    "bbox": [
      155.4,
      284.4,
      199.8,
      293.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b011",
    "text": "4.5 mg BID",
    "bbox": [
      155.4,
      294.4,
      199.8,
      303.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b012",
    "text": "6.0 mg BID",
    "bbox": [
      155.4,
      304.4,
      199.8,
      313.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b013",
    "text": "The actual dosing regime was to be as follows:",
    "bbox": [
      90.0,
      328.1,
      342.1,
      341.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b014",
    "text": "• For the titration period",
    "bbox": [
      108.0,
      355.4,
      246.8,
      370.1
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b015",
    "text": "All patients were to begin at Dose Level 1 (regardless of their treatment",
    "bbox": [
      162.0,
      384.1,
      511.8,
      396.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b016",
    "text": "assignment in Study 2311)",
    "bbox": [
      162.0,
      396.8,
      295.2,
      409.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b017",
    "text": "After 4 weeks the dose was to be increased to Dose Level 2 unless there",
    "bbox": [
      162.0,
      409.5,
      520.3,
      421.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b018",
    "text": "tolerability was impaired",
    "bbox": [
      162.0,
      422.1,
      282.4,
      434.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b019",
    "text": "Subsequent increases to Dose Levels 3 and 4 were to be based on the",
    "bbox": [
      162.0,
      434.8,
      510.6,
      447.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b020",
    "text": "tolerability of the preceding dose, and were to be considered only after 4",
    "bbox": [
      162.0,
      447.4,
      516.6,
      459.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b021",
    "text": "weeks of treatment at the previous dose",
    "bbox": [
      162.0,
      460.0,
      360.1,
      472.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b022",
    "text": "In the event of poor tolerability, an investigator could decide to reduce a",
    "bbox": [
      162.0,
      472.7,
      513.0,
      485.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b023",
    "text": "dose to the preceding level, with increases to the next dose level being",
    "bbox": [
      162.0,
      485.4,
      509.4,
      497.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b024",
    "text": "made as clinically indicated after a minimum of 2 weeks",
    "bbox": [
      162.0,
      498.0,
      435.8,
      510.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b025",
    "text": "The aim was to find the highest tolerated dose for each patient by Week",
    "bbox": [
      162.0,
      510.7,
      514.8,
      522.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b026",
    "text": "16.",
    "bbox": [
      162.0,
      523.3,
      183.4,
      535.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b027",
    "text": "• For the maintenance period",
    "bbox": [
      108.0,
      549.4,
      276.0,
      564.0
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b028",
    "text": "The highest well-tolerated dose for each patient was to be maintained for",
    "bbox": [
      162.0,
      578.2,
      519.6,
      590.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b029",
    "text": "the entire maintenance period",
    "bbox": [
      162.0,
      590.8,
      310.6,
      603.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b030",
    "text": "However, dose adjustments were permitted at any time",
    "bbox": [
      162.0,
      603.4,
      433.4,
      615.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b031",
    "text": "8.1.4 Key Inclusion Criteria",
    "bbox": [
      90.0,
      635.9,
      240.6,
      649.3
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b032",
    "text": " Fulfilled eligibility criteria for Study 2311",
    "bbox": [
      108.0,
      652.7,
      340.1,
      666.1
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b033",
    "text": " Either completed double-blind treatment phase of Study 2311 or",
    "bbox": [
      108.0,
      666.5,
      469.6,
      679.9
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b034",
    "text": "discontinued early during that study, but returned for all the remaining",
    "bbox": [
      126.0,
      680.3,
      498.2,
      693.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 51,
    "block_id": "1055_p51_b035",
    "text": "scheduled efficacy assessments without significant protocol violations",
    "bbox": [
      126.0,
      694.1,
      498.8,
      707.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 52,
    "block_id": "1055_p52_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 52,
    "block_id": "1055_p52_b002",
    "text": "Page 52 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 52,
    "block_id": "1055_p52_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 52,
    "block_id": "1055_p52_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 52,
    "block_id": "1055_p52_b005",
    "text": " Informed consent",
    "bbox": [
      108.0,
      72.2,
      222.0,
      85.6
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 52,
    "block_id": "1055_p52_b006",
    "text": " Not treated with other acetylcholinesterase inhibitors or cholinomimetic",
    "bbox": [
      108.0,
      86.0,
      504.1,
      99.4
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 52,
    "block_id": "1055_p52_b007",
    "text": "agents, and anticholinergic drugs (including tricyclic antidepressants)",
    "bbox": [
      126.0,
      99.8,
      494.9,
      113.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 52,
    "block_id": "1055_p52_b008",
    "text": "within 4 weeks prior to entry into the study",
    "bbox": [
      126.0,
      113.6,
      352.7,
      127.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 52,
    "block_id": "1055_p52_b009",
    "text": "8.1.5 Study Schedule",
    "bbox": [
      90.0,
      147.3,
      211.2,
      160.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 52,
    "block_id": "1055_p52_b010",
    "text": "The study schedule is summarized in the following table, which I have copied",
    "bbox": [
      90.0,
      164.0,
      502.2,
      177.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 52,
    "block_id": "1055_p52_b011",
    "text": "from the submission.",
    "bbox": [
      90.0,
      177.8,
      203.9,
      191.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 52,
    "block_id": "1055_p52_b012",
    "text": "8.1.6 Safety Outcome Measures",
    "bbox": [
      90.0,
      508.7,
      269.3,
      522.1
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 52,
    "block_id": "1055_p52_b013",
    "text": "Adverse events, safety laboratory tests, vital signs, body weight,",
    "bbox": [
      90.0,
      525.5,
      433.6,
      538.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 52,
    "block_id": "1055_p52_b014",
    "text": "electrocardiograms, and UPDRS Part III (Motor Function).",
    "bbox": [
      90.0,
      539.3,
      400.8,
      552.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 52,
    "block_id": "1055_p52_b015",
    "text": "8.2 Safety Results Of Study 2311E1",
    "bbox": [
      90.0,
      572.9,
      298.0,
      586.3
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 52,
    "block_id": "1055_p52_b016",
    "text": "8.2.1 Patient Disposition",
    "bbox": [
      90.0,
      595.7,
      226.5,
      609.1
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 52,
    "block_id": "1055_p52_b017",
    "text": "433 patients enrolled in Study 2311 were eligible to be enrolled in Study 2311E1;",
    "bbox": [
      90.0,
      612.5,
      522.3,
      625.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 52,
    "block_id": "1055_p52_b018",
    "text": "334 patients actually consented to participate in the latter study, which 273",
    "bbox": [
      90.0,
      626.3,
      488.9,
      639.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 52,
    "block_id": "1055_p52_b019",
    "text": "patients completed.",
    "bbox": [
      90.0,
      640.1,
      200.8,
      653.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 52,
    "block_id": "1055_p52_b020",
    "text": "Patient disposition is summarized in the following sponsor table, with patients",
    "bbox": [
      90.0,
      667.7,
      502.9,
      681.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 52,
    "block_id": "1055_p52_b021",
    "text": "grouped according to whether they took Exelon® (“Exe”) or placebo (“Plc”) in the",
    "bbox": [
      90.0,
      681.5,
      521.2,
      694.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 52,
    "block_id": "1055_p52_b022",
    "text": "preceding double-blind study. Note that all discontinuations as well as",
    "bbox": [
      90.0,
      695.3,
      463.0,
      708.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 53,
    "block_id": "1055_p53_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 53,
    "block_id": "1055_p53_b002",
    "text": "Page 53 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 53,
    "block_id": "1055_p53_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 53,
    "block_id": "1055_p53_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 53,
    "block_id": "1055_p53_b005",
    "text": "discontinuations due to  adverse events were more common in those earlier",
    "bbox": [
      90.0,
      72.2,
      495.5,
      85.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 53,
    "block_id": "1055_p53_b006",
    "text": "exposed to placebo than in those previously exposed to Exelon®.",
    "bbox": [
      90.0,
      86.0,
      440.9,
      99.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 53,
    "block_id": "1055_p53_b007",
    "text": "8.2.2 Exposure To Study Drug",
    "bbox": [
      90.0,
      405.7,
      258.6,
      419.1
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 53,
    "block_id": "1055_p53_b008",
    "text": "The mean duration of exposure to Exelon® in this study was 21.6 weeks, and",
    "bbox": [
      90.0,
      422.4,
      504.6,
      435.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 53,
    "block_id": "1055_p53_b009",
    "text": "was similar in those exposed to Exelon® earlier as compared with those exposed",
    "bbox": [
      90.0,
      436.2,
      524.3,
      449.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 53,
    "block_id": "1055_p53_b010",
    "text": "to placebo (see the sponsor table below).",
    "bbox": [
      90.0,
      450.0,
      312.8,
      463.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 53,
    "block_id": "1055_p53_b011",
    "text": "8.2.3 Concomitant Medication",
    "bbox": [
      90.0,
      583.7,
      255.9,
      597.1
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 53,
    "block_id": "1055_p53_b012",
    "text": "A slightly larger proportion of those who previously received Exelon® (than those",
    "bbox": [
      90.0,
      600.5,
      522.3,
      613.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 53,
    "block_id": "1055_p53_b013",
    "text": "who earlier received placebo) initiated new dopaminergic therapy or increased",
    "bbox": [
      90.0,
      614.3,
      508.2,
      627.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 53,
    "block_id": "1055_p53_b014",
    "text": "their dose of dopaminergic medication during the open-label extension phase, as",
    "bbox": [
      90.0,
      628.1,
      522.3,
      641.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 53,
    "block_id": "1055_p53_b015",
    "text": "indicated by the table below, which I have copied from the submission.",
    "bbox": [
      90.0,
      641.9,
      467.4,
      655.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 54,
    "block_id": "1055_p54_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 54,
    "block_id": "1055_p54_b002",
    "text": "Page 54 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 54,
    "block_id": "1055_p54_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 54,
    "block_id": "1055_p54_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 54,
    "block_id": "1055_p54_b005",
    "text": "8.2.4 Overall Adverse Event Experience",
    "bbox": [
      90.0,
      328.4,
      309.9,
      341.8
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 54,
    "block_id": "1055_p54_b006",
    "text": "75.4% of patients enrolled in this  study experienced adverse events with the",
    "bbox": [
      90.0,
      345.1,
      500.2,
      358.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 54,
    "block_id": "1055_p54_b007",
    "text": "incidence being comparable across the 2 pre-treatment groups. However,",
    "bbox": [
      90.0,
      358.9,
      484.3,
      372.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 54,
    "block_id": "1055_p54_b008",
    "text": "gastrointestinal adverse events were more common in those  previously exposed",
    "bbox": [
      90.0,
      372.7,
      522.9,
      386.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 54,
    "block_id": "1055_p54_b009",
    "text": "to placebo (38.2%) than in those previously exposed to Exelon® (27.5%).",
    "bbox": [
      90.0,
      386.5,
      483.1,
      399.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 54,
    "block_id": "1055_p54_b010",
    "text": "Adverse events that occurred in ≥ 5% of patients in the entire study cohort are",
    "bbox": [
      90.0,
      414.1,
      506.9,
      427.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 54,
    "block_id": "1055_p54_b011",
    "text": "listed in the following sponsor table. Nausea, vomiting, and tremor were all more",
    "bbox": [
      90.0,
      427.9,
      518.9,
      441.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 54,
    "block_id": "1055_p54_b012",
    "text": "common in those previously exposed to placebo than in those previously",
    "bbox": [
      90.0,
      441.7,
      478.8,
      455.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 54,
    "block_id": "1055_p54_b013",
    "text": "exposed to Exelon®.",
    "bbox": [
      90.0,
      455.5,
      204.2,
      468.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 54,
    "block_id": "1055_p54_b014",
    "text": "The incidence of adverse events potentially indicating a worsening in the",
    "bbox": [
      90.0,
      622.1,
      478.3,
      635.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 54,
    "block_id": "1055_p54_b015",
    "text": "symptoms of Parkinson’s Disease was 18.0% overall, 26.0% in those previously",
    "bbox": [
      90.0,
      635.9,
      517.6,
      649.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 54,
    "block_id": "1055_p54_b016",
    "text": "exposed to placebo, and 13.3% in those previously exposed to Exelon®. The",
    "bbox": [
      90.0,
      649.7,
      502.4,
      663.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 54,
    "block_id": "1055_p54_b017",
    "text": "most common of these adverse events was tremor which had an incidence of",
    "bbox": [
      90.0,
      663.5,
      503.6,
      676.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 54,
    "block_id": "1055_p54_b018",
    "text": "6.9% overall, 12.2% in those previously exposed to placebo, and 3.8% in those",
    "bbox": [
      90.0,
      677.3,
      513.0,
      690.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 54,
    "block_id": "1055_p54_b019",
    "text": "previously exposed to Exelon®. Worsening of Parkinson’s Disease had an",
    "bbox": [
      90.0,
      691.1,
      487.7,
      704.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 55,
    "block_id": "1055_p55_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 55,
    "block_id": "1055_p55_b002",
    "text": "Page 55 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 55,
    "block_id": "1055_p55_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 55,
    "block_id": "1055_p55_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 55,
    "block_id": "1055_p55_b005",
    "text": "incidence of 3.6% overall, 4.1% in those previously exposed to placebo, and",
    "bbox": [
      90.0,
      72.2,
      497.6,
      85.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 55,
    "block_id": "1055_p55_b006",
    "text": "3.3% in those previously exposed to Exelon®.",
    "bbox": [
      90.0,
      86.0,
      337.8,
      99.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 55,
    "block_id": "1055_p55_b007",
    "text": "8.2.5 Deaths, Serious Adverse Events, And Discontinuations Due To Adverse",
    "bbox": [
      90.0,
      119.7,
      509.4,
      133.1
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 55,
    "block_id": "1055_p55_b008",
    "text": "Events",
    "bbox": [
      90.0,
      133.5,
      130.0,
      146.9
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 55,
    "block_id": "1055_p55_b009",
    "text": "The overall incidence of deaths, serious adverse events, and adverse event",
    "bbox": [
      90.0,
      150.2,
      495.0,
      163.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 55,
    "block_id": "1055_p55_b010",
    "text": "discontinuations in this study is summarized in the following table, which I have",
    "bbox": [
      90.0,
      164.0,
      512.2,
      177.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 55,
    "block_id": "1055_p55_b011",
    "text": "copied from the submission:",
    "bbox": [
      90.0,
      177.8,
      242.7,
      191.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 55,
    "block_id": "1055_p55_b012",
    "text": "A full listing of deaths that occurred in this study is in the following table, which I",
    "bbox": [
      90.0,
      332.4,
      515.0,
      345.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 55,
    "block_id": "1055_p55_b013",
    "text": "have copied from the submission.",
    "bbox": [
      90.0,
      346.2,
      272.1,
      359.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 55,
    "block_id": "1055_p55_b014",
    "text": "I have read the narratives for each death. None can  be clearly linked to study",
    "bbox": [
      90.0,
      548.8,
      505.6,
      562.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 55,
    "block_id": "1055_p55_b015",
    "text": "drug; all appear to be due to intercurrent illnesses common in the study",
    "bbox": [
      90.0,
      562.6,
      470.9,
      576.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 55,
    "block_id": "1055_p55_b016",
    "text": "population.",
    "bbox": [
      90.0,
      576.4,
      152.1,
      589.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 55,
    "block_id": "1055_p55_b017",
    "text": "As noted above, 17.1% of patients enrolled in this study experienced a serious",
    "bbox": [
      90.0,
      604.0,
      509.7,
      617.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 55,
    "block_id": "1055_p55_b018",
    "text": "adverse event, and 15.1% of patients enrolled experienced an adverse event that",
    "bbox": [
      90.0,
      617.8,
      525.0,
      631.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 55,
    "block_id": "1055_p55_b019",
    "text": "warranted treatment discontinuation.",
    "bbox": [
      90.0,
      631.6,
      287.4,
      645.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 55,
    "block_id": "1055_p55_b020",
    "text": "The most frequent adverse events leading to treatment discontinuation were as",
    "bbox": [
      90.0,
      659.2,
      513.6,
      672.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 55,
    "block_id": "1055_p55_b021",
    "text": "follows, based on treatment assignment in the earlier double-blind study.",
    "bbox": [
      90.0,
      673.0,
      478.3,
      686.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b002",
    "text": "Page 56 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b005",
    "text": "Adverse Event Leading To Discontinuation",
    "bbox": [
      90.0,
      72.5,
      278.4,
      83.8
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b006",
    "text": "Exe-Exelon®",
    "bbox": [
      287.3,
      72.5,
      345.3,
      83.8
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b007",
    "text": "Plc-Exelon®",
    "bbox": [
      365.3,
      72.5,
      420.6,
      83.8
    ],
    "font_size": 8.0,
    "font_name": "Arial-Black",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b008",
    "text": "Nausea",
    "bbox": [
      90.0,
      84.4,
      119.7,
      93.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b009",
    "text": "0.5%",
    "bbox": [
      287.4,
      84.4,
      307.8,
      93.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b010",
    "text": "4.0%",
    "bbox": [
      365.4,
      84.4,
      385.8,
      93.3
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b011",
    "text": "Hallucination",
    "bbox": [
      90.0,
      94.1,
      138.0,
      103.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b012",
    "text": "1.4%",
    "bbox": [
      287.3,
      94.1,
      307.8,
      103.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b013",
    "text": "1.6%",
    "bbox": [
      365.4,
      94.1,
      385.8,
      103.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b014",
    "text": "Tremor",
    "bbox": [
      90.0,
      103.8,
      118.0,
      112.7
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b015",
    "text": "0.5%",
    "bbox": [
      287.4,
      103.8,
      307.8,
      112.7
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b016",
    "text": "1.6%",
    "bbox": [
      365.4,
      103.8,
      385.8,
      112.7
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b017",
    "text": "Vomiting",
    "bbox": [
      90.0,
      113.5,
      123.3,
      122.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b018",
    "text": "0.0%",
    "bbox": [
      287.3,
      113.5,
      307.8,
      122.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b019",
    "text": "2.4%",
    "bbox": [
      365.4,
      113.5,
      385.8,
      122.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b020",
    "text": "I have read the listings and narratives for serious adverse events and",
    "bbox": [
      90.0,
      132.5,
      460.2,
      145.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b021",
    "text": "discontinuations due to adverse events. With the exception of those events that",
    "bbox": [
      90.0,
      146.3,
      514.3,
      159.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b022",
    "text": "could be attributed to the cholinomimetic effects of Exelon®, the adverse events",
    "bbox": [
      90.0,
      160.1,
      517.2,
      173.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b023",
    "text": "describe are all consistent with intercurrent illnesses that are common in this",
    "bbox": [
      90.0,
      173.9,
      498.2,
      187.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b024",
    "text": "population.",
    "bbox": [
      90.0,
      187.7,
      158.8,
      201.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b025",
    "text": "8.2.6 Laboratory Data",
    "bbox": [
      90.0,
      221.4,
      213.2,
      234.8
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b026",
    "text": "No laboratory testing was performed during the open-label extension phase of",
    "bbox": [
      90.0,
      238.1,
      507.0,
      251.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b027",
    "text": "this study.",
    "bbox": [
      90.0,
      251.9,
      147.4,
      265.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b028",
    "text": "8.2.7 Vital Signs And Weight",
    "bbox": [
      90.0,
      285.5,
      249.2,
      298.9
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b029",
    "text": "Mean changes from baseline in vital sign parameters and weight, and the",
    "bbox": [
      90.0,
      302.3,
      482.2,
      315.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b030",
    "text": "proportion of patients with notable vital sign or weight abnormalities have been",
    "bbox": [
      90.0,
      316.1,
      509.4,
      329.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b031",
    "text": "summarized in tabular form by the sponsor. These changes were small.",
    "bbox": [
      90.0,
      329.9,
      473.5,
      343.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b032",
    "text": "8.2.8 Electrocardiograms",
    "bbox": [
      90.0,
      363.5,
      233.9,
      376.9
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b033",
    "text": "No electrocardiograms were performed during this study.",
    "bbox": [
      90.0,
      380.3,
      395.5,
      393.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b034",
    "text": "8.2.9 UPDRS Part III Scores",
    "bbox": [
      90.0,
      413.9,
      248.5,
      427.3
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b035",
    "text": "Patients enrolled in the open-label extension study worsened by a mean (±",
    "bbox": [
      90.0,
      430.7,
      490.2,
      444.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b036",
    "text": "standard deviation) of 1.8 points (± 9.6 points) on the total UPDRS Part III score.",
    "bbox": [
      90.0,
      444.5,
      520.1,
      457.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b037",
    "text": "Individual tremor score worsened by a mean (± standard deviation) of 0.1 points",
    "bbox": [
      90.0,
      458.3,
      517.4,
      471.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b038",
    "text": "(± 2.3 points).",
    "bbox": [
      90.0,
      472.1,
      166.7,
      485.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b039",
    "text": "8.3 Sponsor’s Conclusions Regarding Safety",
    "bbox": [
      90.0,
      505.7,
      356.5,
      519.1
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b040",
    "text": "In patients treated with Exelon® or placebo in Study 2311, the safety and",
    "bbox": [
      90.0,
      522.5,
      481.2,
      535.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b041",
    "text": "tolerability of Exelon® in a dose of 3 to 12 mg/day in Study 2311E1 remained",
    "bbox": [
      90.0,
      536.3,
      502.6,
      549.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b042",
    "text": "favorable, with no new unexpected adverse events reported and no clinically",
    "bbox": [
      90.0,
      550.1,
      498.9,
      563.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b043",
    "text": "significant worsening of the motor symptoms of Parkinson’s Disease. The",
    "bbox": [
      90.0,
      563.9,
      482.9,
      577.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b044",
    "text": "tolerability profile of profile of Exelon® did not change over the 24-week open-",
    "bbox": [
      90.0,
      577.7,
      503.1,
      591.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b045",
    "text": "label extension study.",
    "bbox": [
      90.0,
      591.5,
      208.7,
      604.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b046",
    "text": "8.4 Reviewer’s Comments",
    "bbox": [
      90.0,
      625.1,
      245.2,
      638.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 56,
    "block_id": "1055_p56_b047",
    "text": "I agree with the sponsor’s conclusions",
    "bbox": [
      90.0,
      641.9,
      296.1,
      655.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b002",
    "text": "Page 57 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b005",
    "text": "9. Study 2314 (Non-Interventional Validation Study)",
    "bbox": [
      90.0,
      72.4,
      435.9,
      88.0
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b006",
    "text": "Note that the study report contained in this submission is an interim report which is",
    "bbox": [
      90.0,
      92.8,
      494.1,
      105.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b007",
    "text": "confined to the validation of various study instruments in Parkinson’s Disease Dementia",
    "bbox": [
      90.0,
      105.5,
      519.2,
      117.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b008",
    "text": "alone, whereas the original study protocol planned to validate these instruments in",
    "bbox": [
      90.0,
      118.2,
      493.0,
      130.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b009",
    "text": "vascular dementia as well. The description of the study protocol and results below is,",
    "bbox": [
      90.0,
      130.8,
      505.3,
      143.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b010",
    "text": "therefore, also confined to the validation of these study instruments in Parkinson’s",
    "bbox": [
      90.0,
      143.5,
      491.2,
      155.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b011",
    "text": "Disease Dementia alone.",
    "bbox": [
      90.0,
      156.1,
      216.0,
      168.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b012",
    "text": "9.1 Protocol",
    "bbox": [
      90.0,
      190.1,
      165.9,
      203.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b013",
    "text": "9.1.1 Title",
    "bbox": [
      90.0,
      212.9,
      149.8,
      226.3
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b014",
    "text": "A 4-Week, Non-Interventional, Cross-Sectional, Multicenter Study To Assess The",
    "bbox": [
      90.0,
      229.6,
      524.8,
      243.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b015",
    "text": "Validity Of Various Assessment Scales Measuring Cognition, Executive Function,",
    "bbox": [
      90.0,
      243.4,
      524.9,
      256.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b016",
    "text": "Behavior And Activities Of Daily Living In Patients With Mild To Moderate",
    "bbox": [
      90.0,
      257.2,
      480.9,
      270.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b017",
    "text": "Parkinson’s Disease Dementia",
    "bbox": [
      90.0,
      271.0,
      260.1,
      284.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b018",
    "text": "9.1.2 Objectives",
    "bbox": [
      90.0,
      304.7,
      183.2,
      318.1
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b019",
    "text": "9.1.2.1 Primary",
    "bbox": [
      90.0,
      327.5,
      178.5,
      340.9
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b020",
    "text": " To assess the criterion-related validity through determination of the ability",
    "bbox": [
      108.0,
      344.2,
      518.1,
      357.6
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b021",
    "text": "of the ADAS-Cog to differentiate between mild and moderate severities of",
    "bbox": [
      126.0,
      358.0,
      519.6,
      371.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b022",
    "text": "Parkinson’s Disease Dementia",
    "bbox": [
      126.0,
      371.8,
      292.7,
      385.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b023",
    "text": " To assess the test-retest reliability of the ADAS-Cog in Parkinson’s",
    "bbox": [
      108.0,
      399.4,
      484.1,
      412.8
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b024",
    "text": "Disease Dementia",
    "bbox": [
      126.0,
      413.2,
      230.7,
      426.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b025",
    "text": "9.1.2.2 Secondary",
    "bbox": [
      90.0,
      446.9,
      194.6,
      460.3
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b026",
    "text": " To assess the criterion-related validity through determination of the ability",
    "bbox": [
      108.0,
      463.6,
      518.1,
      477.0
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b027",
    "text": "of other dementia rating scales to differentiate between mild and moderate",
    "bbox": [
      126.0,
      477.4,
      524.2,
      490.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b028",
    "text": "severities of Parkinson’s Disease Dementia",
    "bbox": [
      126.0,
      491.2,
      360.0,
      504.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b029",
    "text": " To assess the test-retest reliability of other dementia rating scales/tests",
    "bbox": [
      108.0,
      505.0,
      507.0,
      518.4
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b030",
    "text": " To assess the convergent and divergent construct validity of the ADAS-",
    "bbox": [
      108.0,
      518.8,
      504.8,
      532.2
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b031",
    "text": "Cog in patients with Parkinson’s Disease Dementia",
    "bbox": [
      126.0,
      532.6,
      404.1,
      546.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b032",
    "text": " To compare scores on dementia rating scales and tests in patients with",
    "bbox": [
      108.0,
      546.4,
      506.9,
      559.8
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b033",
    "text": "Alzheimer’s Disease with those who have Parkinson’s Disease Dementia",
    "bbox": [
      126.0,
      560.2,
      520.2,
      573.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b034",
    "text": "9.1.3 Design",
    "bbox": [
      90.0,
      593.9,
      164.5,
      607.3
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b035",
    "text": "Non-interventional cross-section study",
    "bbox": [
      90.0,
      610.6,
      296.8,
      624.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b036",
    "text": "9.1.4 Duration",
    "bbox": [
      90.0,
      644.3,
      172.5,
      657.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 57,
    "block_id": "1055_p57_b037",
    "text": "4 weeks",
    "bbox": [
      90.0,
      661.0,
      137.3,
      674.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b002",
    "text": "Page 58 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b005",
    "text": "9.1.5 Sample Size",
    "bbox": [
      90.0,
      72.3,
      194.6,
      85.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b006",
    "text": "The planned sample size was 100 patients, comprising 50 patients with",
    "bbox": [
      90.0,
      89.0,
      471.5,
      102.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b007",
    "text": "Parkinson’s Disease Dementia and 50 patients with Alzheimer’s Disease.",
    "bbox": [
      90.0,
      102.8,
      482.1,
      116.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b008",
    "text": "9.1.6 Main Inclusion Criteria",
    "bbox": [
      90.0,
      136.5,
      245.9,
      149.9
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b009",
    "text": " Age: 50 to 85 years",
    "bbox": [
      108.0,
      153.2,
      236.7,
      166.6
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b010",
    "text": " For patients with Alzheimer’s Disease",
    "bbox": [
      108.0,
      180.8,
      332.7,
      194.2
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b011",
    "text": "o Clinical diagnosis of Alzheimer’s Disease according to DSM-IV criteria",
    "bbox": [
      144.0,
      208.5,
      505.5,
      221.7
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b012",
    "text": "o Probable Alzheimer’s Disease according to the NINCDS-ADRDA criteria",
    "bbox": [
      144.0,
      221.1,
      519.5,
      234.4
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b013",
    "text": " For patients with Parkinson’s Disease Dementia",
    "bbox": [
      108.0,
      247.5,
      390.9,
      260.9
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b014",
    "text": "o Clinical diagnosis of idiopathic Parkinson’s Disease according to the UK",
    "bbox": [
      144.0,
      275.1,
      514.1,
      288.4
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b015",
    "text": "Parkinson’s Disease Society Brain Bank",
    "bbox": [
      162.0,
      287.8,
      363.7,
      300.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b016",
    "text": "o Diagnosis of Dementia Due To Parkinson’s Disease according to DSM-IV",
    "bbox": [
      144.0,
      300.4,
      522.0,
      313.7
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b017",
    "text": "criteria",
    "bbox": [
      162.0,
      313.1,
      201.2,
      325.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b018",
    "text": " Mini-Mental Status Examination score at entry between 10 and 24, further",
    "bbox": [
      108.0,
      339.5,
      521.0,
      352.9
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b019",
    "text": "divided into mild dementia (Mini-Mental Status Examination score of 18 to",
    "bbox": [
      126.0,
      353.3,
      520.3,
      366.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b020",
    "text": "24) or moderate dementia (Mini-Mental Status Examination score of 10 to",
    "bbox": [
      126.0,
      367.1,
      519.6,
      380.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b021",
    "text": "17)",
    "bbox": [
      126.0,
      380.9,
      146.7,
      394.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b022",
    "text": " Stable dose of existing therapy for at least 6 weeks prior to baseline and",
    "bbox": [
      108.0,
      408.5,
      512.2,
      421.9
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b023",
    "text": "not expected to change medication doses during the study",
    "bbox": [
      126.0,
      422.3,
      439.5,
      435.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b024",
    "text": "9.1.7 Study Schedule",
    "bbox": [
      90.0,
      455.9,
      211.2,
      469.3
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b025",
    "text": "The study schedule is summarized in the following table, which I have copied",
    "bbox": [
      90.0,
      472.7,
      502.1,
      486.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 58,
    "block_id": "1055_p58_b026",
    "text": "from the submission.",
    "bbox": [
      90.0,
      486.5,
      203.9,
      499.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 59,
    "block_id": "1055_p59_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 59,
    "block_id": "1055_p59_b002",
    "text": "Page 59 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 59,
    "block_id": "1055_p59_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 59,
    "block_id": "1055_p59_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 59,
    "block_id": "1055_p59_b005",
    "text": "9.1.8 Assessment Scales To Be Validated",
    "bbox": [
      90.0,
      458.1,
      320.7,
      471.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 59,
    "block_id": "1055_p59_b006",
    "text": "• ADAS-Cog",
    "bbox": [
      108.0,
      474.5,
      191.4,
      489.2
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 59,
    "block_id": "1055_p59_b007",
    "text": "• D-KEFS Verbal Fluency Test",
    "bbox": [
      108.0,
      489.1,
      283.4,
      503.7
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 59,
    "block_id": "1055_p59_b008",
    "text": "• Ten-Point Clock Test",
    "bbox": [
      108.0,
      503.7,
      241.4,
      518.4
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 59,
    "block_id": "1055_p59_b009",
    "text": "• Trailmaking Tests A and B",
    "bbox": [
      108.0,
      518.3,
      270.0,
      533.0
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 59,
    "block_id": "1055_p59_b010",
    "text": "• Neuropsychiatry Inventory, including Neuropsychiatry Inventory-Distress",
    "bbox": [
      108.0,
      532.9,
      512.8,
      547.6
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 59,
    "block_id": "1055_p59_b011",
    "text": "• ADCS-ADL",
    "bbox": [
      108.0,
      547.5,
      193.4,
      562.2
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 59,
    "block_id": "1055_p59_b012",
    "text": "• Cognitive Drug Research Computerized Assessment System tests for the",
    "bbox": [
      108.0,
      562.1,
      519.5,
      576.8
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 59,
    "block_id": "1055_p59_b013",
    "text": "assessment of attention",
    "bbox": [
      126.0,
      577.1,
      256.1,
      590.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 59,
    "block_id": "1055_p59_b014",
    "text": "9.1.9 Assessments Used For Staging",
    "bbox": [
      90.0,
      610.7,
      295.2,
      624.1
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 59,
    "block_id": "1055_p59_b015",
    "text": "• Mini-Mental Status Examination",
    "bbox": [
      108.0,
      627.1,
      301.4,
      641.8
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 59,
    "block_id": "1055_p59_b016",
    "text": "• Global Deterioration Scale",
    "bbox": [
      108.0,
      641.8,
      269.4,
      656.4
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 60,
    "block_id": "1055_p60_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 60,
    "block_id": "1055_p60_b002",
    "text": "Page 60 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 60,
    "block_id": "1055_p60_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 60,
    "block_id": "1055_p60_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 60,
    "block_id": "1055_p60_b005",
    "text": "9.2 Main Results",
    "bbox": [
      90.0,
      72.3,
      191.2,
      85.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 60,
    "block_id": "1055_p60_b006",
    "text": "9.2.1 Patient Disposition",
    "bbox": [
      90.0,
      95.1,
      226.5,
      108.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 60,
    "block_id": "1055_p60_b007",
    "text": "Patient disposition by dementia type and Mini-Mental Status Examination stratum",
    "bbox": [
      90.0,
      111.8,
      524.3,
      125.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 60,
    "block_id": "1055_p60_b008",
    "text": "is summarized in the following table, which I have copied from the submission.",
    "bbox": [
      90.0,
      125.6,
      508.9,
      139.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 60,
    "block_id": "1055_p60_b009",
    "text": "9.2.2 Demographic And Other Baseline Characteristics",
    "bbox": [
      90.0,
      270.6,
      388.7,
      284.0
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 60,
    "block_id": "1055_p60_b010",
    "text": "These are summarized in the next table, which I have copied from the",
    "bbox": [
      90.0,
      287.3,
      463.5,
      300.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 60,
    "block_id": "1055_p60_b011",
    "text": "submission.",
    "bbox": [
      90.0,
      301.1,
      156.7,
      314.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 61,
    "block_id": "1055_p61_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 61,
    "block_id": "1055_p61_b002",
    "text": "Page 61 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 61,
    "block_id": "1055_p61_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 61,
    "block_id": "1055_p61_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 61,
    "block_id": "1055_p61_b005",
    "text": "9.2.3 Primary Analysis Results",
    "bbox": [
      90.0,
      72.3,
      260.0,
      85.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 61,
    "block_id": "1055_p61_b006",
    "text": "The sponsor table below is intended to illustrate the ability of the mean ADAS-",
    "bbox": [
      90.0,
      89.0,
      504.3,
      102.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 61,
    "block_id": "1055_p61_b007",
    "text": "Cog score at baseline to differentiate between mild and moderate Parkinson’s",
    "bbox": [
      90.0,
      102.8,
      505.5,
      116.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 61,
    "block_id": "1055_p61_b008",
    "text": "Disease Dementia (and Alzheimer’s Disease), based on a t-test and supported",
    "bbox": [
      90.0,
      116.6,
      510.9,
      130.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 61,
    "block_id": "1055_p61_b009",
    "text": "by an analysis of variance with severity group and center as fixed effects.",
    "bbox": [
      90.0,
      130.4,
      488.4,
      143.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 61,
    "block_id": "1055_p61_b010",
    "text": "The sponsor points out that the mean ADAS-Cog score at baseline shows a",
    "bbox": [
      90.0,
      389.3,
      495.6,
      402.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 61,
    "block_id": "1055_p61_b011",
    "text": "distinct separation between mild and moderate patients in both the Parkinson’s",
    "bbox": [
      90.0,
      403.1,
      511.5,
      416.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 61,
    "block_id": "1055_p61_b012",
    "text": "Disease Dementia and Alzheimer’s Disease groups, with a similar variance",
    "bbox": [
      90.0,
      416.9,
      491.5,
      430.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 61,
    "block_id": "1055_p61_b013",
    "text": "associated with the mean in each dementia type and severity. The difference in",
    "bbox": [
      90.0,
      430.7,
      513.5,
      444.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 61,
    "block_id": "1055_p61_b014",
    "text": "mean ADAS-Cog score between the mild and moderate groups was statistically",
    "bbox": [
      90.0,
      444.5,
      515.4,
      457.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 61,
    "block_id": "1055_p61_b015",
    "text": "significant for each dementia type.",
    "bbox": [
      90.0,
      458.3,
      278.9,
      471.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 61,
    "block_id": "1055_p61_b016",
    "text": "The size of the mean difference between Mini-Mental Status Examination strata",
    "bbox": [
      90.0,
      485.9,
      515.5,
      499.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 61,
    "block_id": "1055_p61_b017",
    "text": "was also examined using a Cohen’s effect size computation. Using that",
    "bbox": [
      90.0,
      499.7,
      471.6,
      513.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 61,
    "block_id": "1055_p61_b018",
    "text": "computation, effect sizes of 0.2, 0.5, and 0.8 are generally considered small,",
    "bbox": [
      90.0,
      513.5,
      498.2,
      526.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 61,
    "block_id": "1055_p61_b019",
    "text": "medium, and large, respectively. Cohen’s effect size for the mean difference",
    "bbox": [
      90.0,
      527.3,
      497.6,
      540.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 61,
    "block_id": "1055_p61_b020",
    "text": "between disease severities by dementia type, as determined by the sponsor, is in",
    "bbox": [
      90.0,
      541.1,
      525.1,
      554.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 61,
    "block_id": "1055_p61_b021",
    "text": "the following table; while this effect size was larger for the Alzheimer’s Disease",
    "bbox": [
      90.0,
      554.9,
      510.9,
      568.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 61,
    "block_id": "1055_p61_b022",
    "text": "group, it remained large for the group with Parkinson’s Disease Dementia as",
    "bbox": [
      90.0,
      568.7,
      498.9,
      582.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 61,
    "block_id": "1055_p61_b023",
    "text": "well. These results also suggest that the ADAS-Cog is a scale that can produce a",
    "bbox": [
      90.0,
      582.5,
      524.9,
      595.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 61,
    "block_id": "1055_p61_b024",
    "text": "good separation between Mini-Mental Status Examination strata in the patients",
    "bbox": [
      90.0,
      596.3,
      511.5,
      609.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 61,
    "block_id": "1055_p61_b025",
    "text": "studied.",
    "bbox": [
      90.0,
      610.1,
      135.3,
      623.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 62,
    "block_id": "1055_p62_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 62,
    "block_id": "1055_p62_b002",
    "text": "Page 62 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 62,
    "block_id": "1055_p62_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 62,
    "block_id": "1055_p62_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 62,
    "block_id": "1055_p62_b005",
    "text": "The test-retest reliability of the ADAS-Cog in this population was evaluated by",
    "bbox": [
      90.0,
      162.5,
      505.5,
      175.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 62,
    "block_id": "1055_p62_b006",
    "text": "determining the correlation coefficient between the ADAS-Cog value at baseline",
    "bbox": [
      90.0,
      176.3,
      516.9,
      189.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 62,
    "block_id": "1055_p62_b007",
    "text": "and that at Week 4 for each dementia type and severity; the results are in the",
    "bbox": [
      90.0,
      190.1,
      503.0,
      203.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 62,
    "block_id": "1055_p62_b008",
    "text": "following table contained in the submission, which indicates, according to the",
    "bbox": [
      90.0,
      203.9,
      500.9,
      217.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 62,
    "block_id": "1055_p62_b009",
    "text": "sponsor, that the correlation coefficients for the ADAS-Cog at baseline and Week",
    "bbox": [
      90.0,
      217.7,
      523.5,
      231.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 62,
    "block_id": "1055_p62_b010",
    "text": "4 were strongly positive regardless of dementia type and severity; the sponsor",
    "bbox": [
      90.0,
      231.5,
      507.6,
      244.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 62,
    "block_id": "1055_p62_b011",
    "text": "further states that although the confidence intervals for each correlation",
    "bbox": [
      90.0,
      245.3,
      471.3,
      258.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 62,
    "block_id": "1055_p62_b012",
    "text": "coefficient were wide, even their lower limits showed a positive correlation.",
    "bbox": [
      90.0,
      259.1,
      488.1,
      272.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 62,
    "block_id": "1055_p62_b013",
    "text": "9.2.4 Secondary Analyses",
    "bbox": [
      90.0,
      460.7,
      236.5,
      474.1
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 62,
    "block_id": "1055_p62_b014",
    "text": "9.2.4.1 Ability Of Dementia-Rating Scales And Tests Other Than The ADAS-",
    "bbox": [
      90.0,
      483.5,
      500.1,
      496.9
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 62,
    "block_id": "1055_p62_b015",
    "text": "Cog To Differentiate Between Alzheimer’s Disease Of Mild And Moderate",
    "bbox": [
      90.0,
      497.3,
      482.8,
      510.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 62,
    "block_id": "1055_p62_b016",
    "text": "Severity (Assessment Of Criterion-Related Validity)",
    "bbox": [
      90.0,
      511.1,
      365.4,
      524.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 62,
    "block_id": "1055_p62_b017",
    "text": "The ability of dementia rating scales and tests other than the ADAS-Cog to",
    "bbox": [
      90.0,
      527.8,
      489.5,
      541.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 62,
    "block_id": "1055_p62_b018",
    "text": "differentiate between mild and moderate severity Parkinson’s Disease Dementia",
    "bbox": [
      90.0,
      541.6,
      518.8,
      555.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 62,
    "block_id": "1055_p62_b019",
    "text": "and Alzheimer’s Disease were evaluated as with the ADAS-Cog by comparing",
    "bbox": [
      90.0,
      555.4,
      508.1,
      568.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 62,
    "block_id": "1055_p62_b020",
    "text": "the mean values obtained for each severity category at baseline and at Week 4,",
    "bbox": [
      90.0,
      569.2,
      516.8,
      582.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 62,
    "block_id": "1055_p62_b021",
    "text": "using a t-test. The results are in the following table, which indicate that for both",
    "bbox": [
      90.0,
      583.0,
      510.2,
      596.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 62,
    "block_id": "1055_p62_b022",
    "text": "types of dementia, the separation between mild and moderate severities was",
    "bbox": [
      90.0,
      596.8,
      500.9,
      610.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 62,
    "block_id": "1055_p62_b023",
    "text": "nominally statistically significant for the ADCS-ADL, Ten-Point Clock Test,",
    "bbox": [
      90.0,
      610.6,
      485.6,
      624.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 62,
    "block_id": "1055_p62_b024",
    "text": "Trailmaking Test A, and D-KEFS Verbal Fluency Test.",
    "bbox": [
      90.0,
      624.4,
      380.8,
      637.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 63,
    "block_id": "1055_p63_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 63,
    "block_id": "1055_p63_b002",
    "text": "Page 63 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 63,
    "block_id": "1055_p63_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 63,
    "block_id": "1055_p63_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 63,
    "block_id": "1055_p63_b005",
    "text": "The differences for other measures are in the above table.",
    "bbox": [
      90.0,
      517.4,
      402.2,
      530.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 63,
    "block_id": "1055_p63_b006",
    "text": "Test-retest reliability by dementia type and Mini-Mental Status Examination",
    "bbox": [
      90.0,
      545.0,
      490.7,
      558.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 63,
    "block_id": "1055_p63_b007",
    "text": "stratum is summarized in the following table, taken from the submission;",
    "bbox": [
      90.0,
      558.8,
      476.0,
      572.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 63,
    "block_id": "1055_p63_b008",
    "text": "reliability was determined, as with the ADAS-Cog by calculating correlation",
    "bbox": [
      90.0,
      572.6,
      489.5,
      586.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 63,
    "block_id": "1055_p63_b009",
    "text": "coefficients based on the baseline and Week 4 scores . The correlations were",
    "bbox": [
      90.0,
      586.4,
      505.4,
      599.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 63,
    "block_id": "1055_p63_b010",
    "text": "best for the ADCS-ADL and Neuropsychiatry Inventory-10 for both populations.",
    "bbox": [
      90.0,
      600.2,
      513.0,
      613.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 64,
    "block_id": "1055_p64_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 64,
    "block_id": "1055_p64_b002",
    "text": "Page 64 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 64,
    "block_id": "1055_p64_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 64,
    "block_id": "1055_p64_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 64,
    "block_id": "1055_p64_b005",
    "text": "9.2.4.2 Comparison Of Scores On Dementia Rating Scales In Patients With",
    "bbox": [
      90.0,
      460.3,
      497.5,
      473.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 64,
    "block_id": "1055_p64_b006",
    "text": "Alzheimer’s Disease Versus Parkinson’s Disease Dementia",
    "bbox": [
      90.0,
      474.1,
      412.8,
      487.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 64,
    "block_id": "1055_p64_b007",
    "text": "The total scores at baseline in the 2 populations were compared as indicated in",
    "bbox": [
      90.0,
      490.9,
      513.5,
      504.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 64,
    "block_id": "1055_p64_b008",
    "text": "the following table. The sponsor points out that statistically significant differences",
    "bbox": [
      90.0,
      504.7,
      521.6,
      518.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 64,
    "block_id": "1055_p64_b009",
    "text": "between the 2 populations were not apparent except for the ADCS-ADL score.",
    "bbox": [
      90.0,
      518.5,
      509.7,
      531.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 65,
    "block_id": "1055_p65_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 65,
    "block_id": "1055_p65_b002",
    "text": "Page 65 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 65,
    "block_id": "1055_p65_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 65,
    "block_id": "1055_p65_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 65,
    "block_id": "1055_p65_b005",
    "text": "The sponsor has performed a factor analysis of the ADAS-Cog sub-item scores",
    "bbox": [
      90.0,
      326.8,
      514.1,
      340.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 65,
    "block_id": "1055_p65_b006",
    "text": "at baseline for the Parkinson’s Disease Dementia and Alzheimer’s Disease",
    "bbox": [
      90.0,
      340.6,
      490.8,
      354.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 65,
    "block_id": "1055_p65_b007",
    "text": "populations, as indicated in the following table, taken from the submission. The",
    "bbox": [
      90.0,
      354.4,
      511.6,
      367.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 65,
    "block_id": "1055_p65_b008",
    "text": "sponsor has observed that the sub-items group differently in each population,",
    "bbox": [
      90.0,
      368.2,
      503.6,
      381.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 65,
    "block_id": "1055_p65_b009",
    "text": "which may indicate a different profile of cognitive impairment. The sponsor does",
    "bbox": [
      90.0,
      382.0,
      517.0,
      395.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 65,
    "block_id": "1055_p65_b010",
    "text": "acknowledge that the sample sizes were small for these analyses.",
    "bbox": [
      90.0,
      395.8,
      444.2,
      409.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 65,
    "block_id": "1055_p65_b011",
    "text": "9.2.4.3 Convergent And Divergent Construct Validity Of The ADAS-Cog In",
    "bbox": [
      90.0,
      599.2,
      490.8,
      612.6
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 65,
    "block_id": "1055_p65_b012",
    "text": "Patients With Alzheimer’s Disease And With Parkinson’s Disease Dementia",
    "bbox": [
      90.0,
      613.0,
      498.1,
      626.4
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 65,
    "block_id": "1055_p65_b013",
    "text": "The degree of association between the ADAS-Cog and other scales was",
    "bbox": [
      90.0,
      629.8,
      478.2,
      643.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 65,
    "block_id": "1055_p65_b014",
    "text": "explored by performing a correlation test between the ADAS-Cog scores and",
    "bbox": [
      90.0,
      643.6,
      500.8,
      657.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 65,
    "block_id": "1055_p65_b015",
    "text": "those of each of the other scales at baseline. The sponsor considers the results,",
    "bbox": [
      90.0,
      657.4,
      518.3,
      670.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 65,
    "block_id": "1055_p65_b016",
    "text": "summarized in the table below, to indicate at least a moderate correlation of the",
    "bbox": [
      90.0,
      671.2,
      515.7,
      684.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 65,
    "block_id": "1055_p65_b017",
    "text": "ADAS-Cog with all assessments other than the Neuropsychiatry Inventory and",
    "bbox": [
      90.0,
      685.0,
      508.8,
      698.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b002",
    "text": "Page 66 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b005",
    "text": "Neuropsychiatry Inventory-Distress. Correlation was best between the ADAS-",
    "bbox": [
      90.0,
      72.2,
      501.5,
      85.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b006",
    "text": "Cog and Mini-Mental Status Examination, in both populations.",
    "bbox": [
      90.0,
      86.0,
      421.5,
      99.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b007",
    "text": "9.3 Sponsor’s Conclusions",
    "bbox": [
      90.0,
      353.2,
      251.2,
      366.6
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b008",
    "text": "The following is a summary of the sponsor’s conclusions:",
    "bbox": [
      90.0,
      370.0,
      396.1,
      383.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b009",
    "text": " In patients with Parkinson’s Disease Dementia, grouped into “mild” and",
    "bbox": [
      108.0,
      397.6,
      506.2,
      411.0
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b010",
    "text": "“moderate” categories by baseline Mini-Mental Status Examination score,",
    "bbox": [
      126.0,
      411.4,
      518.9,
      424.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b011",
    "text": "the ADAS-Cog score at baseline showed a statistically significant",
    "bbox": [
      126.0,
      425.2,
      474.9,
      438.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b012",
    "text": "difference between these categories, thus demonstrating criterion-related",
    "bbox": [
      126.0,
      439.0,
      517.5,
      452.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b013",
    "text": "validity for the ADAS-Cog, based on severity as the criterion. In the same",
    "bbox": [
      126.0,
      452.8,
      517.6,
      466.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b014",
    "text": "population, a similar criterion-related validity was also demonstrated for",
    "bbox": [
      126.0,
      466.6,
      506.9,
      480.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b015",
    "text": "the ADCS-ADL, Ten-Point Clock Test, Trailmaking Test A, and D-KEFS",
    "bbox": [
      126.0,
      480.4,
      509.3,
      493.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b016",
    "text": "Verbal Fluency Test",
    "bbox": [
      126.0,
      494.2,
      236.1,
      507.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b017",
    "text": " The ADAS-Cog and several other scales demonstrated test-retest",
    "bbox": [
      108.0,
      521.8,
      478.8,
      535.2
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b018",
    "text": "reliability when used in patients with Parkinson’s Disease Dementia.",
    "bbox": [
      126.0,
      535.6,
      493.6,
      549.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b019",
    "text": " When the ADAS-Cog was correlated with scales that measured similar",
    "bbox": [
      108.0,
      563.2,
      504.2,
      576.6
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b020",
    "text": "and different symptom domains, convergent and divergent construct",
    "bbox": [
      126.0,
      577.0,
      490.9,
      590.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b021",
    "text": "validity was demonstrated for the ADAS-Cog in patients with Parkinson’s",
    "bbox": [
      126.0,
      590.8,
      514.8,
      604.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b022",
    "text": "Disease Dementia.",
    "bbox": [
      126.0,
      604.6,
      230.7,
      618.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b023",
    "text": " For patients with a similar severity of dementia, as determined by Mini-",
    "bbox": [
      108.0,
      632.2,
      500.8,
      645.6
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b024",
    "text": "Mental Status Examination score, total scores achieved on specific",
    "bbox": [
      126.0,
      646.0,
      484.2,
      659.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b025",
    "text": "dementia rating scales in patients with Parkinson’s Disease Dementia",
    "bbox": [
      126.0,
      659.8,
      498.8,
      673.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b026",
    "text": "were similar to those in patients with Alzheimer’s Disease. However, a",
    "bbox": [
      126.0,
      673.6,
      501.5,
      687.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b027",
    "text": "factor analysis that compared the 2 populations on ADAS-Cog sub-item",
    "bbox": [
      126.0,
      687.4,
      508.9,
      700.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 66,
    "block_id": "1055_p66_b028",
    "text": "scores has indicated that the sub-items group differently in each",
    "bbox": [
      126.0,
      701.2,
      468.9,
      714.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b002",
    "text": "Page 67 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b005",
    "text": "population suggesting that cognitive and behavioral symptom profiles in",
    "bbox": [
      126.0,
      72.2,
      508.9,
      85.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b006",
    "text": "these populations may differ.",
    "bbox": [
      126.0,
      86.0,
      282.8,
      99.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b007",
    "text": "10. Summary Of Earlier Meeting Between Division And Sponsor",
    "bbox": [
      90.0,
      125.8,
      518.9,
      141.4
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b008",
    "text": "Regarding This Application.",
    "bbox": [
      90.0,
      141.9,
      279.2,
      157.5
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b009",
    "text": "A meeting was held with the sponsor on May 18, 2005, at which the results of",
    "bbox": [
      90.0,
      160.9,
      504.3,
      174.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b010",
    "text": "Study 2311 (EXPRESS Study) were discussed in outline and on a preliminary",
    "bbox": [
      90.0,
      174.7,
      505.6,
      188.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b011",
    "text": "basis, in the context of a sponsor proposal to expand the current indication for",
    "bbox": [
      90.0,
      188.5,
      506.3,
      201.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b012",
    "text": "Exelon® to include “the treatment of mild to moderate dementia associated with",
    "bbox": [
      90.0,
      202.3,
      515.7,
      215.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b013",
    "text": "Parkinson’s Disease.”",
    "bbox": [
      90.0,
      216.0,
      209.4,
      229.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b014",
    "text": "The following is a summary of the salient views conveyed by the sponsor’s team",
    "bbox": [
      90.0,
      243.6,
      518.8,
      257.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b015",
    "text": "at that meeting.",
    "bbox": [
      90.0,
      257.4,
      176.1,
      270.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b016",
    "text": "The entity of dementia associated with Parkinson’s Disease (as exemplified by",
    "bbox": [
      126.0,
      285.0,
      510.6,
      297.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b017",
    "text": "the patients enrolled in the EXPRESS Study) is linked to distinctive",
    "bbox": [
      126.0,
      297.7,
      454.4,
      309.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b018",
    "text": "neuropathological findings (i.e., widespread Lewy bodies and Lewy neurites),",
    "bbox": [
      126.0,
      310.3,
      503.8,
      322.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b019",
    "text": "with more recent publications strongly suggesting that the contribution of  co-",
    "bbox": [
      126.0,
      323.0,
      499.5,
      335.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b020",
    "text": "existing Alzheimer’s-type neuropathological changes (e.g., senile plaques and",
    "bbox": [
      126.0,
      335.7,
      508.1,
      347.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b021",
    "text": "neurofibrillary tangles) to the dementia are minor",
    "bbox": [
      126.0,
      348.3,
      365.6,
      360.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b022",
    "text": "A cholinergic deficiency state is the basis for dementia associated with",
    "bbox": [
      126.0,
      373.6,
      471.4,
      385.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b023",
    "text": "Parkinson’s Disease, just as with Alzheimer’s Disease",
    "bbox": [
      126.0,
      386.2,
      395.0,
      398.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b024",
    "text": "The population enrolled in the EXPRESS trial was distinct from that enrolled in",
    "bbox": [
      126.0,
      411.6,
      510.0,
      423.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b025",
    "text": "the pre-approval clinical trials of rivastigmine in Alzheimer’s Disease (and was",
    "bbox": [
      126.0,
      424.2,
      507.3,
      436.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b026",
    "text": "actually excluded from those trials)",
    "bbox": [
      126.0,
      436.8,
      298.5,
      449.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b027",
    "text": "Although patients enrolled in the EXPRESS trial were not selected based on",
    "bbox": [
      126.0,
      462.1,
      499.6,
      474.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b028",
    "text": "those neuropsychological deficits that, according to the DSM IV definition of",
    "bbox": [
      126.0,
      474.8,
      496.5,
      487.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b029",
    "text": "“Dementia Due To Parkinson’s Disease,” (294.1) are distinctive for that disorder",
    "bbox": [
      126.0,
      487.4,
      516.7,
      499.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b030",
    "text": "(i.e., “cognitive and motor slowing, executive dysfunction, and impairment in",
    "bbox": [
      126.0,
      500.1,
      497.7,
      512.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b031",
    "text": "memory retrieval”), selecting patients based on the extent of such deficits is",
    "bbox": [
      126.0,
      512.7,
      495.9,
      525.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b032",
    "text": "unlikely to help differentiate them from patients with Alzheimer’s Disease",
    "bbox": [
      126.0,
      525.4,
      481.8,
      537.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b033",
    "text": "The results of the EXPRESS Study are sufficiently robust for that study alone to",
    "bbox": [
      126.0,
      550.7,
      516.0,
      563.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b034",
    "text": "be the basis for the expansion of the current claim to include dementia",
    "bbox": [
      126.0,
      563.3,
      470.8,
      575.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b035",
    "text": "associated with Parkinson’s Disease, especially since the mechanism by which",
    "bbox": [
      126.0,
      576.0,
      513.4,
      588.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b036",
    "text": "rivastigmine may have its effect in that condition and in Alzheimer’s Disease may",
    "bbox": [
      126.0,
      588.6,
      522.0,
      600.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b037",
    "text": "be the same.",
    "bbox": [
      126.0,
      601.3,
      201.8,
      613.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b038",
    "text": "The Division’s key concerns about an expansion of the current claim for",
    "bbox": [
      90.0,
      627.7,
      472.8,
      641.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b039",
    "text": "rivastigmine to include dementia associated with Parkinson’s Disease, especially",
    "bbox": [
      90.0,
      641.5,
      521.5,
      654.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b040",
    "text": "on the basis of the results of the EXPRESS study alone, were as follows",
    "bbox": [
      90.0,
      655.3,
      476.9,
      668.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b041",
    "text": "The criteria used to diagnose dementia when including patients in the EXPRESS",
    "bbox": [
      126.0,
      682.9,
      521.5,
      695.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 67,
    "block_id": "1055_p67_b042",
    "text": "Study were no different from those used to enroll patients in the pre-approval",
    "bbox": [
      126.0,
      695.5,
      502.6,
      707.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b002",
    "text": "Page 68 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b005",
    "text": "efficacy studies of rivastigmine in Alzheimer’s Disease; i.e., these patients were",
    "bbox": [
      126.0,
      72.3,
      514.8,
      84.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b006",
    "text": "not identified on the basis of any purportedly distinctive features of dementia",
    "bbox": [
      126.0,
      84.9,
      499.6,
      97.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b007",
    "text": "associated with Parkinson’s Disease. In addition, the clinical course of the",
    "bbox": [
      126.0,
      97.6,
      487.9,
      109.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b008",
    "text": "placebo arm and the size of the effect seen with rivastigmine in the EXPRESS",
    "bbox": [
      126.0,
      110.2,
      508.6,
      122.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b009",
    "text": "trial were no different from similar observations in pre-approval efficacy trials of",
    "bbox": [
      126.0,
      122.8,
      512.5,
      135.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b010",
    "text": "rivastigmine in Alzheimer’s Disease. These observations call into question how",
    "bbox": [
      126.0,
      135.5,
      512.3,
      147.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b011",
    "text": "distinct the patients in the EXPRESS trial were from those enrolled in the pre-",
    "bbox": [
      126.0,
      148.2,
      502.6,
      160.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b012",
    "text": "approval Alzheimer’s Disease trials, and whether any effect of rivastigmine on",
    "bbox": [
      126.0,
      160.8,
      506.9,
      173.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b013",
    "text": "performance that was seen in the former study was mediated through its effects",
    "bbox": [
      126.0,
      173.5,
      516.7,
      185.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b014",
    "text": "on co-existing Alzheimer’s Disease.",
    "bbox": [
      126.0,
      186.1,
      302.7,
      198.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b015",
    "text": "DSM-IV is a standard reference manual containing diagnostic criteria for the",
    "bbox": [
      126.0,
      211.4,
      498.3,
      223.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b016",
    "text": "entire spectrum of psychiatric and neuropsychiatric disorders, including",
    "bbox": [
      126.0,
      224.1,
      474.6,
      236.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b017",
    "text": "“Dementia Due To Parkinson’s Disease” (294.1). In the EXPRESS Study,",
    "bbox": [
      126.0,
      236.7,
      486.0,
      249.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b018",
    "text": "patients with dementia associated with Parkinson’s Disease were enrolled based",
    "bbox": [
      126.0,
      249.3,
      521.6,
      261.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b019",
    "text": "on their having dementia, but without the more distinctive cognitive deficits",
    "bbox": [
      126.0,
      262.0,
      490.5,
      274.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b020",
    "text": "described in DSM-IV, thus raising the possibility that the appropriate diagnostic",
    "bbox": [
      126.0,
      274.6,
      512.4,
      286.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b021",
    "text": "criteria for that entity may not have been applied in that study.",
    "bbox": [
      126.0,
      287.3,
      438.4,
      299.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b022",
    "text": "The sponsor is currently seeking a claim for the use of rivastigmine in dementia",
    "bbox": [
      126.0,
      312.6,
      514.1,
      324.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b023",
    "text": "associated with Parkinson’s Disease based on a single study (i.e., EXPRESS).",
    "bbox": [
      126.0,
      325.2,
      511.6,
      337.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b024",
    "text": "While the sponsor considers the results of that study to be robust, the Division",
    "bbox": [
      126.0,
      337.9,
      508.2,
      350.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b025",
    "text": "has generally required that evidence for the efficacy of a drug in a distinct clinical",
    "bbox": [
      126.0,
      350.5,
      521.7,
      362.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b026",
    "text": "entity be replicated, and a second study would, therefore, ordinarily be required",
    "bbox": [
      126.0,
      363.2,
      514.3,
      375.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b027",
    "text": "to address the claim that the sponsor is currently pursuing",
    "bbox": [
      126.0,
      375.9,
      413.9,
      388.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b028",
    "text": "The Division was of the view that the entity of dementia associated with",
    "bbox": [
      90.0,
      401.1,
      471.4,
      414.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b029",
    "text": "Parkinson’s Disease should be discussed at a meeting of the Peripheral and",
    "bbox": [
      90.0,
      414.9,
      498.2,
      428.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b030",
    "text": "Central Nervous Systems Drugs Advisory Committee. The sponsor proposed",
    "bbox": [
      90.0,
      428.7,
      502.1,
      442.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b031",
    "text": "submitting a Supplemental NDA based on efficacy data from the EXPRESS",
    "bbox": [
      90.0,
      442.5,
      494.1,
      455.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b032",
    "text": "Study only, with a request for a standard review and the possibility of holding a",
    "bbox": [
      90.0,
      456.3,
      510.2,
      469.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b033",
    "text": "meeting of the Advisory Committee during the course of that review was",
    "bbox": [
      90.0,
      470.1,
      475.4,
      483.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b034",
    "text": "discussed.",
    "bbox": [
      90.0,
      483.9,
      153.4,
      497.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b035",
    "text": "The Division was, very shortly after the meeting, to discuss internally whether it",
    "bbox": [
      90.0,
      511.5,
      512.3,
      524.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b036",
    "text": "would be prepared to file a Supplemental NDA for rivastigmine in the treatment of",
    "bbox": [
      90.0,
      525.3,
      525.0,
      538.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b037",
    "text": "dementia associated with Parkinson’s Disease, based on efficacy data derived",
    "bbox": [
      90.0,
      539.1,
      509.5,
      552.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b038",
    "text": "from the EXPRESS Study alone, given the proposed common mechanism of",
    "bbox": [
      90.0,
      552.9,
      500.3,
      566.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b039",
    "text": "action of rivastigmine in both dementia associated with Parkinson’s Disease and",
    "bbox": [
      90.0,
      566.7,
      518.9,
      580.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b040",
    "text": "Alzheimer’s Disease, and was to inform the sponsor of its view shortly.",
    "bbox": [
      90.0,
      580.5,
      470.9,
      593.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b041",
    "text": "On May 24, 2005, the Division informed the sponsor that it would accept the filing",
    "bbox": [
      90.0,
      608.1,
      524.2,
      621.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b042",
    "text": "of a Supplemental NDA for Exelon® in the treatment of dementia associated with",
    "bbox": [
      90.0,
      621.9,
      523.0,
      635.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b043",
    "text": "Parkinson’s Disease based on the results of the EXPRESS Study alone and that",
    "bbox": [
      90.0,
      635.7,
      520.3,
      649.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b044",
    "text": "review of  that application would include a discussion with the Peripheral and",
    "bbox": [
      90.0,
      649.5,
      500.1,
      662.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b045",
    "text": "Central Nervous Systems Drugs Advisory Committee during the 10-month review",
    "bbox": [
      90.0,
      663.3,
      524.0,
      676.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 68,
    "block_id": "1055_p68_b046",
    "text": "period.",
    "bbox": [
      90.0,
      677.1,
      133.4,
      690.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b002",
    "text": "Page 69 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b005",
    "text": "11. Sponsor’s Current View Of Dementia Associated With",
    "bbox": [
      90.0,
      72.4,
      477.2,
      88.0
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b006",
    "text": "Parkinson’s Disease, And Appropriateness Of ADAS-Cog And",
    "bbox": [
      90.0,
      88.5,
      503.5,
      104.1
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b007",
    "text": "ADCS-ADL In Evaluating Treatment Effects In Dementia",
    "bbox": [
      90.0,
      104.7,
      461.9,
      120.3
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b008",
    "text": "Associated With Parkinson’s Disease",
    "bbox": [
      90.0,
      120.7,
      346.2,
      136.3
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b009",
    "text": "Separate independent expert reports have been commissioned by the sponsor to",
    "bbox": [
      90.0,
      139.6,
      523.6,
      153.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b010",
    "text": "address each of these 2 subjects. The contents of these reports, with which the",
    "bbox": [
      90.0,
      153.4,
      513.5,
      166.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b011",
    "text": "sponsor appears to concur, are summarized below. Note that the sponsor has",
    "bbox": [
      90.0,
      167.2,
      506.9,
      180.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b012",
    "text": "supplemented the results of the second of the reports below with the conclusions",
    "bbox": [
      90.0,
      181.0,
      522.3,
      194.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b013",
    "text": "drawn from Study 2314.",
    "bbox": [
      90.0,
      194.8,
      220.8,
      208.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b014",
    "text": "11.1 Dementia Associated With Parkinson’s Disease (Expert Report:",
    "bbox": [
      90.0,
      228.5,
      485.3,
      241.9
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b015",
    "text": "Diagnosing Dementia Associated With Parkinson’s Disease And",
    "bbox": [
      90.0,
      242.3,
      459.4,
      255.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b016",
    "text": "Distinguishing It From Alzheimer’s Disease)",
    "bbox": [
      90.0,
      256.1,
      344.1,
      269.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b017",
    "text": "The report has been prepared by 3 academics at the request of the sponsor.",
    "bbox": [
      90.0,
      272.8,
      499.0,
      286.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b018",
    "text": "These individuals are Professors J. Cummings, M. Emre, and C. W. Olanow.",
    "bbox": [
      90.0,
      286.6,
      500.2,
      300.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b019",
    "text": "In the report they have provided their opinion in 2 areas",
    "bbox": [
      90.0,
      314.2,
      387.5,
      327.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b020",
    "text": "• Whether the dementia associated with Parkinson’s Disease is a different",
    "bbox": [
      108.0,
      341.5,
      513.6,
      356.1
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b021",
    "text": "disease entity from the dementia associated with Alzheimer’s Disease",
    "bbox": [
      126.0,
      356.4,
      503.4,
      369.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b022",
    "text": "• Whether practitioners can differentiate the 2 conditions",
    "bbox": [
      108.0,
      369.8,
      422.9,
      384.5
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b023",
    "text": "They have concluded that",
    "bbox": [
      90.0,
      398.6,
      234.1,
      412.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b024",
    "text": "• There is a distinction between dementia associated with Parkinson’s",
    "bbox": [
      108.0,
      425.9,
      491.5,
      440.6
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b025",
    "text": "Disease and Alzheimer’s Disease",
    "bbox": [
      126.0,
      440.8,
      311.4,
      454.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b026",
    "text": "• Operational criteria permit the 2 conditions to be readily distinguished",
    "bbox": [
      108.0,
      454.3,
      496.8,
      468.9
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b027",
    "text": "• The same operational criteria can be applied by community practitioners",
    "bbox": [
      108.0,
      468.9,
      512.2,
      483.6
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b028",
    "text": "to easily differentiate between the 2 conditions",
    "bbox": [
      126.0,
      483.8,
      375.5,
      497.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b029",
    "text": "The basis for their conclusions, as stated in the report, is provided under the",
    "bbox": [
      90.0,
      511.4,
      496.9,
      524.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b030",
    "text": "headings below, which are the same as those used by the authors of the report;",
    "bbox": [
      90.0,
      525.2,
      516.3,
      538.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b031",
    "text": "Please see the text of the report for full details.  Note that although many",
    "bbox": [
      90.0,
      539.0,
      478.3,
      552.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b032",
    "text": "publications are cited in the report, full citations are provided for only some of",
    "bbox": [
      90.0,
      552.8,
      501.6,
      566.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b033",
    "text": "those publications; also note that some publications cited are untraceable",
    "bbox": [
      90.0,
      566.6,
      482.7,
      580.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b034",
    "text": "through standard search engines.",
    "bbox": [
      90.0,
      580.4,
      272.1,
      593.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b035",
    "text": "11.1.1 Prevalence And Incidence Of Dementia Associated With Parkinson’s",
    "bbox": [
      90.0,
      614.1,
      498.8,
      627.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b036",
    "text": "Disease",
    "bbox": [
      90.0,
      627.9,
      140.0,
      641.3
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b037",
    "text": "• Based on a published meta-analysis, the prevalence of dementia in",
    "bbox": [
      108.0,
      644.3,
      486.2,
      659.0
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b038",
    "text": "patients with Parkinson’s Disease is about 40%. However, since dementia",
    "bbox": [
      126.0,
      659.2,
      522.3,
      672.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b039",
    "text": "in Parkinson’s Disease is associated with increased mortality, it is likely to",
    "bbox": [
      126.0,
      673.0,
      520.2,
      686.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b040",
    "text": "be under-represented in cross-sectional studies or in longitudinal studies",
    "bbox": [
      126.0,
      686.8,
      514.2,
      700.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 69,
    "block_id": "1055_p69_b041",
    "text": "that do not account for differential mortality",
    "bbox": [
      126.0,
      700.6,
      356.1,
      714.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b002",
    "text": "Page 70 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b005",
    "text": "• Incidence studies, which are relatively free of survival bias indicate a 4-6",
    "bbox": [
      108.0,
      85.7,
      512.9,
      100.4
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b006",
    "text": "times higher incidence of dementia in patients with Parkinson’s Disease",
    "bbox": [
      126.0,
      100.6,
      509.5,
      114.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b007",
    "text": "as compared with age-matched controls; since the incidence of dementia",
    "bbox": [
      126.0,
      114.4,
      516.8,
      127.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b008",
    "text": "in the control population probably represents the occurrence of",
    "bbox": [
      126.0,
      128.2,
      462.1,
      141.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b009",
    "text": "Alzheimer’s Disease and other degenerative and symptomatic dementias",
    "bbox": [
      126.0,
      142.0,
      517.6,
      155.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b010",
    "text": "in the population, the increased incidence of dementia in populations with",
    "bbox": [
      126.0,
      155.8,
      518.3,
      169.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b011",
    "text": "Parkinson’s Disease in all likelihood represents an excess of dementia",
    "bbox": [
      126.0,
      169.6,
      502.8,
      183.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b012",
    "text": "that is directly attributable to Parkinson’s Disease",
    "bbox": [
      126.0,
      183.4,
      394.1,
      196.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b013",
    "text": "11.1.2 Risk Factors For Dementia Associated With Parkinson’s Disease",
    "bbox": [
      90.0,
      217.1,
      481.3,
      230.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b014",
    "text": "• The most significant risk factors for dementia in patients with Parkinson’s",
    "bbox": [
      108.0,
      233.5,
      515.4,
      248.1
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b015",
    "text": "Disease are old age, duration of Parkinson’s Disease, age at onset of",
    "bbox": [
      126.0,
      248.5,
      497.7,
      261.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b016",
    "text": "Parkinson’s Disease, akinetic-rigid form of the disease, and the severity of",
    "bbox": [
      126.0,
      262.3,
      522.1,
      275.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b017",
    "text": "motor symptoms",
    "bbox": [
      126.0,
      276.1,
      218.0,
      289.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b018",
    "text": "• The presence of subtle involvement of executive functions in non-",
    "bbox": [
      108.0,
      303.3,
      474.2,
      318.0
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b019",
    "text": "demented Parkinson’s Disease patients predicts the emergence of",
    "bbox": [
      126.0,
      318.2,
      482.2,
      331.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b020",
    "text": "dementia later",
    "bbox": [
      126.0,
      332.0,
      205.4,
      345.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b021",
    "text": "• Dementia becomes more common with advancing Parkinson’s Disease",
    "bbox": [
      108.0,
      359.3,
      507.4,
      374.0
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b022",
    "text": "• Risk factors for dementia associated with Parkinson’s Disease differ from",
    "bbox": [
      108.0,
      387.7,
      516.9,
      402.3
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b023",
    "text": "those for Alzheimer’s Disease, with the principal risk factor for the former",
    "bbox": [
      126.0,
      402.7,
      514.9,
      416.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b024",
    "text": "being the presence of Parkinson’s Disease itself",
    "bbox": [
      126.0,
      416.5,
      388.2,
      429.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b025",
    "text": "• The diagnostic entities of dementia associated with Parkinson’s Disease",
    "bbox": [
      108.0,
      443.7,
      512.1,
      458.4
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b026",
    "text": "and probable Alzheimer’s Disease are mutually exclusive by definition,",
    "bbox": [
      126.0,
      458.6,
      503.6,
      472.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b027",
    "text": "since the diagnosis of probable Alzheimer’s Disease (NINCDS-ADRDA",
    "bbox": [
      126.0,
      472.4,
      506.1,
      485.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b028",
    "text": "criteria)/dementia of the Alzheimer’s type (American Psychiatric",
    "bbox": [
      126.0,
      486.2,
      466.1,
      499.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b029",
    "text": "Association criteria) requires the exclusion of other brain disorders",
    "bbox": [
      126.0,
      500.0,
      480.9,
      513.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b030",
    "text": "capable of causing a dementia syndrome",
    "bbox": [
      126.0,
      513.8,
      348.1,
      527.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b031",
    "text": "11.1.3 Genetic Distinctions Between Alzheimer’s Disease And Parkinson’s",
    "bbox": [
      90.0,
      547.5,
      492.0,
      560.9
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b032",
    "text": "Disease",
    "bbox": [
      90.0,
      561.3,
      140.0,
      574.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b033",
    "text": "• The majority of cases of both Parkinson’s Disease and Alzheimer’s",
    "bbox": [
      108.0,
      577.7,
      484.1,
      592.4
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b034",
    "text": "Disease occur sporadically. However, genetic mutations have been",
    "bbox": [
      126.0,
      592.7,
      486.3,
      606.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b035",
    "text": "identified in some Alzheimer’s Disease and Parkinson’s Disease patients;",
    "bbox": [
      126.0,
      606.5,
      518.9,
      619.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b036",
    "text": "the genetic mutations associated with Parkinson’s Disease differ from",
    "bbox": [
      126.0,
      620.3,
      498.2,
      633.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b037",
    "text": "those associated with Alzheimer’s Disease, and no gene mutation has",
    "bbox": [
      126.0,
      634.1,
      501.5,
      647.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b038",
    "text": "been identified which causes both. Such genetic defects as have been",
    "bbox": [
      126.0,
      647.9,
      503.0,
      661.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b039",
    "text": "associated with Alzheimer’s Disease tend to be associated with disorders",
    "bbox": [
      126.0,
      661.7,
      518.2,
      675.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b040",
    "text": "of amyloid production and metabolism, while some genetic forms of",
    "bbox": [
      126.0,
      675.5,
      487.0,
      688.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b041",
    "text": "Parkinson’s Disease are associated with mutations and increased",
    "bbox": [
      126.0,
      689.2,
      478.1,
      702.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 70,
    "block_id": "1055_p70_b042",
    "text": "deposition of alpha-synuclein",
    "bbox": [
      126.0,
      703.0,
      284.0,
      716.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b002",
    "text": "Page 71 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b005",
    "text": "• There is no excess of Alzheimer’s Disease among probands with",
    "bbox": [
      108.0,
      85.7,
      473.4,
      100.4
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b006",
    "text": "Parkinson’s Disease as might be anticipated if the major genetic factors",
    "bbox": [
      126.0,
      100.6,
      509.0,
      114.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b007",
    "text": "contributing to their etiologies are shared",
    "bbox": [
      126.0,
      114.4,
      346.2,
      127.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b008",
    "text": "• Specific APOE alleles tend to be associated with Alzheimer’s Disease and",
    "bbox": [
      108.0,
      141.7,
      522.7,
      156.3
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b009",
    "text": "Parkinson’s Disease, respectively.",
    "bbox": [
      126.0,
      156.7,
      314.8,
      170.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b010",
    "text": "• The genetic distinctions between Alzheimer’s Disease and Parkinson’s",
    "bbox": [
      108.0,
      183.9,
      504.1,
      198.6
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b011",
    "text": "Disease are summarized in the table below",
    "bbox": [
      126.0,
      198.8,
      358.7,
      212.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b012",
    "text": "Genetic Feature",
    "bbox": [
      122.4,
      226.8,
      185.1,
      235.7
    ],
    "font_size": 8.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b013",
    "text": "Dementia Associated with Parkinson’s Disease",
    "bbox": [
      202.6,
      226.8,
      384.0,
      235.7
    ],
    "font_size": 8.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b014",
    "text": "Alzheimer’s Disease",
    "bbox": [
      437.5,
      226.8,
      517.0,
      235.7
    ],
    "font_size": 8.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b015",
    "text": "Causative mutations Alpha-synuclein, PARKIN, UCH-L1, PARK-8, PINK-1, DJ-1",
    "bbox": [
      122.4,
      266.6,
      413.6,
      275.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b016",
    "text": "PS1, PS2, APP",
    "bbox": [
      437.5,
      266.6,
      494.7,
      275.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b017",
    "text": "APOE-4 influence",
    "bbox": [
      122.4,
      303.2,
      188.2,
      312.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b018",
    "text": "No effect on PDD; increases age-related or AD-type pathology",
    "bbox": [
      202.5,
      303.2,
      425.6,
      312.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b019",
    "text": "Major risk factor",
    "bbox": [
      437.4,
      303.2,
      496.4,
      312.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b020",
    "text": "APOE-2 influence",
    "bbox": [
      122.4,
      339.3,
      188.2,
      348.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b021",
    "text": "Increases PDD",
    "bbox": [
      202.5,
      339.3,
      258.5,
      348.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b022",
    "text": "Decreases AD",
    "bbox": [
      437.4,
      339.3,
      491.1,
      348.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b023",
    "text": "AD: Alzheimer’s Disease",
    "bbox": [
      117.0,
      358.2,
      221.0,
      368.3
    ],
    "font_size": 9.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b024",
    "text": "PDD: dementia associated with Parkinson’s Disease",
    "bbox": [
      117.0,
      368.5,
      331.1,
      378.6
    ],
    "font_size": 9.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b025",
    "text": "11.1.4 Neuropathological Distinctions Between Alzheimer’s Disease And",
    "bbox": [
      90.0,
      398.8,
      482.0,
      412.2
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b026",
    "text": "Parkinson’s Disease",
    "bbox": [
      90.0,
      412.6,
      205.4,
      426.0
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b027",
    "text": "• Stains that are specific and sensitive for detecting Lewy body and neurite",
    "bbox": [
      108.0,
      429.0,
      516.9,
      443.7
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b028",
    "text": "pathology in Parkinson’s Disease have been helpful in understanding the",
    "bbox": [
      126.0,
      443.9,
      516.2,
      457.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b029",
    "text": "basis for dementia associated with Parkinson’s Disease",
    "bbox": [
      126.0,
      457.7,
      424.8,
      471.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b030",
    "text": "• Cortical Lewy bodies and the extent of Lewy neurites in the CA2 region of",
    "bbox": [
      108.0,
      485.0,
      519.6,
      499.7
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b031",
    "text": "the hippocampus show a strong correlation with the extent of cognitive",
    "bbox": [
      126.0,
      500.0,
      502.9,
      513.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b032",
    "text": "impairment",
    "bbox": [
      126.0,
      513.8,
      188.7,
      527.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b033",
    "text": "• Marked nigrostriatal dopaminergic neuronal degeneration is a unique",
    "bbox": [
      108.0,
      541.0,
      494.8,
      555.7
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b034",
    "text": "pathological feature of dementia associated with Parkinson’s Disease.",
    "bbox": [
      126.0,
      556.0,
      500.9,
      569.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b035",
    "text": "Pathological abnormalities in the locus ceruleus may also contribute to",
    "bbox": [
      126.0,
      569.8,
      502.9,
      583.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b036",
    "text": "dementia associated with Parkinson’s Disease",
    "bbox": [
      126.0,
      583.6,
      376.1,
      597.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b037",
    "text": "• In Parkinson’s Disease, there is also a loss of cholinergic neurons in the",
    "bbox": [
      108.0,
      610.8,
      510.9,
      625.5
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b038",
    "text": "nucleus basalis of Meynert and a marked cholinergic deficiency, both of",
    "bbox": [
      126.0,
      625.7,
      508.9,
      639.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b039",
    "text": "which may occur early in the course of that disorder. These changes are",
    "bbox": [
      126.0,
      639.5,
      512.9,
      652.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b040",
    "text": "most pronounced in patients with dementia associated with Parkinson’s",
    "bbox": [
      126.0,
      653.3,
      508.1,
      666.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b041",
    "text": "Disease. The severity of the cholinergic deficiency in dementia associated",
    "bbox": [
      126.0,
      667.1,
      521.5,
      680.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b042",
    "text": "with Parkinson’s Disease is greater than that occurring in Alzheimer’s",
    "bbox": [
      126.0,
      680.9,
      496.9,
      694.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 71,
    "block_id": "1055_p71_b043",
    "text": "Disease.",
    "bbox": [
      126.0,
      694.7,
      186.1,
      708.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b002",
    "text": "Page 72 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b005",
    "text": "• While the pathological abnormalities characteristic of Alzheimer’s Disease",
    "bbox": [
      108.0,
      85.7,
      520.8,
      100.4
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b006",
    "text": "(i.e., neurofibrillary tangles and senile plaques) are commonly present in",
    "bbox": [
      126.0,
      100.6,
      512.2,
      114.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b007",
    "text": "patients with dementia associated with Parkinson’s Disease, they are",
    "bbox": [
      126.0,
      114.4,
      496.1,
      127.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b008",
    "text": "more commonly present when dementia is advanced, and they do not",
    "bbox": [
      126.0,
      128.2,
      499.6,
      141.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b009",
    "text": "account for all or even a majority of cases of dementia associated with",
    "bbox": [
      126.0,
      142.0,
      502.1,
      155.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b010",
    "text": "Parkinson’s Disease",
    "bbox": [
      126.0,
      155.8,
      241.4,
      169.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b011",
    "text": "• Differences in the neuropathology of dementia associated with",
    "bbox": [
      108.0,
      183.1,
      460.2,
      197.7
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b012",
    "text": "Parkinson’s Disease and Alzheimer’s Disease are summarized in the",
    "bbox": [
      126.0,
      198.1,
      495.4,
      211.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b013",
    "text": "following table, which I have copied from the submission",
    "bbox": [
      126.0,
      211.9,
      428.2,
      225.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b014",
    "text": "Pathological Feature",
    "bbox": [
      113.4,
      239.9,
      214.6,
      251.1
    ],
    "font_size": 10.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b015",
    "text": "Dementia Associated with",
    "bbox": [
      238.3,
      239.9,
      365.1,
      251.1
    ],
    "font_size": 10.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b016",
    "text": "Parkinson’s Disease",
    "bbox": [
      238.3,
      251.4,
      338.4,
      262.6
    ],
    "font_size": 10.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b017",
    "text": "Alzheimer’s Disease",
    "bbox": [
      395.1,
      239.9,
      494.7,
      251.1
    ],
    "font_size": 10.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b018",
    "text": "Lewy bodies",
    "bbox": [
      113.4,
      263.3,
      171.8,
      274.5
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b019",
    "text": "Correlate highly with cognitive",
    "bbox": [
      238.3,
      263.3,
      373.8,
      274.5
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b020",
    "text": "impairment",
    "bbox": [
      238.3,
      274.9,
      290.6,
      286.0
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b021",
    "text": "Rare",
    "bbox": [
      395.1,
      263.3,
      419.6,
      274.5
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b022",
    "text": "Senile plaques",
    "bbox": [
      113.4,
      286.9,
      181.7,
      298.0
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b023",
    "text": "Low sensitivity for dementia",
    "bbox": [
      238.2,
      286.9,
      363.9,
      298.0
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b024",
    "text": "Present in all cases",
    "bbox": [
      395.1,
      286.9,
      484.7,
      298.0
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b025",
    "text": "Neurofibrillary tangles",
    "bbox": [
      113.4,
      310.4,
      212.9,
      321.6
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b026",
    "text": "Low sensitivity for dementia",
    "bbox": [
      238.2,
      310.4,
      363.9,
      321.6
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b027",
    "text": "Present in nearly all cases",
    "bbox": [
      395.1,
      310.4,
      514.6,
      321.6
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b028",
    "text": "Cholinergic deficit",
    "bbox": [
      113.4,
      333.8,
      195.1,
      345.0
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b029",
    "text": "More marked",
    "bbox": [
      238.3,
      333.8,
      300.0,
      345.0
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b030",
    "text": "Less marked",
    "bbox": [
      395.1,
      333.8,
      455.1,
      345.0
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b031",
    "text": "Dopaminergic deficit",
    "bbox": [
      113.4,
      357.4,
      206.8,
      368.5
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b032",
    "text": "Present",
    "bbox": [
      238.3,
      357.4,
      275.6,
      368.5
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b033",
    "text": "Absent",
    "bbox": [
      395.1,
      357.4,
      429.1,
      368.5
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b034",
    "text": "Noradrenergic deficit",
    "bbox": [
      113.4,
      380.9,
      208.5,
      392.1
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b035",
    "text": "Present",
    "bbox": [
      238.3,
      380.9,
      275.6,
      392.1
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b036",
    "text": "Present",
    "bbox": [
      395.1,
      380.9,
      432.4,
      392.1
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b037",
    "text": "11.1.5 Neuroimaging In Dementia Associated With Parkinson’s Disease",
    "bbox": [
      90.0,
      424.3,
      481.4,
      437.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b038",
    "text": "Only limited neuroimaging studies have been done in dementia associated with",
    "bbox": [
      90.0,
      441.0,
      513.6,
      454.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b039",
    "text": "Parkinson’s Disease.",
    "bbox": [
      90.0,
      454.8,
      205.4,
      468.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b040",
    "text": "Preliminary MRI observations suggest that while atrophy of the temporal lobes,",
    "bbox": [
      90.0,
      482.4,
      511.5,
      495.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b041",
    "text": "including the hippocampus and parahippocampal gyrus, is more severe in",
    "bbox": [
      90.0,
      496.2,
      485.0,
      509.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b042",
    "text": "patients with Alzheimer’s Disease, severe atrophy of the thalamus and occipital",
    "bbox": [
      90.0,
      510.0,
      513.5,
      523.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b043",
    "text": "lobes is more characteristic of Parkinson’s Disease.",
    "bbox": [
      90.0,
      523.8,
      370.8,
      537.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b044",
    "text": "Functional imaging studies (single-photon emission computerized tomography;",
    "bbox": [
      90.0,
      551.4,
      510.9,
      564.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b045",
    "text": "positron emission tomography) using radiolabeled ligands which provide a",
    "bbox": [
      90.0,
      565.2,
      486.1,
      578.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b046",
    "text": "measure of pre-synaptic dopaminergic neurons and terminals have revealed",
    "bbox": [
      90.0,
      579.0,
      498.1,
      592.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b047",
    "text": "significant reductions in striatal uptake or binding of these ligands, as compared",
    "bbox": [
      90.0,
      592.8,
      515.6,
      606.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b048",
    "text": "with patients who have Alzheimer’s Disease or controls.",
    "bbox": [
      90.0,
      606.6,
      389.5,
      620.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b049",
    "text": "11.1.6 Neuropsychological Differences Between Dementia Associated With",
    "bbox": [
      90.0,
      640.3,
      496.7,
      653.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b050",
    "text": "Parkinson’s Disease And Alzheimer’s Disease",
    "bbox": [
      90.0,
      654.1,
      338.7,
      667.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b051",
    "text": "These differences are summarized in the following table, which I have modified",
    "bbox": [
      90.0,
      670.8,
      512.2,
      684.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 72,
    "block_id": "1055_p72_b052",
    "text": "slightly, for the sake of clarity, from one contained in the submission.",
    "bbox": [
      90.0,
      684.6,
      459.5,
      698.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b002",
    "text": "Page 73 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b005",
    "text": "Neuropsychological Domain",
    "bbox": [
      90.0,
      72.6,
      200.2,
      81.5
    ],
    "font_size": 8.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b006",
    "text": "Dementia Associated with Parkinson’s Disease",
    "bbox": [
      212.4,
      72.6,
      391.6,
      81.5
    ],
    "font_size": 8.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b007",
    "text": "Alzheimer’s Disease",
    "bbox": [
      401.5,
      72.6,
      481.0,
      81.5
    ],
    "font_size": 8.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b008",
    "text": "Memory",
    "bbox": [
      90.0,
      108.2,
      121.0,
      117.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b009",
    "text": "Retrieval deficit syndrome",
    "bbox": [
      212.4,
      108.2,
      306.6,
      117.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b010",
    "text": "Amnestic type of memory disturbance",
    "bbox": [
      401.4,
      108.2,
      537.4,
      117.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b011",
    "text": "Executive function deficit",
    "bbox": [
      90.0,
      133.1,
      180.2,
      142.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b012",
    "text": "Prominent",
    "bbox": [
      212.3,
      133.1,
      251.0,
      142.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b013",
    "text": "Moderate",
    "bbox": [
      401.3,
      133.1,
      437.3,
      142.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b014",
    "text": "Language deficit",
    "bbox": [
      90.0,
      158.0,
      150.9,
      166.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b015",
    "text": "Limited",
    "bbox": [
      212.4,
      158.0,
      240.4,
      166.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b016",
    "text": "Prominent",
    "bbox": [
      401.4,
      158.0,
      440.0,
      166.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b017",
    "text": "Visuospatial deficits",
    "bbox": [
      90.0,
      182.9,
      162.5,
      191.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b018",
    "text": "Prominent, may be attributable to executive",
    "bbox": [
      212.4,
      182.9,
      368.4,
      191.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b019",
    "text": "abnormalities",
    "bbox": [
      212.4,
      192.0,
      262.2,
      200.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b020",
    "text": "Milder, independent of executive dysfunction",
    "bbox": [
      401.4,
      182.9,
      559.3,
      191.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b021",
    "text": "Bradyphrenia",
    "bbox": [
      90.0,
      215.0,
      139.7,
      223.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b022",
    "text": "Present",
    "bbox": [
      212.4,
      215.0,
      242.2,
      223.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b023",
    "text": "Absent",
    "bbox": [
      401.4,
      215.0,
      428.5,
      223.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b024",
    "text": "Fluctuation in attention",
    "bbox": [
      90.0,
      239.9,
      172.7,
      248.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b025",
    "text": "Characteristic",
    "bbox": [
      212.4,
      239.9,
      263.5,
      248.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b026",
    "text": "Uncommon",
    "bbox": [
      401.4,
      239.9,
      444.4,
      248.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b027",
    "text": "11.1.7 Distinction Between Dementia Associated With Parkinson’s Disease And",
    "bbox": [
      90.0,
      284.8,
      520.0,
      298.2
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b028",
    "text": "Alzheimer’s Disease Based On Non-Cognitive Clinical Features",
    "bbox": [
      90.0,
      298.6,
      430.8,
      312.0
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b029",
    "text": "These differences are summarized in the following table, which I have modified,",
    "bbox": [
      90.0,
      315.3,
      515.6,
      328.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b030",
    "text": "for the sake of clarity, from one contained in the submission.",
    "bbox": [
      90.0,
      329.1,
      416.3,
      342.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b031",
    "text": "Non-Cognitive Feature",
    "bbox": [
      90.0,
      357.1,
      178.0,
      366.0
    ],
    "font_size": 8.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b032",
    "text": "Dementia Associated with Parkinson’s",
    "bbox": [
      230.4,
      357.1,
      379.3,
      366.0
    ],
    "font_size": 8.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b033",
    "text": "Disease",
    "bbox": [
      230.4,
      366.3,
      262.8,
      375.2
    ],
    "font_size": 8.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b034",
    "text": "Alzheimer’s Disease",
    "bbox": [
      392.4,
      357.1,
      472.0,
      366.0
    ],
    "font_size": 8.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b035",
    "text": "Motor signs of Parkinson’s Disease",
    "bbox": [
      90.0,
      376.0,
      219.3,
      384.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b036",
    "text": "Present",
    "bbox": [
      230.3,
      376.0,
      260.2,
      384.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b037",
    "text": "Absent (parkinsonism may emerge late)",
    "bbox": [
      392.4,
      376.0,
      535.9,
      384.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b038",
    "text": "Neuroleptic sensitivity",
    "bbox": [
      90.0,
      394.9,
      169.5,
      403.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b039",
    "text": "Present",
    "bbox": [
      230.4,
      394.9,
      260.1,
      403.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b040",
    "text": "Absent",
    "bbox": [
      392.4,
      394.9,
      419.5,
      403.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b041",
    "text": "Autonomic dysfunction",
    "bbox": [
      90.0,
      413.8,
      172.7,
      422.7
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b042",
    "text": "Common",
    "bbox": [
      230.3,
      413.8,
      265.0,
      422.7
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b043",
    "text": "Uncommon",
    "bbox": [
      392.4,
      413.8,
      435.4,
      422.7
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b044",
    "text": "REM sleep behavior disorder",
    "bbox": [
      90.0,
      432.6,
      195.3,
      441.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b045",
    "text": "Common",
    "bbox": [
      230.4,
      432.6,
      265.0,
      441.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b046",
    "text": "Absent",
    "bbox": [
      392.4,
      432.6,
      419.5,
      441.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b047",
    "text": "11.1.8 Parkinson’s Disease Can Be Distinguished From Alzheimer’s Disease By",
    "bbox": [
      90.0,
      471.5,
      521.9,
      484.9
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b048",
    "text": "A Practitioner",
    "bbox": [
      90.0,
      485.3,
      165.4,
      498.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b049",
    "text": "The currently available diagnostic criteria for dementia associated with",
    "bbox": [
      90.0,
      502.1,
      466.2,
      515.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b050",
    "text": "Parkinson’s Disease are those contained in DSM-IV. According to the authors of",
    "bbox": [
      90.0,
      515.9,
      519.0,
      529.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b051",
    "text": "the report, all major criteria, which are listed below, should be present for a",
    "bbox": [
      90.0,
      529.7,
      489.5,
      543.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b052",
    "text": "diagnosis to be made.",
    "bbox": [
      90.0,
      543.5,
      210.8,
      556.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b053",
    "text": "• Parkinson’s disease",
    "bbox": [
      112.0,
      570.7,
      239.9,
      585.4
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b054",
    "text": "• Dementia comprising the following",
    "bbox": [
      112.0,
      585.3,
      316.0,
      600.0
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b055",
    "text": "o Memory impairment",
    "bbox": [
      148.0,
      600.3,
      266.2,
      613.6
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b056",
    "text": "o Impairment of at least one other cognitive domain",
    "bbox": [
      148.0,
      612.9,
      409.9,
      626.2
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b057",
    "text": "o Impairment  represents a decline from a previous level of function",
    "bbox": [
      148.0,
      625.6,
      487.6,
      638.8
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b058",
    "text": "o Impairment sufficient to cause occupational or social disability",
    "bbox": [
      148.0,
      638.2,
      469.1,
      651.5
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b059",
    "text": "o Impairment not present exclusively during a delirium",
    "bbox": [
      148.0,
      650.9,
      422.6,
      664.1
    ],
    "font_size": 11.0,
    "font_name": "CourierNewPSMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b060",
    "text": "• Onset of Parkinson’s disease preceded the onset of dementia",
    "bbox": [
      112.0,
      663.2,
      460.9,
      677.9
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 73,
    "block_id": "1055_p73_b061",
    "text": "• Alternate causes of dementia have been excluded",
    "bbox": [
      112.0,
      677.8,
      399.5,
      692.4
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b002",
    "text": "Page 74 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b005",
    "text": "Reviewer’s Note: What is actually stated in DSM-IV (see below) is not",
    "bbox": [
      126.0,
      72.7,
      499.0,
      86.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b006",
    "text": "quite the same as the above",
    "bbox": [
      126.0,
      86.5,
      280.1,
      99.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b007",
    "text": "294.1    Dementia Due To Parkinson’s Disease",
    "bbox": [
      126.0,
      112.4,
      299.8,
      125.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b008",
    "text": "The essential feature of Dementia Due To Parkinson’s Disease is the presence of dementia that is judged to",
    "bbox": [
      126.0,
      139.1,
      520.3,
      150.6
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b009",
    "text": "be of direct pathophysiological consequence of Parkinson’s disease. Parkinson’s disease is a slowly",
    "bbox": [
      126.0,
      150.6,
      491.1,
      162.1
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b010",
    "text": "progressive neurological condition, characterized by tremor, rigidity, bradykinesia, and postural instability.",
    "bbox": [
      126.0,
      162.1,
      509.7,
      173.6
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b011",
    "text": "Dementia has been reported to occur in approximately 20%-60% of individuals with Parkinson’s disease and",
    "bbox": [
      126.0,
      173.6,
      521.1,
      185.1
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b012",
    "text": "is more likely to be present in older individuals or in those with more severe or advanced disease. The",
    "bbox": [
      126.0,
      185.0,
      497.6,
      196.5
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b013",
    "text": "dementia associated with Parkinson’s disease is characterized by cognitive and motor slowing, executive",
    "bbox": [
      126.0,
      196.5,
      508.8,
      208.0
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b014",
    "text": "dysfunction and impairment in memory retrieval. Declining cognitive performance in individuals with",
    "bbox": [
      126.0,
      208.0,
      487.8,
      219.5
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b015",
    "text": "Parkinson’s disease is frequently exacerbated by depression. Findings on physical examination include the",
    "bbox": [
      126.0,
      219.5,
      515.8,
      231.0
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b016",
    "text": "characteristic abnormal motor signs of resting tremor, evidence of slowness and poverty of movement (such",
    "bbox": [
      126.0,
      231.0,
      519.3,
      242.4
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b017",
    "text": "as micrographia), or muscular rigidity and loss of associated movements. At autopsy, neuronal loss and",
    "bbox": [
      126.0,
      242.4,
      503.4,
      253.9
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b018",
    "text": "Lewy bodies are evident in the substantia nigra. There are a number of syndromes that manifest with",
    "bbox": [
      126.0,
      253.9,
      493.9,
      265.4
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b019",
    "text": "dementia, Parkinsonian movement disorders, and additional neurological features (e.g., progressive",
    "bbox": [
      126.0,
      265.4,
      490.2,
      276.9
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b020",
    "text": "supranuclear palsy, olivopontocerebellar degeneration, and Vascular Dementia). Some individuals with",
    "bbox": [
      126.0,
      276.9,
      501.1,
      288.3
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b021",
    "text": "Parkinson’s disease and dementia are found at autopsy to have coexisting neuropathology indicative of",
    "bbox": [
      126.0,
      288.3,
      502.5,
      299.8
    ],
    "font_size": 10.0,
    "font_name": "ArialNarrow",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b022",
    "text": "Alzheimer’s disease or of diffuse Lewy body disease.",
    "bbox": [
      126.0,
      298.3,
      321.7,
      311.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b023",
    "text": "A medical practitioner can apply these criteria easily.",
    "bbox": [
      90.0,
      325.8,
      372.8,
      339.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b024",
    "text": "11.2 Appropriateness Of Using The ADAS-Cog And ADCS-ADL As",
    "bbox": [
      90.0,
      359.5,
      473.1,
      372.9
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b025",
    "text": "Outcome Measures In Dementia Associated With Parkinson’s Disease",
    "bbox": [
      90.0,
      373.3,
      495.4,
      386.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b026",
    "text": "An expert report prepared by Philip D. Harvey, PhD, has been provided in this",
    "bbox": [
      90.0,
      390.0,
      506.3,
      403.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b027",
    "text": "submission. Although this report addresses both the use of the ADAS-Cog and",
    "bbox": [
      90.0,
      403.8,
      510.7,
      417.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b028",
    "text": "ADCS-ADL in this condition, it is entitled: “Reliability and Validity of the",
    "bbox": [
      90.0,
      417.6,
      467.5,
      431.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b029",
    "text": "Alzheimer’s Disease Assessment Scale – Cognitive Subscale in Clinical Trials for",
    "bbox": [
      90.0,
      431.5,
      524.9,
      444.9
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b030",
    "text": "Dementia Associated with Parkinson’s Disease.”",
    "bbox": [
      90.0,
      445.3,
      354.1,
      458.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b031",
    "text": "The report was created partly in response to comments made by the European",
    "bbox": [
      90.0,
      472.8,
      511.4,
      486.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b032",
    "text": "Agency for the Evaluation of Medicinal Products/Committee for Proprietary",
    "bbox": [
      90.0,
      486.6,
      488.9,
      500.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b033",
    "text": "Medicinal Products after review of an earlier version of the protocol for the non-",
    "bbox": [
      90.0,
      500.4,
      509.6,
      513.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b034",
    "text": "interventional study 2314.",
    "bbox": [
      90.0,
      514.2,
      233.5,
      527.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b035",
    "text": "Note that this report, which was completed on October 28, 2004, does not cite",
    "bbox": [
      90.0,
      541.8,
      506.9,
      555.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b036",
    "text": "the results of either Study 2311 or Study 2314, and appears to have been",
    "bbox": [
      90.0,
      555.6,
      483.6,
      569.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b037",
    "text": "completed without taking these data into consideration. It is based on a review of",
    "bbox": [
      90.0,
      569.4,
      521.6,
      582.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b038",
    "text": "the medical literature (but that review does not include the published results of",
    "bbox": [
      90.0,
      583.2,
      507.6,
      596.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b039",
    "text": "Study 2311).",
    "bbox": [
      90.0,
      597.0,
      161.5,
      610.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b040",
    "text": "The contents of this report are briefly summarized below under the following",
    "bbox": [
      90.0,
      624.6,
      496.2,
      638.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 74,
    "block_id": "1055_p74_b041",
    "text": "headings.",
    "bbox": [
      90.0,
      638.4,
      145.4,
      651.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b002",
    "text": "Page 75 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b005",
    "text": "11.2.1 ADAS-Cog",
    "bbox": [
      90.0,
      72.3,
      195.9,
      85.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b006",
    "text": "11.2.1.1 ADAS-Cog In Alzheimer’s Disease",
    "bbox": [
      90.0,
      95.1,
      331.3,
      108.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b007",
    "text": "The author of the report states that the ADAS-Cog has the following properties",
    "bbox": [
      90.0,
      111.8,
      509.5,
      125.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b008",
    "text": "when used in Alzheimer’s Disease.",
    "bbox": [
      90.0,
      125.6,
      282.8,
      139.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b009",
    "text": " Reliability",
    "bbox": [
      108.0,
      153.2,
      180.6,
      166.6
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b010",
    "text": " Face validity and sensitivity to impairment",
    "bbox": [
      108.0,
      167.0,
      350.8,
      180.4
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b011",
    "text": " Sensitivity to change (criterion validity)",
    "bbox": [
      108.0,
      180.8,
      333.4,
      194.2
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b012",
    "text": "The author also points out that in efficacy studies in this population, the benefits",
    "bbox": [
      90.0,
      208.4,
      515.6,
      221.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b013",
    "text": "of active treatment are evaluated in relation to placebo groups which experience",
    "bbox": [
      90.0,
      222.2,
      518.2,
      235.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b014",
    "text": "a decline in cognition over the study; in some of these studies, the active",
    "bbox": [
      90.0,
      236.0,
      478.3,
      249.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b015",
    "text": "treatment group experienced no improvement relative to baseline. In other",
    "bbox": [
      90.0,
      249.8,
      487.1,
      263.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b016",
    "text": "words, a net benefit relative to placebo is assessed rather than an absolute",
    "bbox": [
      90.0,
      263.6,
      491.6,
      277.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b017",
    "text": "improvement with active treatment relative to baseline.",
    "bbox": [
      90.0,
      277.4,
      382.9,
      290.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b018",
    "text": "11.2.1.2 ADAS-Cog In Parkinson’s Disease Dementia",
    "bbox": [
      90.0,
      311.1,
      361.9,
      323.4
    ],
    "font_size": 11.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b019",
    "text": "The following is a summary of what is stated by the author of this report.",
    "bbox": [
      90.0,
      326.7,
      475.6,
      340.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b020",
    "text": "11.2.1.2.1 Face Validity Of ADAS-Cog",
    "bbox": [
      90.0,
      366.3,
      286.7,
      378.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b021",
    "text": "Parkinson’s Disease Dementia is characterized by the following",
    "bbox": [
      90.0,
      381.9,
      430.1,
      395.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b022",
    "text": " Impaired memory, but of less severity than that seen in Alzheimer’s",
    "bbox": [
      108.0,
      409.5,
      486.2,
      422.9
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b023",
    "text": "Disease. (The memory deficit seen in Parkinson’s Disease Dementia is of",
    "bbox": [
      126.0,
      423.3,
      519.5,
      436.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b024",
    "text": "the subcortical variety with impaired rate of learning and free recall, but",
    "bbox": [
      126.0,
      437.1,
      505.5,
      450.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b025",
    "text": "with preserved delayed recognition memory [the impairments of memory",
    "bbox": [
      126.0,
      450.9,
      513.4,
      464.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b026",
    "text": "are related to changes in cortical cholinergic function])",
    "bbox": [
      126.0,
      464.7,
      416.2,
      478.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b027",
    "text": " Executive function deficits along with deficits in motor speed and working",
    "bbox": [
      108.0,
      478.5,
      516.2,
      491.9
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b028",
    "text": "memory, which in themselves are unlikely to fully account for the memory",
    "bbox": [
      126.0,
      492.3,
      518.2,
      505.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b029",
    "text": "deficits seen in this condition. (The author also indicates that cognitive test",
    "bbox": [
      126.0,
      506.1,
      523.6,
      519.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b030",
    "text": "performance may be influenced by depression, motor symptoms,",
    "bbox": [
      126.0,
      519.9,
      474.1,
      533.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b031",
    "text": "bradykinesia, and bradyphrenia)",
    "bbox": [
      126.0,
      533.7,
      307.5,
      547.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b032",
    "text": "While executive dysfunction is not well assessed by the ADAS-Cog, it is a feature",
    "bbox": [
      90.0,
      561.3,
      524.9,
      574.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b033",
    "text": "of both Alzheimer’s Disease and Parkinson’s Disease Dementia.",
    "bbox": [
      90.0,
      575.1,
      438.8,
      588.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b034",
    "text": "The ADAS-Cog is sufficient to evaluate episodic memory impairment in",
    "bbox": [
      90.0,
      602.7,
      470.1,
      616.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b035",
    "text": "Parkinson’s Disease Dementia and therefore captures critical features of that",
    "bbox": [
      90.0,
      616.5,
      501.6,
      629.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b036",
    "text": "condition.",
    "bbox": [
      90.0,
      630.3,
      144.7,
      643.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b037",
    "text": "11.2.1.2.2 Temporal Change In ADAS-Cog",
    "bbox": [
      90.0,
      669.9,
      309.3,
      682.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b038",
    "text": "The course of cognitive decline in Parkinson’s Disease Dementia has not been",
    "bbox": [
      90.0,
      685.6,
      510.9,
      699.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 75,
    "block_id": "1055_p75_b039",
    "text": "adequately studied; existing published studies have a number of limitations. The",
    "bbox": [
      90.0,
      699.4,
      518.3,
      712.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b002",
    "text": "Page 76 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b005",
    "text": "few treatment studies in this condition prior to Study 2311 suggest that the",
    "bbox": [
      90.0,
      72.2,
      487.0,
      85.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b006",
    "text": "cognitive change that occurs in Parkinson’s Disease Dementia over time is not",
    "bbox": [
      90.0,
      86.0,
      509.6,
      99.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b007",
    "text": "as rapid or extensive as that seen over a similar period in patients with",
    "bbox": [
      90.0,
      99.8,
      466.8,
      113.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b008",
    "text": "Alzheimer’s Disease.",
    "bbox": [
      90.0,
      113.6,
      205.4,
      127.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b009",
    "text": "11.2.1.2.3   Sensitivity To Impairment And To Effects Of Treatment",
    "bbox": [
      90.0,
      153.3,
      421.9,
      165.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b010",
    "text": "The very limited literature covering the use of the ADAS-Cog in Parkinson’s",
    "bbox": [
      90.0,
      168.9,
      492.8,
      182.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b011",
    "text": "Disease Dementia suggests that scores on that instrument  correlate with those",
    "bbox": [
      90.0,
      182.7,
      514.9,
      196.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b012",
    "text": "on the Mini-Mental Status Examination, suggesting that the ADAS-Cog is",
    "bbox": [
      90.0,
      196.5,
      480.7,
      209.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b013",
    "text": "sensitive to impairment in that condition. The limited literature available also",
    "bbox": [
      90.0,
      210.3,
      494.8,
      223.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b014",
    "text": "suggests that the ADAS-Cog is as sensitive to treatment effects in Parkinson’s",
    "bbox": [
      90.0,
      224.1,
      508.9,
      237.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b015",
    "text": "Disease Dementia as in Alzheimer’s Disease.",
    "bbox": [
      90.0,
      237.9,
      335.5,
      251.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b016",
    "text": "11.2.1.2.4 Criterion Validity: Clinically Relevant Differences",
    "bbox": [
      90.0,
      277.5,
      384.0,
      289.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b017",
    "text": "Based on the small number of published studies, treatment effects in Parkinson’s",
    "bbox": [
      90.0,
      293.1,
      522.9,
      306.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b018",
    "text": "Disease Dementia, as measured by the ADAS-Cog, are at least as large as",
    "bbox": [
      90.0,
      306.9,
      493.6,
      320.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b019",
    "text": "those in Alzheimer’s Disease and, therefore, at least as clinically meaningful.",
    "bbox": [
      90.0,
      320.7,
      500.2,
      334.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b020",
    "text": "11.2.2 ADCS-ADL",
    "bbox": [
      90.0,
      354.4,
      197.9,
      367.8
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b021",
    "text": "11.2.2.1 ADCS-ADL In Alzheimer’s Disease",
    "bbox": [
      90.0,
      377.2,
      317.6,
      390.6
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b022",
    "text": "The author highlights the following properties of the ADCS-ADL in Alzheimer’s",
    "bbox": [
      90.0,
      393.7,
      507.5,
      407.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b023",
    "text": "Disease, based on the published literature:",
    "bbox": [
      90.0,
      407.5,
      327.4,
      420.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b024",
    "text": "• Good test-retest reliability",
    "bbox": [
      108.0,
      434.8,
      265.4,
      449.4
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b025",
    "text": "• Convergent validity",
    "bbox": [
      108.0,
      463.1,
      231.4,
      477.8
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b026",
    "text": "Good correlation of individual items on the scale with the level of",
    "bbox": [
      162.0,
      492.0,
      478.2,
      504.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b027",
    "text": "dementia severity as measured by the Mini-Mental Status Examination",
    "bbox": [
      162.0,
      504.6,
      511.7,
      516.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b028",
    "text": "Ability to detect a decline in activities of daily living across levels of",
    "bbox": [
      162.0,
      517.2,
      488.4,
      529.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b029",
    "text": "dementia severity",
    "bbox": [
      162.0,
      529.9,
      254.3,
      542.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b030",
    "text": "Significant correlation with scores on various cognitive measures such as",
    "bbox": [
      162.0,
      542.5,
      520.9,
      554.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b031",
    "text": "the ADAS-Cog and Mini-Mental Status Examination",
    "bbox": [
      162.0,
      555.2,
      419.4,
      567.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b032",
    "text": "• Sensitivity to treatment effects in clinical drug trials in Alzheimer’s Disease",
    "bbox": [
      108.0,
      580.1,
      528.9,
      594.8
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b033",
    "text": "11.2.2.2 ADCS-ADL In Parkinson’s Disease Dementia",
    "bbox": [
      90.0,
      614.9,
      388.0,
      628.3
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b034",
    "text": "While there are no published studies of the use of the ADCS-ADL in Parkinson’s",
    "bbox": [
      90.0,
      631.7,
      518.9,
      645.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b035",
    "text": "Disease Dementia, the experience in Alzheimer’s Disease supports its use as a",
    "bbox": [
      90.0,
      645.5,
      514.9,
      658.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b036",
    "text": "“secondary” outcome measure in Parkinson’s Disease Dementia.",
    "bbox": [
      90.0,
      659.3,
      438.7,
      672.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b037",
    "text": "However, clinical changes in domains in Parkinson’s Disease other than",
    "bbox": [
      90.0,
      686.9,
      475.5,
      700.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 76,
    "block_id": "1055_p76_b038",
    "text": "cognition can result in changes in performance on activities of daily living.",
    "bbox": [
      90.0,
      700.7,
      482.9,
      714.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b002",
    "text": "Page 77 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b005",
    "text": "12. Financial Disclosure Certification",
    "bbox": [
      90.0,
      98.2,
      342.3,
      113.8
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b006",
    "text": "Financial disclosure information has been collected for the following studies:",
    "bbox": [
      90.0,
      117.1,
      496.9,
      130.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b007",
    "text": "2311, 2311E1, and 2314.",
    "bbox": [
      90.0,
      130.9,
      228.1,
      144.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b008",
    "text": "12.1 Components Of Certification",
    "bbox": [
      90.0,
      164.6,
      287.3,
      178.0
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b009",
    "text": "This certification provided by the sponsor has 2 components.",
    "bbox": [
      90.0,
      181.3,
      416.3,
      194.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b010",
    "text": "12.1.1 Certification Pertinent To Investigators/Sub-Investigators Who Declared",
    "bbox": [
      90.0,
      215.0,
      513.3,
      228.4
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b011",
    "text": "That They Did Not Have Any Relevant Financial Interests",
    "bbox": [
      126.0,
      228.8,
      433.6,
      242.2
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b012",
    "text": "The sponsor has supplied a list of all such investigators and sub-investigators",
    "bbox": [
      90.0,
      245.5,
      504.2,
      258.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b013",
    "text": "who were involved in these studies. In regard to this list the sponsor has",
    "bbox": [
      90.0,
      259.3,
      475.6,
      272.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b014",
    "text": "• Certified that it has not entered into any financial agreement with the clinical",
    "bbox": [
      90.0,
      286.6,
      512.8,
      301.2
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b015",
    "text": "investigators listed in the application, whereby the compensation to the",
    "bbox": [
      108.0,
      301.6,
      486.9,
      315.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b016",
    "text": "investigator could be affected by the outcome of the study in which the",
    "bbox": [
      108.0,
      315.4,
      485.0,
      328.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b017",
    "text": "investigator was a participant, as defined by 21 CFR 54.2 (a)",
    "bbox": [
      108.0,
      329.1,
      433.7,
      342.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b018",
    "text": "• Certified that each listed clinical investigator required to disclose to the",
    "bbox": [
      90.0,
      342.5,
      484.9,
      357.2
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b019",
    "text": "sponsor whether the investigator had a proprietary interest in this product or a",
    "bbox": [
      108.0,
      357.5,
      523.8,
      370.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b020",
    "text": "significant equity in the sponsor as defined in 21 CFR 54.2 (b) did not",
    "bbox": [
      108.0,
      371.3,
      478.9,
      384.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b021",
    "text": "disclose any such arrangements",
    "bbox": [
      108.0,
      385.1,
      283.4,
      398.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b022",
    "text": "• Certified that no listed investigator was the recipient of significant payments of",
    "bbox": [
      90.0,
      398.6,
      524.3,
      413.3
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b023",
    "text": "other sorts as defined in 21 CFR 54.2 (f)",
    "bbox": [
      108.0,
      413.5,
      325.5,
      426.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b024",
    "text": "This certification has been provided on FDA Form 3454.",
    "bbox": [
      90.0,
      441.1,
      390.8,
      454.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b025",
    "text": "12.1.2 Certification Pertinent To Investigators/Sub-Investigators With",
    "bbox": [
      90.0,
      474.8,
      461.3,
      488.2
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b026",
    "text": "Disclosable Financial Interests",
    "bbox": [
      126.0,
      488.6,
      291.4,
      502.0
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b027",
    "text": "The sponsor has provided the name of a single investigator participating in Study",
    "bbox": [
      90.0,
      505.3,
      523.0,
      518.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b028",
    "text": "2311 who had a disclosable financial interest. This investigator had received a",
    "bbox": [
      90.0,
      519.1,
      507.6,
      532.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b029",
    "text": "grant from the sponsor to conduct a study of rivastigmine in nursing home",
    "bbox": [
      90.0,
      532.9,
      484.3,
      546.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b030",
    "text": "patients with severe dementia.",
    "bbox": [
      90.0,
      546.7,
      255.4,
      560.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b031",
    "text": "This certification has been provided on FDA Form 3455.",
    "bbox": [
      90.0,
      574.3,
      390.8,
      587.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b032",
    "text": "12.2 Reviewer’s Comments",
    "bbox": [
      90.0,
      608.0,
      251.9,
      621.4
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b033",
    "text": "It appears unlikely that the financial arrangements disclosed above introduced",
    "bbox": [
      90.0,
      624.7,
      506.9,
      638.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b034",
    "text": "significant bias into the results of trials submitted with this application.",
    "bbox": [
      90.0,
      638.5,
      461.5,
      651.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b035",
    "text": "13. Site Inspection Report",
    "bbox": [
      90.0,
      678.3,
      269.0,
      693.9
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 77,
    "block_id": "1055_p77_b036",
    "text": "Pending",
    "bbox": [
      90.0,
      697.2,
      137.3,
      710.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b002",
    "text": "Page 78 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b005",
    "text": "14. Review Of Proposed Labeling",
    "bbox": [
      90.0,
      98.2,
      318.0,
      113.8
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b006",
    "text": "Deferred",
    "bbox": [
      90.0,
      117.1,
      140.0,
      130.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b007",
    "text": "15. Comments",
    "bbox": [
      90.0,
      156.9,
      192.5,
      172.5
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b008",
    "text": "15.1 General",
    "bbox": [
      90.0,
      181.9,
      168.6,
      195.3
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b009",
    "text": "In this supplemental New Drug Application, the sponsor is seeking the approval",
    "bbox": [
      90.0,
      198.7,
      514.3,
      212.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b010",
    "text": "of Exelon® (rivastigmine tartrate) capsules for the treatment of “mild to moderate",
    "bbox": [
      90.0,
      212.5,
      521.0,
      225.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b011",
    "text": "dementia associated with Parkinson’s Disease.” The putative entity of  “mild to",
    "bbox": [
      90.0,
      226.3,
      508.3,
      239.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b012",
    "text": "moderate dementia associated with Parkinson’s Disease” has also been referred",
    "bbox": [
      90.0,
      240.0,
      521.5,
      253.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b013",
    "text": "to, interchangeably, as “Parkinson’s Disease Dementia” in this application.",
    "bbox": [
      90.0,
      253.8,
      487.5,
      267.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b014",
    "text": "Exelon® is currently approved for marketing in this country, as both capsule and",
    "bbox": [
      90.0,
      281.4,
      518.4,
      294.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b015",
    "text": "oral solution formulations, for the treatment of mild to moderate dementia of the",
    "bbox": [
      90.0,
      295.2,
      513.5,
      308.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b016",
    "text": "Alzheimer’s type.",
    "bbox": [
      90.0,
      309.0,
      184.8,
      322.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b017",
    "text": "The sponsor has provided evidence from two completed clinical studies in",
    "bbox": [
      90.0,
      336.6,
      484.8,
      350.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b018",
    "text": "support of the efficacy and safety of Exelon® for the proposed new indication.",
    "bbox": [
      90.0,
      350.4,
      505.1,
      363.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b019",
    "text": "These are:",
    "bbox": [
      90.0,
      364.2,
      154.1,
      377.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b020",
    "text": "Study 2311, which was randomized, double-blind, placebo-controlled, and",
    "bbox": [
      126.0,
      391.8,
      488.6,
      404.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b021",
    "text": "parallel-arm in design",
    "bbox": [
      126.0,
      404.5,
      234.3,
      416.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b022",
    "text": "Study 2311E1, the open-label uncontrolled extension to Study 2311",
    "bbox": [
      126.0,
      417.1,
      458.0,
      429.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b023",
    "text": "In addition, the sponsor has performed a non-interventional study (Study 2314) of",
    "bbox": [
      90.0,
      443.6,
      525.0,
      457.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b024",
    "text": "the validity of a number of assessment scales in the Parkinson’s Disease",
    "bbox": [
      90.0,
      457.4,
      480.2,
      470.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b025",
    "text": "Dementia (and vascular dementia); partial results for this study have been",
    "bbox": [
      90.0,
      471.2,
      485.6,
      484.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b026",
    "text": "submitted in this application.",
    "bbox": [
      90.0,
      485.0,
      244.1,
      498.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b027",
    "text": "15.2 Efficacy",
    "bbox": [
      90.0,
      518.6,
      173.2,
      532.0
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b028",
    "text": "15.2.1 Summary Of Study 2311",
    "bbox": [
      90.0,
      541.4,
      268.7,
      554.8
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b029",
    "text": "The results of a single randomized, double-blind, placebo-controlled study (also",
    "bbox": [
      90.0,
      558.2,
      514.9,
      571.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b030",
    "text": "referred to as the EXPRESS Study) of the efficacy of rivastigmine in the",
    "bbox": [
      90.0,
      572.0,
      473.6,
      585.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b031",
    "text": "proposed entity of Parkinson’s Disease Dementia or dementia associated with",
    "bbox": [
      90.0,
      585.8,
      507.5,
      599.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b032",
    "text": "Parkinson’s Disease has been submitted in this application.  The main features",
    "bbox": [
      90.0,
      599.6,
      512.2,
      613.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b033",
    "text": "of this study were as follows",
    "bbox": [
      90.0,
      613.3,
      242.8,
      626.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b034",
    "text": "This was a randomized (2:1 [Exelon®:Placebo]), double-blind, placebo-",
    "bbox": [
      126.0,
      640.9,
      472.9,
      653.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b035",
    "text": "controlled, parallel-arm study",
    "bbox": [
      126.0,
      653.6,
      273.2,
      665.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 78,
    "block_id": "1055_p78_b036",
    "text": "The key inclusion criteria for the study were as follows",
    "bbox": [
      126.0,
      678.9,
      391.8,
      691.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b002",
    "text": "Page 79 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b005",
    "text": "Clinical diagnosis of idiopathic Parkinson’s Disease according to the UK",
    "bbox": [
      198.0,
      72.2,
      518.1,
      83.4
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b006",
    "text": "Parkinson’s Disease Society Brain Bank clinical diagnostic criteria",
    "bbox": [
      198.0,
      83.7,
      492.0,
      94.9
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b007",
    "text": "Clinical diagnosis of Parkinson’s Disease Dementia according to DSM-IV",
    "bbox": [
      198.0,
      95.2,
      523.0,
      106.3
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b008",
    "text": "criteria (Code 294.1) with onset of symptoms of dementia within at least",
    "bbox": [
      198.0,
      106.7,
      517.5,
      117.9
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b009",
    "text": "2 years of the first diagnosis of idiopathic Parkinson’s Disease",
    "bbox": [
      198.0,
      118.2,
      480.3,
      129.4
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b010",
    "text": "Mini-Mental Status Examination score of 10 – 24 at entry",
    "bbox": [
      198.0,
      129.7,
      452.0,
      140.8
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b011",
    "text": "The study was of 24 weeks’ duration",
    "bbox": [
      126.0,
      154.7,
      306.9,
      167.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b012",
    "text": "The 2 parallel treatment arms were",
    "bbox": [
      126.0,
      180.7,
      299.6,
      193.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b013",
    "text": "Rivastigmine 3 to 12 mg/day (flexible dose; BID administration)",
    "bbox": [
      198.0,
      205.9,
      479.2,
      217.1
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b014",
    "text": "Placebo",
    "bbox": [
      198.0,
      217.4,
      237.0,
      228.6
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b015",
    "text": "The primary efficacy measures were the ADAS-Cog and ADCS-CGIC. The",
    "bbox": [
      126.0,
      241.3,
      492.8,
      253.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b016",
    "text": "primary efficacy analysis was performed on the intent-to-treat plus retrieved",
    "bbox": [
      126.0,
      253.9,
      495.8,
      266.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b017",
    "text": "dropouts population. In the sponsor’s primary efficacy analysis, the 2 treatment",
    "bbox": [
      126.0,
      266.5,
      512.4,
      278.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b018",
    "text": "groups were compared on the ADAS-Cog using an analysis of covariance, and",
    "bbox": [
      126.0,
      279.1,
      512.3,
      291.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b019",
    "text": "on the ADCS-CGIC using the Cochran-Mantel-Haenszel test",
    "bbox": [
      126.0,
      291.8,
      423.7,
      304.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b020",
    "text": "The secondary efficacy measures were the following: ADCS-ADL;",
    "bbox": [
      126.0,
      317.9,
      449.3,
      330.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b021",
    "text": "Neuropsychiatry Inventory-10; Mini-Mental Status Examination; Cognitive Drug",
    "bbox": [
      126.0,
      330.5,
      512.3,
      342.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b022",
    "text": "Research Computerized Assessment System; D-KEFS Verbal Fluency Test; and",
    "bbox": [
      126.0,
      343.2,
      522.1,
      355.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b023",
    "text": "Ten Point Clock-Drawing Test",
    "bbox": [
      126.0,
      355.8,
      275.2,
      368.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b024",
    "text": "Safety was assessed through adverse events, vital signs, safety laboratory tests,",
    "bbox": [
      126.0,
      381.9,
      521.6,
      394.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b025",
    "text": "electrocardiograms, and Unified Parkinson’s Disease Rating Scale score",
    "bbox": [
      126.0,
      394.5,
      482.4,
      406.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b026",
    "text": "The sponsor’s primary efficacy analysis was performed on the intent-to-treat plus",
    "bbox": [
      126.0,
      420.6,
      522.1,
      432.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b027",
    "text": "retrieved dropouts dataset using the following statistical models",
    "bbox": [
      126.0,
      433.2,
      440.4,
      445.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b028",
    "text": "The change from baseline to endpoint in the ADAS-Cog score was to be",
    "bbox": [
      162.0,
      458.4,
      484.3,
      469.6
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b029",
    "text": "compared between the treatment groups using an analysis of covariance with",
    "bbox": [
      162.0,
      469.9,
      507.0,
      481.1
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b030",
    "text": "treatment, country, and baseline ADAS-Cog score as explanatory variables",
    "bbox": [
      162.0,
      481.4,
      497.2,
      492.6
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b031",
    "text": "The ADCS-CGIC score at endpoint was to be analyzed using a Cochran-Mantel-",
    "bbox": [
      162.0,
      492.9,
      518.3,
      504.1
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b032",
    "text": "Haenszel test with modified ridits scores and with country as a stratification",
    "bbox": [
      162.0,
      504.4,
      496.1,
      515.6
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b033",
    "text": "variable",
    "bbox": [
      162.0,
      515.9,
      202.6,
      527.1
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b034",
    "text": "Note that the study procedures included a number of precautions to minimize the",
    "bbox": [
      126.0,
      540.9,
      522.2,
      553.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b035",
    "text": "effects of the motor manifestations of Parkinson’s Disease on the efficacy",
    "bbox": [
      126.0,
      553.5,
      486.1,
      565.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b036",
    "text": "assessments",
    "bbox": [
      126.0,
      566.2,
      193.2,
      578.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b037",
    "text": "All primary and other cognitive outcome variables were to be assessed before",
    "bbox": [
      162.0,
      591.4,
      508.9,
      602.5
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b038",
    "text": "lunch, beginning 1 hour after the intake of dopaminergic medications, at the",
    "bbox": [
      162.0,
      602.9,
      498.3,
      614.1
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b039",
    "text": "same time of day throughout the study for each patient, and using the same",
    "bbox": [
      162.0,
      614.4,
      499.5,
      625.6
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b040",
    "text": "sequence of tests",
    "bbox": [
      162.0,
      625.9,
      243.3,
      637.0
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b041",
    "text": "For patients with motor fluctuations and/or dyskinesias, efficacy assessments",
    "bbox": [
      162.0,
      637.4,
      506.1,
      648.6
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b042",
    "text": "were to be performed during their “on” time (defined as intervals when",
    "bbox": [
      162.0,
      648.8,
      473.8,
      660.0
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b043",
    "text": "parkinsonian symptoms were replaced by increased mobility)",
    "bbox": [
      162.0,
      660.4,
      434.9,
      671.5
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b044",
    "text": "For patients with an acute psychosis, efficacy assessments were to be performed",
    "bbox": [
      162.0,
      671.9,
      524.4,
      683.1
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b045",
    "text": "after remission of the psychosis",
    "bbox": [
      162.0,
      683.3,
      304.9,
      694.5
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b046",
    "text": "Raters were advised to identify and discount, if possible, potential behavioral and",
    "bbox": [
      162.0,
      694.9,
      522.7,
      706.0
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 79,
    "block_id": "1055_p79_b047",
    "text": "functional changes due to the motor symptoms of Parkinson’s Disease",
    "bbox": [
      162.0,
      706.4,
      479.4,
      717.6
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b002",
    "text": "Page 80 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b005",
    "text": "Key efficacy results for this study were as follows",
    "bbox": [
      90.0,
      84.9,
      353.4,
      98.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b006",
    "text": "541 patients were randomized, of whom 442 patients completed the study. Their",
    "bbox": [
      126.0,
      113.3,
      519.7,
      125.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b007",
    "text": "distribution by treatment group was as follows:",
    "bbox": [
      126.0,
      125.9,
      354.7,
      138.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b008",
    "text": "Treatment Group",
    "bbox": [
      131.4,
      151.1,
      192.2,
      160.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b009",
    "text": "Exelon®",
    "bbox": [
      239.4,
      151.1,
      271.9,
      160.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b010",
    "text": "Placebo",
    "bbox": [
      293.4,
      151.1,
      322.3,
      160.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b011",
    "text": "Number randomized",
    "bbox": [
      131.4,
      160.3,
      206.1,
      169.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b012",
    "text": "362",
    "bbox": [
      239.4,
      160.3,
      254.9,
      169.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b013",
    "text": "179",
    "bbox": [
      293.4,
      160.3,
      308.9,
      169.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b014",
    "text": "Number completed",
    "bbox": [
      131.4,
      169.5,
      201.1,
      178.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b015",
    "text": "263",
    "bbox": [
      239.4,
      169.5,
      254.9,
      178.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b016",
    "text": "147",
    "bbox": [
      293.4,
      169.5,
      308.9,
      178.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b017",
    "text": "The primary efficacy analysis, using Study Week 24 as the endpoint, revealed",
    "bbox": [
      126.0,
      201.4,
      507.5,
      213.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b018",
    "text": "statistically significant differences between the treatment groups on the ADAS-",
    "bbox": [
      126.0,
      214.0,
      507.4,
      226.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b019",
    "text": "Cog (difference in mean change from baseline score at endpoint: 2.90; p <",
    "bbox": [
      126.0,
      226.7,
      491.3,
      239.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b020",
    "text": "0.001) and ADCS-CGIC (difference in mean score between treatment groups at",
    "bbox": [
      126.0,
      239.3,
      516.7,
      251.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b021",
    "text": "endpoint: 0.5; p = 0.007). Note that an Agency statistical reviewer has judged the",
    "bbox": [
      126.0,
      252.0,
      522.5,
      264.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b022",
    "text": "distribution of ADAS-Cog data not to be normal and therefore in violation of the",
    "bbox": [
      126.0,
      264.6,
      512.3,
      276.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b023",
    "text": "assumptions of the analysis of covariance model proposed; however, even with",
    "bbox": [
      126.0,
      277.3,
      514.8,
      289.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b024",
    "text": "the use of a non-parametric model, the Wilcoxon rank sum test, the Exelon®",
    "bbox": [
      126.0,
      289.9,
      501.0,
      302.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b025",
    "text": "group showed a statistically significant superiority over placebo on this measure",
    "bbox": [
      126.0,
      302.6,
      516.6,
      314.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b026",
    "text": "Nominally statistically significant differences were seen between the treatment",
    "bbox": [
      126.0,
      328.6,
      508.6,
      340.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b027",
    "text": "groups on all secondary efficacy variables at Week 24 in the same dataset as",
    "bbox": [
      126.0,
      341.2,
      505.6,
      353.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b028",
    "text": "that used for the primary efficacy analysis",
    "bbox": [
      126.0,
      353.9,
      331.4,
      366.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b029",
    "text": "Analyses of the primary efficacy parameters using other datasets (intent-to-treat",
    "bbox": [
      126.0,
      382.1,
      517.3,
      394.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b030",
    "text": "last-observation-carried-forward, and observed cases) yielded similar results.",
    "bbox": [
      126.0,
      393.8,
      504.2,
      407.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b031",
    "text": "15.2.2 Sponsor’s View Of The Entity Of Parkinson’s Disease Dementia",
    "bbox": [
      90.0,
      427.3,
      472.6,
      440.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b032",
    "text": "(Dementia Associated With Parkinson’s Disease)",
    "bbox": [
      90.0,
      441.1,
      354.2,
      454.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b033",
    "text": "The sponsor’s view of the entity of dementia associated with Parkinson’s Disease",
    "bbox": [
      90.0,
      457.8,
      524.8,
      471.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b034",
    "text": "appears to be consistent with an expert report included in this submission. The",
    "bbox": [
      90.0,
      471.6,
      510.3,
      485.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b035",
    "text": "main conclusions of the expert report may be summarized as follows:",
    "bbox": [
      90.0,
      485.4,
      464.3,
      498.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b036",
    "text": "Based on epidemiologic, genetic, neuropathological, neuroimaging, and cognitive",
    "bbox": [
      126.0,
      513.8,
      524.1,
      526.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b037",
    "text": "and non-cognitive clinical data, dementia associated with Parkinson’s Disease is",
    "bbox": [
      126.0,
      526.4,
      519.7,
      538.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b038",
    "text": "an entity distinct from Alzheimer’s Disease.",
    "bbox": [
      126.0,
      539.1,
      341.8,
      551.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b039",
    "text": "The severity of dementia associated with Parkinson’s Disease is better correlated",
    "bbox": [
      126.0,
      565.1,
      524.6,
      577.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b040",
    "text": "with pathological changes that are distinctive for Parkinson’s Disease such as the",
    "bbox": [
      126.0,
      577.7,
      524.6,
      589.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b041",
    "text": "presence of cortical Lewy bodies. Although neurofibrillary tangles and senile",
    "bbox": [
      126.0,
      590.4,
      499.0,
      602.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b042",
    "text": "plaques are frequently present in the brains of patients with dementia associated",
    "bbox": [
      126.0,
      603.0,
      521.0,
      615.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b043",
    "text": "with Parkinson’s Disease, the extent of these changes is less pronounced than",
    "bbox": [
      126.0,
      615.7,
      511.8,
      627.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b044",
    "text": "those that are distinctive for Parkinson’s Disease and less well-correlated with",
    "bbox": [
      126.0,
      628.3,
      507.5,
      640.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b045",
    "text": "the severity of dementia. The neuropathological changes in the brains of patients",
    "bbox": [
      126.0,
      640.9,
      522.3,
      653.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b046",
    "text": "with dementia associated with Parkinson’s Disease include lesions of cholinergic",
    "bbox": [
      126.0,
      653.6,
      521.0,
      665.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b047",
    "text": "pathways distinct from those seen in Alzheimer’s Disease.",
    "bbox": [
      126.0,
      666.2,
      415.2,
      678.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b048",
    "text": "Marked nigrostriatal neuronal degeneration is a unique feature of dementia",
    "bbox": [
      126.0,
      691.6,
      492.8,
      703.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 80,
    "block_id": "1055_p80_b049",
    "text": "associated with Parkinson’s Disease; cell loss in the medial substantia nigra is",
    "bbox": [
      126.0,
      704.2,
      509.4,
      716.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b002",
    "text": "Page 81 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b005",
    "text": "associated with the presence of dementia. Pathological abnormalities in the locus",
    "bbox": [
      126.0,
      72.3,
      524.6,
      84.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b006",
    "text": "ceruleus may also contribute to the dementia of Alzheimer’s Disease.",
    "bbox": [
      126.0,
      84.9,
      465.9,
      97.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b007",
    "text": "The diagnostic entities of dementia associated with Parkinson’s Disease and",
    "bbox": [
      126.0,
      111.0,
      501.4,
      123.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b008",
    "text": "Alzheimer’s Disease are mutually exclusive by definition. The diagnosis of",
    "bbox": [
      126.0,
      123.6,
      488.5,
      135.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b009",
    "text": "dementia associated with Parkinson’s Disease should be based on the presence",
    "bbox": [
      126.0,
      136.2,
      521.0,
      148.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b010",
    "text": "of all of the following criteria [which the sponsor believes are stipulated in DSM-",
    "bbox": [
      126.0,
      148.9,
      511.7,
      161.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b011",
    "text": "IV (294.1)]",
    "bbox": [
      126.0,
      161.5,
      180.4,
      173.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b012",
    "text": "Presence of Parkinson’s Disease",
    "bbox": [
      198.0,
      186.8,
      347.6,
      198.0
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b013",
    "text": "Presence of dementia syndrome",
    "bbox": [
      198.0,
      198.2,
      344.7,
      209.4
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b014",
    "text": "Evidence of Parkinson’s Disease prior to the onset of dementia",
    "bbox": [
      198.0,
      209.8,
      479.3,
      220.9
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b015",
    "text": "Exclusion of other causes of dementia",
    "bbox": [
      198.0,
      221.3,
      369.8,
      232.5
    ],
    "font_size": 10.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b016",
    "text": "Dementia associated with Parkinson’s Disease is an entity that be diagnosed by",
    "bbox": [
      126.0,
      246.3,
      517.8,
      258.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b017",
    "text": "a community medical practitioner",
    "bbox": [
      126.0,
      258.9,
      289.9,
      271.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b018",
    "text": "15.2.3 Implications Of Efficacy Results Of Study 2311 (EXPRESS Study)",
    "bbox": [
      90.0,
      291.4,
      484.0,
      304.8
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b019",
    "text": "Study 2311 may be considered “positive” in that it demonstrates the efficacy of",
    "bbox": [
      90.0,
      308.1,
      509.7,
      321.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b020",
    "text": "Exelon® in the study population based on prospectively-specified criteria for",
    "bbox": [
      90.0,
      321.9,
      496.4,
      335.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b021",
    "text": "success. The dual efficacy outcome measure paradigm used for demonstrating",
    "bbox": [
      90.0,
      335.7,
      512.9,
      349.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b022",
    "text": "the efficacy of Exelon® in this study is the same as used to demonstrate the",
    "bbox": [
      90.0,
      349.5,
      496.5,
      362.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b023",
    "text": "efficacy of drugs approved for the treatment of Alzheimer’s Disease (dementia of",
    "bbox": [
      90.0,
      363.3,
      520.9,
      376.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b024",
    "text": "the Alzheimer’s type).",
    "bbox": [
      90.0,
      377.1,
      208.7,
      390.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b025",
    "text": "However, the key regulatory question that needs to be addressed in the",
    "bbox": [
      90.0,
      404.7,
      498.2,
      418.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b026",
    "text": "context of  this application is whether the results of Study 2311 establish",
    "bbox": [
      90.0,
      418.6,
      508.7,
      432.0
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b027",
    "text": "that Exelon® is effective in the treatment of an entity (dementia associated",
    "bbox": [
      90.0,
      432.4,
      518.3,
      445.8
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b028",
    "text": "with Parkinson’s Disease [Parkinson’s Disease Dementia]) that is",
    "bbox": [
      90.0,
      446.2,
      465.6,
      459.6
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b029",
    "text": "sufficiently distinct from mild to moderate dementia of the Alzheimer’s type",
    "bbox": [
      90.0,
      460.0,
      523.4,
      473.4
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b030",
    "text": "[for the treatment of which Exelon® is already approved] to justify a",
    "bbox": [
      90.0,
      473.8,
      479.6,
      487.2
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b031",
    "text": "separate regulatory claim.",
    "bbox": [
      90.0,
      487.5,
      245.5,
      500.9
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b032",
    "text": "Note that for a drug to be approved for a specific condition the following must",
    "bbox": [
      90.0,
      515.1,
      501.5,
      528.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b033",
    "text": "generally be true",
    "bbox": [
      90.0,
      528.9,
      182.7,
      542.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b034",
    "text": "The condition can be defined without ambiguity using criteria that have wide",
    "bbox": [
      126.0,
      556.5,
      497.6,
      568.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b035",
    "text": "acceptance, and are both valid and reliable",
    "bbox": [
      126.0,
      569.2,
      338.8,
      581.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b036",
    "text": "Appropriate instruments be used for measurement of the clinical effect of the",
    "bbox": [
      126.0,
      581.8,
      501.4,
      594.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b037",
    "text": "drug on that condition; such instruments must measure what they are intended to",
    "bbox": [
      126.0,
      594.4,
      523.5,
      606.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b038",
    "text": "under the conditions under which they are actively employed",
    "bbox": [
      126.0,
      607.1,
      423.7,
      619.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b039",
    "text": "Clinical trials should be appropriately designed to measure that effect",
    "bbox": [
      126.0,
      619.8,
      465.4,
      632.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b040",
    "text": "The effect measured should be clinically meaningful",
    "bbox": [
      126.0,
      632.0,
      381.9,
      645.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b041",
    "text": "I will address the question (in bolded text) above, and several additional",
    "bbox": [
      90.0,
      659.3,
      473.5,
      672.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 81,
    "block_id": "1055_p81_b042",
    "text": "questions under the following headings",
    "bbox": [
      90.0,
      673.1,
      300.8,
      686.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b002",
    "text": "Page 82 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b005",
    "text": "15.2.3.1 Is Parkinson’s Disease Dementia (dementia associated with",
    "bbox": [
      90.0,
      72.3,
      462.0,
      85.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b006",
    "text": "Parkinson’s Disease) a distinct entity (i.e., distinct from Alzheimer’s Disease) and",
    "bbox": [
      90.0,
      86.1,
      522.9,
      99.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b007",
    "text": "do widely accepted, valid, and reliable criteria exist for its clinical diagnosis?",
    "bbox": [
      90.0,
      99.9,
      495.6,
      113.3
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b008",
    "text": " While it is widely accepted that there is an increased prevalence of",
    "bbox": [
      108.0,
      116.6,
      482.9,
      130.0
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b009",
    "text": "dementia in Parkinson’s Disease, the pathological basis for that dementia",
    "bbox": [
      126.0,
      130.4,
      518.8,
      143.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b010",
    "text": "has been a matter of controversy, in regard to both the specific",
    "bbox": [
      126.0,
      144.2,
      462.1,
      157.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b011",
    "text": "histopathological  abnormalities seen and their location. The medical",
    "bbox": [
      126.0,
      158.0,
      492.8,
      171.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b012",
    "text": "literature indicates that in patients with Parkinson’s Disease who develop",
    "bbox": [
      126.0,
      171.8,
      515.5,
      185.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b013",
    "text": "dementia, the neuropathological findings are varied; while a number of the",
    "bbox": [
      126.0,
      185.6,
      522.9,
      199.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b014",
    "text": "pathological abnormalities seen are considered distinctive for that entity",
    "bbox": [
      126.0,
      199.4,
      508.8,
      212.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b015",
    "text": "(e.g., cortical Lewy bodies and degeneration of the medial substantia",
    "bbox": [
      126.0,
      213.2,
      494.9,
      226.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b016",
    "text": "nigra) and may correlate best with the severity of dementia, Alzheimer’s-",
    "bbox": [
      126.0,
      227.0,
      510.2,
      240.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b017",
    "text": "type pathology (such as neurofibrillary tangles and amyloid plaques)",
    "bbox": [
      126.0,
      240.8,
      490.9,
      254.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b018",
    "text": "frequently co-exists, albeit often not to a sufficient degree for a separate",
    "bbox": [
      126.0,
      254.6,
      510.2,
      268.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b019",
    "text": "pathological diagnosis of Alzheimer’s Disease to be made; pathological",
    "bbox": [
      126.0,
      268.4,
      506.9,
      281.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b020",
    "text": "lesions attributed to cerebrovascular disease may also co-exist. The",
    "bbox": [
      126.0,
      282.2,
      490.2,
      295.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b021",
    "text": "variability in pathological abnormalities described in those studies may, in",
    "bbox": [
      126.0,
      296.0,
      518.3,
      309.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b022",
    "text": "part, reflect differences in the methods used in each instance.",
    "bbox": [
      126.0,
      309.8,
      459.6,
      323.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b023",
    "text": "More recently published studies are considered by some to indicate that",
    "bbox": [
      126.0,
      337.4,
      511.0,
      350.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b024",
    "text": "earlier histopathological data may have underestimated the extent to",
    "bbox": [
      126.0,
      351.2,
      492.9,
      364.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b025",
    "text": "which Lewy bodies were present in the brain (and especially in the",
    "bbox": [
      126.0,
      365.0,
      481.5,
      378.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b026",
    "text": "neocortex and limbic cortex) of patients with Parkinson’s Disease and",
    "bbox": [
      126.0,
      378.8,
      498.1,
      392.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b027",
    "text": "dementia; these studies were done prior to the availability of modern",
    "bbox": [
      126.0,
      392.6,
      492.2,
      406.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b028",
    "text": "immunohistochemical techniques such as stains for ubiquitin and alpha-",
    "bbox": [
      126.0,
      406.4,
      507.6,
      419.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b029",
    "text": "synuclein. The earlier studies may, therefore, according to the sponsor",
    "bbox": [
      126.0,
      420.2,
      503.5,
      433.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b030",
    "text": "and others, have attributed a greater-than-justified role for Alzheimer’s",
    "bbox": [
      126.0,
      434.0,
      501.6,
      447.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b031",
    "text": "type pathology in the pathogenesis of dementia in these patients, while",
    "bbox": [
      126.0,
      447.8,
      505.5,
      461.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b032",
    "text": "more recent studies suggest that cortical Lewy bodies may have a greater",
    "bbox": [
      126.0,
      461.6,
      521.6,
      475.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b033",
    "text": "role in the pathogenesis of dementia, although their extent may not",
    "bbox": [
      126.0,
      475.4,
      484.2,
      488.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b034",
    "text": "correlate with the severity of dementia (see Braak H et al below).",
    "bbox": [
      126.0,
      489.2,
      472.8,
      502.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b035",
    "text": "Thus, recently published data suggest that the pathological substrate",
    "bbox": [
      126.0,
      516.8,
      494.9,
      530.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b036",
    "text": "underlying the dementia that occurs in Parkinson’s Disease may be more",
    "bbox": [
      126.0,
      530.6,
      517.6,
      544.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b037",
    "text": "distinctive for that disease than previously believed. Note that a recent",
    "bbox": [
      126.0,
      544.4,
      501.6,
      557.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b038",
    "text": "consensus report (McKeith et al [2005]) for a closely-linked disorder,",
    "bbox": [
      126.0,
      558.2,
      491.6,
      571.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b039",
    "text": "dementia with Lewy bodies (see below), states that “the relative",
    "bbox": [
      126.0,
      572.0,
      466.8,
      585.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b040",
    "text": "contributions of Lewy body formation and synuclein pathology, Alzheimer’s",
    "bbox": [
      126.0,
      583.9,
      524.4,
      599.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b041",
    "text": "Disease-type pathology, neuron loss, or neurochemical deficits as",
    "bbox": [
      126.0,
      597.7,
      477.7,
      613.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b042",
    "text": "determinants of dementia in Parkinson’s Disease remain unresolved",
    "bbox": [
      126.0,
      611.5,
      490.3,
      626.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b043",
    "text": "although recent studies suggest that Lewy-related pathology is more",
    "bbox": [
      126.0,
      625.3,
      491.1,
      640.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b044",
    "text": "strongly associated than Alzheimer’s Disease-type changes.",
    "bbox": [
      126.0,
      641.0,
      449.4,
      654.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b045",
    "text": "The cholinergic deficit seen in patients with Parkinson’s Disease dementia",
    "bbox": [
      126.0,
      668.6,
      522.1,
      682.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 82,
    "block_id": "1055_p82_b046",
    "text": "has been linked to the loss of neurons in the nucleus basalis of Meynert",
    "bbox": [
      126.0,
      682.4,
      509.6,
      695.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b002",
    "text": "Page 83 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b005",
    "text": "and to a more marked brain cholinergic deficiency than in Alzheimer’s",
    "bbox": [
      126.0,
      72.2,
      498.8,
      85.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b006",
    "text": "Disease.",
    "bbox": [
      126.0,
      86.0,
      176.0,
      99.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b007",
    "text": "• A further question is whether the dementia that occurs in Parkinson’s",
    "bbox": [
      108.0,
      113.3,
      494.9,
      128.0
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b008",
    "text": "Disease is clinically distinct or dissimilar from that which occurs in",
    "bbox": [
      126.0,
      128.2,
      476.8,
      141.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b009",
    "text": "Alzheimer’s Disease, and in other types of primary degenerative",
    "bbox": [
      126.0,
      142.0,
      469.5,
      155.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b010",
    "text": "dementia, and whether validated criteria exist for the diagnosis of the",
    "bbox": [
      126.0,
      155.8,
      495.1,
      169.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b011",
    "text": "former.",
    "bbox": [
      126.0,
      169.6,
      170.8,
      183.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b012",
    "text": "Many publications, including relatively recent articles, state that the",
    "bbox": [
      126.0,
      197.2,
      484.2,
      210.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b013",
    "text": "cognitive deficits that are seen in the dementia that occurs in Parkinson’s",
    "bbox": [
      126.0,
      211.0,
      516.2,
      224.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b014",
    "text": "Disease are distinctive to at least some degree, with the following higher",
    "bbox": [
      126.0,
      224.8,
      512.8,
      238.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b015",
    "text": "cortical process being impaired to a greater degree, and, in some",
    "bbox": [
      126.0,
      238.6,
      475.6,
      252.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b016",
    "text": "instances, qualitatively, as compared with patients with Alzheimer’s",
    "bbox": [
      126.0,
      252.4,
      485.4,
      265.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b017",
    "text": "Disease:",
    "bbox": [
      126.0,
      266.2,
      179.4,
      279.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b018",
    "text": "Attention (fluctuations in attention are also seen)",
    "bbox": [
      162.0,
      293.8,
      400.4,
      306.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b019",
    "text": "Executive functions",
    "bbox": [
      162.0,
      306.5,
      259.9,
      318.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b020",
    "text": "Free recall memory (with preserved recognition memory)",
    "bbox": [
      162.0,
      319.2,
      441.3,
      331.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b021",
    "text": "Visuospatial function",
    "bbox": [
      162.0,
      331.8,
      269.0,
      344.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b022",
    "text": "Verbal fluency (with other aspects of language function, as well as praxis,",
    "bbox": [
      162.0,
      344.4,
      522.2,
      356.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b023",
    "text": "being preserved)",
    "bbox": [
      162.0,
      357.1,
      247.5,
      369.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b024",
    "text": "Speed of mental processing",
    "bbox": [
      162.0,
      369.7,
      301.5,
      382.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b025",
    "text": "Behavioral and personality changes are also stated to be more common in",
    "bbox": [
      126.0,
      395.1,
      491.0,
      407.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b026",
    "text": "Parkinson’s Disease than in Alzheimer’s Disease",
    "bbox": [
      126.0,
      407.7,
      370.6,
      420.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b027",
    "text": "• Criteria for diagnosing “Dementia Due To Parkinson’s Disease” exist",
    "bbox": [
      108.0,
      433.7,
      492.2,
      448.4
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b028",
    "text": "under DSM-IV (294.1). These criteria state that “the essential feature of",
    "bbox": [
      126.0,
      448.7,
      507.5,
      462.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b029",
    "text": "Dementia Due To Parkinson’s Disease is the presence of dementia that is",
    "bbox": [
      126.0,
      462.6,
      521.6,
      476.0
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b030",
    "text": "judged to be of direct pathophysiological consequence of Parkinson’s",
    "bbox": [
      126.0,
      476.4,
      500.2,
      489.8
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b031",
    "text": "disease”  but do not provide a further indication of how that judgment is to",
    "bbox": [
      126.0,
      490.1,
      519.7,
      503.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b032",
    "text": "be made beyond stating that “dementia associated with Parkinson’s",
    "bbox": [
      126.0,
      503.9,
      488.2,
      517.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b033",
    "text": "Disease” is “characterized by cognitive and motor slowing, executive",
    "bbox": [
      126.0,
      517.7,
      492.8,
      531.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b034",
    "text": "dysfunction, and impairment in memory retrieval.” The criteria are primarily",
    "bbox": [
      126.0,
      531.5,
      524.8,
      544.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b035",
    "text": "descriptive, and, importantly, do not clearly state how this entity is to be",
    "bbox": [
      126.0,
      545.3,
      507.5,
      558.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b036",
    "text": "distinguished from other dementias such as Alzheimer’s Disease; they",
    "bbox": [
      126.0,
      559.1,
      502.3,
      572.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b037",
    "text": "have never been validated against the histopathological abnormalities that",
    "bbox": [
      126.0,
      572.9,
      522.9,
      586.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b038",
    "text": "have recently been described as being more distinctive for dementia in",
    "bbox": [
      126.0,
      586.7,
      504.2,
      600.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b039",
    "text": "Parkinson’s Disease; in fact, these criteria are deficient enough in their",
    "bbox": [
      126.0,
      600.5,
      503.6,
      613.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b040",
    "text": "specifications, or lack thereof, that they are likely to be difficult to apply in",
    "bbox": [
      126.0,
      614.3,
      516.3,
      627.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b041",
    "text": "a validation study. Note that a just-issued American Academy of",
    "bbox": [
      126.0,
      628.1,
      468.8,
      641.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b042",
    "text": "Neurology Practice Parameter (see Miyasaki et al, below) suggests that",
    "bbox": [
      126.0,
      641.9,
      509.6,
      655.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b043",
    "text": "given the pattern of deficits reported to seen in patients with dementia",
    "bbox": [
      126.0,
      655.7,
      498.9,
      669.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b044",
    "text": "associated with Parkinson’s Disease, the DSM-IV criteria for establishing",
    "bbox": [
      126.0,
      669.5,
      515.5,
      682.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 83,
    "block_id": "1055_p83_b045",
    "text": "dementia per se may not be appropriate to use.",
    "bbox": [
      126.0,
      683.3,
      381.7,
      696.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b002",
    "text": "Page 84 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b005",
    "text": "A recently published relatively large study (see Braak H et al below) that",
    "bbox": [
      126.0,
      72.2,
      511.6,
      85.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b006",
    "text": "correlated cognitive status with neuropathological stage in Parkinson’s",
    "bbox": [
      126.0,
      86.0,
      502.1,
      99.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b007",
    "text": "Disease, and concluded that the burden of Alzheimer -type pathological",
    "bbox": [
      126.0,
      99.8,
      508.8,
      113.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b008",
    "text": "changes was relatively low in such patients, did not require that patients",
    "bbox": [
      126.0,
      113.6,
      510.4,
      127.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b009",
    "text": "with dementia who were included in that study needed to have a specific",
    "bbox": [
      126.0,
      127.4,
      513.6,
      140.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b010",
    "text": "pattern of cognitive deficits such as that considered by some authors to be",
    "bbox": [
      126.0,
      141.2,
      523.7,
      154.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b011",
    "text": "distinctive for Parkinson’s Disease (see above). The criteria used were as",
    "bbox": [
      126.0,
      155.0,
      519.5,
      168.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b012",
    "text": "follows",
    "bbox": [
      126.0,
      168.8,
      165.9,
      182.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b013",
    "text": "Clinical diagnosis of Parkinson’s Disease",
    "bbox": [
      162.0,
      196.5,
      365.0,
      208.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b014",
    "text": "Presence of dementia, without that dementia syndrome needing to have",
    "bbox": [
      162.0,
      209.1,
      515.4,
      221.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b015",
    "text": "any distinctive features",
    "bbox": [
      162.0,
      221.7,
      280.0,
      234.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b016",
    "text": "Evidence of Parkinson’s Disease more than a year prior to the onset of",
    "bbox": [
      162.0,
      234.4,
      509.3,
      246.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b017",
    "text": "dementia",
    "bbox": [
      162.0,
      247.0,
      210.3,
      259.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b018",
    "text": "A number of other published studies that have reported clinicopathological",
    "bbox": [
      126.0,
      273.5,
      522.8,
      286.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b019",
    "text": "correlations in demented patients with Parkinson’s Disease have also not",
    "bbox": [
      126.0,
      287.3,
      517.5,
      300.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b020",
    "text": "required such patients to have a specific qualitative pattern of cognitive",
    "bbox": [
      126.0,
      301.1,
      505.6,
      314.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b021",
    "text": "deficits",
    "bbox": [
      126.0,
      314.9,
      166.7,
      328.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b022",
    "text": "Thus, there do not appear to be validated diagnostic criteria for",
    "bbox": [
      126.0,
      342.5,
      463.0,
      355.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b023",
    "text": "Parkinson’s Disease Dementia, let alone criteria that stipulate that a",
    "bbox": [
      126.0,
      356.3,
      488.8,
      369.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b024",
    "text": "specific pattern of cognitive deficits must be present. The remaining",
    "bbox": [
      126.0,
      370.1,
      487.4,
      383.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b025",
    "text": "question is whether the clinical diagnosis of Parkinson’s Disease together",
    "bbox": [
      126.0,
      383.9,
      518.9,
      397.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b026",
    "text": "with the presence of dementia (but without a specific pattern of cognitive",
    "bbox": [
      126.0,
      397.7,
      513.0,
      411.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b027",
    "text": "deficits), with the onset of Parkinson’s Disease preceding the onset of",
    "bbox": [
      126.0,
      411.5,
      498.9,
      424.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b028",
    "text": "dementia by not more than two years and the exclusion of other causes of",
    "bbox": [
      126.0,
      425.3,
      522.3,
      438.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b029",
    "text": "dementia to the extent clinically possible, are together sufficient to define a",
    "bbox": [
      126.0,
      439.1,
      524.9,
      452.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b030",
    "text": "clinical syndrome that is sufficiently distinct from Alzheimer’s Disease to",
    "bbox": [
      126.0,
      452.9,
      509.5,
      466.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b031",
    "text": "justify a separate treatment claim.",
    "bbox": [
      126.0,
      466.7,
      308.7,
      480.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b032",
    "text": "• Note that the recently-issued American Academy of Neurology Practice",
    "bbox": [
      108.0,
      493.9,
      507.5,
      508.6
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b033",
    "text": "Parameter (see Miyasaki et al, below) contains the following statements,",
    "bbox": [
      126.0,
      508.9,
      513.5,
      522.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b034",
    "text": "among others, in regard to dementia in Parkinson’s Disease (PD)",
    "bbox": [
      126.0,
      522.7,
      475.5,
      536.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b035",
    "text": " “The etiology of dementia in PD is unclear”",
    "bbox": [
      144.0,
      550.0,
      350.8,
      563.8
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b036",
    "text": " Cognitive decline in PD is characterized by impaired executive function,",
    "bbox": [
      144.0,
      577.6,
      476.0,
      591.3
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b037",
    "text": "visuospatial abnormalities, impaired memory, and language deficits. An",
    "bbox": [
      162.0,
      591.3,
      474.8,
      605.1
    ],
    "font_size": 12.0,
    "font_name": "ArialNarrow-Italic",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b038",
    "text": "appropriate scale that reliably incorporates executive function (e.g., frontal",
    "bbox": [
      162.0,
      605.1,
      487.0,
      618.9
    ],
    "font_size": 12.0,
    "font_name": "ArialNarrow-Italic",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b039",
    "text": "assessment battery and other practical tests of executive function) should be",
    "bbox": [
      162.0,
      618.8,
      498.4,
      632.6
    ],
    "font_size": 12.0,
    "font_name": "ArialNarrow-Italic",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b040",
    "text": "incorporated into a screening test for PD dementia. When evaluating new",
    "bbox": [
      162.0,
      632.6,
      483.7,
      646.4
    ],
    "font_size": 12.0,
    "font_name": "ArialNarrow-Italic",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b041",
    "text": "screening tools, the DSM-IV criteria for dementia may not be the most appropriate",
    "bbox": [
      162.0,
      646.4,
      521.5,
      660.1
    ],
    "font_size": 12.0,
    "font_name": "ArialNarrow-Italic",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b042",
    "text": "gold standard for patients with PD. DSM-IV criteria for dementia have not been",
    "bbox": [
      162.0,
      660.2,
      507.3,
      673.9
    ],
    "font_size": 12.0,
    "font_name": "ArialNarrow-Italic",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b043",
    "text": "validated in PD. In PD patients, it may be difficult to assess impairments in",
    "bbox": [
      162.0,
      673.9,
      488.0,
      687.7
    ],
    "font_size": 12.0,
    "font_name": "ArialNarrow-Italic",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 84,
    "block_id": "1055_p84_b044",
    "text": "domains other than memory.",
    "bbox": [
      162.0,
      687.7,
      290.1,
      701.5
    ],
    "font_size": 12.0,
    "font_name": "ArialNarrow-Italic",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b002",
    "text": "Page 85 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b005",
    "text": "15.2.3.2 What are the implications of the diagnostic criteria for dementia with",
    "bbox": [
      90.0,
      72.3,
      503.5,
      85.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b006",
    "text": "Lewy bodies for the entity of Parkinson’s Disease Dementia?",
    "bbox": [
      90.0,
      86.1,
      416.2,
      99.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b007",
    "text": "Another entity that combines dementia with features of Parkinson’s Disease is",
    "bbox": [
      90.0,
      102.8,
      506.8,
      116.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b008",
    "text": "dementia with Lewy bodies for which revised diagnostic criteria have recently",
    "bbox": [
      90.0,
      116.6,
      502.2,
      130.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b009",
    "text": "been proposed (see McKeith et al [2005] below). In the more recent medical",
    "bbox": [
      90.0,
      130.4,
      496.8,
      143.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b010",
    "text": "literature, this entity has generally been distinguished from Parkinson’s Disease",
    "bbox": [
      90.0,
      144.2,
      514.9,
      157.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b011",
    "text": "Dementia by the (arbitrary) “one-year rule” criterion where the onset of dementia",
    "bbox": [
      90.0,
      158.0,
      518.8,
      171.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b012",
    "text": "within 12 months of the onset of parkinsonism is stated to be consistent with",
    "bbox": [
      90.0,
      171.8,
      496.9,
      185.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b013",
    "text": "dementia with Lewy bodies whereas if parkinsonism has been present for more",
    "bbox": [
      90.0,
      185.6,
      513.6,
      199.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b014",
    "text": "than 12 months prior to the onset of dementia, the condition is considered to",
    "bbox": [
      90.0,
      199.4,
      497.6,
      212.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b015",
    "text": "represent Parkinson’s Disease Dementia. The neuropathological abnormalities",
    "bbox": [
      90.0,
      213.2,
      510.9,
      226.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b016",
    "text": "that underlie both conditions are considered to be similar with changes",
    "bbox": [
      90.0,
      227.0,
      467.5,
      240.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b017",
    "text": "considered distinctive for Parkinson’s Disease being combined with other",
    "bbox": [
      90.0,
      240.8,
      480.9,
      254.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b018",
    "text": "pathology, notably Alzheimer-type changes. Whether these entities are the same",
    "bbox": [
      90.0,
      254.6,
      522.2,
      268.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b019",
    "text": "disease or separate distinct entities is still a matter of some controversy, although",
    "bbox": [
      90.0,
      268.4,
      524.9,
      281.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b020",
    "text": "the consensus view appears to be that they are the same neurobiological entity",
    "bbox": [
      90.0,
      282.2,
      513.7,
      295.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b021",
    "text": "with clinical phenotypes that differ, based solely on the arbitrary “one-year rule.”",
    "bbox": [
      90.0,
      296.0,
      519.0,
      309.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b022",
    "text": "Note that the revised criteria for the diagnosis of dementia with Lewy bodies",
    "bbox": [
      90.0,
      323.6,
      495.4,
      337.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b023",
    "text": "include the following “central” (required) feature: “Dementia defined as",
    "bbox": [
      90.0,
      337.4,
      465.4,
      350.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b024",
    "text": "progressive cognitive decline of sufficient magnitude to interfere  with normal",
    "bbox": [
      90.0,
      351.3,
      499.5,
      364.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b025",
    "text": "social or occupational function. Prominent or persistent memory impairment may",
    "bbox": [
      90.0,
      365.1,
      520.2,
      378.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b026",
    "text": "not necessarily occur in the early stages, but is usually evident with progression.",
    "bbox": [
      90.0,
      378.9,
      518.8,
      392.3
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b027",
    "text": "Deficits on tests of attention, executive function, and visuospatial ability may be",
    "bbox": [
      90.0,
      392.7,
      512.8,
      406.1
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b028",
    "text": "especially prominent.” The publication that describes these revised diagnostic",
    "bbox": [
      90.0,
      406.4,
      504.8,
      419.8
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b029",
    "text": "criteria (McKeith et al [2005]) further states the following: “The cognitive profile of",
    "bbox": [
      90.0,
      420.2,
      521.6,
      433.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b030",
    "text": "dementia with Lewy bodies (DLB) comprises both cortical and subcortical",
    "bbox": [
      90.0,
      434.0,
      482.1,
      447.4
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b031",
    "text": "impairments with substantial attentional deficits and prominent executive and",
    "bbox": [
      90.0,
      447.8,
      500.9,
      461.2
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b032",
    "text": "visuospatial dysfunction.  A “double discrimination” can help differentiate DLB",
    "bbox": [
      90.0,
      461.6,
      503.5,
      475.0
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b033",
    "text": "from Alzheimer disease (AD), with relative preservation of confrontation naming",
    "bbox": [
      90.0,
      475.4,
      514.7,
      488.8
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b034",
    "text": "and short and medium term recall as well as recognition, and greater impairment",
    "bbox": [
      90.0,
      489.2,
      520.8,
      502.6
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b035",
    "text": "on verbal fluency, visual perception and performance tasks.” These cognitive",
    "bbox": [
      90.0,
      503.0,
      500.8,
      516.4
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b036",
    "text": "abnormalities are similar to those described by a number of authors as being",
    "bbox": [
      90.0,
      516.8,
      500.3,
      530.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b037",
    "text": "distinctive for Parkinson’s Disease Dementia",
    "bbox": [
      90.0,
      530.6,
      330.1,
      544.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b038",
    "text": "Thus the same (reportedly) distinctive clinical features may be common to both",
    "bbox": [
      90.0,
      558.2,
      511.5,
      571.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b039",
    "text": "dementia with Lewy bodies and Parkinson’s Disease Dementia, while both",
    "bbox": [
      90.0,
      572.0,
      488.2,
      585.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 85,
    "block_id": "1055_p85_b040",
    "text": "entities may also have the same neuropathological basis.",
    "bbox": [
      90.0,
      585.8,
      397.5,
      599.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b002",
    "text": "Page 86 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b005",
    "text": "15.2.3.3 Was the population enrolled in Study 2311 selected appropriately in the",
    "bbox": [
      90.0,
      72.3,
      522.8,
      85.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b006",
    "text": "context of the proposed new indication, such that the effects of Exelon® in that",
    "bbox": [
      90.0,
      86.1,
      510.6,
      99.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b007",
    "text": "population could be considered distinct from those already established as",
    "bbox": [
      90.0,
      99.9,
      482.9,
      113.3
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b008",
    "text": "occurring in patients with Alzheimer’s Disease?",
    "bbox": [
      90.0,
      113.7,
      344.1,
      127.1
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b009",
    "text": " The key inclusion criteria used to identify patients as having Parkinson’s",
    "bbox": [
      108.0,
      136.4,
      510.8,
      149.8
    ],
    "font_size": 12.0,
    "font_name": "Wingdings-Regular",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b010",
    "text": "Disease Dementia were prospectively specified as being as follows",
    "bbox": [
      126.0,
      150.2,
      485.6,
      163.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b011",
    "text": "Clinical diagnosis of idiopathic Parkinson’s Disease according to the UK",
    "bbox": [
      162.0,
      180.9,
      514.1,
      193.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b012",
    "text": "Parkinson’s Disease Society Brain Bank clinical diagnostic criteria",
    "bbox": [
      162.0,
      193.5,
      485.4,
      205.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b013",
    "text": "Clinical diagnosis of Parkinson’s Disease Dementia according to DSM-IV",
    "bbox": [
      162.0,
      206.1,
      519.5,
      218.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b014",
    "text": "criteria (Code 294.1) with onset of symptoms of dementia within at least 2",
    "bbox": [
      162.0,
      218.8,
      522.7,
      231.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b015",
    "text": "years of the first diagnosis of idiopathic Parkinson’s Disease",
    "bbox": [
      162.0,
      231.4,
      463.4,
      243.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b016",
    "text": "As noted earlier, there are serious limitations to the practical application of",
    "bbox": [
      126.0,
      257.9,
      522.2,
      271.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b017",
    "text": "the DSM-IV criteria for “Dementia due to Parkinson’s Disease.” In addition,",
    "bbox": [
      126.0,
      271.7,
      524.8,
      285.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b018",
    "text": "no evidence has been supplied in this submission that dementia",
    "bbox": [
      126.0,
      285.5,
      468.9,
      298.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b019",
    "text": "associated with Parkinson’s Disease was diagnosed at study entry  based",
    "bbox": [
      126.0,
      299.3,
      521.7,
      312.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b020",
    "text": "on the features that are stated to distinctive for that condition such as",
    "bbox": [
      126.0,
      313.1,
      495.6,
      326.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b021",
    "text": "deficits of attention, executive function, and memory retrieval (which in any",
    "bbox": [
      126.0,
      326.9,
      524.8,
      340.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b022",
    "text": "case have never been validated). In fact, the criteria used to diagnose",
    "bbox": [
      126.0,
      340.7,
      499.4,
      354.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b023",
    "text": "dementia itself in these patients may have been no different than those",
    "bbox": [
      126.0,
      354.5,
      505.6,
      367.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b024",
    "text": "used for patients enrolled in the key pre-approval efficacy trials of Exelon®",
    "bbox": [
      126.0,
      368.3,
      524.4,
      381.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b025",
    "text": "in Alzheimer’s Disease. Admittedly, the NINCDS-ADRDA criteria for the",
    "bbox": [
      126.0,
      382.1,
      508.9,
      395.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b026",
    "text": "diagnosis of probable Alzheimer’s Disease, which were used to enroll",
    "bbox": [
      126.0,
      395.9,
      497.5,
      409.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b027",
    "text": "patients in the pre-approval efficacy trials of Exelon®, if strictly applied,",
    "bbox": [
      126.0,
      409.7,
      505.0,
      423.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b028",
    "text": "required the exclusion of patients with Parkinson’s Disease.",
    "bbox": [
      126.0,
      423.5,
      445.4,
      436.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b029",
    "text": "In their essence, the criteria used to diagnose dementia associated with",
    "bbox": [
      126.0,
      451.1,
      509.5,
      464.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b030",
    "text": "Parkinson’s Disease in Study 2311 consisted of the following",
    "bbox": [
      126.0,
      464.9,
      455.5,
      478.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b031",
    "text": "Presence of Parkinson’s Disease",
    "bbox": [
      162.0,
      492.5,
      326.5,
      504.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b032",
    "text": "Presence of dementia syndrome, without that dementia syndrome",
    "bbox": [
      162.0,
      505.1,
      485.3,
      517.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b033",
    "text": "needing to have any distinctive features specific to Parkinson’s Disease",
    "bbox": [
      162.0,
      517.8,
      513.0,
      530.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b034",
    "text": "Dementia",
    "bbox": [
      162.0,
      530.4,
      215.2,
      542.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b035",
    "text": "Evidence of Parkinson’s Disease prior to, but within 2 years of, the onset",
    "bbox": [
      162.0,
      543.1,
      518.0,
      555.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b036",
    "text": "of dementia",
    "bbox": [
      162.0,
      555.7,
      222.5,
      568.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b037",
    "text": "Exclusion of other causes of dementia",
    "bbox": [
      162.0,
      567.9,
      351.2,
      581.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b038",
    "text": "While the latter criteria do have face validity for diagnosing dementia in",
    "bbox": [
      126.0,
      595.3,
      504.9,
      608.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b039",
    "text": "patients with Parkinson’s Disease, they themselves do not appear to have",
    "bbox": [
      126.0,
      609.1,
      521.6,
      622.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b040",
    "text": "been correlated with neuropathological findings in a formal study",
    "bbox": [
      126.0,
      622.9,
      471.6,
      636.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b041",
    "text": "(especially one that was prospective) of sufficient size (the recently-",
    "bbox": [
      126.0,
      636.7,
      484.9,
      650.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b042",
    "text": "published study by Braak et al [see below] might, however, address that",
    "bbox": [
      126.0,
      650.5,
      511.0,
      663.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 86,
    "block_id": "1055_p86_b043",
    "text": "objective to some extent)",
    "bbox": [
      126.0,
      664.3,
      266.2,
      677.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 87,
    "block_id": "1055_p87_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 87,
    "block_id": "1055_p87_b002",
    "text": "Page 87 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 87,
    "block_id": "1055_p87_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 87,
    "block_id": "1055_p87_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 87,
    "block_id": "1055_p87_b005",
    "text": "• It is noteworthy that the effects or rivastigmine on the primary efficacy",
    "bbox": [
      108.0,
      71.9,
      497.5,
      86.6
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 87,
    "block_id": "1055_p87_b006",
    "text": "measures in Study 2311 are not very different from those observed for",
    "bbox": [
      126.0,
      86.8,
      502.2,
      100.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 87,
    "block_id": "1055_p87_b007",
    "text": "rivastigmine, and, indeed other acetylcholinesterase inhibitors, on the",
    "bbox": [
      126.0,
      100.6,
      496.9,
      114.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 87,
    "block_id": "1055_p87_b008",
    "text": "same measures in the key pre-approval efficacy trials of those drugs in",
    "bbox": [
      126.0,
      114.4,
      504.9,
      127.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 87,
    "block_id": "1055_p87_b009",
    "text": "mild to moderate probable Alzheimer’s Disease: in addition, the clinical",
    "bbox": [
      126.0,
      128.2,
      504.7,
      141.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 87,
    "block_id": "1055_p87_b010",
    "text": "course of the placebo group in Study 2311 and the placebo groups in the",
    "bbox": [
      126.0,
      142.0,
      516.4,
      155.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 87,
    "block_id": "1055_p87_b011",
    "text": "pre-approval efficacy trials of Exelon® in Alzheimer’s Disease were",
    "bbox": [
      126.0,
      155.8,
      485.6,
      169.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 87,
    "block_id": "1055_p87_b012",
    "text": "similar, also suggesting that the study populations in each instance may",
    "bbox": [
      126.0,
      169.6,
      510.4,
      183.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 87,
    "block_id": "1055_p87_b013",
    "text": "have been similar too (see below):",
    "bbox": [
      126.0,
      183.4,
      312.1,
      196.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 87,
    "block_id": "1055_p87_b014",
    "text": "The following were the changes seen in the Exelon® and placebo groups on the",
    "bbox": [
      126.0,
      211.0,
      518.7,
      223.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 87,
    "block_id": "1055_p87_b015",
    "text": "ADAS-Cog in a key pre-approval efficacy trial in Alzheimer’s Disease (the figure",
    "bbox": [
      126.0,
      223.7,
      516.7,
      236.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 87,
    "block_id": "1055_p87_b016",
    "text": "is taken from the approved product labeling",
    "bbox": [
      126.0,
      236.4,
      340.1,
      248.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 87,
    "block_id": "1055_p87_b017",
    "text": "The following were the corresponding changes seen in Study 2311",
    "bbox": [
      126.0,
      411.9,
      453.7,
      424.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 87,
    "block_id": "1055_p87_b018",
    "text": "As noted earlier, in patients with Parkinson’s Disease who develop dementia,",
    "bbox": [
      108.0,
      637.3,
      520.3,
      650.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 87,
    "block_id": "1055_p87_b019",
    "text": "Alzheimer’s-type pathology (neurofibrillary tangles, amyloid plaques)",
    "bbox": [
      108.0,
      651.1,
      474.2,
      664.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 87,
    "block_id": "1055_p87_b020",
    "text": "frequently co-exists, albeit often not to a sufficient degree for a separate",
    "bbox": [
      108.0,
      664.9,
      492.3,
      678.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 87,
    "block_id": "1055_p87_b021",
    "text": "pathological diagnosis of Alzheimer’s Disease to be made.  If a similar mixed",
    "bbox": [
      108.0,
      678.7,
      518.3,
      692.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 87,
    "block_id": "1055_p87_b022",
    "text": "pathology underlay the dementia in patients enrolled in the Study 2311, it is",
    "bbox": [
      108.0,
      692.5,
      511.1,
      705.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 87,
    "block_id": "1055_p87_b023",
    "text": "possible (and no evidence to the contrary has been supplied) that the",
    "bbox": [
      108.0,
      706.3,
      479.0,
      719.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b002",
    "text": "Page 88 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b005",
    "text": "apparent benefit of rivastigmine in that study was mediated through its effects",
    "bbox": [
      108.0,
      72.2,
      522.1,
      85.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b006",
    "text": "on co-existing Alzheimer’s-type pathology.  It is unlikely that the criteria used",
    "bbox": [
      108.0,
      86.0,
      516.8,
      99.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b007",
    "text": "to diagnose dementia associated with Parkinson’s Disease in Study 2311,",
    "bbox": [
      108.0,
      99.8,
      503.6,
      113.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b008",
    "text": "could have excluded those with co-existing Alzheimer’s-type pathology,",
    "bbox": [
      108.0,
      113.6,
      489.5,
      127.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b009",
    "text": "despite a stipulation in those criteria that other causes of dementia should be",
    "bbox": [
      108.0,
      127.4,
      518.9,
      140.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b010",
    "text": "excluded.",
    "bbox": [
      108.0,
      141.2,
      162.7,
      154.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b011",
    "text": "These observations raise the question of whether the efficacy of rivastigmine",
    "bbox": [
      108.0,
      168.8,
      518.2,
      182.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b012",
    "text": "in dementia associated with Parkinson’s Disease, as seen in the population",
    "bbox": [
      108.0,
      182.6,
      510.9,
      196.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b013",
    "text": "enrolled in Study 2311, is really distinct from its already-established effects in",
    "bbox": [
      108.0,
      196.4,
      520.2,
      209.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b014",
    "text": "mild to moderate probable Alzheimer’s Disease, and for which rivastigmine is",
    "bbox": [
      108.0,
      210.2,
      520.1,
      223.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b015",
    "text": "already approved.",
    "bbox": [
      108.0,
      224.0,
      210.8,
      237.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b016",
    "text": "As explained further below, the overall design of this trial was otherwise",
    "bbox": [
      108.0,
      251.6,
      490.9,
      265.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b017",
    "text": "similar in many ways to the now-standard study design used to demonstrate",
    "bbox": [
      108.0,
      265.4,
      514.9,
      278.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b018",
    "text": "the efficacy of drugs intended for the treatment of Alzheimer’s Disease, again",
    "bbox": [
      108.0,
      279.2,
      520.8,
      292.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b019",
    "text": "raising the question of how distinct the effects of Exelon® in this study were",
    "bbox": [
      108.0,
      293.0,
      511.8,
      306.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b020",
    "text": "from those already established in Alzheimer’s Disease.",
    "bbox": [
      108.0,
      306.8,
      402.8,
      320.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b021",
    "text": "Unless the efficacy of rivastigmine as demonstrated in Study 2311 is judged",
    "bbox": [
      108.0,
      334.4,
      513.6,
      347.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b022",
    "text": "to be mechanistically distinct from its established effects in Alzheimer’s",
    "bbox": [
      108.0,
      348.2,
      486.8,
      361.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b023",
    "text": "Disease,  the grant of a separate claim for the treatment of mild to moderate",
    "bbox": [
      108.0,
      362.0,
      514.3,
      375.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b024",
    "text": "dementia associated with Parkinson’s Disease may not be justified.",
    "bbox": [
      108.0,
      375.8,
      468.2,
      389.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b025",
    "text": "15.2.3.4 Was the population enrolled in Study 2311 otherwise selected",
    "bbox": [
      90.0,
      409.5,
      472.1,
      422.9
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b026",
    "text": "appropriately?",
    "bbox": [
      90.0,
      423.3,
      169.3,
      436.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b027",
    "text": "• Among the exclusion criteria for this study were the following (I have",
    "bbox": [
      108.0,
      439.6,
      490.8,
      454.3
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b028",
    "text": "emphasized elements of these criteria in bold underlined font)",
    "bbox": [
      126.0,
      454.6,
      456.9,
      468.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b029",
    "text": "Current diagnosis of any primary neurodegenerative disease other than",
    "bbox": [
      162.0,
      482.2,
      512.3,
      494.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b030",
    "text": "Parkinson’s Disease or any other causes of dementia (e.g., Alzheimer’s",
    "bbox": [
      162.0,
      494.9,
      523.4,
      507.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b031",
    "text": "Disease, frontotemporal dementia, Huntington’s Disease, dementia with",
    "bbox": [
      162.0,
      507.6,
      514.2,
      519.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b032",
    "text": "Lewy bodies, Parkinson-plus syndromes such as progressive",
    "bbox": [
      162.0,
      520.2,
      462.6,
      532.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b033",
    "text": "supranuclear palsy or olivopontocerebellar degeneration, Vitamin B12 or",
    "bbox": [
      162.0,
      532.8,
      517.2,
      545.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b034",
    "text": "folate deficiency, hypothyroidism or syphilis)",
    "bbox": [
      162.0,
      545.5,
      379.6,
      557.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b035",
    "text": "A current diagnosis of probable or possible vascular dementia according",
    "bbox": [
      162.0,
      558.1,
      516.7,
      570.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b036",
    "text": "to the NINDS-AIREN criteria, i.e., clinical and brain imaging evidence of",
    "bbox": [
      162.0,
      570.8,
      513.1,
      583.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b037",
    "text": "cerebrovascular disease and a relationship between dementia and",
    "bbox": [
      162.0,
      583.4,
      488.5,
      595.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b038",
    "text": "cerebrovascular disease (Reviewer’s note: these are criteria for the",
    "bbox": [
      162.0,
      596.1,
      491.5,
      608.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b039",
    "text": "diagnosis of probable vascular dementia only; the diagnosis of possible",
    "bbox": [
      162.0,
      608.7,
      511.7,
      621.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b040",
    "text": "vascular dementia does not require the demonstration of a clear",
    "bbox": [
      162.0,
      621.4,
      476.3,
      633.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b041",
    "text": "relationship between dementia and stroke)",
    "bbox": [
      162.0,
      634.0,
      372.4,
      646.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b042",
    "text": "• Special diagnostic laboratory tests that were performed at screening and",
    "bbox": [
      108.0,
      660.1,
      514.2,
      674.7
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b043",
    "text": "which were intended to help exclude other causes of dementia were",
    "bbox": [
      126.0,
      675.1,
      490.3,
      688.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 88,
    "block_id": "1055_p88_b044",
    "text": "serum TSH, folic acid, Vitamin B12 and RPR.",
    "bbox": [
      126.0,
      688.9,
      373.5,
      702.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b002",
    "text": "Page 89 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b005",
    "text": "• However, under the protocol for Study 2311, brain imaging (i.e.,",
    "bbox": [
      108.0,
      71.9,
      490.8,
      86.6
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b006",
    "text": "computerized tomography or magnetic resonance scanning) was not",
    "bbox": [
      126.0,
      86.9,
      522.8,
      100.3
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b007",
    "text": "required prior to entry into the study. Study Case Report Forms do not",
    "bbox": [
      126.0,
      100.6,
      519.5,
      114.0
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b008",
    "text": "document which patients may have had brain imaging prior to entry into",
    "bbox": [
      126.0,
      114.4,
      509.0,
      127.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b009",
    "text": "the study, and at the time that this review was completed, data as to the",
    "bbox": [
      126.0,
      128.2,
      510.2,
      141.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b010",
    "text": "proportion of study patients who had undergone brain imaging had not yet",
    "bbox": [
      126.0,
      142.0,
      521.6,
      155.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b011",
    "text": "been made available by the sponsor in response to a request from us. The",
    "bbox": [
      126.0,
      155.8,
      524.9,
      169.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b012",
    "text": "following observations may be pertinent in this context:",
    "bbox": [
      126.0,
      169.6,
      420.2,
      183.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b013",
    "text": "The American Academy of Neurology Practice Parameter for Dementia",
    "bbox": [
      162.0,
      197.2,
      511.0,
      209.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b014",
    "text": "(see Knopman et al below) recommends the use of a neuroimaging",
    "bbox": [
      162.0,
      209.9,
      492.7,
      222.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b015",
    "text": "examination (either a non-contrast CT scan or MRI scan) “under most",
    "bbox": [
      162.0,
      222.6,
      503.7,
      234.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b016",
    "text": "circumstances” at the time of the initial dementia assessment to identify",
    "bbox": [
      162.0,
      235.2,
      512.3,
      247.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b017",
    "text": "pathology such as brain neoplasms or subdural hematomas, although it is",
    "bbox": [
      162.0,
      247.9,
      524.0,
      260.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b018",
    "text": "also stated that a third condition, normal pressure hydrocephalus, which",
    "bbox": [
      162.0,
      260.5,
      514.8,
      272.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b019",
    "text": "might be detected by CT or MRI is very rare",
    "bbox": [
      162.0,
      273.1,
      381.4,
      285.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b020",
    "text": "The UK Parkinson’s Disease Society Brain Bank clinical diagnostic",
    "bbox": [
      162.0,
      299.6,
      489.8,
      311.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b021",
    "text": "criteria for Parkinson’s Disease list as an exclusion criterion (Step 2) “the",
    "bbox": [
      162.0,
      312.3,
      518.5,
      324.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b022",
    "text": "presence of cerebral tumor or communicating hydrocephalus on CT",
    "bbox": [
      162.0,
      324.9,
      493.9,
      337.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b023",
    "text": "scan.” [However, it can hardly be considered standard clinical practice  for",
    "bbox": [
      162.0,
      337.5,
      524.6,
      349.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b024",
    "text": "brain imaging to be performed  routinely for the diagnosis of Parkinson’s",
    "bbox": [
      162.0,
      350.2,
      515.3,
      362.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b025",
    "text": "Disease]",
    "bbox": [
      162.0,
      362.8,
      207.9,
      375.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b026",
    "text": "In key efficacy trials of drugs in Alzheimer’s Disease, it is standard",
    "bbox": [
      162.0,
      388.2,
      486.6,
      400.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b027",
    "text": "practice to perform either a CT scan of the head or MRI at screening, if",
    "bbox": [
      162.0,
      400.8,
      509.2,
      413.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b028",
    "text": "not performed within the preceding 12 months",
    "bbox": [
      162.0,
      413.4,
      388.8,
      425.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b029",
    "text": "A standard neurological examination directed at detecting focal",
    "bbox": [
      162.0,
      438.7,
      471.4,
      451.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b030",
    "text": "neurological deficits is more difficult to perform in patients with",
    "bbox": [
      162.0,
      451.4,
      466.9,
      463.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b031",
    "text": "Parkinson’s Disease, and often considerably more difficult",
    "bbox": [
      162.0,
      464.1,
      446.9,
      476.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b032",
    "text": "• The question may therefore be raised as to how adequately patients",
    "bbox": [
      108.0,
      489.0,
      516.9,
      503.7
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b033",
    "text": "enrolled in Study 2311 were evaluated for “non-degenerative” causes",
    "bbox": [
      126.0,
      504.0,
      524.8,
      517.4
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b034",
    "text": "of dementia such as cerebrovascular lesions, brain tumors, subdural",
    "bbox": [
      126.0,
      517.8,
      522.8,
      531.2
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b035",
    "text": "hematomas, and communicating hydrocephalus in the absence of",
    "bbox": [
      126.0,
      531.6,
      506.1,
      545.0
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b036",
    "text": "brain imaging. Admittedly, those conditions are often associated",
    "bbox": [
      126.0,
      545.4,
      498.6,
      558.8
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b037",
    "text": "with additional symptoms and signs on neurological evaluation, but",
    "bbox": [
      126.0,
      559.2,
      516.8,
      572.6
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b038",
    "text": "a standard neurological evaluation can be more difficult than usual",
    "bbox": [
      126.0,
      573.0,
      511.7,
      586.4
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b039",
    "text": "to perform in patients with co-existing Parkinson’s Disease so that",
    "bbox": [
      126.0,
      586.8,
      509.4,
      600.2
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b040",
    "text": "subtle physical signs may not be detected.",
    "bbox": [
      126.0,
      600.6,
      373.5,
      614.0
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b041",
    "text": "15.2.3.5 Was the overall design of Study 2311 appropriate and were the primary",
    "bbox": [
      90.0,
      634.2,
      522.7,
      647.6
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b042",
    "text": "efficacy measures used suitable for evaluating the efficacy and safety of",
    "bbox": [
      90.0,
      647.9,
      475.4,
      661.3
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b043",
    "text": "rivastigmine in mild to moderate dementia associated with Parkinson’s Disease?",
    "bbox": [
      90.0,
      661.7,
      522.9,
      675.1
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b044",
    "text": "• The paradigm used for designing this study is very similar to that used in",
    "bbox": [
      108.0,
      678.1,
      513.5,
      692.8
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 89,
    "block_id": "1055_p89_b045",
    "text": "standard efficacy trials in Alzheimer’s Disease. More specifically:",
    "bbox": [
      126.0,
      693.1,
      472.2,
      706.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b002",
    "text": "Page 90 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b005",
    "text": "This was a randomized, double-blind, placebo-controlled, parallel-arm",
    "bbox": [
      162.0,
      86.1,
      504.4,
      98.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b006",
    "text": "trial of 6 months’ duration",
    "bbox": [
      162.0,
      98.7,
      288.6,
      111.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b007",
    "text": "The stipulated entry Mini-Mental Status Examination score range was",
    "bbox": [
      162.0,
      111.4,
      503.2,
      123.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b008",
    "text": "consistent with that used to define the “mild to moderate” range for",
    "bbox": [
      162.0,
      124.0,
      488.5,
      136.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b009",
    "text": "Alzheimer’s Disease",
    "bbox": [
      162.0,
      136.6,
      264.7,
      148.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b010",
    "text": "For the study to be considered to have demonstrated the efficacy of",
    "bbox": [
      162.0,
      149.3,
      494.0,
      161.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b011",
    "text": "Exelon® in treating mild to moderate Parkinson’s Disease Dementia, it",
    "bbox": [
      162.0,
      162.0,
      507.6,
      174.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b012",
    "text": "was required that a statistically significant superiority of Exelon® be",
    "bbox": [
      162.0,
      174.6,
      492.9,
      186.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b013",
    "text": "demonstrated on both cognitive and global primary efficacy measures",
    "bbox": [
      162.0,
      187.3,
      503.7,
      199.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b014",
    "text": "The cognitive and global primary efficacy measures used in this study,",
    "bbox": [
      162.0,
      199.9,
      506.9,
      212.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b015",
    "text": "the ADAS-Cog and ADCS-CGIC were identical to those used in the",
    "bbox": [
      162.0,
      212.5,
      492.7,
      224.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b016",
    "text": "efficacy studies in Alzheimer’s Disease",
    "bbox": [
      162.0,
      225.2,
      357.6,
      237.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b017",
    "text": "• Whether this design is an appropriate one for trials in Parkinson’s Disease",
    "bbox": [
      108.0,
      250.1,
      522.2,
      264.8
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b018",
    "text": "Dementia is a matter for further discussion. Assuming that the condition",
    "bbox": [
      126.0,
      265.1,
      508.9,
      278.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b019",
    "text": "itself is a distinct entity justifying a separate claim, the following might",
    "bbox": [
      126.0,
      278.9,
      496.0,
      292.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b020",
    "text": "need consideration in deciding whether the design for that study was",
    "bbox": [
      126.0,
      292.7,
      493.6,
      306.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b021",
    "text": "appropriate for the proposed indication:",
    "bbox": [
      126.0,
      306.5,
      338.1,
      319.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b022",
    "text": "The natural clinical course of Parkinson’s Disease Dementia, for which",
    "bbox": [
      162.0,
      334.1,
      508.0,
      346.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b023",
    "text": "information is lacking",
    "bbox": [
      162.0,
      346.8,
      267.8,
      359.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b024",
    "text": "The nature of the cognitive deficits seen in that entity",
    "bbox": [
      162.0,
      359.4,
      421.9,
      371.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b025",
    "text": "Whether the outcome measures, and especially, the ADAS-Cog were",
    "bbox": [
      162.0,
      372.0,
      502.5,
      384.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b026",
    "text": "appropriate to use in Parkinson’s Disease Dementia. The ADAS-Cog is",
    "bbox": [
      162.0,
      384.7,
      511.0,
      396.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b027",
    "text": "not, for example, particularly appropriate for evaluating executive function",
    "bbox": [
      162.0,
      397.3,
      522.2,
      409.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b028",
    "text": "(also note that the just-issued American Academy of Neurology Practice",
    "bbox": [
      162.0,
      410.0,
      515.4,
      422.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b029",
    "text": "Parameter [see Miyasaki et al, below] also states that in patients with",
    "bbox": [
      162.0,
      422.7,
      500.7,
      434.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b030",
    "text": "Parkinson’s Disease, it may be difficult to assess impairments in domains",
    "bbox": [
      162.0,
      435.3,
      521.4,
      447.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b031",
    "text": "other than memory).",
    "bbox": [
      162.0,
      447.9,
      267.1,
      460.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b032",
    "text": "• The results of non-interventional study (Study 2314) that was intended to",
    "bbox": [
      108.0,
      472.9,
      515.7,
      487.5
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b033",
    "text": "validate several assessment scales used in Study 2311 have been",
    "bbox": [
      126.0,
      487.8,
      482.9,
      501.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b034",
    "text": "interpreted by the sponsor to demonstrate the following:",
    "bbox": [
      126.0,
      501.6,
      425.5,
      515.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b035",
    "text": "That the ADAS-Cog score can differentiate between dementia associated",
    "bbox": [
      162.0,
      529.2,
      522.1,
      541.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b036",
    "text": "with Parkinson’s Disease of mild and moderate severities, as can the",
    "bbox": [
      162.0,
      541.9,
      500.2,
      554.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b037",
    "text": "scores several of the secondary efficacy assessment instruments used in",
    "bbox": [
      162.0,
      554.5,
      520.9,
      566.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b038",
    "text": "this study",
    "bbox": [
      162.0,
      567.2,
      211.5,
      579.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b039",
    "text": "That the ADAS-Cog and several secondary efficacy measures had test-",
    "bbox": [
      162.0,
      579.9,
      510.6,
      592.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b040",
    "text": "retest reliability in this population",
    "bbox": [
      162.0,
      592.5,
      324.1,
      604.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b041",
    "text": "That the ADAS-Cog scores correlated with those of several other efficacy",
    "bbox": [
      162.0,
      605.1,
      521.5,
      617.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b042",
    "text": "instruments, whether those measures assessed cognition or other",
    "bbox": [
      162.0,
      617.8,
      486.0,
      630.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b043",
    "text": "domains",
    "bbox": [
      162.0,
      630.4,
      206.6,
      642.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b044",
    "text": "A factor analysis that compared populations with Parkinson’s Disease",
    "bbox": [
      162.0,
      643.1,
      503.8,
      655.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b045",
    "text": "Dementia and Alzheimer’s Disease on ADAS-Cog sub-item scores had",
    "bbox": [
      162.0,
      655.7,
      510.6,
      667.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b046",
    "text": "indicated that the sub-items grouped differently in each  population,",
    "bbox": [
      162.0,
      668.4,
      492.3,
      680.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b047",
    "text": "suggesting that the cognitive and behavioral profiles in these populations",
    "bbox": [
      162.0,
      681.0,
      519.1,
      693.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 90,
    "block_id": "1055_p90_b048",
    "text": "might differ",
    "bbox": [
      162.0,
      693.7,
      219.5,
      705.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b002",
    "text": "Page 91 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b005",
    "text": "• This study does not address whether the efficacy measures used in Study",
    "bbox": [
      108.0,
      71.9,
      521.6,
      86.6
    ],
    "font_size": 12.0,
    "font_name": "SymbolMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b006",
    "text": "2311, and especially the ADAS-Cog, had “content” validity; i.e., did the",
    "bbox": [
      126.0,
      86.8,
      503.4,
      100.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b007",
    "text": "components of the ADAS-Cog evaluate the main cognitive domains",
    "bbox": [
      126.0,
      100.6,
      487.6,
      114.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b008",
    "text": "believed to be impaired in that  condition. It is currently unclear as to",
    "bbox": [
      126.0,
      114.4,
      491.0,
      127.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b009",
    "text": "whether it is currently possible for a conclusion to be reached that the",
    "bbox": [
      126.0,
      128.2,
      497.5,
      141.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b010",
    "text": "ADAS-Cog has content validity in this population. The factor analysis",
    "bbox": [
      126.0,
      142.0,
      494.2,
      155.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b011",
    "text": "referred to above suggested that the cognitive profiles in Alzheimer’s",
    "bbox": [
      126.0,
      155.8,
      493.5,
      169.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b012",
    "text": "Disease and Parkinson’s Disease differ.",
    "bbox": [
      126.0,
      169.6,
      344.9,
      183.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b013",
    "text": "15.2.3.6 Could the apparent beneficial effects of Exelon® on cognition and/or",
    "bbox": [
      90.0,
      202.1,
      506.4,
      215.5
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b014",
    "text": "global function in Study 2311 have been due to a beneficial effect on the motor",
    "bbox": [
      90.0,
      215.9,
      511.0,
      229.3
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b015",
    "text": "manifestations of Parkinson’s Disease rather than on the dementia itself?",
    "bbox": [
      90.0,
      229.7,
      481.6,
      243.1
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b016",
    "text": "If there was a beneficial effect of Exelon® on specific motor manifestations of",
    "bbox": [
      90.0,
      246.5,
      502.5,
      259.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b017",
    "text": "Parkinson’s Disease such as bradykinesia or dysarthria, it is possible that such a",
    "bbox": [
      90.0,
      260.3,
      521.7,
      273.7
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b018",
    "text": "benefit may have been reflected in a beneficial effect on the ADAS-Cog and/or",
    "bbox": [
      90.0,
      274.1,
      509.5,
      287.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b019",
    "text": "ADCS-CGIC, in the absence of a true effect on the dementia itself",
    "bbox": [
      90.0,
      287.9,
      442.8,
      301.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b020",
    "text": "Such a possibility is unlikely for the following reasons",
    "bbox": [
      90.0,
      315.5,
      374.9,
      328.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b021",
    "text": "There was no overall difference between treatment groups in the mean change",
    "bbox": [
      126.0,
      343.1,
      513.0,
      355.4
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b022",
    "text": "from baseline to endpoint in total UPDRS motor scores. Notable differences",
    "bbox": [
      126.0,
      355.8,
      497.2,
      368.0
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b023",
    "text": "between treatment groups were not seen for important individual UPDRS item",
    "bbox": [
      126.0,
      368.4,
      508.1,
      380.7
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b024",
    "text": "scores",
    "bbox": [
      126.0,
      381.0,
      164.6,
      393.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b025",
    "text": "Adverse events that might be considered to represent a worsening in the motor",
    "bbox": [
      126.0,
      393.7,
      513.7,
      405.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b026",
    "text": "manifestations of Parkinson’s Disease were, in aggregate, more common in",
    "bbox": [
      126.0,
      406.3,
      497.1,
      418.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b027",
    "text": "those assigned to Exelon® than in those assigned to placebo",
    "bbox": [
      126.0,
      419.0,
      426.9,
      431.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b028",
    "text": "[Also note that the study procedures included a number of precautions to",
    "bbox": [
      90.0,
      444.2,
      479.6,
      457.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b029",
    "text": "minimize the effects of the motor manifestations of Parkinson’s Disease on the",
    "bbox": [
      90.0,
      458.0,
      509.5,
      471.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b030",
    "text": "efficacy assessments].",
    "bbox": [
      90.0,
      471.8,
      214.1,
      485.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b031",
    "text": "15.2.3.7  Do the results of Study 2311 warrant replication for a claim for the",
    "bbox": [
      90.0,
      505.5,
      496.1,
      518.9
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b032",
    "text": "treatment of dementia associated with Parkinson’s Disease to be granted?",
    "bbox": [
      90.0,
      519.3,
      488.3,
      532.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b033",
    "text": "All drugs approved by this Agency so far for the treatment of dementia of the",
    "bbox": [
      90.0,
      536.0,
      499.0,
      549.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b034",
    "text": "Alzheimer’s type (Alzheimer’s Disease) have been approved based on the",
    "bbox": [
      90.0,
      549.8,
      486.9,
      563.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b035",
    "text": "demonstration of the desired treatment effect in at least 2 adequate and well-",
    "bbox": [
      90.0,
      563.6,
      498.3,
      577.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b036",
    "text": "controlled trials; the same has applied to the approval of drugs for other discrete",
    "bbox": [
      90.0,
      577.4,
      517.6,
      590.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b037",
    "text": "clinical entities. This Division’s view so far is that the same principle must apply",
    "bbox": [
      90.0,
      591.2,
      512.0,
      604.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b038",
    "text": "to other types of dementia, unless they are variants or grades of severity of",
    "bbox": [
      90.0,
      605.0,
      491.0,
      618.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b039",
    "text": "Alzheimer’s Disease not subsumed under the current claim.",
    "bbox": [
      90.0,
      618.8,
      410.1,
      632.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b040",
    "text": "Therefore, if dementia associated with Parkinson’s Disease is indeed a form of",
    "bbox": [
      90.0,
      646.4,
      510.4,
      659.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b041",
    "text": "dementia that is distinct from Alzheimer’s Disease, it would be appropriate to",
    "bbox": [
      90.0,
      660.2,
      499.6,
      673.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 91,
    "block_id": "1055_p91_b042",
    "text": "require that the results of Study 2311 be replicated.",
    "bbox": [
      90.0,
      674.0,
      365.5,
      687.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b002",
    "text": "Page 92 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b005",
    "text": "15.2.3.8 References",
    "bbox": [
      90.0,
      72.3,
      205.3,
      85.7
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b006",
    "text": "The references, based upon which a number of the above comments have been",
    "bbox": [
      90.0,
      89.0,
      518.8,
      102.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b007",
    "text": "made are listed",
    "bbox": [
      90.0,
      102.8,
      175.3,
      116.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b008",
    "text": "Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic stage in",
    "bbox": [
      90.0,
      130.4,
      520.8,
      139.3
    ],
    "font_size": 8.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b009",
    "text": "Parkinson disease. Neurology 2005;64:1404-10",
    "bbox": [
      90.0,
      139.5,
      261.0,
      148.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b010",
    "text": "Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson's disease: a",
    "bbox": [
      90.1,
      158.0,
      482.3,
      166.9
    ],
    "font_size": 8.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b011",
    "text": "prospective, community-based study. Ann Neurol 2005;58:663-5.",
    "bbox": [
      90.0,
      167.1,
      322.4,
      176.0
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b012",
    "text": "Emre M. Dementia associated with Parkinson’s disease. Lancet Neurol 2003;2:229-37",
    "bbox": [
      90.0,
      185.6,
      398.1,
      194.5
    ],
    "font_size": 8.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b013",
    "text": "Aarsland D, Litvan I, Salmon D, Galasko D, Wentzel-Larsen T, Larsen JP. Performance on the dementia rating scale",
    "bbox": [
      90.1,
      203.9,
      518.1,
      212.8
    ],
    "font_size": 8.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b014",
    "text": "in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy",
    "bbox": [
      90.0,
      213.2,
      512.0,
      222.1
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b015",
    "text": "and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003;74:1215-20",
    "bbox": [
      90.0,
      222.3,
      354.2,
      231.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b016",
    "text": "McKeith IG, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB",
    "bbox": [
      90.0,
      240.8,
      499.9,
      249.7
    ],
    "font_size": 8.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b017",
    "text": "Consortium. Neurology 2005;65:1863-72",
    "bbox": [
      90.0,
      249.9,
      236.6,
      258.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b018",
    "text": "McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda JE, Feldman H,",
    "bbox": [
      90.0,
      268.4,
      517.5,
      277.3
    ],
    "font_size": 8.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b019",
    "text": "Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez OL, Carlos Machado J, O'Brien J, Playfer J, Reid W; International",
    "bbox": [
      90.0,
      277.5,
      523.9,
      286.4
    ],
    "font_size": 8.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b020",
    "text": "Psychogeriatric Association Expert Meeting on DLB. Dementia with Lewy bodies. Lancet Neurol 2004; 3:19-28",
    "bbox": [
      90.0,
      286.7,
      497.6,
      295.6
    ],
    "font_size": 8.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b021",
    "text": "Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, Shulman LM, Gronseth G, Weiner",
    "bbox": [
      90.0,
      305.1,
      508.3,
      314.0
    ],
    "font_size": 8.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b022",
    "text": "WJ; Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: evaluation and",
    "bbox": [
      90.0,
      314.3,
      516.4,
      323.2
    ],
    "font_size": 8.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b023",
    "text": "treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality",
    "bbox": [
      90.0,
      323.6,
      519.9,
      332.5
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b024",
    "text": "Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002",
    "bbox": [
      90.0,
      332.7,
      431.4,
      341.6
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b025",
    "text": "Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC.",
    "bbox": [
      90.0,
      351.2,
      503.9,
      360.1
    ],
    "font_size": 8.0,
    "font_name": "Arial-BoldMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b026",
    "text": "Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of",
    "bbox": [
      90.0,
      360.3,
      521.3,
      369.2
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b027",
    "text": "the American Academy of Neurology. Neurology 2001;56:1143-53 [Guideline reaffirmed: February 13, 2004]",
    "bbox": [
      90.0,
      369.5,
      474.5,
      378.4
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b028",
    "text": "15.3 Safety",
    "bbox": [
      90.0,
      398.7,
      159.9,
      412.1
    ],
    "font_size": 12.0,
    "font_name": "Arial-BoldItalicMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b029",
    "text": "Evidence for the safety of Exelon® in dementia associated with Parkinson’s",
    "bbox": [
      90.0,
      415.4,
      493.6,
      428.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b030",
    "text": "Disease is derived from 2 sources",
    "bbox": [
      90.0,
      429.2,
      274.1,
      442.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b031",
    "text": "15.3.1 Study 2311",
    "bbox": [
      90.0,
      462.8,
      194.6,
      476.2
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b032",
    "text": "This study has already been summarized above. Salient safety findings for this",
    "bbox": [
      90.0,
      479.6,
      510.9,
      493.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b033",
    "text": "study were as follows.",
    "bbox": [
      90.0,
      493.4,
      210.8,
      506.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b034",
    "text": "The incidence of nausea, vomiting, and tremor was appreciably higher in the",
    "bbox": [
      126.0,
      521.0,
      500.7,
      533.3
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b035",
    "text": "rivastigmine group than in the placebo group; a similar adverse event profile was",
    "bbox": [
      126.0,
      533.7,
      521.0,
      545.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b036",
    "text": "seen in the key controlled clinical trials of Exelon® in Alzheimer’s Disease",
    "bbox": [
      126.0,
      546.3,
      487.5,
      558.6
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b037",
    "text": "Several treatment-emergent adverse events that may have represented a",
    "bbox": [
      126.0,
      559.0,
      486.7,
      571.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b038",
    "text": "worsening in the motor manifestations of Parkinson’s Disease, tremor in",
    "bbox": [
      126.0,
      571.6,
      478.7,
      583.9
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b039",
    "text": "particular, were more frequent in those treated with Exelon® than in those",
    "bbox": [
      126.0,
      584.2,
      488.1,
      596.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b040",
    "text": "treated with placebo. However, changes in UPDRS total motor scores, probably",
    "bbox": [
      126.0,
      596.9,
      516.6,
      609.2
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b041",
    "text": "a more objective measure of change in the motor manifestations of Parkinson’s",
    "bbox": [
      126.0,
      609.6,
      514.2,
      621.8
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b042",
    "text": "Disease than the incidence of treatment-emergent adverse events, showed no",
    "bbox": [
      126.0,
      622.2,
      510.0,
      634.5
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b043",
    "text": "meaningful difference between treatment groups.",
    "bbox": [
      126.0,
      634.9,
      368.1,
      647.1
    ],
    "font_size": 11.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b044",
    "text": "15.3.2 Study 2311E1",
    "bbox": [
      90.0,
      666.2,
      209.3,
      679.6
    ],
    "font_size": 12.0,
    "font_name": "Arial-ItalicMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b045",
    "text": "This was an 24-week open-label uncontrolled extension to Study 2311 intended",
    "bbox": [
      90.0,
      682.9,
      515.6,
      696.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 92,
    "block_id": "1055_p92_b046",
    "text": "primarily to evaluate the safety and tolerability of Exelon® in the study",
    "bbox": [
      90.0,
      696.7,
      463.7,
      710.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b001",
    "text": "Ranjit B. Mani, MD, HFD-120 Medical Review",
    "bbox": [
      90.0,
      39.9,
      254.0,
      48.8
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b002",
    "text": "Page 93 of 93",
    "bbox": [
      457.5,
      36.2,
      524.8,
      49.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b003",
    "text": "NDA 20823 (SE1-016), Exelon® (rivastigmine tartrate) , Novartis",
    "bbox": [
      90.0,
      50.0,
      320.8,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b004",
    "text": "4/18/06",
    "bbox": [
      495.3,
      50.0,
      524.2,
      58.9
    ],
    "font_size": 8.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b005",
    "text": "population. Patients given the option of enrolling in this study had either",
    "bbox": [
      90.0,
      72.2,
      472.4,
      85.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b006",
    "text": "completed the double-blind treatment phase of Study 2311 or discontinued early",
    "bbox": [
      90.0,
      86.0,
      518.9,
      99.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b007",
    "text": "during that study, but returned for all the remaining scheduled efficacy",
    "bbox": [
      90.0,
      99.8,
      464.2,
      113.2
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b008",
    "text": "assessments without significant protocol violations. Regardless of their previous",
    "bbox": [
      90.0,
      113.6,
      516.9,
      127.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b009",
    "text": "treatment assignment, patients enrolled in the extension study were all re-titrated",
    "bbox": [
      90.0,
      127.4,
      522.3,
      140.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b010",
    "text": "to a flexible dose of Exelon® that ranged from 1.5 mg BID to 6.0 mg BID, based",
    "bbox": [
      90.0,
      141.2,
      516.5,
      154.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b011",
    "text": "on tolerability.",
    "bbox": [
      90.0,
      155.0,
      170.8,
      168.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b012",
    "text": "433 patients enrolled in Study 2311 were eligible to enroll in Study 2311E1 of",
    "bbox": [
      90.0,
      182.6,
      502.3,
      196.0
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b013",
    "text": "whom 334 actually consented to participate and 273 completed the study. The",
    "bbox": [
      90.0,
      196.4,
      508.2,
      209.8
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b014",
    "text": "adverse event profile of Exelon® in Study 2311 was broadly similar to that seen",
    "bbox": [
      90.0,
      210.2,
      515.0,
      223.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b015",
    "text": "in Study 2311E1",
    "bbox": [
      90.0,
      224.0,
      181.4,
      237.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b016",
    "text": "16. Conclusions",
    "bbox": [
      90.0,
      263.8,
      204.5,
      279.4
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b017",
    "text": "Deferred, pending discussion of this application at a scheduled meeting of the",
    "bbox": [
      90.0,
      282.7,
      505.6,
      296.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b018",
    "text": "Peripheral and Central Nervous Systems Drugs Advisory Committee",
    "bbox": [
      90.0,
      296.5,
      456.9,
      309.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b019",
    "text": "17. Recommendation",
    "bbox": [
      90.0,
      336.3,
      238.0,
      351.9
    ],
    "font_size": 14.0,
    "font_name": "Arial-BoldMT",
    "label": "HH1"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b020",
    "text": "Deferred, pending discussion of this application at a scheduled meeting of the",
    "bbox": [
      90.0,
      355.2,
      505.6,
      368.6
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b021",
    "text": "Peripheral and Central Nervous Systems Drugs Advisory Committee",
    "bbox": [
      90.0,
      369.0,
      456.9,
      382.4
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b022",
    "text": "Ranjit B. Mani, M.D.",
    "bbox": [
      301.5,
      399.1,
      416.2,
      412.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b023",
    "text": "Medical Reviewer",
    "bbox": [
      306.0,
      412.9,
      403.9,
      426.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b024",
    "text": "rbm 4/18/06",
    "bbox": [
      90.0,
      468.1,
      157.4,
      481.5
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b025",
    "text": "cc:",
    "bbox": [
      90.0,
      481.9,
      108.7,
      495.3
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b026",
    "text": "HFD-120",
    "bbox": [
      90.0,
      495.7,
      141.9,
      509.1
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  },
  {
    "pdf_id": "1055",
    "page_number": 93,
    "block_id": "1055_p93_b027",
    "text": "NDA 20823 (SE1-016)",
    "bbox": [
      90.0,
      509.5,
      210.1,
      522.9
    ],
    "font_size": 12.0,
    "font_name": "ArialMT",
    "label": "BODY"
  }
]